nymox_20f.htm

0001640334-22-000622.txt : 20220330 0001640334-22-000622.hdr.sgml : 20220330 20220330171647 ACCESSION NUMBER: 0001640334-22-000622 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 108 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220330 DATE AS OF CHANGE: 20220330 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NYMOX PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0001018735 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-12033 FILM NUMBER: 22787686 BUSINESS ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 BUSINESS PHONE: 1-800-936-9669 MAIL ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 20-F 1 nymox_20f.htm FORM 20-F nymox_20f.htm

United States

Securities and Exchange Commission

Washington, D.C. 20549

Form 20-F

☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934

☒ Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

For the fiscal year ended December 31, 2021

☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

☐ Shell Corporation Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of event requiring this Shell Corporation Report for the transition period from ________ to ________

Commission File Number: 001-12033

NYMOX PHARMACEUTICAL CORPORATION

(Exact name of registrant as specified in its charter)

Bahamas

(Jurisdiction of incorporation or organization)

Bay & Deveaux Streets

Nassau, The Bahamas

(Address of principal executive offices)

Contact person: Erik Danielsen

Tel. 800-936-9669, e-mail: edanielsen@nymox.com, fax: 514-332-222

(name, telephone, e-mail and/or facsimile number and address of company contact person)

Securities registered or to be registered pursuant to Section 12(b) of the Act.

Title of each class

Name of each exchange on which registered

Common Stock

The NASDAQ Stock Market LLC

(NASDAQ Capital Market)

Securities registered or to be registered pursuant to Section 12(g) of the Act

None

Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act

None

Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report.

85,545,875 shares as of December 31, 2021

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website; if any, every interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232-405 of this chapter) during the preceding twelve months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☒

Non-accelerated filer ☐

Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:

U.S. GAAP ☐	International Financial Reporting Standards ☒	Other ☐
	as issued by the International Accounting Standards Board.

If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:

Item 17 ☐ Item 18 ☐

If this is an annual report, indicate by check mark whether the registrant is a shell Company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

In this annual report, the terms “Nymox”, “The Corporation”, “The Company”, “we” and “us” refers to both Nymox Pharmaceutical Corporation and its subsidiaries, Nymox Corporation and Serex Inc. Unless otherwise indicated all dollar amounts are in United States Dollars.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

You should be aware that this report contains forward-looking statements about, among other things, the anticipated operations, product development, financial condition and operating results of Nymox, proposed clinical trials and proposed transactions, including collaboration agreements.

By forward-looking statements, we mean any statements that are not statements of historical fact, including (but not limited to) statements preceded by or that include the words, “believes”, “expects”, “anticipates”, “hopes”, “targets” or similar expressions.

In connection with the “safe harbor” provisions in the Private Securities Litigation Reform Act of 1995, we are including this cautionary statement to identify some of the important factors that could cause Nymox’s actual results or plans to differ materially from those projected in forward-looking statements made by, or on behalf of, Nymox. These factors, many of which are beyond the control of Nymox, include Nymox’s ability to:

	•	Identify and capitalize on possible collaboration, strategic partnering or divestiture opportunities;

	•	Obtain suitable financing to support its operations and clinical trials;

	•	Successfully defend pending and/or unforeseeable future litigation;

	•	Manage its growth and the commercialization of its products;

	•	Achieve operating efficiencies as it progresses from a development-stage to a later-stage biotechnology corporation;

	•	Successfully compete in its markets;

	•	Realize the results it anticipates from the clinical trials of its products;

	•	Overcome negative results from its clinical trials; and eventually obtain regulatory clearance for its products.

	•	Succeed in finding and retaining joint venture and collaboration partners to assist it in the successful marketing, distribution and commercialization of its products;

	•	Achieve regulatory clearances for its products;

	•	Obtain on commercially reasonable terms adequate product liability insurance for its commercialized products and avoid product liability claims;

	•	Adequately protect its proprietary information and technology from competitors and avoid infringement of proprietary information and technology of its competitors;

	•	Assure that its products, if successfully developed and commercialized following regulatory approval, are not rendered obsolete by products or technologies of competitors; and

	•	Not encounter problems with third parties, including key personnel, upon whom it is dependent.

Although Nymox believes that the forward-looking statements contained in this annual report are reasonable, it cannot ensure that its expectations will be met. These statements involve risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. Factors that could cause such differences include, but are not limited to, those discussed under “Risk Factors.”

Part I

ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Not Applicable

ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE

Not Applicable

ITEM 3. KEY INFORMATION

Selected Financial Data

The following table sets forth selected consolidated financial data for Nymox for the periods indicated, derived from financial statements prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”) the financial statements have been audited by TPS THAYER Company, LLC of Houston, Texas in the United States as of December 31, 2021, 2020 and by Thayer O’Neal for the year ended December 31, 2019, 2018 and 2017 and are reported in U.S. dollars. The data set forth below should be read in conjunction with the Corporation’s consolidated financial statements and notes thereto included in Part I, Item 8 of this report.

NYMOX PHARMACEUTICAL CORPORATION

Selected Consolidated Financial Data (In U.S. dollars)

Fiscal Year Ended December 31,	2021			2020			2019			2018			2017
Total Assets	$	1,442,843		$	4,343,577		$	5,489,286		$	8,075,988		$	979,137
Share Capital	$	165,061,049		$	151,722,076		$	136,554,101		$	126,684,101		$	108,196,243
Total Equity	$	(505,968	)	$	2,145,311		$	3,448,246		$	7,001,318	)	$	(1,251,350	)
Sales	$	-		$	5,350		$	115,648		$	299,412		$	223,719
Total Revenues (including sales)	$	-		$	5,350		$	115,648		$	299.412		$	223,719
Loss from operating activities	$	(12,504,248	)	$	(11,719,323	)	$	(13,324,918	)	$	(10,640,620	)	$	(13,235,302	)
Net Loss	$	(12,537,622	)	$	(11,737,761	)	$	(13,161,976	)	$	(10,593,859	)	$	(13,428,878	)
Loss per Share (basic & diluted)	$	(0.15	)	$	(0.16	)	$	(0.19	)	$	(0.18	)	$	(0.26	)
Weighted Avg. No. of Common Shares		81,976,321			73,823,141			68,845,225			60,466,449			52,647,913

Nymox has never paid any dividends and does not expect to do so in the foreseeable future.

Risk Factors

Investing in our securities involves a significant degree of risk. You should carefully consider the risks described below, together with all of the other information in our publicly filed documents, before making an investment decision. If any of the following risks actually occurs, our business, financial condition or results of operations could be adversely affected. In such an event, the trading price of our Common Shares could decline, and shareholders may lose part or all of their investment in our securities.

Our Clinical Trials for our Therapeutic Products in Development, Such as Fexapotide Triflutate (NX-1207), May Not Be Successful and We May Not Receive the Required Regulatory Approvals Necessary to Commercialize These Products

Products requiring regulatory approval, such as Fexapotide Triflutate (NX-1207), will be approved for commercial sale only if governmental regulatory authorities are satisfied that our clinical trials are properly designed and conducted and that the results of those trials provide valid and acceptable evidence that the product is safe and effective for the conditions or diseases it is intended to treat. We do not know whether our already collected clinical trial results on a stand-alone basis and/or in combination with any future clinical trial results will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products. Clinical trials are lengthy, complex, expensive and uncertain processes and failure can occur at any stage of testing. If we fail to adequately demonstrate the safety and efficacy of our products under development, we will not be able to obtain the required regulatory approvals to commercialize our product candidates. On November 2, 2014, following the completion of data verification and auditing procedures, top-line results of the Phase 3 NX02-0017 and NX02-0018 U.S. clinical trials of NX-1207 for BPH at 12 months post-treatment were not statistically significant compared to placebo. The Corporation expects to continue its efforts to work on the development program.

Setbacks in our clinical trials or in our efforts to seek regulatory approval for NX-1207 or failure to obtain regulatory approval could cause the price of our shares to decline and adversely affect our business, operations, product development programs and financial condition. See “A Setback in Any of Our Clinical Trials Would Likely Cause a Drop in the Price of Our Shares”.

Our Clinical Trials for Certain of Our Therapeutic Products May Be Delayed, making it Impossible to Achieve Anticipated Development or Commercialization Timelines and Our Development of Fexapotide Triflutate (NX-1207) for BPH Has Been Delayed Due To Negative Results In Phase III Clinical Trials.

Delays in the initiation, conduct or completion of clinical trials are not uncommon. If one or more of our clinical trials is delayed, we may be unable to meet our anticipated development or commercialization timelines. Either circumstance could cause the price of our shares to decline, increase clinical trial and product development costs, and affect the Corporation’s business, operations, product development programs and financial condition.

The design, conduct and completion of clinical trials is a complex process involving many third parties, including governmental authorities, institutional review boards, contract manufacturers, contract research organizations, consultants, investigators, patients, and data monitoring committees. The initiation, progress, completion and success of a clinical trial is in part dependent on third parties providing necessary approvals, agreements and consents, performing necessary tasks in a timely, competent manner, and complying with protocols, good clinical practices and applicable laws, rules and regulations. Failure of a third party to perform as expected or agreed upon may result in delays or failure in initiating or completing a clinical trial.

Our clinical trials are subject to prior approvals and continuing oversight by governmental regulatory authorities and institutional review boards. We must meet and comply with their requirements in order to start, continue and successfully complete a clinical trial. We may not be able to comply with one or more of these requirements or there may be delays in doing so. Governmental regulatory authorities may change approvals or requirements, resulting in changes to the design or conduct of a clinical trial or the need for new or further clinical trials.

On November 2, 2014, following the completion of data verification and auditing procedures and the unblinding and top line analysis of efficacy of the studies, Nymox announced that the NX02-0017 and NX02-0018 Phase 3 clinical trials had failed to meet their primary endpoints. Top-line results of the Phase 3 NX02-0017 and NX02-0018 U.S. clinical trials of NX-1207 for BPH at 12 months post-treatment were not statistically significant compared to placebo. The Corporation is in the process of further data analysis and assessments of the two studies and expects to continue its efforts to work on the development program. On July 27, 2015 Nymox announced that the Company’s U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. The Company announced that Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies. As a result of the clinical benefits observed in the long-term extension trial, the Company intends to meet with regulatory authorities in various jurisdictions around the world and in due course to proceed to file for approval where possible.

A Setback in Any of Our Clinical Trials or Efforts to Obtain Regulatory Clearance for Our Products Would Likely Cause a Drop in the Price of Our Shares

The clinical testing of drug candidates is fraught with uncertainties and positive results from earlier clinical trials may not be repeated in later trials. As well, government regulators such as the U.S. Food and Drug Administration, or FDA, may require additional testing or further documentation relating to the preclinical testing, clinical studies, manufacturing or other issues at any time. These requirements may result in substantial delays in obtaining regulatory approval or make obtaining such approval much more difficult. Setbacks in any phase of the clinical development of our product candidates could have a negative impact on our business, operations, product development programs and financial condition, could jeopardize FDA or other regulatory approval and would likely cause a further drop in the price of our shares.

We May Not be Able to Make Adequate Arrangements with Third Parties for the Commercialization of Our Product Candidates, such as NX-1207

In order to commercialize our product candidates successfully, we intend, on a product-by-product basis, either to make arrangements with third parties to perform some or all of these services or to expand our existing sales, marketing and distribution capabilities. We currently have limited sales and marketing capabilities and limited experience in developing, training or managing a large marketing or sales force. We currently rely primarily upon distributors for the sales of our existing products. The cost of establishing and maintaining a larger sales force would be substantial and may exceed its cost effectiveness. In addition, in marketing our products, we would likely compete with many companies that currently have extensive and well-funded marketing and sales operations. Despite our marketing and sales efforts, we may be unable to compete successfully against these companies. We may make arrangements with third parties to market and sell some or all of our products under development in certain territories, rather than establish our own sales force. We may not be able to do so on favorable terms. If we contract with third parties for the sales and marketing of our products, our revenues will depend upon the efforts of these third parties, whose efforts may not be successful.

We anticipate entering into co-development and co-marketing agreements with one or more partners with established sales, marketing and regulatory capabilities in order to assist in the completion of the development and commercialization of NX-1207. We may not be able to do so on favorable terms. If we fail to establish or make adequate arrangements with third parties for such purposes, our business, operations, product development programs and financial condition will be materially adversely affected.

We May Not Achieve Our Projected Development Goals in the Time Frames We Announce and Expect

We make public statements regarding the achievement of our milestones, such as the commencement and completion of clinical trials, regulatory submission and approval dates and time of product launch. The actual timing of these events can vary dramatically due to factors such as delays or failures in our clinical trials, the uncertainties inherent in the regulatory approval process and delays in achieving manufacturing or marketing arrangements sufficient to commercialize our products. There can be no assurance that our clinical trials will be completed, that we will make regulatory submissions or receive regulatory approvals as planned or that we will be able to adhere to our current schedule for the launch of any of our products. If we fail to achieve one or more of these milestones as planned, for instance, such as the completion of our Phase 3 development of NX-1207 for BPH, which has been delayed due to certain negative results, the price of our shares could decline.

Even If We Obtain Regulatory Approvals for Our Product Candidates, We Will be Subject to Stringent Ongoing Government Regulation

Even if regulatory authorities approve any of our product candidates, the manufacture, marketing and sale of such products will be subject to strict and ongoing regulation. Compliance with such regulation will be expensive and consume substantial financial and management resources. For example, an approval for a product may be conditioned on our conducting costly post-marketing follow-up studies. In addition, if based on these studies, a regulatory authority does not believe that the product demonstrates a benefit to patients, such authority could limit the indications for which the product may be sold or revoke the product’s regulatory approval.

We and our contract manufacturers will be required to comply with applicable current Good Manufacturing Practice (“cGMP”) regulations for the manufacture of our products. These regulations include requirements relating to quality assurance, as well as the corresponding maintenance of records and documentation. Manufacturing facilities must be approved before we can use them in commercial manufacturing of our products and are subject to subsequent periodic inspection by regulatory authorities. In addition, material changes in the methods of manufacturing or changes in the suppliers of raw materials are subject to further regulatory review and approval.

If we or any marketing collaborators or contract manufacturers fail to comply with applicable regulatory requirements, we may be subject to sanctions including fines, product recalls or seizures, injunctions, total or partial suspension of production, civil penalties, and withdrawals of previously granted regulatory approvals and criminal prosecution. Any of these penalties could delay or prevent the development, marketing or sale of our products.

It is Uncertain When, if Ever, We Will Make a Profit

We first began operations in 1995 and are only in the early stages of commercial marketing of our diagnostic products, NicAlert™ and TobacAlert™. We have never made a profit. We incurred a net loss of approximately $11.7 million in 2020 and $12.5 million in 2021. As of December 31, 2021, Nymox’s accumulated deficit was approximately $192.6 million and we have Negative cash flows from operations of $9,820,621 for the year ended December 31, 2021. As of December 31, 2021, we had negative working capital of $520,000.

We cannot say when, if ever, Nymox will become profitable or operate with positive cash flows from operations. Profitability will depend on our uncertain ability to generate revenues from the sale of our products and the licensing of our technology that will offset the significant expenditures required for us to advance our research, protect and extend our intellectual property and develop, manufacture, license, market, distribute and sell our technology and products successfully. Similar types of expenditures in the past have contributed to the net losses reported above.

We Will Continue as a Going Concern

The Corporation will require additional funds to pursue its operations as a going concern for the fiscal year ending December 31, 2021 and beyond, some of the funds of which would be used to conduct further research and development, schedule clinical testing, obtain regulatory approvals and the commercialization of its product candidates. The Corporation had available cash of approximately $829,669 and a negative working capital of $521,000 as of December 31, 2021. Cash flows used in operations during 2021 were $9,820,621.

Management believes that current cash balances as at December 31, 2021 and anticipated funds from product sales will not besufficient to fund its planned business operations and research and development programs over the next 12 months. The Corporation’s primary sources of financing since 2003 has been the Common Stock Private Purchase Agreement.. If necessary, the Corporation intends to seek additional equity or finance through the existing private placements and/or other sources of capital in order to fund these operations and activities over the next year.

There can be no assurance that any additional funding will be available at terms that are acceptable to the Corporation to enable the Corporation to continue to pursue its operations. Considering recent developments and the need for additional financing, there exists a material uncertainty that casts substantial doubt about the Corporation’s ability to continue as a going concern. Our consolidated financial statements do not reflect adjustments that would be necessary if the going concern assumption was not appropriate. If the going concern assumption is not appropriate, then adjustments may be necessary to the carrying value and classification of assets and liabilities and reported results of operations and such adjustments could be material.

We have incurred operating losses throughout our history. Management believes that such operating losses will continue for at least the next few years as a result of expenditures relating to research and development of our potential therapeutic products.

We Face Challenges in Developing, Manufacturing and Improving Our Products

We are still developing many of our products and have not yet brought them to market. We cannot make any assurances that we will be able to develop our products and to market them successfully. Developing and improving our diagnostic products is challenging. The science and technology of the detection and measurement of very small amounts of biochemicals in bodily fluids and tissue is evolving rapidly. We may need to make significant expenditures in research and development costs and licensing fees in order to take advantage of new technologies. If any major changes to our testing technologies used in our NicAlert™ or TobacAlert™ tests are made, further validation studies will be required. Developing new diagnostic products is more challenging, requiring identification and validation of the biochemical marker being detected by the new product in the clinical context and the development and validation of the product designed to detect the marker.

We anticipate outsourcing at least some of the manufacturing required for new products we may develop in order to control start-up and operating costs and to take advantage of the existing manufacturing capabilities and capacity in the large contract manufacturing sectors in the pharmaceutical and diagnostic industries. There are risks associated with this strategy, including difficulties in the transfer of manufacturing, the possibility of production interruption due to causes beyond our control and the need to arrange alternative suppliers. We currently out-source some of the manufacturing services required for our NicAlert™ and TobacAlert™ products to a contract manufacturer. We do not anticipate any significant risk of long-term interruption of manufacture due to this arrangement. The services supplied are not unique or unduly complicated and other contract manufacturers are available to provide similar services.

Our Products and Services May Not Receive Necessary Regulatory Approvals

Our diagnostic products, NicAlert™ and TobacAlert™, and our products in development, are subject to a wide range of government regulation governing laboratory standards, product safety and efficacy. The actual regulatory schemes in place vary from country to country and regulatory compliance can take several years and involve substantial expenditures.

We cannot be sure that we can obtain necessary regulatory approvals on a timely basis, if at all, for our products in development and all of the following could have a material adverse effect on our business:

	•	failure to obtain or significant delays in obtaining requisite approvals;

	•	loss of or changes to previously obtained approvals; and

	•	failure to comply with existing or future regulatory requirements.

Any changes in the Centers for Medicare and Medicaid Services (“CMS”) or state law requirements or in the U.S. Food and Drug Administration (“FDA”) regulations could have a detrimental impact on our ability to offer or market any reference laboratory services and/or on our ability to obtain reimbursement from the Medicare and Medicaid programs and providers.

Similar requirements exist in many other countries. Obtaining these approvals and complying with the subsequent global regulatory requirements can be both time-consuming and expensive.

In the United States, our drugs in development will require final FDA approval before their sale or distribution. Such approval comes only at the end of a lengthy, expensive and often arduous process. In September, 2006, we announced the successful completion of a multi-center, double-blind, placebo-controlled Phase 2 trial of NX-1207, our lead candidate for the treatment of BPH, a common disorder of older men. In February 2008, the Corporation reported positive results in a 32 site U.S. Phase 2 prospective randomized clinical trial, with statistically significant improvement compared to an approved BPH drug (finasteride). Subsequent to the completion of the Phase 2 studies, the Corporation has reported positive results in several follow-up studies of BPH patients that participated in the Phase 2 studies. In February 2009, the Corporation reported concluding a positive and productive End of Phase 2 (“EOP2”) meeting with the FDA concerning the Phase 3 program for NX-1207. In June 2009, the Corporation began conducting the first of two pivotal double blind placebo controlled Phase 3 trials for NX-1207 that incorporate the specific protocol design recommendations provided to the Corporation by the FDA. Top-line results of the Phase 3 NX02-0017 and NX02-0018 U.S. clinical trials of NX-1207 for BPH at 12 months post-treatment were not statistically significant compared to placebo. The Corporation is in the process of further data analysis and assessments of the two studies, and expects to continue its efforts to work on the development program. On July 27, 2015 Nymox announced that the Company’s U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. The Company announced that Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies. As a result of the clinical benefits observed in the long-term extension trial, the Company has to met with regulatory authorities in various jurisdictions around the world and has filed for regulatory approval in Europe and intends to file with the FDA later this year. Nevertheless, we cannot predict with any certainty the outcome of this program, what further steps may be required or whether regulatory authorities will ultimately grant us such approval.

We Face Significant and Growing Competition

The modern pharmaceutical and biotechnology industries are intensely competitive. Our treatments under development for enlarged prostate BPH face significant competition from existing products. There are at least nine drugs approved for treatment of BPH: five proprietary drugs (dutasteride (Avodart®), tamsulosin (Flomax®), alfusozin, (Uroxatral®), silodosin (Rapaflo®), and tadalofil (Cialis®)), a combination of two drugs (dutasteride and tamsulosin) (Jalyn™), and four generics (finasteride, terazozin, doxazozin, and prazosin). There are a number of thermal treatments on the market designed to shrink the enlarged prostate by heating its tissue with a device inserted through the urethra (the passage leading from the bladder through the penis through which men urinate). The devices on the market use microwave energy (Prostatron®, Targis Therapy® or TherMatrx®), low level radiowaves (TUNA System®), lasers (Indigo LaserOptic Treatment System® or Laserscope GreenLight PVP™), direct heat, energy or hot water to heat or burn away prostate tissue. A variety of surgical procedures exist to surgically reduce or remove the prostate or to widen the urethra. These include procedures to cut away prostate tissue such as TURP (transurethral resection of the prostate) and using a resectoscope with an electrical loop inserted through the penis to cut the prostate tissue. A small device used to widen the constricted urethra called a prostatic stent can also be inserted. In 2013, the FDA approved the Urolift™ system, a permanent surgical implant designed to pull back prostate tissue to improve urination in men with BPH.

The diagnostic testing industry is also highly competitive. The FDA has approved two radioactive diagnostic agents for Positron Emission Tomography (“PET”) imaging as an aid to the evaluation of patients with signs of Alzheimer’s disease: Amyvid® (florbetapir), marketed by Lilly, and Vizamyl® (flutemetamol), marketed by GE Healthcare. Other companies are also developing similar technologies. The introduction of other diagnostics products for tobacco product use that are cheaper, easier to perform, more accurate or otherwise more attractive to the physicians, health care payers or other potential customers would have a significant impact on the sales of our NicAlert™ or TobacAlert™ products.

We May Not Be Able to Successfully Market Our Products

To increase our marketing, distribution and sales capabilities both in the United States and around the world, we will need to enter into licensing arrangements, contract sales agreements and co-marketing deals. We cannot assure you that we will be able to enter into agreements with other companies on terms acceptable to us, that any licensing arrangement will generate any revenue for the Corporation or that the costs of engaging and retaining the services of a contract sales organization will not exceed the revenues generated.

Protecting Our Patents and Proprietary Information is Costly and Difficult

Obtaining and maintaining our patent position is costly. We pay for the filing, prosecution and fees of several hundred patents and patent applications in countries around the world, including the United States, Europe, Japan, Canada, Australia, New Zealand and South Korea.

While we believe that we have strong patent protection for the products we sell and for our product development programs and we are in the process of extending that patent protection to cover more countries or new discoveries or products, we cannot assure you that additional patents covering new products or improvements will be issued or that any new or existing patents will be of commercial benefit or be valid and enforceable if challenged.

We believe that the patents issued to date should not preclude Nymox from developing and marketing our products; however, it is impossible to predict the extent to which licenses from third parties will be necessary. If Nymox were to need licenses from third parties there can be no assurance that we could obtain such licenses on commercially reasonable terms, if at all.

In the fields of diagnostic methods and diagnostic tests for common human diseases and conditions, where Serex has many of its patents, there are many patents issued covering many areas of diagnostic methods, tests and technologies. We believe that these patents issued to date to other companies will not preclude Serex from developing and marketing its products but you should be aware that it is often difficult to determine the nature, breadth and validity of competing patent claims in these fields, that there has been significant litigation in some of these areas (not involving Serex) and that, if and when Serex’s products become more commercially successful, Serex’s products or patents may become the subject matter of litigation. If Serex were to need licenses from third parties there can be no assurance that it could obtain such licenses on commercially reasonable terms, if at all.

We are not currently involved in patent litigation. In the pharmaceutical and biotechnology industry patent disputes are frequent and can preclude the commercialization of products. Patent litigation is costly and the outcome often difficult to predict. It can expose us to significant liabilities to third parties and may require us to obtain third-party licenses at a material cost or cease using the technology or product in dispute.

We Face Changing Market Conditions

The healthcare industry is in transition with a number of changes that affect the market for therapeutic and diagnostic test products. The U.S. federal and various state governments have under consideration a number of proposals that may have the effect of directly or indirectly limiting drug prices in the U.S. markets. In March 2010, the United States enacted health care reform legislation, the Patient Protection and Affordable Care Act. Important market reforms have begun and will continue through full implementation in 2016 and beyond. The new law is expected to expand access to health care to more than 32 million Americans by the end of the decade. These changes may adversely affect the prices we may charge for any therapeutic drug we develop. Funding changes and budgetary considerations can lead major health care payers and providers to make changes in reimbursement policies for our products. These changes can seriously impact the potential for growth for the market for our products, either favorably when the decision is to offer coverage for our products at a reasonable price or negatively when the decision is to deny coverage altogether. Changes in the healthcare delivery system have resulted in consolidations and in the formation of multi-hospital alliances, reducing the number of institutional customers for therapeutic and diagnostic test products. There can be no assurance that Nymox will be able to enter into and/or sustain contractual or other marketing or distribution arrangements on a satisfactory commercial basis with these institutional customers.

Health Care Plans May Not Cover or Adequately Pay for Our Products and Services

Throughout the developed world, both public and private health care plans are under considerable financial and political pressure to contain their costs. The two principal methods of restricting expenditures on drugs and diagnostic products and services are to deny coverage or, if coverage is granted, to limit reimbursement. For single-payer government health care systems, a decision to deny coverage or to severely restrict reimbursement for one of our products can have an adverse effect on our business and revenues.

In the United States, where, to a significant degree, the patient population for our products is elderly, Medicare and Medicaid are sources of reimbursement. In general, any restriction on reimbursement, coverage or eligibility under either program could adversely affect reimbursement to Nymox for products and services provided to beneficiaries of the Medicare and/or Medicaid programs. Many elderly people are covered by a variety of private health care organizations either operating private health care plans or Medicare or Medicaid programs subject to government regulation. These organizations are also under considerable financial constraints and we may not be able to secure coverage or adequate reimbursement from these organizations. Without coverage, we will have to look to the patients themselves who may be unwilling or unable to pay for the product; in turn, doctors may be reluctant to order or prescribe our products in the absence of coverage of the product for the patient.

We Are Subject to Continuing Potential Product Liability Risks, Which Could Cost Us Material Amounts of Money

We may be subject to product liability which could task our critical resources, delay the implementation of our business strategy, result in products being recalled or removed from the market, and materially and adversely harm our business and financial condition due to the costs of defending such legal actions or the payment of any judgments or settlements relating to such actions or both. Our business exposes us to the risk of product liability claims that is inherent in the development and marketing, distribution, and sale of pharmaceutical and diagnostic products. If any of our product candidates or marketed products harms people, or is alleged to be harmful, we may be subject to costly and damaging product liability claims brought against us by clinical trial participants, consumers, patients, health care providers, corporate partners or others.

We have product liability insurance covering our ongoing clinical trials and marketed products. Our insurance coverage may not be sufficient to cover fully all potential claims, nor can we guarantee the solvency of any of our insurers. If our claims experience results in higher rates, or if product liability insurance otherwise becomes costlier because of general economic, market or industry conditions, then we may not be able to maintain product liability coverage on acceptable terms. If sales of our products increase materially, or if we add significant products to our portfolio, then we will require increased coverage and may not be able to secure such coverage at reasonable rates or terms. If our insurance coverage is not sufficient to cover fully all potential claims, the Corporation would be exposed to the risk that our litigation costs and liability could exceed our total assets and our ability to pay.

The Issuance of New Shares May Dilute Nymox’s Stock

The Corporation relies almost exclusively on financing to fund its operations. In order to achieve the Corporation’s business plan and realization of its assets and liabilities in the normal course of operations, the Corporation anticipates the need to raise additional capital and/or achieve sales and other revenue generating activities. The Corporation has historically primarily depended on financing under the Common Stock Private Purchase Agreement as well as direct private placements of its Common Stock to qualified investors to fund its operations. Moreover, Nymox may use its shares as currency in acquisitions. The issuance of further shares and the eligibility of issued shares for sale will dilute our common stock and may lower its share price. There were 90,279,794 common shares of Nymox issued and outstanding as of March 29, 2022. In addition, 6,428,000 share options are outstanding, of which 6,348,833 are currently vested. Expiry dates for Nymox options range from 0.5 years to 9.8 years (see note 11 to our consolidated financial statements). These options have been granted to employees, officers, directors and consultants of the Corporation.

If We Fail to Maintain Compliance with the Requirements for Continued Listing on The NASDAQ Stock Market, Our Common Shares Could be Delisted from Trading on the NASDAQ Stock Market, Which Would Adversely Affect the Liquidity of Our Common Shares and Our Ability to Raise Additional Capital.

Our common shares are currently listed for quotation on the NASDAQ Stock Market. We are required to meet specified financial requirements in order to maintain our listing on the NASDAQ Stock Market. Failure to meet the listing requirements may lead to delisting from the Nasdaq Capital Market in which case the Corporation will consider an alternate trading platform for its common shares. Any potential delisting of our common shares from the NASDAQ Stock Market would make it more difficult for our shareholders to sell our shares in the public market and would likely result in decreased liquidity, limited availability of market quotations for common shares, limited availability of news and analyst coverage regarding our company, a decreased ability to issue additional securities and increased volatility in the price of our common shares. Further, if we were no longer listed on the NASDAQ Stock Market or any other U.S. exchange, our ability to raise additional capital could be impeded and thus have a material adverse effect on our business and operations.

We Face Potential Losses Due to Foreign Currency Exchange Risks

Nymox incurs certain expenses, principally relating to salaries and operating expenses at its Bahamian, U.S. and Canadian offices. Most of our expenses are derived in U.S. dollars. As a result, we are exposed to the risk of losses due to fluctuations primarily in the exchange rates between the U.S. dollar and the Canadian dollar. We protect ourselves against this risk by maintaining cash balances in both currencies. We do not currently engage in hedging activities. The Corporation may suffer losses as a result of unfavorable fluctuations in the exchange rates between the United States dollar and Canadian dollar.

We Have Never Paid a Dividend and are Unlikely to do so in the Foreseeable Future

Nymox has never paid any dividends and does not expect to do so in the foreseeable future. We expect to retain any earnings or positive cash flow in order to finance and develop Nymox’s business.

COVID-19 pandemic impact

As is generally and clearly understood, the COVID-19 pandemic has had and continues to have a major slowdown effect on worldwide business activity. Although the Company does not anticipate any fundamental change in its business plans, management does expect some degree of unavoidable slowdown due to the Company’s inherent reliance on business activities from multiple external partners, supply chains, and participation of organizations outside our control. Due to the downstream effect of these factors, it is not possible at this time to expect or to provide exact timelines for key corporate forward events. The Company cannot predict or comment on behalf of third parties (such as vendors, suppliers, partners, collaborators, etc) and their restrictions and challenges in the current business environment. However, the Company will give all relevant updates in a timely fashion.

Nymox works with and relies upon contract research organizations (CROs); the Company relies on external manufacturing activities (such as raw material suppliers; contract manufacturing vendors; specialized laboratory testing service providers); and works with other service providers in the life sciences and biotechnology sectors; any of the preceding which alone or in combination may lead to unanticipated delays in the Company’s activities and projected timelines for milestones. In addition, Nymox relies on travel for many of its essential business activities, such as quality assurance and other undertakings, which are restricted during the current disruption. At this time there have been no material changes to any of the fundamental conclusions of our scientific research documentation and no material changes in past results in the reportable financial, or other business related disclosures. These COVID-19 related business effects and risks described above are additional to prior statements by the Company in regard to other risk factors that have been outlined in past SEC filings by the Company and are updated where and when appropriate.

Differences between Bahamas and NASDAQ Corporate Governance Practices

Nymox Pharmaceutical Corporation is subject to corporate governance requirements imposed by NASDAQ because Nymox Pharmaceutical’s Shares are listed on the Nasdaq Capital Market.

Nymox Pharmaceutical Corporation is incorporated in the Bahamas. Under NASDAQ Marketplace Rule 5615(a)(3), NASDAQ-listed non-US companies may, in general, follow their home country corporate governance practices in lieu of certain NASDAQ corporate governance requirements. A NASDAQ-listed non-U.S. company is required to provide a general summary of the significant differences between its home country corporate governance practices and NASDAQ corporate governance requirements to its shareholders, either in the company’s annual report filed on Form 20-F or on the company’s website. Nymox is committed to a high standard of corporate governance. As such, Nymox endeavors to comply with most of the NASDAQ corporate governance practices, with the following exceptions. Under NASDAQ Marketplace Rule 5635(c), shareholders must be given the opportunity to vote on any material amendment to the terms of a company’s equity compensation plan (i.e., an amendment to the plan to include repricing provisions). There is no requirement under Bahamas law that equity compensation plan, or any material amendment thereto, be subject to shareholder approval. Nymox will continue to follow the Bahamas practice and require any material amendment to the terms of its plan to be subject only to approval by its board of directors.

Also under NASDAQ Marketplace Rule 5635(d), shareholders must be given the opportunity to vote prior to the issuance of securities in connection with a transaction other than a public offering involving: (1) the sale, issuance or potential issuance by the Company of common stock (or securities convertible into or exercisable for common stock) at a price less than the greater of book or market value which together with sales by officers, directors or substantial shareholders of the Company equals 20% or more of common stock or 20% or more of the voting power outstanding before the issuance; or (2) the sale, issuance or potential issuance by the Company of common stock (or securities convertible into or exercisable common stock) equal to 20% or more of the common stock or 20% or more of the voting power outstanding before the issuance for less than the greater of book or market value of the stock. There is no requirement under Bahamas law that stock issuances pursuant to private placements be subject to shareholder approval. Nymox will continue to follow the Bahamas practice and require private placement transactions to be subject only to approval by its board of directors.

ITEM 4. INFORMATION ON THE CORPORATION

History of the Corporation

Nymox Pharmaceutical Corporation was incorporated under the Canada Business Corporations Act in May 1995 to acquire all of the common shares of DMS Pharmaceutical Inc., a private Corporation which had been carrying on research and development since 1989 on diagnostics and drugs for brain disorders and diseases of the aged with an emphasis on Alzheimer’s disease. In 2015, the Corporation changed domicile to The Bahamas.

We have funded our operations and projects primarily by selling shares of Nymox’s common stock. On December 1, 1996, our common shares began trading on the Nasdaq Stock Market. Nymox’s common shares also traded on the Montreal Exchange from December 18, 1995 to November 19, 1999. In total through December 31, 2021, Nymox has raised over $145 million through the issuance of common stock or securities exercisable for shares of common stock since its incorporation in May 1995.

Organizational Structure

Nymox has two subsidiaries: one wholly-owned subsidiary named Nymox Corporation and the other wholly-owned subsidiary named Serex, Inc., acquired in 2000. Both subsidiaries are based in the same building in Hasbrouck Heights, New Jersey. Nymox Corporation also opened a new office in California (USA) in August, 2018. Nymox Corporation conducts some research and development as well as maintain all Quality Assurance activities, while Serex conducts research and development, and some of the manufacturing for NicAlert™ and TobacAlert™.

Nymox’s offices are located at:

Nymox Pharmaceutical Corporation

Bay & Deveaux Sts., Nassau, The Bahamas

Phone: (800) 936-9669 Fax: (514) 332-2227

Nymox’s registered agent in the United States is:

CT Corporation System

111 Eighth Avenue, 13^thFloor

New York, NY, 10011

Nymox’s two subsidiaries are located at:

Nymox Corporation

4 Park Plaza

Ste 630

Irvine, CA 92614-2525

and

777 Terrace Avenue

Hasbrouck Heights, NJ, USA 07604

Serex, Inc.

777 Terrace Avenue

Hasbrouck Heights, NJ, USA 07604

Business Overview

Nymox Pharmaceutical Corporation is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. The Corporation currently markets NicAlert^TMand TobacAlert^TM, tests that use urine or saliva to detect use of tobacco products. The Corporation also has an extensive patent portfolio covering its marketed products, its investigational drug as well as other therapeutic and diagnostic indications.

Nymox also has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. On March 24, 2015, the Corporation announced that it would hold a special shareholders meeting on April 15, 2015 in Montreal for a motion to transfer the Corporation’s head office from Montreal (Quebec) to the Bahamas. Over 94% of the shareholders agreed to move the Corporation Domicile from Canada to The Bahamas. On October 6, 2015, the Canada authority issued certification for discontinuance of the Canada Business Corporations to the Corporation and the Corporation was deemed to be continued in the commonwealth of the Bahamas as an International Business Company.

Products

NicAlert™ for Tobacco Product Use and TobacAlert™ for Second-Hand Smoke Exposure

Nymox has developed and markets NicAlert™ and TobacAlert™, which are inexpensive, simple-to-use test strips for determining whether a person is using tobacco products (NicAlert™) or has been recently exposed to second-hand smoke (TobacAlert™). Both NicAlert™ and TobacAlert™ employ Serex, Inc.’s patented technology to provide an accurate read-out of levels of cotinine, a by-product of the body’s breakdown of nicotine and generally regarded as the best indicator of tobacco exposure for smokers and nonsmokers. The technology can be used with saliva as well as urine samples in order to detect tobacco product use. NicAlert™ and TobacAlert™ do not require instruments or special training to use and offer a quick, convenient means to test on-site whether a person, such as a child, teenager, student athlete or insurance applicant, is using a tobacco product or has been exposed to second-hand smoke.

Smoking and other tobacco product use is a serious public health problem around the world. Smoking kills. According to the Centers for Disease Control and Prevention, cigarette smoking is responsible for more than 443,000 deaths per year in the United States alone. Smoking can cause cancer of the lung, mouth, bladder, larynx, esophagus and other organs, as well as heart disease and stroke and chronic lung disease. Every year, exposure to second-hand smoke (environmental tobacco smoke or ETS) causes an estimated 3,400 nonsmoking Americans to die of lung cancer and up to 300,000 American infants and small children to suffer from lower respiratory tract infections.

NicAlert™ received clearance from the FDA in October 2002 for medical use to determine if an individual has been exposed to tobacco products. In January, 2006, Nymox announced the certification of the urine-based version of NicAlert™ with a CE Mark making it eligible for sale in the European Union and in May, 2006 the certification of the saliva-based version of NicAlert™ with a CE Mark. In September, 2003, Nymox launched TobacAlert™ for nonmedical testing for second hand smoke exposure in the U.S.

We market the NicAlert™ and TobacAlert™ tests through our own marketing arm and distributors in North America, Europe and Asia. TobacAlert™ is also available online at www.tobacalert.com. Nymox has entered into distribution and marketing agreements with companies and organizations in the U.S. for these products.

Our NicAlert™ and TobacAlert™ products face competition from clinical laboratories such as LabCorp and Quest Diagnostics which provide off-site lab testing for cotinine, the by-product of the body’s breakdown of nicotine measured by NicAlert™ and TobacAlert™, and from assay suppliers, including immunoassay developers such as OraSure Technologies Inc. and Abraxis LLC, and diagnostic system manufacturers such as Roche Diagnostics, Abbott and Siemens Medical Solutions. NicAlert™ and TobacAlert™ also face competition from distributors who supply yes-no smoking status tests such as NicQuick, and QuickScreen, from NicCheck™ I, an FDA-cleared smoking status test being marketed by Mossman & Associates Ltd, from SmokeScreen, a chemical color-based tobacco test being marketed by GFC Diagnostics Ltd. in the United Kingdom, and from carbon monoxide (“CO”) monitors such as SmokeCheck.

NicAlert™ and TobacAlert™ products are currently partly manufactured through out-sourcing arrangements with contract manufacturers. To date, we have not experienced any significant interruptions in the manufacture of these products and the cost of the manufacturing services has not been volatile. The manufacturing services supplied by our current contract manufacturers are not unique or unduly complicated and other contract manufacturers are available to provide similar services in the event that our current contract manufacturers fail to meet our needs.

The technology used in these products is covered by patents and patent applications held by Nymox’s subsidiary, Serex, Inc., both in the U.S. and elsewhere in the world

AlzheimAlert ™; an Aid to the Diagnosis of Alzheimer ‘s disease

We have developed AlzheimAlert™, a proprietary urine assay that can aid physicians in the diagnosis of Alzheimer’s disease. We have developed a kit version of the AlzheimAlert™ assay for sale in Europe. The AlzheimAlert™ kit has the CE Mark. The kit allows clinical reference laboratories to perform the AlzheimAlert™ assay on site with urine samples sent directly to the laboratory.

Products in Development:

NX-1207 for Enlarged Prostate (BPH)

We are developing treatments for BPH, using novel compounds. Our lead candidate NX-1207 successfully completed a multi-center, double-blind, placebo-controlled Phase 2 trial in September 2006. Top-line results of the Phase 3 NX02-0017 and NX02-0018 U.S. clinical trials of NX-1207 for BPH at 12 months post-treatment were not statistically significant compared to placebo. The Corporation is in the process of further data analysis and assessments of the two studies and expects to continue its efforts to work on the development program. We cannot predict with any certainty the outcome of this program, what further steps may be required in order to apply for final FDA approval for this drug or whether the FDA will ultimately grant us such approval.

We believe, there is a significant need for an effective treatment for BPH. More than half of men in their sixties and as many as 90% of men in their seventies and eighties have the symptoms or signs of BPH according to the 2010 AUA Guideline on the Management of Benign Prostatic Hyperplasia, American Urological Association. Symptoms include more frequent urination (especially at night), difficulty urinating, incomplete emptying of the bladder and sometimes complete inability to urinate. More serious cases may require surgical intervention to reduce the size of the prostate. There is a need for a simple, effective treatment for BPH, particularly in cases where existing drug treatments have proven to be ineffective and where more intrusive procedures such as surgery may be inadvisable or bring unacceptable risks.

In July 2012, Nymox reported positive results from a study of long-term treatment outcomes for men who had received a single injection of NX-1207 2.5 mg for treatment for their BPH. The study analysis found that a statistically significant greater number of men who had received NX-1207 2.5 mg reported positive treatment outcomes as compared to men who had received a placebo. The study involved the latest blinded follow-up study data (an average of 57 months post-injection) from the completed clinical trials for these treatment groups. A positive treatment outcome was seen if the patient was not using other BPH medications and no surgical treatment (including MIST) for BPH was reported at any time during the post-injection follow-up period. The statistical analysis of blinded study data showed NX-1207 2.5 mg to have a lasting benefit in terms of positive treatment outcomes that was significantly superior to placebo.

Completed Phase 2 studies have shown that a single administration of NX-1207 resulted in symptomatic improvements which reached statistical significance compared to double-blinded placebo and study controls. The drug is administered by a urologist in an office setting in a brief procedure that does not require anesthesia, sedation, or catheterization and involves little or no pain or discomfort. NX-1207 treatment has not been found to have the sexual, blood pressure, or other side effects associated with the use of the approved drugs for the treatment of BPH. Follow-up studies have shown clinical efficacy effects lasting up to 7½ years after a single treatment.

In February 2009, the Corporation reported concluding a positive and productive EOP2 meeting with the FDA concerning the Phase 3 program for NX-1207. In June 2009, the Corporation began conducting the first of two pivotal double blind placebo controlled Phase 3 trials for NX-1207 that incorporate the specific protocol design recommendations provided to the Corporation by the FDA. On November 2, 2014, following the completion of data verification and auditing procedures and the unblinding and top line analysis of efficacy of the studies, Nymox announced that the NX02-0017 and NX02-0018 Phase 3 clinical trials had failed to meet their primary endpoints. Top-line results of the Phase 3 NX02-0017 and NX02-0018 U.S. clinical trials of NX-1207 for BPH at 12 months post-treatment were not statistically significant compared to placebo. At the time, the Corporation announced that it was is in the process of performing further data analysis and assessments of the two studies. The Company further announced that it expects to continue its efforts to work on the development program.

On July 27, 2015 Nymox announced initial clinical results from its ongoing analysis and assessment of its Phase 3 development program in BPH. The Company announced that the U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH had successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an excellent safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies. As a result of the clinical benefits observed in the long-term extension trial, the Company announced that it intends to meet with regulatory authorities in various jurisdictions around the world and in due course explore the possibility to proceed to file for approval where possible.

Our treatments under development for enlarged prostate (benign prostatic hyperplasia or BPH) face significant competition from existing products. There are nine drugs approved for treatment of BPH: five proprietary drugs (dutasteride (Avodart®), tamsulosin (Flomax®), alfusozin (Uroxatral®), silodosin (Rapaflo®), and tadalafil (Cialis®)) a combination of two drugs (dutasteride and tamsulosin) (Jalyn™), and four generics (finasteride, terazozin, doxazozin, and prazosin). There are a number of thermal treatments on the market designed to shrink the enlarged prostate by heating its tissue with a device inserted through the urethra (the passage leading from the bladder through the penis through which men urinate). The devices on the market use microwave energy (Prostatron®, Targis Therapy® or TherMatrx®), low level radiowaves (TUNA System®), lasers (Indigo LaserOptic Treatment System® or Laserscope GreenLight PVP™), direct heat or hot water to heat or burn away prostate tissue. A variety of surgical procedures exist to surgically reduce or remove the prostate or to widen the urethra. These include procedures to cut away prostate tissue such as TURP (transurethral resection of the prostate) and using a resectoscope with an electrical loop inserted through the penis to cut the prostate tissue. A small device used to widen the constricted urethra called a prostatic stent can also be inserted. In 2013, the FDA approved the Urolift™ system, a permanent surgical implant designed to pull back prostate tissue to improve urination in men with BPH.

NX-1207 for Prostate Cancer

We are also developing NX-1207 as a focal treatment for certain types of cancer. In March 2012, we initiated a Phase 2 U.S. clinical trial enrolling a total of 147 patients at 28 clinical centers across the U.S. to evaluate the Corporation’s NX-1207 drug for the treatment of low grade localized prostate cancer. The trial was initiated in accordance with an Investigational New Drug (“IND”) application filed with the FDA and specific direction and guidance provided by the FDA in pre-IND meetings. Initial positive results from this trial were reported in 2014.

The Corporation is in the process of working towards definitive studies for this indication.

Preclinical Studies of NX-1207 for Hepatocellular Carcinoma

Preclinical studies of NX-1207 also showed positive results when given to animals with hepatocellular carcinoma (“HCC”). In the experimental studies, the cancers were significantly reduced in size after 2 local injections of NX-1207. The Corporation intends to advance NX-1207 into human clinical trials for the treatment of HCC.

We cannot predict with any certainty whether the use of NX-1207 for any oncological indication will successfully complete preclinical testing, whether government regulatory agencies, such as the FDA, will permit such products to proceed to human trials, or whether ultimately the use of NX-1207 for any such indications will be granted approval for sale and marketing in the U.S., Canada, or elsewhere in the world. The development of cancer therapeutics in particular is associated with high risks and many uncertainties and a drug candidate that shows efficacy in pre-clinical testing and in animal models may fail in human trials or take a long period (7 years or more) to achieve regulatory approval.

Research and Development of New Products

New Therapeutics for Alzheimer’s disease

Nymox has a number of proprietary drug development programs aimed at treatments for Alzheimer’s disease and other indications including research on. NTP and its role in the extensive brain cell loss associated with AD and another program based on spherons, which Nymox researchers regard as a source of senile plaques, the characteristic abnormality found in abundance in the brains of patients with AD and widely believed to play a major role in the cause and course of the illness.

At present, there is no cure for Alzheimer’s disease.

Nymox’s research into drug treatments for Alzheimer’s disease is aimed at compounds that could arrest the progression of the disease and therefore are targeted for long term use.

New Diagnostic Products

Nymox has a number of proprietary diagnostic markers and technologies, including a patented platform for point-of-care testing, and has tests utilizing these technologies in the early stages of development. The Corporation also owns patent rights to several novel biochemical indicators for Alzheimer’s disease.

Historical Expenditures for Research and Development Activities

Since 2005, expenses have primarily related to the development and clinical trials of NX-1207, our candidate for the treatment of BPH. The breakdown of research and development costs for these periods is as follows:

Period	Amount (In Thousands of US$)
Prior to 2005	$	18,507
2005		2,293
2006		3,171
2007		3,468
2008		2,389
2009		3,043
2010		4,552
2011		6,602
2012		6,586
2013		5,698
2014		3,859
2015		2,967
2016		2,722
2017		5,284
2018		4,925
2019		5,962
2020		7,167
2021		5,949
Total	$	95,144

Total research and development expenditures to date, excluding stock-based compensation, depreciation and amortization expenses, are $95,144,000.

According to industry statistics, on average it takes 10 to 15 years to research, develop and bring to market a new prescription medicine in the United States. In light of the steps and complexities involved, the successful development of our product candidates is highly uncertain. Actual product timelines and costs are subject to enormous variability and are very difficult to predict. Accordingly, we cannot provide reliable estimates of the nature, timing and estimated costs of the efforts necessary to complete our programs. This is particularly the case for our programs in early stage development. The risk of failure to complete any such program is high because of uncertain feasibility and commercial viability, long lead times to program completion and potentially high costs in relation to anticipated returns. We update and change our product development programs to reflect the most recent preclinical and clinical data and other relevant information. Many of our products under development require regulatory approval before being sold. The process of obtaining such approvals is often lengthy and uncertain and requires the expenditure of substantial resources. Any failure by us to obtain, or any delay in obtaining, regulatory approvals could materially adversely affect our business. We cannot assure you that any such approvals required will be obtained on a timely basis, if at all.

Manufacturing Arrangements

Our NicAlert™ and TobacAlert™ products kits are currently partly manufactured through out-sourcing arrangements with contract manufacturers. To date, we have not experienced any significant interruptions in the manufacture of these products and the cost of the manufacturing services has not been volatile. The manufacturing services supplied by our current contract manufacturer are not unique or unduly complicated and other contract manufacturers are available to provide similar services in the event that our current contract manufacturer fails to meet our needs.

Governmental Regulation

All our products – approved and under development - are subject to extensive government regulation in the United States and in international markets. Any changes in any national or regional legislation could have an impact on our future ability to offer or market any pharmaceutical and/or diagnostic product and thus have a negative effect on our ability to obtain reimbursement from any health insurance programs and providers.

Our therapeutic products under development by Nymox would also have to receive regulatory approval. This is a costly, lengthy and risky process. In the United States, in order for a product to be marketed, it must go through four distinct development and evaluation stages:

Product Evaluation

We must conduct preliminary studies of potential drug candidates using various screening methods to evaluate them for further testing, development and marketing.

Optimization of Product Formulation

The activities in this stage of development involve consultations between us and investigators and scientific personnel. Preliminary selection of screening candidates to become product candidates for further development and further evaluation of drug efficacy is based on research based biochemical measurements. Extensive formulation work and in vitro testing are conducted for each of various selected screening candidates and/or product candidates.

Clinical Screening and Evaluation

During this phase of development, portions of which may overlap with product evaluation and optimization of product formulation, initial clinical screening of product candidates is undertaken and full scale clinical trials commence. The FDA must approve any clinical testing on healthy subjects (Phase 1) and on patients (Phase 2 and 3).

Final Product Development

The activities to be undertaken in final product development include performing final clinical evaluations, conducting large-scale experiments to confirm the reproducibility of clinical responses, making clinical lots for any additional extensive clinical testing that may be required, performing any further safety studies required by the FDA, carrying out process development work to allow pilot scale production of the product, completing production demonstration runs for each potential product, filing new drug applications, product license applications, investigational device exemptions (and any necessary supplements or amendments) and undergoing comprehensive regulatory approval programs and processes.

We cannot assure you that we will successfully complete the development and commercialization of any therapeutic products.

In the United States, obtaining the necessary FDA approval for any drug is a lengthy, expensive and often arduous process. We cannot predict with any certainty the amount of time the FDA will take to approve one of our drugs or even whether any such approval will be forthcoming. Similar requirements exist in many other countries.

In the United States, the FDA approval procedure is a two-step process. We must file an IND application for each product with the FDA before beginning the initial (Phase 1) clinical testing of the new drug in healthy subjects. If the FDA has not commented on or questioned the application within 30 days of its filing, initial clinical studies may begin. If, however, the FDA has comments or questions, the questions must be answered to the satisfaction of the FDA before initial clinical testing can begin. In some instances, this process could result in substantial delay and expense. Phase I studies are intended to demonstrate the functional characteristics and safety of a product.

After Phase 1 testing, we must conduct extensive clinical trials with patients in order to establish the efficacy and safety of our drug. Once we complete the required clinical testing, we expect to have to file a new drug application for FDA approval in order to market most, if not all, of our new drugs. The application is complicated and detailed and must include the results of extensive clinical and other testing, the cost of which is substantial. The FDA conducts an extensive and often lengthy review of such applications. The agency is required to review applications within 180 days of their filing, but, during the review, frequently requests that additional information be submitted. This starts the 180-day regulatory review period anew when the requested additional information is submitted and, as a result, can significantly extend the review period. Until the FDA actually approves the new drug application, there can be no assurance that the agency will consider the information requested and submitted to justify approval. The packaging and labeling of products are also subject to FDA regulation. Accordingly, it is impossible to anticipate when the FDA will approve a new drug application.

Our lead candidate is NX-1207, a treatment for BPH and for low grade localized prostate cancer. We cannot predict with any certainty what further steps may be required in order to apply for final FDA approval for this drug or whether the FDA will ultimately grant us such approval.

We must also obtain approval for our drugs or diagnostic devices from the comparable regulatory authority in other countries before we can begin marketing our product in that country. The approval procedure varies from country to country and can involve additional testing. The time required may differ from that required for FDA approval. Although there are some procedures for unified filings for certain European countries, in general each country has its own procedures and requirements, many of which are time-consuming and expensive. Thus, there can be substantial delays in obtaining required approvals from both the FDA and foreign regulatory authorities after the relevant applications are filed.

After such approvals are obtained, further delays may be encountered before the products become commercially available. If, subsequent to approval, new information becomes available concerning the safety or effectiveness of any approved product, the regulatory authority may require the labeling for the affected product to be revised or the product to be withdrawn. Our manufacturing of any approved drug must conform with the FDA’s good manufacturing practice regulations which govern the production of pharmaceutical products and be subject to inspections and compliance orders.

Government regulation also affects our ability to receive an appropriate level of reimbursement for our products. Throughout the developed world, both public and private health care plans are under considerable financial and political pressure to contain their costs. The two principal methods of restricting expenditures on drugs and diagnostic products and services are to deny coverage or, if coverage is granted, to limit reimbursement. For single-payer government health care systems, a decision to deny coverage or to severely restrict reimbursement for one of our products can have an adverse effect on our business and revenues.

In March 2010, the United States enacted sweeping health care reform legislation, the Patient Protection and Affordable Care Act. Important market reforms have begun and continued through full implementation in 2014. These changes may adversely affect the prices we may charge for any therapeutic drug we develop. The long-term impact of legislative changes in terms of their efficiency, effectiveness and financial viability in delivering health care services to an aging population is uncertain at present. Any legislative or regulatory actions to reduce or contain federal spending under either the Medicare or Medicaid programs could adversely affect our ability to participate in either program as a provider or supplier of services or products and the amount of reimbursement under these programs potentially available to us.

Patents and Proprietary Information

We believe that patent and trade secret protection is important to our business, and that our success will depend, in part, on our ability to obtain strong patents, to maintain trade secret protection and to operate without infringing the proprietary rights of others. The commercial success of products incorporating our technologies may depend, in part, upon our ability to obtain strong patent protection. We cannot assure you that additional patents covering new products or improvements will be issued or that any new or existing patents will be of commercial benefit or be valid and enforceable if challenged.

We pursue a policy of seeking patent protection for valuable patentable subject matter of our proprietary technology and require all employees, consultants and other persons who may have access to its proprietary technology to sign confidentiality agreements.

Nymox has issued patents in the main European markets, including Great Britain, Germany, France, Italy, The Netherlands, Sweden and Spain among others and in other countries such as Japan, Canada and Australia. These patents cover much of our current product development and technologies.

Nymox’s subsidiary, Serex, has patents issued or allowed in the United States and a corresponding patents worldwide. These patents and patent applications cover such areas as Serex’s proprietary diagnostic technologies and methodologies

The Corporation has issued U.S. patents and other countries covering NX-1207 that relate to the composition of the compound, its formulation and its methods of use. The earliest expiry date for these U.S. patents is in 2022. Under current U.S. laws, if NX-1207 is approved for marketing by the FDA, the product is eligible for a patent term extension of up to five years or more depending on the jurisdiction. The Corporation does not license any material patents related to NX-1207 from any third parties.

We also rely upon trade secrets, know-how, and continuing technological advancement to develop and maintain our competitive position. We control the disclosure and use of our know-how and confidential information through agreements with the parties involved. In addition, we have confidentiality agreements with our key employees, consultants, officers and directors. There can be no assurance, however, that all confidentiality agreements will be honored, that others will not independently develop equivalent technology, that disputes will not arise as to the ownership of intellectual property, or that disclosure of our trade secrets will not occur. Furthermore, there can be no assurance that others have not obtained or will not obtain patent protection that will exclude us from using our trade secrets and confidential information. To the extent that consultants or research collaborators use intellectual property owned by others in their work with us, disputes may also arise as to the rights to related or resulting know-how or inventions.

Competition

Rapidly evolving technology and intense competition are the hallmarks of modern pharmaceutical and biotechnology industries. Our competitors include:

	•	Major pharmaceutical, diagnostic, chemical and biotechnology companies, many of which have financial, technical and marketing resources significantly greater than ours;

	•	Biotechnology companies, either alone or in collaborations with large, established pharmaceutical companies to support research, development and commercialization of products that may be competitive with ours; and

	•	Academic institutions, government agencies and other public and private research organizations which are conducting research into Alzheimer’s disease and which increasingly are patenting, licensing and commercializing their products either on their own or through joint ventures.

Our NicAlert™ and TobacAlert™ products face competition from clinical laboratories such as LabCorp and Quest Diagnostics which provide off-site lab testing for cotinine, the by-product of the body’s breakdown of nicotine measured by NicAlert™ and TobacAlert™, and from assay suppliers, including immunoassay developers such as OraSure Technologies Inc. and Abraxis LLC, and diagnostic system manufacturers such as Roche Diagnostics, Abbott and Diagnostic Products Corporation. NicAlert™ and TobacAlert™ also face competition from distributors who supply simple yes-no smoking status tests such as NicQuick, and QuickScreen, from NicCheck™ I, an FDA-cleared smoking status test being marketed by Mossman & Associates Ltd, from SmokeScreen, a chemical color-based tobacco test being marketed by GFC Diagnostics Ltd. in the United Kingdom, and from CO monitors such as SmokeCheck.

Our treatments under development for BPH face significant competition from existing products. There are eight drugs approved for treatment of BPH: five proprietary drugs (tadalofil (Cialis®), dutasteride (Avodart®), tamsulosin (Flomax®), alfusozin (Uroxatral®), and silodosin (Rapaflo®)) a combination of two drugs (dutasteride and tamsulosin) (Jalyn™), and four generics (finasteride, terazozin, doxazozin, and prazosin). There are a number of thermal treatments on the market designed to shrink the enlarged prostate by heating its tissue with a device inserted through the urethra (the tube leading from the bladder through the penis through which men urinate) or through the abdomen. The devices on the market use microwave energy (Prostatron®, Targis Therapy® or TherMatrx®), low level radiowaves (TUNA System®), lasers (Indigo LaserOptic Treatment System® or Laserscope GreenLight PVP™), direct heat or hot water to heat or burn away prostate tissue. A variety of surgical procedures exist to surgically reduce or remove the prostate or to widen the urethra. These include procedures to cut away prostate tissue such as TURP (transurethral resection of the prostate) and using a resectoscope with an electrical loop inserted through the penis to cut the prostate tissue. A small device used to widen the constricted urethra called a prostatic stent can also be inserted. In 2013, the FDA approved the Urolift™ system, a permanent surgical implant designed to pull back prostate tissue to improve urination in men with BPH.

Marketing

At present, we do most of our marketing ourselves. To increase our marketing, distribution and sales, we will need to enter into licensing arrangements, contract sales agreements and co-marketing deals. We cannot assure you that we will be able to enter into agreements with other companies on terms acceptable to us, that any licensing arrangement will generate any revenue for the Corporation or that the costs of engaging and retaining the services of a contract sales organization will not exceed the revenues generated.

If successfully developed and approved, we plan to market and sell our therapeutic and diagnostic products directly or through co-promotion arrangements or other licensing arrangements with third parties. In cases where we have sole or shared marketing rights, we plan to build a small, focused sales force if and when such products approach marketing approval in some markets, including Europe. Implementation of this strategy will depend on many factors, including the market potential of any products we develop as well as on our financial resources. To the extent we will enter into co-promotion or other licensing arrangements, any revenues received by us will be dependent on the efforts of third parties.

Principal Markets

The Corporation markets its products for sale principally in the United States, Canada and overseas. Set forth below is a breakdown of the Corporation’s revenues by geographic market for the last three years.

Revenue by Geographic Market
Year Ended	Canada		United States		Europe & Other		Total
2021	$	-	$	-	$	-	$	-
2020	$	193	$	3,167	$	1,990	$	5,350
2019	$	1,445	$	90,101	$	24,102	$	115,648

Property and Equipment

Nymox Pharmaceutical Corporation leases office and in St. Laurent, Quebec, Canada that comprise of approximately 3,070 square feet of leased space.This space is primarily used to store records including records related to clinical trials. Nymox Corporation and Serex, Inc. facilities in Hasbrouck Heights, New Jersey comprise 4,799 square feet of leased space. A new lease was signed in October 2020 and expires on October 31, 2023. Since July, 2018, Nymox Corporation leased a new office in California that comprised of approximately 2,408 square feet of leased space. A new lease was signed in August 2021 and expires on July 31, 2023.

Nymox Pharmaceutical Corporation and its two US subsidiaries Nymox Corporation and Serex, Inc. own equipment used in research and development work. Nymox believes that its facilities in Quebec and New Jersey are adequate for its current needs and that additional space, if required, would be available on commercially reasonable terms.

ITEM 4A. UNRESOLVED STAFF COMMENTS

None.

ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS

MANAGEMENT’S DISCUSSION AND ANALYSIS

(In US dollars)

This Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the years ended December 31, 2021, 2020 and 2019. This MD&A should be read together with the audited Consolidated Financial Statements and the related notes. This MD&A is dated March 29, 2022. All amounts in this report are in U.S. dollars, unless otherwise noted.

Except as otherwise indicated, all financial information contained in this MD&A and in the Consolidated Financial Statements has been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). The Consolidated Financial Statements and this MD&A were reviewed by the Corporation’s Audit Committee and were approved by our Board of Directors.

Additional information about the Corporation can be obtained on EDGAR at www.sec.gov or on SEDAR at www.sedar.com.

All figures are presented in U.S. dollars, unless otherwise stated.

Overview

We have incurred substantial operating losses since our inception due in large part to expenditures for our research and development activities. Management believes that such operating losses will continue for at least the next few years as a result of expenditures relating to research and development of our potential products.

As of December 31, 2021, we had an accumulated deficit of $193 million. Even our total assets exceeded our total liabilities. However our current level of annual expenditures exceeds the anticipated revenues from sales of goods and may not be covered by additional sources of funds. Management believes that such operating losses will continue for at least the next few years because of expenditures relating to research and development of our potential therapeutic products.

Management believes that current cash balances as at December 31, 2021 and anticipated funds from product sales are not sufficient to fund substantially all its planned business operations and research and development programs over next 12 months. However, if necessary, the Company intends to seek additional equity or other financing, should the Company’s liquidity needs change.

Critical Accounting Policies

The Consolidated Financial Statements of the Corporation have been prepared under International Financial Reporting Standards as issued by the International Accounting Standards Board. The Corporation’s functional and presentation currency is the United States dollar. Our accounting policies are described in the notes to our annual audited consolidated financial statements which are included later in this report.

Operating Results

Results of Operations – 2021 compared to 2020

Net losses were $12,537,622, or $0.15 per share, for the year ended December 31, 2021, compared to $11,737,761, or $0.16 per share, for the year ended December 31, 2020. Net loss includes stock and stock option compensation charges of $2,602,992 in 2021 and $1,747,919 in 2020.

Revenues

Revenues from sales of goods were nil for the year ended December 31, 2021, compared with $5,350 for the year ended December 31, 2020. The development of therapeutic candidates and of moving therapeutic product candidates through clinical trials is a priority for the Corporation currently. The growth of sales will become more of a priority once these candidates have reached the marketing stage. The Corporation expects that revenues will increase if and when product candidates pass clinical trials and are launched on the market.

Research and Development

Research and development expenditures were $6,657,684 for the year ended December 31, 2021, compared with $8,119,818 for the year ended December 31, 2020. Research and development expenditures include costs incurred mainly for advancing Nymox’s BPH and prostate cancer product candidate NX-1207 through clinical trials, as well as demonstrating product efficacy and regulatory compliance prior to launch. Research and development expenditures also include stock and stock option compensation charges of $478,884 for the year ended December 31, 2021 and $1,046,034 for the year ended December 31, 2020. For the year ended December 31, 2021, a decrease of $1,241,069 in clinical lab expenditures and a decrease of $567,150 in stock and stock option compensation charges offset with an increase of $398,473 in professional fees contribute to the decrease of expenses compared to the same period in 2020.

The Corporation expects that research and development expenditures will decrease more as a result of the Corporation’s U.S. BPH trial activity reduction, pending the evaluation of the data. Because of the early stage of development and the uncertainty related to the Corporation’s R&D projects, it is impossible to outline the nature, timing or estimated costs of the efforts necessary to complete these projects, nor the anticipated completion dates for these projects. The facts and circumstances indicating the uncertainties that preclude us from making a reasonable estimate of the costs and timing necessary to complete projects include the risks inherent in any field trials, the uncertainty as to the nature and extent of regulatory requirements both for safety and efficacy, and the ability to manufacture the products in accordance with current good manufacturing requirements (cGMP) and in sufficient quantities both for large scale trials and for commercial use as further described in the section entitled “Risk Factors”. A drug candidate that shows efficacy can take a long period (7 years or more) to achieve regulatory approval. There is also uncertainty whether we will be able to successfully adapt our patented technologies or whether any new products we develop will pass proof-of-principle testing both in the laboratory and in clinical trials, and whether we will be able to manufacture such products at a commercially competitive price. In addition, given the very high costs of development of therapeutic products, we anticipate having to partner with larger pharmaceutical companies to bring therapeutic products to market. The terms of such partnership arrangements along with our related financial obligations cannot be determined at this time and the timing of completion of the approval of such products will likely not be within our sole control.

Marketing Expenses

Marketing expenditures were nil for the year ended December 31, 2021 and 2020 respectively. The Corporation expects that marketing expenditures will increase if and when new products are launched on the market.

General and Administrative Expenses

General and administrative expenses were $5,846,564 for the year ended December 31, 2021, compared with $3,600,901 for the year ended December 31, 2020. General and administrative expenditures also include stock compensation charges of $2,124,108 for the year ended December 31, 2021 and $701,885 in the comparative period in 2020. The increase of $2,245,663 in expenses for the year ended December 31, 2021 is primarily due to an increase of $1,422,223 in employee stock compensation and an increase of $776,053 in director and employees compensation compared to the same period in 2020. The Corporation expects that general and administrative expenditures will increase if and when product development leads to expanded operations.

Finance Costs

Finance costs was $33,374 for the year ended December 31, 2021, compared with finance costs of $18,438 for the year ended December 31, 2020. The finance costs increase of $14,936 for the year ended December 31, 2021 is mainly due to a decrease of $17,690 in interest income.

The Corporation incurs expenses in the local currency of the countries in which it operates, which include the United States, Canada and the Bahamas. Foreign exchange fluctuations had no meaningful impact on the Corporation’s results in 2021 or 2020.

Inflation

The Corporation does not believe that inflation has had a significant impact on its results of operations.

Results of Operations – 2020 compared to 2019

Net losses were $11,737,761, or $0.16 per share, for the year ended December 31, 2020, compared to $13,161,976, or $0.19 per share, for the year ended December 31, 2019. Net loss includes stock and stock option compensation charges of $1,747,919 in 2020 and $3,011,324 in 2019.

Revenues

Revenues from sales of goods amounted to $5,350 for the year ended December 31, 2020, compared with $115,648 for the year ended December 31, 2019. The development of therapeutic candidates and of moving therapeutic product candidates through clinical trials is a priority for the Corporation currently. The growth of sales will become more of a priority once these candidates have reached the marketing stage. The Corporation expects that revenues will increase if and when product candidates pass clinical trials and are launched on the market.

Research and Development

Research and development expenditures were $8,119,818 for the year ended December 31, 2020, compared with $7,376,827 for the year ended December 31, 2019. Research and development expenditures include costs incurred mainly for advancing Nymox’s BPH and prostate cancer product candidate NX-1207 through clinical trials, as well as demonstrating product efficacy and regulatory compliance prior to launch. Research and development expenditures also include stock and stock option compensation charges of $1,046,034 for the year ended December 31, 2020 and $1,172,036 for the year ended December 31, 2019. For the year ended December 31, 2020, an increase of $999,029 in clinical lab expenditures offset with a decrease of $87,918 in professional fees and a decrease of $126,002 in stock and stock option compensation charges contribute to the increase of expenses compared to the same period in 2019.

The Corporation expects that research and development expenditures will decrease as a result of the Corporation’s U.S. BPH trial activity reduction, pending the evaluation of the data. Because of the early stage of development and the uncertainty related to the Corporation’s R&D projects, it is impossible to outline the nature, timing or estimated costs of the efforts necessary to complete these projects, nor the anticipated completion dates for these projects. The facts and circumstances indicating the uncertainties that preclude us from making a reasonable estimate of the costs and timing necessary to complete projects include the risks inherent in any field trials, the uncertainty as to the nature and extent of regulatory requirements both for safety and efficacy, and the ability to manufacture the products in accordance with current good manufacturing requirements (cGMP) and in sufficient quantities both for large scale trials and for commercial use as further described in the section entitled “Risk Factors”. A drug candidate that shows efficacy can take a long period (7 years or more) to achieve regulatory approval. There is also uncertainty whether we will be able to successfully adapt our patented technologies or whether any new products we develop will pass proof-of-principle testing both in the laboratory and in clinical trials, and whether we will be able to manufacture such products at a commercially competitive price. In addition, given the very high costs of development of therapeutic products, we anticipate having to partner with larger pharmaceutical companies to bring therapeutic products to market. The terms of such partnership arrangements along with our related financial obligations cannot be determined at this time and the timing of completion of the approval of such products will likely not be within our sole control.

Marketing Expenses

Marketing expenditures were nil for the year ended December 31, 2020 and 2019 respectively. The Corporation expects that marketing expenditures will increase if and when new products are launched on the market.

General and Administrative Expenses

General and administrative expenses were $3,600,901 for the year ended December 31, 2020, compared with $6,005,465 for the year ended December 31, 2019. General and administrative expenditures also include stock compensation charges of $701,885 for the year ended December 31, 2020 and $1,839,288 in the comparative period in 2019. The decrease of $2,404,564 in expenses for the year ended December 31, 2020 is primarily due to a decrease of $1,179,410 in various professional fees, and a decrease of $1,137,404 in stock compensation charges compared to the same period in 2019. The Corporation expects that general and administrative expenditures will increase if and when product development leads to expanded operations.

Finance Costs

Finance costs was $18,438 for the year ended December 31, 2020, compared with finance income of $162,943 for the year ended December 31, 2019. The decrease of $181,380 mainly due to a decrease of $177,216 in interest income and an increase of $4,164 in operation lease and financial interest expense.

Liquidity and Capital Resources

Financial Position

Liquidity and Capital Resources

As of December 31, 2021, cash and receivables totaled $843,000 compared with $3,631,000 and $5,257,000 at December 31, 2020 and 2019, respectively. Our operating expenses of demonstrating product efficacy and regulatory compliance prior to launch have continued during the period of year 2021.

Cash and cash equivalents amounted to $830,000, $3,611,000 and $5,239,000 as of December 31, 2021, 2020 and 2019, respectively.

We used cash in our operating activities in the amounts of $10 million, $10 million and $7 million for the years ended December 31, 2021, 2020 and 2019, respectively.

Investing activities have been insignificant and substantially all cash flows have been provided by financing activities, specifically proceeds from the issuance of common stock.

A detailed analysis of our capital activities for the years ended December 31, 2021, 2020 and 2019 is included in the footnotes to the financial statements.

Capital disclosures

The Corporation’s objective in managing capital is to ensure a sufficient liquidity position to finance its research and development activities, general and administrative expenses, working capital and overall capital expenditures, including those associated with patents. The Corporation makes every attempt to manage its liquidity to minimize shareholder dilution when possible.

The Corporation defines capital as total equity. To fund its activities, the Corporation has followed an approach that relied almost exclusively on the issuance of common shares. Since inception, the Corporation has financed its liquidity needs primarily through private placements and, In February 2016, the Corporation filed a prospectus supplement and accompanying prospectus related to the potential issuance and sale of up to $12,000,000 of our common stock, no par value per share, from time to time through our sales agent, Chardan Capital Markets, LLC, or Chardan. These sales have been made under an equity distribution agreement, dated February 5, 2016, between the Corporation and Chardan, which we refer to as the equity distribution agreement.

During the second quarter of the year ended at December 31, 2021, the Corporation raised a total of $8,000,000 in share capital before various fee charges which totaled $681,652 and issued 3,669,724 common shares and 2,018,348 warrants to purchase up shares of common stock at an exercise price of $2.50 per share through one private placement.

Contractual Obligations

We have contractual obligations under short-term lease commitments for our premises in New Jersey (United States) of $11,632 per month until October 2023. Effective from August 2021, we renewed a long-term lease commitment for our premises in California (United States) of $7,874 per month until July 2022 and of $8,187 per month until July 2023. Our contractual obligations are summarized in the table below.

	Payments Due by Period
Contractual Obligations	Total		Less than 1 year		1-3 Years		4-5 years
Operating lease and rent for office space and equipment	$	410,825	$	237,190	$	173,635	$	-
Insurance premium installments		233,475		233,475
Total Contractual Obligations other than accounts payable and accrued liabilities	$	644,300	$	470,665	$	173,635	$	-

Off-Balance Sheet Arrangements

The Corporation has no binding commitments for the purchase of property, equipment or intellectual property. The Corporation has no commitments that are not reflected in the statement of financial position except for insurance premium installments.

ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

Directors and Senior Management

Paul Averback, M.D., D.A.B.P., 71, President and Director since September 1995 and Chairman since June of 2001, is the founder of Nymox and the inventor of much of its initial technology. Prior to founding Nymox, Dr. Averback served as President of Nymox’s predecessor, DMS Pharmaceuticals Inc. He received his M.D. in 1975 and taught pathology at universities, including Cambridge University, England (1977-1980), during which time he initiated his research on Alzheimer’s disease. He has practiced medicine in numerous institutions as well as in private practice. Dr. Averback has published extensively in the scientific and medical literature.

Randall Lanham, Esquire, 57, has been a director since June 8, 2006. He attained his Juris Doctor from Whittier College School of Law in 1991 and a Bachelor of Science degree from the University of Delaware in 1987. Mr. Lanham has vast experience in both domestic and international corporate legal matters. Currently Mr. Lanham manages his own law office in California specializing in corporate mergers and acquisitions. In addition, Mr. Lanham has a broad base of entrepreneurial experience and currently owns and operates several small entertainment companies.

Professor David Morse, Ph.D., 65, has been a director since June 8, 2006. He is a world expert in the biochemistry, proteomics and genomics of cell function particularly as it relates to circadian regulation in single cell organisms. He received a Ph.D. from McGill University in 1984, completed a post-doctoral fellowship at Harvard University in 1989 and has been a Full Professor at the University of Montreal since 2001. He has published extensively in the peer-reviewed scientific literature, including papers in journals such as Science, Cell, Proceedings of the National Academy of Science, Journal of Biological Chemistry, and Nature. Dr. Morse has previously collaborated with Nymox scientists in research and development projects.

Mr. James G. Robinson, 86, CEO of Morgan Creek Productions, which for over 25 years has continued to be one of the leading and most successful independent production entities in the film business. Under Robinson’s leadership, Morgan Creek has produced an assortment of highly successful and critically acclaimed feature films.

Mr.Richard Cutler, Esq. 64, is a graduate of Brigham Young University and Columbia University School of Law. Mr. Cutler has worked at several major national law firms, and in 1996, formed Cutler Law Group in Newport Beach, California and subsequently Augusta, Georgia and Houston, Texas, a firm which specializes in corporate and securities law, as well as international business transactions.

Mr. Erik Danielsen, Chief Financial Officer, 58, is a graduate from University de Fribourg with a Master’s in Business Law and Corporate Finance. Mr. Danielsen a former Senior Auditor for Price Waterhouse and has extensive experience in international business. Mr. Danielsen is a former Credit Suisse Equity Strategist.

Compensation

Named Executive Officers

The Summary Compensation Table and Outstanding Incentive Plan Awards tables below for Named Executive Officers summarize the total compensation paid during the Corporation’s financial year ended on December 31, 2021 to the Named Executive Officers of the Corporation and all incentive plan awards outstanding at December 31, 2021 for the Named Executive Officers. The Named Executive Officers are the Corporation’s Chief Executive Officer, Chief Financial Officer, and two most highly compensated executive officers.

On July 17, 2015, the Corporation approved the long-term employment agreement of Dr. Paul Averback as President and Chief Executive Officer. Dr. Averback has not taken a salary since November of 2014. The employment agreement retains the services of Dr. Averback for an initial period of seven years. Dr Averback has agreed to forgo his salary until the Company receives a significant increase in its financing to expand its operations and execute its business plans.. Dr. Averback received 3,000,000 restricted shares on July, 2015 and shall receive 250,000 restricted stock each month for the duration of the contract, totaling up to 21,000,000 restricted shares, in lieu of cash salary. The Corporation determined that a grant date for all of the restricted shares occurred on July 17, 2015 and established the fair value of each share at $1.36. The Corporation is recording the expense on a pro-rata basis and recorded an expense of $11.4 million in fiscal 2015. The unrecognized compensation cost as of December 31, 2021, which will be recognized on a pro-rata basis over the duration of the employment contract as services are performed assuming Dr. Averback continued to elect equity compensation is $0.09 million. On May 14, 2015, the CEO was also granted 5,025,000 options. Dr Aveback received 750 thousand cash compensation during the year ended at December 31,2021 after successfully raised 8M fund before deducting fees and other estimated offering expense through one private placement in April,2021.

Erik Danielsen, the Chief Financial Officer received option grant totaling 450,000 options. Randall Lanham, Secretary received total 300,000 in options; James G. Robinson received 160,000; Richard Cutler received 70,000 and, David Morse received 185,000; On July 27, 2017, the Chief Financial Officer and Secretary received 200,000 and 50,000 shares as stock compensation as share-based awards respectively. During the year ended at December 31, 2021, Randall Lanham received total 900,000 shares as stock compensation. The Corporation does not have a share-based incentive plan, other than its stock option plan as described below, non-equity incentive plan or pension plan for its executive officers. The Corporation has not made any agreements or arrangements with any of its executive officers in connection with any termination or change of employment or change of control of the Corporation.

Compensation Discussion and Analysis

The Human Resources and Compensation Committee of the Board of Directors oversees the compensation of executive officers of the Corporation. The members of the Human Resources and Compensation Committee for the financial year ended December 31, 2021 were James G. Robinson, Dr. David Morse and Richard Cutler, Esq.

The Corporation’s current compensation policy for its executive officers, including the Chief Executive Officer and the Named Executive Officers, emphasizes the granting of options over base salary as a means of attracting, motivating and retaining talented individuals. Such a policy is believed to better further the Corporation’s business goals by allocating more financial resources to the Corporation’s ongoing product development programs. Given the current stage of the Corporation’s development, the Corporation has not established and does not use formal benchmarks, performance goals, review processes or other qualitative or quantitative criteria or targets relating to the performance of the Corporation or the individual in order to determine compensation. The Corporation does not have a non-equity incentive plan or a policy of annually granting performance bonuses or salary increases to its executive officers. However from time to time, the Corporation rewards one time compensation to its executive officers for their service.

The Corporation grants option-based awards to its executive officers in accordance with a stock option plan approved by the shareholders. Further details of the stock option plan are provided below. The stock option plan provides long-term incentives to the Corporation’s officers and employees to advance the Corporation’s product development programs towards commercialization and to enhance shareholder value. The Corporation endeavors to provide salaries and option grants that are internally equitable and that are consistent with both job performance and ongoing progress towards corporate goals. The amount of option grants is determined in part by the amount and terms of outstanding and expiring options, the experience and expertise of each executive officer and the needs of the Corporation, among other factors. The Human Resources and Compensation Committee of the Board of Directors reviews all proposals for awards of stock options to executive officers and decides on the appropriateness of the awards. In doing so, the Committee relies solely on discussion among the independent board members on the Committee without any formal pre-determined objectives, criteria or analytic processes but with a view to attracting and retaining executive officers who can help further the Corporation’s business plan.

By relying on option grants as a primary means of compensating its executive officers, the Corporation’s intention is to provide a direct link between corporate performance and executive compensation while maximizing shareholder value and controlling cash expenditures.

Directors

The Summary Compensation Table and Outstanding Incentive Plan Awards tables below for the directors of the Corporation summarize the total compensation paid during the Corporation’s financial year ended on December 31, 2021 to the directors of the Corporation and all incentive plan awards outstanding at December 31, 2021 for the directors. One current director, Dr. Paul Averback, the President and CEO of the Corporation, is member of the senior management of the Corporation and does not receive any compensation for acting as a director until April, 2021. His compensation as Named Executive Officer is summarized in the summary tables for compensation and incentive plans for Named Executive Officers below.

Summary Compensation Table: Named Executive Officers

								Non-equity incentive plan compensation
Name and principal position	Year	Salary US$		Share based awards		Option- based awards (#)		Annual incentive plans		Long-term incentive		Pension value		All Other		Total US$
Dr. Paul Averback CEO and President	2021		-		657,838				-				-		750,000	$	1,407,830
Erik Danielsen CFO¹	2021		-						-				-		580,000	$	580,000
Randall Lanham General Counsel²	2021		-		1,569,000		-		-		-		-		435,289	$	2,004,289

_______________

¹Erik Danielsen became an Executive Officer on June 1, 2015. Mr. Danielsen receives no compensation as an individual and receives no deferred or incentive compensation. All other amounts are service fee paid to a corporation which is a separate legal entity controlled by Mr. Danielsen.

²Randall Lanham became an Executive Officer on June 1, 2015. Mr. Lanham receives no compensation as an individual and receives no deferred or incentive compensation. All other amounts are paid to a corporation which is a separate legal entity controlled by Mr. Lanham.

³Dr Averback received 750,000 compensation during the year ended at December 31, 2021. Also under the employment agreement, he receives restricted stock on a monthly basis. Refer to note 13 of Consolidated Financial Statements.

Outstanding Incentive Plan Awards as of December 31, 2021: Named Executive Officers

	Option-based Awards
	Number of securities									Value of
	Underlying Unexercised Options						Option Exercise		Option Expiration	Unexercised In-the-money
Name	Total		Unvested		Vested		price		Date	Options
Dr. Paul Averback		5,025,000		-		5,025,000	$	1.74	05/14/2025	$	-
Erik Danielsen		200,000		-		200,000	$	1.74	05/14/2025	$	-
Erik Danielsen		50,000		-		50,000	$	2.93	01/10/2027	$	-
Erik Danielsen		200,000		-		200,000		2.08	04/01/2029	$	-
Randall Lanham		200,000		-		200,000	$	1.74	05/14/2025	$	-
Randall Lanham		100,000		-		100,000		2.08	04/01/2029	$	-
Total		5,775,000		-		5,775,000				$	-

Option exercise prices and the values of unexercised in-the-money options are expressed in US$. From time to time the Corporation issue reward shares to directors for their service.

Summary Compensation Table: Directors

The following is a summary of independent director compensation for the year ended December 31, 2021:

Name	Fees Earned		Share-basedawards		Option-based awards (#)		Non-equity incentive plan compensation		Pension value		All other compensation		Total ($)
David Morse	$	-	$	-		40,000	$	-	$	-	$	-	$	64,403
James Robinson	$	-	$	-		40,000	$	-	$	-	$	-	$	64,403
Richard Cutler	$	-	$	-		40,000	$	-	$	-	$	-	$	64,403

Outstanding Incentive Plan Awards as of December 31, 2021: Directors and Officers

	Option-based Awards
	Number of securities underlying unexercised options						Option exercise		Option expiration date	Value of unexercised in-the-money
Name	Total		Unvested		Vested		price		(mm/dd/yy)	options
David Morse		125,000		-		125,000	$	1.74	05/14/2025	$	-
David Morse		20,000		-		20,000	$	2.08	04/01/2029	$	-
David Morse		30,000		-		30,000		1.75	05/11/2031	$	-
David Morse		10,000		-		10,000		1.83	11/03/2031		-
Richard Cutler		10,000		-		10,000	$	1.74	05/14/2025	$	-
Richard Cutler		20,000		-		20,000	$	2.08	04/01/2029	$	-
Richard Cutler		30,000		-		30,000		1.75	05/11/2031	$	-
Richard Cutler		10,000		-		10,000		1.83	11/03/2031		-
James G. Robinson		100,000		-		100,000	$	1.74	05/14/2025	$	-
James G. Robinson		20,000		-		20,000	$	2.08	04/01/2029	$	-
James G. Robinson		30,000		-		30,000		1.75	05/11/2031	$	-
James G. Robinson		10,000		-		10,000		1.83	11/03/2031		-
Dr. Russel Thomson		200,000		-		120,833	$	2.86	12/31/2029	$	-
		-		-						$	-
Total		615,000		-		535,833				$	-

The options may be exercised until the expiration of the option or the date that is 90 days following the termination date, whichever occurs first.

Outstanding Incentive Plan Awards as of December 31, 2021: Employees

	Option-based Awards
	Number of securities underlying unexercised options						Option exercise		Option expiration date	Value of unexercised in-the-money
Name	Total		Unvested		Vested		price		(mm/dd/yy)	options
Lin Dodd		10,000		-		10,000	$	3.43	07/16/2022	$	-
Anthony Bailey		10,000		-		10,000	$	3.43	07/23/2022	$	-
Shaira Mendoza		10,000		-		10,000	$	2.35	01/01/2024	$	-
Total		30,000		-		30,000				$	-

The options may be exercised any time after six months vest period until the expiration date of the option.

Share Ownership

As of March 30, 2022, the number of shares beneficially owned or controlled by directors and senior officers of the Corporation were as follows:

Name	Shares Beneficially Owned and controlled		Percentage of shares Beneficially Owned and Controlled
Paul Averback, M.D. (1)		37,925,979		36.0	%
Paul Averback, M.D., Trustee (2)		607,031		0.6	%
James G. Robinson (3)		6,013,580		5.7	%
David Morse, Ph.D.(4)		185,396		-
Richard Culter (5)		70,000		-
Erik Danielson (6)		1,632,500		1.6	%
Randall Lanham (7)		1,125,000		1.1	%
Total		47,559,486		45.2	%

(1)	Represents 32,900,979 shares of common stock and 5,025,000 shares of common stock issuable upon the exercise of options held by Dr.Averback under the Company’s share option plan.

(2)	Represents 607,031 shares of common stock held by Paul Averback, M.D., Trustee.

(3)	Represents 4,702,065 shares of common stock, 160,000 shares of common stock issuable upon the exercise of options held by Mr. Robinson under the Company’s share option plan and 1,151,515 shares of common stock underlying the warrants. Mr. Robinson is a director of the Company.

(4)	Represents 396 shares of common stock and 185,000 shares of common stock issuable upon the exercise of options held by Mr. Morse under the Company’s share option plan.

(5)	Represents 70,000 shares of common stock issuable upon the exercise of options held by Mr. Culter under the Company’s share option plan.

(6)	Represents 1,182,500 shares of common stock and 450,000 shares of common stock issuable upon the exercise of options held by Mr.Danielson under the Company’s share option plan.

(7)	Represents 825,000 shares of common stock and 300,000 shares of common stock issuable upon the exercise of options held by Mr.Lanham under the Company’s share option plan.

Nymox has created a stock option plan for its employees, officers and directors, and for consultants. The board of directors of Nymox administers the stock option plan and authorizes the granting of options in accordance with the terms of the plan. Each option gives the individual granted the option the right to purchase a common share of the Corporation at a fixed price during a specified period of no more than ten years. The board may also make all or a portion of the options granted effective only as of a specific future date or dates. The option price must not be less than the market price of the common shares when the option is granted. The total number of shares under option to any one individual may not exceed fifteen percent of the total number of issued and outstanding common shares of the Corporation. The options may not be assigned, transferred or pledged, and expire within three months of the termination of employment or active office with the Corporation and six months of the death of the individual.

No more than 7,500,000 common shares may be under option at any time and a maximum of 7,500,000 common shares are available to be issued under the stock option plan as the result of the exercise of options. Options that expire or terminate without being exercised become available to be granted again. Material changes to the stock option plan such as the number of shares available to be optioned require shareholder approval, Since the inception of the stock option plan in 1995, 383,400 options have been exercised under the plan and 100,514 shares have been issued as a result of cashless exercises.

Board Practices

Directors are elected at each annual meeting for a term of office until the next annual meeting. Executive officers are appointed by the board of directors and serve at the pleasure of the board.

Nymox does not have written contracts with any of the directors named above. We do not have any pension plans or other type of plans providing retirement or similar benefits for directors, nor any benefits upon termination of service as a director.

Nymox’s Audit Committee consists of three directors appointed by the Board who are independent of management and who are generally knowledgeable in financial and auditing matters. The Chairman of the Audit Committee is Mr. Richard Cutler, Esq.; the other members are James G. Robinson and Dr. David Morse. The primary role of the Audit Committee is to provide independent oversight of the quality and integrity of the accounting, auditing, and reporting practices of Nymox with a particular focus on financial statements and financial reporting to shareholders. The Committee is responsible for the appointment, compensation, and oversight of the public accounting firm engaged to prepare or issue an audit report on our financial statements. It oversees all relationships between Nymox and the auditor, including reviewing on an ongoing basis any non-audit services and special engagements that may impact the objectivity or independence of the auditors. The auditor reports directly to the Audit Committee. The Audit Committee reviews the scope and results of the audit with the independent auditors.

The Audit Committee meets at least four times a year to review with management and the independent auditors the Corporation’s interim and year-end financial condition and results of operations. Its review includes an assessment of the adequacy of the internal accounting, bookkeeping and control procedures of the Corporation. The Audit Committee also has the responsibility for reviewing on an ongoing basis all material transactions between Nymox and its affiliates and other related parties such as officers, directors, other key management personnel, major shareholders and their close family members, affiliated companies or associated enterprises.

The Audit Committee has the power to conduct or authorize investigations into any matters within the Committee’s scope of responsibilities, including the power and authority to retain and determine funding for independent counsel, accountants, or other advisors as it determines necessary to carry out its duties.

The Human Resources and Compensation Committee consists of the independent directors of the Board. The Chairman of the Committee is James G. Robinson; the other members are Mr. Richard Cutler, Esq., and Dr. David Morse. The Committee establishes and reviews overall policy and structure with respect to compensation and employment matters, including the determination of compensation arrangements for directors, executive officers and key employees of the Corporation. The Committee is also responsible for the administration and award of options to purchase shares pursuant to our share option plan.

The Corporate Governance Committee consists of the independent directors of the Board. The Chairman of the Committee is Mr. Randall Lanham, Esq.; the other members are Mr. Richard Cutler, Esq. and Dr. Paul Averback. This Committee has the general mandate of providing an independent and regular review of the management, business and affairs of Nymox, including our corporate governance. This Committee also reviews and approves director nominations to ensure each nominee meets the requisite requirements under applicable corporate and securities laws, rules and regulations and otherwise possesses the skills, judgment and independence appropriate for a director of a public corporation.

Employees

In addition to the employees in its St. Laurent, Hasbrouck Heights and Orange Country offices, Nymox carries out its work with the assistance of an extensive group of research collaborators, out-sourced manufacturing teams, research suppliers, research institutions, service providers and research consultants. To help carrying out its marketing, Nymox has independent medical representatives detailing its products.

In its St. Laurent, Hasbrouck Heights and Orange Country offices, as at December 31, 2021, the Corporation employed three persons in research and development, and one of them also responsible for administration. For the years 2020 and 2019, the Corporation employed three persons in research and development and one of them is also responsible for administration. 9

ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY INFORMATION

Major Shareholders

The following table sets out as of March 30, 2022, the number of shares beneficially owned and controlled by Dr. Paul Averback, the President and CEO of Nymox and a member of the Nymox board of directors, and by all directors and officers as a group.

Name of Shareholder	Number of Shares Beneficially Owned and controlled		Percent of Shares Beneficially Owned and controlled
Dr. Paul Averback (1)		38,533,010		36.6	%
James G. Robinson (2)		6,013,580		5.7	%
All directors and officers as a group(3)		47,559,486		45.2	%

(1)	Represents 33,508,010 shares of common stock and 5,025,000 shares of common stock issuable upon the exercise of options held by Dr.Averback under the Company’s share option plan.

(2)	Represents 4,702,065 shares of common stock, 160,000 shares of common stock issuable upon the exercise of options held by Mr. Robinson under the Company’s share option plan and 1,151,515 shares of common stock underlying the warrants.

(3)	Represents 40,217,971 shares of common stock , 6,190,000 shares of common stock issuable upon the exercise of options and 1,151,515 shares of common stock underlying the warrants held by all directors and officers.

The above shares beneficially owned shareholders have the same voting rights as all other shareholders. The percent of shares held by Dr. Paul Averback is 36.6% as of March 30, 2022.

All shareholders of Nymox stock have the same voting rights. Other than Dr. Paul Averback, Mr. Robinson and the individuals above, Nymox does not know of any other shareholders that beneficially own or hold dispositive power over more than 5% of its shares.

Related Party Transactions

The Corporation’s related party transactions include salaries, benefits and stock-based compensation disclosed above for the years ended December 31, 2021, 2020 and 2019. The Corporation also entered into a long-term employment agreement with its President and Chief Executive Officer. Since 2015, the Corporation also has made payment in the form of contract for service rendered to two individual corporations controlled by two Executive officers respectively. (Note 20)

Dividends

The Corporation has not issued dividends since inception.

Cease Trade Orders, or Bankruptcies

To the knowledge of the Corporation, no director or officer of the Corporation or shareholder of the Corporation holding a sufficient number of securities of the Corporation to affect materially the control of the Corporation is, or has been within the past 10 years, a director or officer of any other Corporation that, while such person was acting in that capacity, was the subject of a cease trade or similar order or an order that denied such Corporation access to any exemptions under Canadian securities legislation for a period of more than 30 consecutive days, or was declared bankrupt or made a voluntary assignment in bankruptcy, made a proposal under any legislation relating to bankruptcy or insolvency or was subject to or instituted any proceedings, arrangement or compromise with creditors or had a receiver, receiver manager or trustee appointed to hold its assets.

Penalties or Sanctions

To the knowledge of the Corporation, no director, officer or control person of the Corporation has been subject to any penalties or sanctions imposed by a court relating to U.S. or Canadian securities legislation or by a U.S. or Canadian securities regulatory authority or has entered into a settlement agreement with a U.S. or Canadian securities authority, nor has any director, officer or control person of the Corporation been subject to any penalties or sanctions imposed by a court or regulatory body that would likely be considered important to a reasonable investor in making an investment decision.

Personal Bankruptcies

To the knowledge of the Corporation, no director, officer or control person of the Corporation, nor any personal holding Corporation of any such person, has within the past 10 years, been declared bankrupt or made a voluntary assignment in bankruptcy, made a proposal under any legislation relating to bankruptcy or insolvency or been subject to or instituted any proceedings, arrangement or compromise with creditors, or had a receiver, receiver manager or trustee appointed to hold the assets of that individual.

Conflicts of Interest

To the knowledge of the Corporation, there are no existing or potential material conflicts of interest between the Corporation, or subsidiary of the Corporation, and any director, officer or control person of the Corporation.

Legal Proceedings

Dismissal of Lawsuit. On November 24, 2014, Roy Sapir, a shareholder of the Corporation, filed a proposed class action suit in the United States District Court, District of New Jersey, against the Corporation and the President and the CEO of the Corporation. On February 10, 2016, the Court dismissed the lawsuit. No provision has been recognized in our financial statements for this legal proceeding.

Legal proceedings were filed before the Superior Court of the District of Montreal bearing Court file number 500-17-093342-163 on or about April 1, 2016 by the Commission des Normes du Travail against Nymox Pharmaceutical Corporation as a result of a collective dismissal of the Company’s former employees. The value of the claim amounts to $147,164.38 (plus interest). The proceedings have been suspended in order to allow time for the parties to begin settlement discussions. Chances of success on the merits cannot be presently assessed given the preliminary stages of the file (examinations on discovery to be scheduled should the suspension be lifted).

ITEM 8. FINANCIAL INFORMATION

NYMOX PHARMACEUTICAL CORPORATION

Consolidated Financial Statements

As of December 31, 2021, 2020 and 2019 and for the years ended December 31, 2021, 2020 and 2019

Financial Statements	Page
Report of Independent Registered Accounting Firm (PCAOB ID: 6706)		35
Consolidated Statements of Comprehensive Income		39
Consolidated Statements of Financial Position		40
Consolidated Statements of Cash Flows		41
Consolidated Statements of Changes in Equity		42
Index to notes forming part of the consolidated financial statements		43

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of Nymox Pharmaceutical Corporation

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of Nymox Pharmaceutical Corporation (the Company) as of December 31, 2019, 2018 and 2017, and the related consolidated statements of comprehensive income, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes (collectively referred to as the financial statements). We also have audited the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2019, 2018 and 2017, and the consolidated results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2019, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control—Integrated Framework (2013) issued by COSO.

Basis for Opinion

The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Form 20-F. Our responsibility is to express an opinion on the Company’s financial statements and an opinion on the Company’s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Emphasis of a Matter

Without qualifying our opinion, we draw attention to Note 1 in the financial statements which indicates that the failure of U.S. phase 3 studies of NX – 1207 materially affects Nymox Pharmaceutical Corporation’s current ability to fund its operations, meet its cash flow requirements, realize its assets and discharge its obligations. These conditions, along with other matters as set forth in Note 1 in the financial statements, indicate the existence of the material uncertainty that casts substantial doubt about Nymox Pharmaceutical Corporation’s ability to continue as a going concern.

/S/ Thayer O’Neal Company, LLC

Thayer O’Neal Company, LLC

We have served as the Company’s auditor since 2015.

Sugar Land, Texas

March 30, 2020

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

Stockholders of Nymox Pharmaceutical Corporation

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated financial positions of Nymox Pharmaceutical Corporation (the Company) as of December 31, 2021 and 2020, and the related consolidated statements of comprehensive loss, changes in equity, and cash flows for each of the years in the two year period ended December 31, 2021, and the related notes (collectively referred to as the financial statements). We also have audited the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2021 and 2020, and the consolidated results of its operations and its cash flows for each of the years in the two year period ended December 31, 2021 and 2020, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control—Integrated Framework (2013) issued by COSO.

Basis for Opinion

The Company’s management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Form 20-F. Our responsibility is to express an opinion on the Company’s financial statements and an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

Our audits of the financial statements included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our audits of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting

Going Concern

Without qualifying our opinion, we draw attention to Note 2 in the financial statements which indicates that the failure of U.S. phase 3 studies of NX – 1207 materially affects Nymox Pharmaceutical Corporation’s current ability to fund its operations, meet its cash flow requirements, realize its assets and discharge its obligations. These conditions, along with other matters as set forth in Note 2 in the financial statements and in critical audit matters below, indicate the existence of the material uncertainty that casts substantial doubt about Nymox Pharmaceutical Corporation’s ability to continue as a going concern.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgements. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.

Going Concern Assessment

As described in Note 2 to the consolidated financial statements and in the going concern paragraph above, the Company prepared its financial statements on a going concern basis, and management has concluded that the Company has not generated significant income to date. For the year ended December 31, 2021, the Company incurred net losses of USD 12.5 million and used the net cash in operating activities of USD 9.8 million. As of December 31, 2021, the accumulated deficit amounted to USD 192.6 million. For the year ended December 31, 2020, the Company incurred net losses of USD 11.7 million and used the net cash in operating activities of USD 10 million. As of December 31, 2020, the accumulated deficit amounted to USD 180 million.

The principal consideration for our determination that performing procedures relating to the Company’s going concern assessment is a critical audit matter is there was significant judgment by management for the going concern assessment, which is dependent upon the Company’s ability to raise capital and generate revenue and profits in the future.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management’s going concern analysis. These procedures also included, among others, testing management’s process for projecting cash flow requirements for the twelve months after the year end, testing the completeness and accuracy of underlying data and assumptions used in the projected cash flow analysis and their disclosure in the consolidated financial statements regarding their going concern.

/S/ TPS Thayer, LLC

TPS Thayer, LLC - PCAOB ID 6706

We have served as the Company’s auditor since 2020.

Sugar Land, Texas

March 30, 2022

NYMOX PHARMACEUTICAL CORPORATION

Consolidated Statements of Operations and Comprehensive Loss

For the Years Ended December 31, 2021, 2020 and 2019

(In Thousands of US dollars Other Than per Share Amounts and Thousands of Shares)

	Notes		2021			2020			2019
Revenues
Sales of goods		4	$	-		$	5		$	116
Total revenue				-			5			116

Cost of goods sold and operating Expenses
Cost of goods sold				-			4			58
Research and development		21		6,658			8,120			7,377
General and administrative		20.22		5,846			3,601			6,006
Total operating expenses				12,504			11,725			13,441

Loss from operations				(12,504	)		(11,720	)		(13,325	)
Other income (expense)
Finance income		17		6			24			201
Finance costs		17		(20	)		(30	)		(18	)
Operating lease interest expense				(19	)		(12	)		(20
Loss before income taxes				(33	)		(18	)		(163	)
Income tax provision (recovery)		14		-			-			-
Net loss			$	(12,537	)	$	(11,738	)	$	(13,162	)
Attributable to:
Net loss attributable to Nymox shareholders				(12,537	)		(11,738	)		(13,162	)
Basic and diluted loss per share		15	$	(0.15	)	$	(0.16	)	$	(0.19	)
Weighted average number of common shares outstanding		15		81,976			73,823			68,845

The accompanying notes are on integral part of these consolidated financial statements.

NYMOX PHARMACEUTICAL CORPORATION

Consolidated Statements of Financial Position

For the Years Ended December 31, 2021, 2020 and 2019

(In Thousands of US Dollars and Thousands of Shares)

	Notes		2021			2020			2019
ASSETS
Current assets
Cash			$	830		$	3,611		$	5,239
Accounts receivable				-			-			4
Other receivables				13			20			14
Inventory				34			34			23
Security deposit				28			28			28
Prepaid expenses and other current assets				132			200			20
Total current assets				1,037			3,893			5,328
Non-current assets
Property and equipment		6		22			28			25
Operating lease right-of-use asset, net				384			422			136
Total assets			$	1,443		$	4,343		$	5,489

LIABILITIES AND EQUITY
Current liabilities
Accounts payable and accrued liabilities		8	$	1,558		$	1,772			1,894
Operating lease liability due within one year		9		228			193			144
Total current liabilities				1,786			1,965			2,038
Long term operating lease liability				163			233			3
Total liabilities				1,949			2,198			2,041
Equity
Share capital – unlimited authorized shares at no par value.85,546, 77,961 and 71,218 shares outstanding at December 31, 2021, 2020 and 2019, respectively		10,12		165,061			151,722			136,554
Share capital subscription receivable		10		(589	)		(589	)		(589	)
Additional paid-in capital		11-13		27,584			31,037			35,770
Accumulated deficit				(192,562	)		(180,025	)		(168,287	)
Total Stockholders’ equity (deficit)				(506	)		2,145			3,448
Commitments and contingencies		9
Subsequent events		28
Total liabilities and stockholders’ equity			$	1,443		$	4,343			5,489

The accompanying notes are on integral part of these consolidated financial statements

NYMOX PHARMACEUTICAL CORPORATION

Consolidated Statements of Cash Flow

For the Years Ended December 31, 2021, 2020 and 2019

(In Thousands of US Dollars)

CASH FLOWS FROM OPERATING ACTIVITIES	Notes		2021			2020			2019
Net loss			$	(12,537	)	$	11,738	)	$	(13,162	)
Adjustments for:
Depreciation		4		12			9			9
Stock-based compensation		12		2,603			1,748			3,011
Issued stock for service fee				-			-			1,330
Amortization and others				242			258			556
Changes in non-cash operating balances:
Accounts receivable and other receivables				7			(1	)		(4	)
Security deposit				-			-			12
Prepaid expense				68			(180	)		(18	)
Inventory				-			(11	)		17
Employee deposit of overpayment				(50	)		50			-
Accounts payable and accrued liabilities				(165	)		(172	)		819
Net cash used in operating activities				(9,820	)		(10,037	)		(7,430	)
CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of property and equipment				(6	)		(13	)		-
Net cash flows used in investing activities				(6	)		(13	)		-
CASH FLOWS FROM (USED IN) FINANCING ACTIVITIES
Proceeds from the issuance of share capital		10		7,283			8,687			5,000
Repayment of operating lease and financing obligation				(238	)		(265	)		(277	)
Net cash provided from financing activities				7,045			8,422			4,723
Net (decrease) increase in cash and cash equivalents				(2,781	)		(1,628	)		(2,707	)
CASH AT BANK
Beginning of year				3,611			5,239			7,946
End of year			$	830		$	3,611		$	5,239
SUPPLEMENTAL DISCLOSURE
Income taxes paid		14	$	-		$	-		$	-
Interest paid			$	-		$	-		$	-
NON-CASH INVESTING AND FINANCING ACTIVITIES
Shares and warrants issued on connection with convertible notes			$	-		$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements

NYMOX PHARMACEUTICAL CORPORATION

Consolidated Statements of Changes in Equity

For the Years Ended December 31, 2021, 2020 and 2019

(In Thousands of US Dollars and Shares)

	Note		Common Shares		Common Amount		Subscriptions			Additional Paid-In Capital			Accumulated Deficit			Total
December 31, 2018				64,676	$	126,684	$	(868	)	$	36,299		$	(155,113	)	$	7,002
Lease adoption prior year cumulative effect														(12	)	$	(12	)

Shares issuance for cash and subscriptions				2,542		4,800		279			-			-			5,079
Warrant issued		12		-		-					200			-			200
Stock-based compensation and service fee		12		4,000		5,070		-			(729	)		-			4,341
Net loss				-		-		-			-			(13,162	)		(13,162	)
Balance, December 31, 2019				71,218	$	136,554	$	(589	)	$	35,770		$	(168,287	)	$	3,448

Shares issuance for cash and subscriptions				3,743		9,388		-			(701	)		-			8,687

Stock-based compensation and service fee		12		3,000		5,780		-			(4,032	)		-			1,748
Net loss				-		-		-			-			(11,738	)		(11,738	)
Balance, December 31, 2020				77,961	$	151,722	$	(589	)	$	31,037		$	(180,025	)	$	2,145
Shares issuance for cash and subscriptions				3,670		7,670		-			(717	)		-			6,953
Warrant issued											330						330
Stock-based compensation and service fee		12		3,915		5,669		-			(3,066	)		-			2,603
Net loss				-		-		-			-			(12,537	)		(12,537	)
Balance, December 31, 2021				85,546	$	165,061	$	(589	)	$	27,584		$	(192,562	)	$	(506	)

The accompanying notes are on integral part of these consolidated financial statements.

NYMOX PHARMACEUTICAL CORPORATION

Notes Forming Part of the Consolidated Financial Statements

For the Years Ended December 31, 2021, 2020 and 2019

Note	Description	Page	Note	Description	Page
1.	Business activities and basis of presentation	44	15.	Earnings per share	60
2.	Going concern considerations	45	16.	Financial instruments fair value disclosures	60
3.	Significant estimates	45	17.	Finance income and finance costs	60
4.	Significant accounting policies	45	18	Segment disclosures	60
5.	New accounting standards and interpretations	51	19	Concentrations	61
6.	Property and equipment	52	20.	Related party transactions	61
7.	Intangible assets	53	21.	Research and development expenses	62
8.	Accounts payable and accrued liabilities	53	22.	Personnel expenses	62
9.	Operating leases and commitments	53	23.	Capital disclosures and financial risk	63
10.	Share capital	55	24.	Foreign exchange risk	63
11.	Stock options	56	25.	Credit risk	63
12.	Share based compensation	57	26.	Interest rate risk	63
13.	Warrants	58	27.	Liquidity risk	64
14.	Incomes taxes	58	28.	Subsequent events	64

Table of Contents

NYMOX PHARMACEUTICAL CORPORATION

Notes to the Financial Statements

December 31, 2021, 2020 and 2019

NOTE 1 – BUSINESS ACTIVITIES AND BASIS OF PRESENTATION

Nymox Pharmaceutical Corporation is a company which re-domiciled from Canada to the Commonwealth of The Bahamas in 2015 and is incorporated under the International Business Companies Act of the Commonwealth of The Bahamas. Nymox Pharmaceutical Corporation including its whole owned subsidiaries, Nymox Corporation, a Delaware Corporation, and Serex Inc. of New Jersey (together referred to as the “Corporation”), is a biopharmaceutical corporation, which specializes in the research and development of products for the aging population. The head office of the Corporation is located at Bay & Deveaux Sts., 2^nd Floor, Nassau, The Bahamas. The Corporation currently markets NicAlert^TMand TobacAlert^TM, tests that use urine or saliva to detect use of tobacco products. Since 1989, the Corporation’s activities and resources have been primarily focused on developing certain pharmaceutical technologies. Since 2002, the Corporation has been developing its novel proprietary drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and, since 2012, for the treatment of low-grade localized prostate cancer. The Corporation also has an extensive patent portfolio covering its marketed products, its investigational drug as well as other therapeutic and diagnostic indications.

Statement of Compliance

The consolidated financial statements of the Corporation have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and its interpretations as issued by the International Accounting Standards Board (“IASB”).

The consolidated financial statements were authorized for issue by the Audit Committee of the Corporation’s Board of Directors on March 30, 2022.

Basis of measurement

The consolidated financial statements have been prepared on a going concern and on the historical cost basis.

Functional and presentation currency

These consolidated financial statements are presented in United States dollars, which is the Corporation and its subsidiaries’ functional currency.

Use of estimates and judgments

The preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses.

Information about critical judgments in applying accounting policies and assumption and estimation uncertainties that have the most significant effect on the amounts recognized in the consolidated financial statements is noted below:

Judgments in applying accounting policies

The use of the going concern basis (Note 2)

Contingent liability

Assessing the recognition of contingent liabilities requires judgment in evaluating whether it is probable that economic benefits will be required to settle matters subject to litigation .

Stock options and warrants

There is estimation uncertainty with respect to selecting inputs to the Binomial pricing model used to determine the fair value of the stock options and warrants (Note 11).

Other areas of judgment and uncertainty relate to deferred tax assets. Reported amounts and note disclosure reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ from those estimates.

The above estimates and assumptions are reviewed regularly. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Table of Contents

NOTE 2 – GOING CONCERN CONSIDERATIONS

The Corporation is subject to a number of risks, including the successful development and marketing of its technologies the ability to raise financing to pursue the development of its operations. The Corporation depends on private placements and other types of financing as well as collaboration agreements, to fund its operations, achieve its business plan and the realization of its assets and liabilities in the normal course of operations.

The failure of the two Phase 3 studies of NX-1207 for BPH materially affects the Corporation’s current ability to fund its operations, meet its cash flow requirements, realize its assets and discharge its obligations.

Management believes that current cash balances as of December 31, 2021 will not be sufficient to finance all of its planned business operations and research and development programs over the next year. However, the Corporation’s primary sources of financing since 2003 has been the Common Stock Private Purchase Agreement If necessary, the Corporation intends to seek additional equity or finance through the existing private placements and/or other sources of capital in order to fund these operations and activities over the next year.

Considering recent developments and the need for additional financing, there exists a material uncertainty that casts substantial doubt about the Corporation’s ability to continue as a going concern. These financial statements do not reflect adjustments that would be necessary if the going concern assumption was not appropriate. If the going concern assumption is not appropriate, then adjustments may be necessary to the carrying value and classification of assets and liabilities and reported results of operations and such adjustments could be material.

NOTE 3 – SIGNIFICANT ESTIMATES

Significant estimates applied in the preparation of these financial statements include the estimated useful lives of property and equipment, share volatility and estimated life of options and warrants in determining their fair value as well as the expected potential for the realization of deferred tax assets in determining the amount of the valuation allowance thereto.

NOTE 4 – SIGNIFICANT ACCOUNTING POLICIES

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

Consolidation

The consolidated financial statements of the Corporation include the accounts of its subsidiaries. Subsidiaries are those entities over which the Group has control. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has:

-	power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee);

-	exposure, or rights, to variable returns from its involvement with the investee; and

-	The ability to use its power over the investee to affect its returns.

Table of Contents

Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date, irrespective of the extent of any non-controlling interest. The excess of the cost of acquisition is recorded as goodwill. If the cost of acquisition is less than fair value of the net assets of the subsidiary acquired, the difference is recognized directly in the consolidated statement of profit or loss.

The assets, liabilities, income and expenses of subsidiary companies are consolidated on a line by line basis and the carrying value of investments held by the Holding Company is eliminated against the subsidiaries’ shareholders’ equity in the consolidated financial statements.

All intra-group transactions, balances, income, expenses and unrealized gains and losses on transactions between Group companies are eliminated in full.

Subsidiaries have same reporting period as that of the Holding Company. The accounting policies of subsidiaries have been same with the holding parent company. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Intercompany balances and transactions have been eliminated on consolidation.

Financial instruments

The Corporation has classified its cash, trade accounts receivable and other receivables as “loans and receivables”, and its trade accounts payable, accrued liabilities, “other financial liabilities”.

The Corporation must classify the fair value measurements of financial instruments according to a three-level hierarchy, based on the type of inputs used in making these measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Financial assets

The Corporation initially recognizes receivables on the date that they are originated. Receivables are financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, loans and receivables are measured at amortized cost using the effective interest method, less any impairment losses.

The Corporation derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Financial assets and liabilities are offset, and the net amount presented in the consolidated statements of financial position when, and only when, the Corporation has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.

Financial liabilities

The Corporation initially recognizes other financial liabilities on the trade date at which the Corporation becomes a party to the contractual provisions of the instrument. Other financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method.

The Corporation derecognizes a financial liability when its contractual obligations are discharged, cancelled or expired. Interest, losses and gains relating to a financial liability are recognized in the statement of operations and comprehensive loss.

IFRS 9 – Financial Instruments (“IFRS 9”) ultimately replaces IAS 39 – Financial Instruments: Recognition and Measurement (“IAS 39”), with the objective of improving and simplifying the reporting for financial instruments.

In July 2014, the IASB issued the final version of IFRS 9, Financial Instruments (IFRS 9). IFRS 9 supersedes IAS 39, IFRIC 9 and earlier versions of IFRS 9. This standard provides guidance on the classification and measurement of financial liabilities and the presentation of gains and losses on financial liabilities designated at fair value through profit and loss. When an entity elects to measure a financial liability at fair value, gains or losses due to changes in the credit risk of the instrument must be recognized in other comprehensive income.

Table of Contents

This standard was effective for annual periods beginning on or after January 1, 2018 with earlier adoption permitted. The Corporation has implemented this standard yet there is no impact of the adoption of this standard on its consolidated financial statements.

Share capital

Common shares are classified as equity. Incremental costs attributable to the issuance of common shares are recognized as an increase to deficit.

Accounts receivable

Accounts receivable consists of trade receivables. Sales allowance for expected credit losses is recorded against trade receivables and is based on historical experience. The company has zero, zero and $4,000 trade receivables as of December 31, 2021, 2020 and 2019, respectively and no sales allowance was recorded during those three years.

Inventory

Inventory consists primarily of finished goods held for sale and materials and are carried at the lower of first-in, first-out cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less selling expenses.

Property and equipment

Property and equipment are measured at cost, less accumulated depreciation and accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. When parts of an item of property and equipment have significantly different useful lives, they are accounted for as separate items (major components) of property and equipment. Gains and losses on disposal of an item of property and equipment are recognized as the difference in the proceeds from disposal and the carrying amount of property and equipment.

The cost of replacing a part of an item of property and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Corporation, and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of property and equipment are recognized in the statement of operations and comprehensive loss.

Depreciation is calculated on the depreciable amount, which is the cost of an asset less its residual value. Depreciation is recognized on a straight-line basis over the estimated useful lives of each component of an item of property and equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset.

The estimated useful lives for the current and comparative periods are represented by the following estimated useful lives:

Asset Classification		Useful life

Laboratory equipment		5 years
Computer equipment		3 years
Office equipment and fixtures		5 years

Depreciation methods, useful lives and residual values are reviewed on an ongoing basis and adjusted if appropriate.

Table of Contents

Research and development expenditures

Expenditures on research activities, net of research tax credits, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, as well as demonstrating product efficacy and regulatory compliance prior to launch, are expensed in the statement of comprehensive earnings (loss) as incurred. Development activities, net of research tax credits, involve a plan or design to produce new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically, and commercially feasible, future economic benefits are probable, and the Corporation intends to and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are recognized in research and development expenses as incurred.

Amortization

Amortization is calculated on the cost of the asset, less its residual value. Amortization methods, useful lives and residual values are reviewed on an ongoing basis and adjusted if appropriate.

Impairment

Indefinite lived intangibles are subject an assessment for impairment at each reporting date.

Financial assets impairment

Financial assets are assessed at each reporting date to determine whether there is objective evidence that they are impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, restructuring of an amount due to the Corporation on terms that the Corporation would not consider otherwise, and indications that a debtor or issuer will enter bankruptcy. In assessing impairment, the Corporation uses historical trends of the probability of default, timing of recoveries and the amount of loss incurred, adjusted for management’s judgment as to whether current economic and credit conditions are such that the actual losses are likely to be greater or less than suggested by historical trends.

An impairment loss in respect of a financial asset measured at amortized cost is calculated and recognized for the amount by which the asset’s carrying amount exceeds the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed.

Non-financial assets impairment

The carrying amounts of the Corporation’s non-financial assets, including property and equipment, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated.

The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the “cash-generating unit, CGU or segment”).

The Corporation’s corporate assets do not generate separate cash inflows. If there is an indication that a corporate asset may be impaired, then the recoverable amount is determined for the CGU to which the corporate asset belongs.

An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses recognized in respect of CGUs are allocated to reduce the carrying amounts of the assets in the CGU on a pro rata basis. Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.

Table of Contents

Revenue recognition

Revenue from product sales is recognized when the product has been delivered and obligations as defined in the agreement are performed. Collaboration agreements that include multiple deliverables are considered to be multiple-element arrangements. Under this type of arrangement, the identification of separate units of accounting is required and revenue is allocated among the separate units based on their relative fair values.

Payments received under a collaboration agreement may include upfront payments, milestone payments, sale of goods, royalties and license fees. Revenue for each unit of accounting is recorded as described below:

Upfront payments

Upfront payments are deferred and recognized as revenue on a systematic basis over the estimated service period. Changes in estimates are recognized prospectively when changes to the expected term are determined.

Milestone payments

Revenue subject to the achievement of milestones is recognized only when the specified events have occurred, and collectability is reasonably assured.

Specifically, the criteria for recognizing milestone payments are that (i) the milestone is substantive in nature, (ii) the achievement was not reasonably assured at the inception of the agreement, and (iii) the Corporation has no further involvement or obligation to perform associated with the achievement of the milestone, as defined in the related collaboration arrangement.

The company does not have any upfront payments, milestone payments or license revenue for the years ended December 31, 2021, 2020 and 2019.

IFRS 15, Revenue from Contracts with Customers

In May 2014, the IASB issued IFRS 15, Revenue from Contracts with Customers, which establishes principles for reporting the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. It provides a single model in order to depict the transfer of promised goods or services to customers.

IFRS 15 supersedes the following standards: IAS 11, Construction Contracts, IAS 18, Revenue, IFRIC 13, Customer Loyalty Programs, IFRIC 15, Agreements for the Construction of Real Estate, IFRIC 18, Transfers of Assets from Customers, and SIC-31, Revenue – Barter Transactions Involving Advertising Service.

The core principle of IFRS 15 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services.

IFRS 15 also includes a cohesive set of disclosure requirements that would result in an entity providing comprehensive information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts with customers.

The Corporation has adopted this standard in these financial statements yet determined that there is no impact on reported results of operations from its implementation.

Sale of goods

Revenue from the sale of goods is recognized when the Corporation has transferred to the buyer the significant risks and rewards of ownership of the goods, there is no continuing management involvement with the goods, and the amount of revenue can be measured reliably.

Foreign currency

Monetary assets and liabilities of the Corporation’s Canadian and US subsidiaries denominated in currencies other than the US dollar are translated at the rates of exchange at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Income and expenses denominated in foreign currencies are translated at the average rate prevailing during the year.

Foreign exchange loss and gain are reported on a net basis, within finance costs or finance income.

Table of Contents

Research tax credits

Until the corporation re-domiciled from Canada to the commonwealth of Bahamas in 2015, it is entitled to scientific research and experimental development tax credits (“research tax credits”) granted by the Canadian federal government and the government of the province of Québec. Federal research tax credits, which are non-refundable, are earned on qualified research and development expenditures and can only be used to offset federal income taxes otherwise payable. Provincial research tax credits, which are refundable, are earned on qualified research and development expenditures incurred in the province of Québec.

These research tax credits are recognized as a reduction of research and development expenditures in the period in which they become receivable, provided that there is reasonable assurance that they will be received.

Stock-based compensation

The grant date fair value of stock-based compensation awards granted to employees, consultants and directors is recognized as an expense, with a corresponding increase in equity, over the period that the employees, consultants or directors unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service at the vesting date.

The fair value of the stock options is measured using the binomial pricing model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historic volatility), weighted average expected life of the instruments (based on historical experience and general option holder behavior), expected dividends, and the risk-free interest rate (based on government bonds). Service conditions attached to the transactions are not taken into account in determining fair value.

Share based payment arrangements in which the Corporation receives goods or services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions.

Employee benefits

Short-term employee benefits obligations are measured on an undiscounted basis and are expensed as the related service is provided.

In addition to their salaries, employees of the Corporation are covered by a benefit package which includes a health plan, dental plan, disability insurance, life insurance and worker compensation insurance coverage. Participation in this plan is paid by the Corporation in full. Any employee that elects to extend the coverage to members of their family must pay the additional premium.

Operating leases

Effective for annual reporting periods beginning on or after January 1, 2019, IFRS 16 introduced a new approach to lessee accounting that requires a lessee to recognize assets and liabilities for the rights and obligations created by leases. IFRS 16 requires a lessee to recognize assets and liabilities for all leases with a term of more than 12 months. The IASB concluded that such an approach will result in a more faithful representation of a lessee’s assets and liabilities and, together with enhanced disclosures, greater transparency of a lessee’s financial leverage and capital employed. We adopted this standard on January 1, 2019, with an immaterial cumulative adjustment of $11,667 to accumulated deficit rather than retrospectively adjusting prior periods.

Income taxes

Income tax expense comprises current and deferred taxes. Current tax and deferred tax are recognized in the statement of operations and comprehensive loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive loss.

Table of Contents

Current tax is the expected tax payable or receivable on the taxable income or loss of the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss and differences relating to investments in subsidiaries to the extent that it is probable that they will not reverse in the foreseeable future. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously.

A deferred tax asset is recognized for unused tax losses and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

Earnings per share

Basic earnings per share are determined using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed in a manner consistent with basic earnings per share, except that the weighted average shares outstanding are increased to include additional shares from the assumed exercise of options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding options were exercised, and that the proceeds from such exercises as well as the assumed proceeds from future services were used to acquire shares of common stock at the average market price during the reporting period.

Provisions

A provision is recognized if, because of a past event, the Corporation has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as finance cost.

Onerous contracts

A provision for onerous contracts is recognized when the expected benefits to be derived by the Corporation from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Corporation recognizes any impairment loss on the assets associated with that contract.

Reclassification

Certain amounts in the consolidated financial statements for the prior years have been reclassified to conform to the current year presentation. These reclassifications had no impact on net earnings, financial position, or cash flows.

NOTE 5 – NEW ACCOUNTING STANDARDS AND INTERPRETATIONS

Standards, amendments and improvements to the approved accounting standards that are not yet effective for CFY’ 2021.

The following standards, amendments and improvements to the approved accounting standards would be effective from the dates mentioned below against the respective standard or interpretation:

Standard or Interpretation		IASB Effective Date (Annual periods beginning on or after)
IFRS 03	Reference to Conceptual Framework (Amendments)	01 January 2022
IFRS 09	Financial Instruments – Fees in the ‘10 percent’ test for derecognition of financial liabilities	01 January 2022
IFRS 10/IAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendment)	Not Yet Finalized
IAS 01	Classification of Liabilities as Current or Non-current liabilities (Amendments)	01 January 2022*
IAS 16	Proceeds before Intended Use (Amendments)	01 January 2022
IAS 37	Onerous Contracts – Costs of Fulfilling a Contract (Amendments)	01 January 2022

*The IASB has issued an exposure draft proposing to defer the effective date of the Amendments to IAS 01 to 01 January 2023.

The above standards and amendments are not expected to have any material impact on the Company’s unconsolidated financial statements in the period of initial application.

Table of Contents

NOTE 6 – PROPERTY AND EQUIPMENT

The carrying value of property and equipment included the following changes for the years ended December 31, 2021, 2020 and 2019:

In Thousands of US Dollars
	Laboratory Equipment		Computer Equipment		Office Equipment		Total
Cost
Balance at January 1, 2019	$	418	$	43	$	113	$	574
Additions		–		–		–		–
Disposals		–		–		–		–
Balance at December 31, 2019		418	$	43	$	113	$	574
Additions		–		13		–		13
Disposals		–		–		–		–
Balance at December 31, 2020		418	$	56	$	113	$	587
Additions		–		3		3		6
Disposals		–		–		–		–
Balance at December 31, 2021	$	418	$	59	$	116	$	593

Accumulated depreciation
Balance at January1, 2019		418		33		90	$	541
Depreciation for the year		–		4		5		9
Disposals		–		–		–		–
Balance at December 31, 2019	$	418	$	37	$	95	$	550
Depreciation for the year		–		4		5		9
Disposals		–		–		–		–
Balance at December 31, 2020		418	$	41	$	100	$	559
Depreciation for the year		–		7		5		12
Disposals		–		–		–		–
Balance at December 31, 2021	$	418	$	48	$	105	$	571
Carrying amounts
At December 31, 2019	$	-	$	6	$	19	$	25
At December 31, 2020	$	-	$	15	$	13	$	28
At December 31, 2021	$	-	$	11	$	11	$	22

The depreciation expense of property and equipment amounts to $12,357, $9,236 and $8,684 for the years ended December 31, 2021, 2020 and 2019, respectively. .

Table of Contents

NOTE 7 – INTANGIBLE ASSETS

Intangible assets include patents and acquired intellectual property rights. The patent and intellectual property rights, having a cost of $2,222,661 and an accumulated amortization of $2,222,661 at December 31, 2021, 2020 and 2019, are still property of the Corporation. The patent and intellectual rights were fully amortized by year 2009.

NOTE 8 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities as of December 31, 2021, 2020 and 2019, consisted of the following:

In Thousands of US Dollars
Description	2021		2020		2019
Accounts payable	$	1,273	$	1,403	$	1,629
Accrued liabilities:
Payroll related liabilities		262		245		225
Other accrued liabilities		23		74		40
Deposit		-		50		-
Total accounts payable and accrued liabilities	$	1,558	$	1,772	$	1,894

NOTE 9 – OPERATING LEASES AND COMMITMENTS

We adopted this standard on January 1, 2019, with an immaterial cumulative adjustment of $11,667 to accumulated deficit rather than retrospectively adjusting prior periods. This adoption approach resulted in a balance sheet presentation that is not comparable to the prior period.

We used an incremental borrowing rate as a discount rate for our operating leases. The discount rate ranges from 4.75% to 5.00% and the average remaining years for our lease are 1.71 years as of December 31, 2021.

In August 2021, the Corporation renewed its operating lease agreements for its US (California) premises, which is effective from August 1, 2021 and will expire on July 31, 2023. This new lease results in the recognition of operating lease assets and liabilities of approximately $184,000 as of August 1,2021.

Table of Contents

The following table provides the changes in the Corporation’s operating lease right-of-use assets for the year ended December 31, 2021, 2020 and 2019 respectively:

In Thousands of US Dollars
	Operation lease right-of-use asset
Balances as of January 1, 2021	$	422
Renewed office lease		184
Accumulated amortization		(222	)
Balances as of December 31, 2021	$	384

In Thousands of US Dollars
	Operation lease right-of-use asset
Balances as of January 1, 2020	$	136
Renewed office lease		533
Accumulated amortization		(247	)
Balances as of December 31, 2020	$	422

In Thousands of US Dollars
	Operation lease right-of-use asset
Balances as of January 1, 2019	$	393
Accumulated amortization		(247	)
Other		(4	)
Balances as of December 31, 2019	$	136

Table of Contents

The following table provides the changes in the Corporation’s operating lease liability for the year ended December 31, 2021, 2020 and 2019 respectively:

In Thousands of US Dollars
	Total
Balances as of January 1, 2021	$	426
Renewed office lease		184
Repayments of lease liability		(238	)
Other		19
Balances as of December 31, 2021	$	391
Lease liability due within one year	$	228
Lease liability long term	$	163

The total future commitment payment amount for above lease is $409,279 compared to an outstanding lease liability of $391,459 as of December 31, 2021. The difference is due to borrowing rate discount.

In Thousands of US Dollars
	Total
Balances as of January 1, 2020	$	147
Renewed office lease		533
Repayments of lease liability		(265	)
Other		11
Balances as of December 31, 2020	$	426
Lease liability due within one year	$	193
Lease liability long term	$	233

The total future commitment payment amount for above lease is $454,092 compared to an outstanding lease liability of $425,620 as of December 31, 2020. The difference is due to borrowing rate discount.

In Thousands of US Dollars
	Total
Balances as of January 1, 2019	$	405
Repayments of lease liability		(277	)
Other		19
Balances as of December 31, 2019	$	147
Lease liability due within one year	$	144
Lease liability long term	$	3

The total future commitment payment amount for above lease is $151,805 compared to an outstanding lease liability of $147,036 as of December 31, 2019. The difference is due to borrowing rate discount.

NOTE 10 – SHARE CAPITAL

Common shares authorized, issued and related contributed capital by controlling shareholders as of December 31, 2021, 2020 and 2019 were as follows

In Thousands of US Dollars and shares
Description	2021		2020		2019
Authorized:
An unlimited number of common shares, at no par value
Issued, outstanding:
Number of common shares		85,546		77,961		71,218
Dollars	$	165,061	$	151,722	$	136,554

The holders of common shares are entitled to receive dividends as declared, which is at the discretion of the Corporation, and are entitled to one vote per share at the annual general meeting of the Corporation. The Corporation has never paid any dividends.

Table of Contents

Common Stock

In February 2016, the Corporation filed a prospectus supplement and accompanying prospectus related to the potential issuance and sale of up to $12,000,000 of our common stock, no par value per share, from time to time through our sales agent, Chardan Capital Markets, LLC, or Chardan. These sales have been made under an equity distribution agreement, dated February 5, 2016, between the Corporation and Chardan, which we refer to as the equity distribution agreement.

Sales of our common stock under this prospectus supplement and the accompanying prospectus are made by any method permitted by law deemed to be an “at-the-market” offering as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Capital Market, on any other existing trading market for our common. If expressly authorized by us, Chardan may also sell our common stock in privately negotiated transactions. Chardan acts as sales agent on a commercially reasonable efforts basis, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of NASDAQ. There is no specific date on which the offering will end, there are no minimum sale requirements and there are no arrangements to place any of the proceeds of this offering in an escrow, trust or similar account.

On April 28, 2021, the company announced it has entered into a definitive agreement with institutional investors in a private placement of 3,669,724 shares of common stock and warrants to purchase 1,834,862 shares of common stock at a combined purchase price of $2.18 per share for gross proceeds of approximately $8,000,000 before deducting fees and other estimated offering expenses. The warrants will have an exercise price of $2.50 per share, will be immediately exercisable and will expire five years from the date of issuance. A.G.P./Alliance Global Partners is acting as sole placement agent for the private placement.

The private placement was completed on April 30, 2021, and the company raised $7,318,348.46 after deducting fees and other offering expense. In addition, the Company agreed to issue A.G.P. or its assigns warrants to purchase up to 183,486 shares of common stock at an exercise price of $2.50 per share. The Placement Agent Warrants will be immediately exercisable and will expire on the five-year anniversary of the date of offer and are subject to customary anti-dilution provisions.

NOTE 11 – STOCK OPTIONS

The Corporation has established a stock option plan (the “Plan”) for its key employees, officers and directors, and certain consultants. The Plan is administered by the Board of Directors of the Corporation. The Board may from time to time designate individuals to whom options to purchase common shares of the Corporation may be granted, the number of shares to be optioned to each, and the option price per share. The option price per share cannot involve a discount to the market price at the time the option is granted. The maximum number of shares which may be optioned under the stock option plan is 15,000,000. The maximum number of shares which may be optioned to any one individual is 15% of the total issued and outstanding common shares. Options under the Plan expire up to ten years after the grant date and vest either immediately or over periods up to six years and are equity-settled. As of December 31, 2021, 1,072,000 options could still be granted by the Corporation.

The following table provides the activity of stock option awards for the years ended December 31, 2021, 2020 and 2019 and for options outstanding and exercisable as of December 31, 2021, the weighted average exercise price, and the weighted average remaining contractual life.

	Options outstanding
	Number			Weighted average exercise price		Weighted average remaining contractual life (in years)
Outstanding January 1, 2019		5,740,000		$	1.76		6.37
Expired		(10,000	)		3.43		-
Granted		360,000			2.08		9.26
Outstanding December 31, 2019		6,090,000		$	1.78		5.61
Expired		-			-		-
Granted		410,000			2.34		8.94
Outstanding December 31, 2020		6,500,000		$	1.81		4.87
Expired		(200,000	)		1.81		-
Not vested
Granted		128,000			1.77		9.48
Outstanding December 31, 2021		6,428,000		$	1.81		3.86
Options exercisable		6,348,833		$	1.80		3.80

Table of Contents

The fair value of the options granted during the years ended December 31, 2021, 2020 and 2019, was determined using the Binomial Option pricing model using the following weighted average assumptions:

Description	2021			2020			2019
Share price	$	1.75~1.83		$	1.81~2.86			$	2.08
Exercise price	$	1.75~1.83		$	1.81~2.86			$	2.08
Risk-free interest rate		1.60%~1.64	%		1.12%~1.67	%			2.48	%
Expected volatility		107.05%~107.47	%		81.34%~106.56	%			105.36	%
Expected option life in years		10.	Yrs		4~10	Yrs			10	Yrs
Expected dividend yield		-			-				-

The weighted average grant-date fair value of options granted during the year ended December 31, 2021, and 2020 was $ 1.68 and 2.09 per option respectively. Expected volatility was estimated considering historic average share price volatility. Expected dividends were determined to be nil, since the Corporation has never had paid any dividends.

NOTE 12 - SHARE BASED COMPENSATION

On July 17, 2015, the Corporation approved the long-term employment agreement of Dr. Paul Averback as President and Chief Executive Officer. The employment agreement retains the services of Dr. Averback for an initial period of seven years. Dr Averback has agreed to forgo his salary until the Company receives a significant increase in its financing to expand its operations and execute its business plans.. Dr. Averback received 3,000,000 restricted shares in July, 2015 and shall receive 250,000 restricted stock each month for the duration of the contract, totaling up to 21,000,000 restricted shares, in lieu of cash salary. The Corporation determined that a grant date for all the restricted shares occurred on July 17, 2015 and established the fair value of each share at $1.36. The Corporation is recording the expense on a pro-rata basis and recorded an expense of $657,838 in 2021. The unrecognized compensation cost as at December 31, 2021, which will be recognized on a pro-rata basis over the duration of the employment contract as services are performed, assuming Dr. Averback continued to elect equity compensation, is $86,749. After the corporation raised gross proceeds of approximately $8,000,000 before deducting fees and other offering expenses in April,2021, Dr.Averback received total $750,000 compensation by December 31, 2021 as reward for his service.

The stock and stock option-based compensation expense to the directors and employees are disaggregated in the statements of operations and comprehensive loss for the years ended December 31, 2021, 2020 and 2019, as follows:

In Thousands of US Dollars
Functional Expense Category	2021		2020		2019
General and administrative expense	$	2,124	$	702	$	1,839
Research and development expense		479		1,046		1,172
Total	$	2,603	$	1,748	$	3,011

Table of Contents

NOTE 13 - WARRANTS

In the first quarter of 2019, the Corporation issued 2,500,000 warrants in connection with one private placement. Each warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $8.00 with a five year term. The warrant was valued at $200,000.

During the second quarter at the year ended December 31, 2021, the Corporation issued 1,834,862 warrants in connection with one private placement. Each warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $2.50 with a five year term. The warrant was valued at $330,277. In addition, the Corporation issued the associated security broker warrants to purchase up to 183,486 shares of common stock at an exercise price of $2.50 per share for its service. The warrant was valued at $220,457.

A detail of warrant activity for the years ended December 31, 2021, 2020 and 2019 is as follows:

Description	Number		Weighted average exercise price		Weighted average remaining contractual life (in years)
Outstanding 1-Jan-19		-	$	-		-
Exercised		-		-		-
Granted		2,500,000-		8.00		-
Expired		-		-		-
Cancelled		-		-		-
Outstanding 31-Dec-19		2,500,000	$	8.00		4.04
Exercised		-		-		-
Granted						-
Expired		-		-		-
Cancelled		-		-		-
Outstanding 31-Dec-20		2,500,000	$	8.00		3.04
Exercised		-		-		-
Granted		2,018,348		2.50		-
Expired		-		-		-
Cancelled		-		-		-
Outstanding 31-Dec-21		4,518,348	$	5.54		3.07

NOTE 14 - INCOME TAXES

The Corporation was re-domiciled to the Bahamas in 2015. The substantial portion of our operations are generated out of our executive offices in the Bahamas which has no corporate income taxes. We do have operations subject to income tax in the United States of America, primarily the sale of product out of our New Jersey facilities.

The effect of the re-domiciliation from Canada to the Bahamas resulted in the expiration of several tax attributes relative to our prior operations in Canada including Canadian research tax credit carryforwards and Canadian loss carryforwards. Canadian research tax credit carryforwards and Canadian loss carryforwards expired upon determination of the re-domiciliation by the Canadian federal government amount to $1,686,270 and $55,850,632, respectively.

Nymox recognized no provision (recovery) for federal income taxes for the years ended December 31, 2021, 2020 and 2019.

Table of Contents

The following table is a reconciliation of effective tax rate:

In Thousands of US Dollars
Description	2021			2020			2019
Net loss for the year, before income taxes	$	(12,537	)	$	(11,738	)	$	(13,162	)
Net loss attributable to the Bahamas		(11,781	)		(11,012	)		(12,841	)
Net loss attributable the United States		(756	)		(725	)		(321	)
Domestic tax rate applicable to the Corporation		21	%		21	%		21	%
Income taxes at domestic tax statutory rate		(159	)		(152	)		(67	)
Change in valuation allowance		159			152			67
Deferred tax provision (recovery)	$	-		$	-		$	-

As of December 31, 2021, 2020 and 2019, deferred tax assets not recognized were as follows:

In Thousands of US Dollars
Description	2021		2020		2019
Tax loss carry forward	$	1,404	$	1,386	$	1,402
Patents capitalized and amortized for tax purposes		0		0		0
Unrecognized deferred tax assets	$	1,404	$	1.386	$	1,402

Deferred tax assets have not been recognized in respect to these items because it is not probable that future taxable profit will be available against which the Corporation can utilize the benefits therefrom. The generation of future taxable profit is dependent on the successful commercialization of the Corporation’s products and technologies.

The amount of net operating loss carryforwards for US Federal income tax purposes by year of origination and expiration is detailed below:

In Thousands of US Dollars
Year Originated	Year of Expiration	Amount		Year Originated	Year of Expiration	Amount
2002	2022		522	2012	2032		177
2003	2023		564	2013	2033		121
2004	2024		353	2014	2034		70
2005	2025		264	2015	2035		127
2006	2026		355	2016	2036		147
2007	2027		373	2017	2037		140
2008	2028		.351	2018	2038		194
2009	2029		86	2019	2039		337
2010	2030		541	2020	2040		732
2011	2031		480	2021	2041		753

		Total				$	6,687

Table of Contents

NOTE 15 - EARNINGS PER SHARE

Weighted average number of common shares outstanding:

In Thousands of Shares
Description	2021		2020		2019
Issued common shares at January 1		77,961		71,218		64,676
Effect of shares issued		4,015		2,605		4,169
Weighted average number of common shares outstanding at December 31		81,976		73,823		68,845

Diluted loss per share was the same amount as basic loss per share, as the effect of options and warrants would have been anti-dilutive because the Corporation incurred losses in each of the years presented. All outstanding options could potentially be dilutive in the future.

NOTE 16 - FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES

The Corporation has determined that the carrying value of its short-term financial assets and liabilities approximates their fair value due to the immediate or short-term maturity of these financial instruments.

NOTE 17 – FINANCE INCOME AND FINANCE COSTS

Finance income and finance costs for the years ended December 31, 2021, 2020 and 2019, are detailed below:

In Thousands of US Dollars
Description	2021			2020			2019

Interest income	$	8		$	27		$	213
Net foreign exchange gain(loss)		(2	)		(3	)		(12	)
Finance income		6			24			201
Interest and bank charges		(20	)		(30	)		(18	)
Financial costs		(20	)		(30	)		(18	)
Operating lease interest expense		(19	)		(12	)		(20	)
Total finance income and costs	$	(33	)	$	(18	)	$	163

NOTE 18 - SEGMENT DISCLOSURES

The Corporation operates in one reportable segment, which is the Corporation’s strategic business unit -the research and development of products for the aging population.

Table of Contents

Information regarding the geographic reportable segment is as follows:

In Thousands of US Dollars
Description	Canada		United States		Europe
Revenues
2021	$	-	$	-	$	-
2020	$	-	$	3	$	2
2019	$	1	$	91	$	24
Property and equipment
December 31, 2021	$	10	$	12	$	–
December 31, 2020	$	9	$	19	$	–
December 31, 2019	$	–	$	25	$	–

Revenues are attributed to geographic locations based on location of customers. Property and equipment is attributed to geographic locations based on its physical location.

NOTE 19 - CONCENTRATIONS

Major customers

Customers that accounted for greater than 10% of revenues from sales of goods in any of the last three years were as follows:

In Thousands of US Dollars
Description	2021		2020		2019
Customer A	$	-	$	-	$	23
Customer B	$	-	$	2	$	-
Customer C	$	-	$	-	$	36

NOTE 20- RELATED PARTY TRANSACTIONS

The transactions we have with related parties are compensation arrangements for both current compensation, share based compensation and compensation under options for our officers and directors. We also paid service fees to two corporations controlled by two of our officers.

Executive officers and directors participate in the Corporation’s stock option plan. Executive officers are covered under the Corporation’s health plan.

Table of Contents

Key management personnel compensation is comprised of:

In Thousands of US Dollars
Description	2021		2020		2019
Salary and Compensation	$	750	$	-	$	-
Short-term employee benefits		14		2		2
Stock-based compensation		2,227		1,404		2,998
Total	$	2,991	$	1,406	$	3,000

Total honorariums earned by the independent directors of the Corporation for participation in Board and Committee meetings were $0, $26,000 and $0 for the years ended December 31, 2021, 2020 and 2019, respectively.

Our Chief Financial Officer receives no compensation as an individual and receives no deferred or incentive compensation. We do make payments in the form of contract for services rendered to a corporation controlled by him. Amounts paid under this arrangement were $580,000, $535,000 and $480,000 for the years ended December 31, 2021, 2020 and 2019, respectively.

Our Corporate Legal Counsel received 900,000 restricted shares of common shares for his exemplary service for over 16 years during the period ended December 31, 2021.We also make payments in the form of contract for professional services rendered to a corporation controlled by him. Amounts paid under this arrangement were $435,289, $324,767 and $289,992 for the years ended December 31, 2021, 2020 and 2019, respectively.

The above honorariums payment to directors and professional service fee paid to officers’ related party are part of the company’s G&A expense.

NOTE 21 – RESEARCH AND DEVELOPMENT EXPENSES

Research and development expenses, excluding stock-based compensation, depreciation and lease amortization expenses, allocated to our major research and development programs are as follows:

In Thousands of US Dollars
	For the Year Ended December 31,
Research and Development Program	2021		2020		2019
Research and Development Program	$	-	$	-	$	4
Alzheimer’s Disease: Therapeutics		4		-		4
Anti-Infectives		-		4		4
BPH (Enlarged Prostate) and Prostate Cancer Therapeutics	5,944			7,162		5,932
Tobacco Exposure Tests: NicAlert™ and TobacAlert™		1		1		18
Total	$	5,949	$	7,167	$	5,962

NOTE 22 - PERSONNEL EXPENSES

A detailed analysis of employee personnel related expenses for the years ended December 31, 2021, 2020 and 2019 is provided below:

In Thousands of US Dollars
Description	2021		2020		2019
Salaries and compensation	$	1,419	$	659	$	689
Employer contributions		49		51		54
Short-term employee benefits		70		18		16
Stock-based compensation		2,227		1,417		3,011
Total	$	3,765	$	2,145	$	3,770

Table of Contents

From above table, G&A related salary and compensation was $874,000, $98,000 and $90,000 for the years 2021, 2020 and 2019 respectively. G&A related stock compensation was $1,897,000, $702,000, and $ 1,839,000 for the years 2021, 2020 and 2019.

NOTE 23 - CAPITAL DISCLOSURES AND FINANCIAL RISK

Approximately 97%, 97% and 98% of expenses that occurred during the years ended December 31, 2021, 2020 and 2019, respectively, were denominated in US dollars. Foreign exchange fluctuations had no meaningful impact on the Corporation’s results in 2021, 2020 or 2019.

NOTE 24 - FOREIGN EXCHANGE RISK

We have no significant items exposed to foreign exchange.

Based on the Corporation’s foreign currency exposures, varying the above foreign exchange rates to reflect a 5% strengthening of the US dollar would have decreased the net loss for the year ended December 31, 2021 by approximately $17,653, assuming that all other variables remained constant.

An assumed 5% weakening of the US dollar against the Canadian dollar would have had an equal but opposite effect on the amount shown above, on the basis that all other variables remained constant.

NOTE 25 - CREDIT RISK

Credit risk results from the possibility that a loss may occur from the failure of another party to perform according to the terms of the contract. Financial instruments that potentially subject the Corporation to concentrations of credit risk consist primarily of cash and trade and other accounts receivable. Cash is maintained with high-credit quality financial institutions. For trade accounts receivable, the Corporation performs periodic credit evaluations and typically does not require collateral. Allowances are maintained for potential credit losses consistent with the credit risk, historical trends, general economic conditions and other information.

The Corporation has a limited number of customers. Included in the consolidated statement of financial position as of December 31, 2021, 2020 and 2019 are trade accounts receivable of $0, $0 and $4,368, respectively, all of which were aged under 45 days. No bad debt expense was recorded on trade accounts receivable for the years ended December 31, 2021, 2020 or 2019.

At December 31, 2021, the Corporation’s maximum credit exposure corresponded to the carrying amount of cash, and other receivables.

NOTE 26 - INTEREST RATE RISK

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Cash bears interest at a variable rate. Trade accounts receivable, other receivables, trade accounts payable and accrued liabilities bear no interest. Based on the value of variable interest-bearing cash during the year ended December 31, 2021, an assumed 0.5% increase or 0.5% decrease in interest rates during such period would have had no significant effect on the net loss.

Table of Contents

NOTE 27 - LIQUIDITY RISK

Liquidity risk is the risk that the Corporation will not be able to meet its financial obligations as they fall due. The Corporation manages liquidity risk through the management of its capital structure, as outlined in Capital Disclosures above. The Corporation does not have an operating credit facility and has historically financed its activities primarily through an equity financing with various investment companies and the issuance of convertible notes.

The following are the contractual maturities of financial liabilities:

In Thousands of US Dollars
Description	Carrying Amount		Less than 1 year		1 year to 5 years
Accounts payable and accrued liabilities
December 31, 2021	$	1,949	$	1,786	$	163
December 31, 2020	$	2,198	$	1,965	$	233

NOTE 28 - SUBSEQUENT EVENTS

The Corporation has evaluated subsequent events through March 30, 2022, the date the financial statements were authorized for issuance by the Audit Committee of the Board of Directors. Although it has expressed no intention to do so the Audit Committee has the authorization to amend these financial statements. The corporation has determined there are no subsequent events except the following.

On March 18, 2022 the Company entered into an agreement with a placement agent in connection with the Company’s issuance and sale of an aggregate of 3,878,789 shares of the Company’s common stock, no par value, at a purchase price of $1.65 per share to select institutional and accredited investors, and concurrent private placement of warrants. A.G.P./Alliance Global Partners is acting as sole placement agent for the private placement.

On March 18, 2022, the Company and the Investors entered into securities purchase agreements (the “Purchase Agreements”) relating to the Offering and concurrent private placement of warrants up to an aggregate of 3,878,789 shares of common stock, at an initial exercise price equal to $2.00 per share and will expire five (5) years from the date of an effective registration statement covering the shares underlying the warrants, subject to customary anti-dilution provisions. James G. Robinson, a director of the company and one of the investors in the offering, purchased 1,151,515 shares and 1,151,515 shares of common stock underlying the warrants.

On March 22, 2022, the company announced it closed the offering for gross proceeds of approximately $6.4 million before deducting placement agent fees and various expenses. In addition, the Company agreed to issue A.G.P. or its assigns warrants to purchase up to 193,939 shares of common stock at an exercise price of $2.06 per share. The Placement Agent Warrants will be immediately exercisable and will expire on the five-year anniversary of the date of offer and are subject to customary anti-dilution provisions.

ITEM 9. OFFER AND LISTING DETAILS

Nymox’s common shares trade on the NASDAQ Stock Market. Nymox’s common shares traded on the NASDAQ National Market from December 1, 1997 until September 16, 1999 when they began trading on the NASDAQ SmallCap Market, now called the NASDAQ Capital Market. Nymox’s common shares also traded on the Montreal Exchange from December 18, 1995 until November 19, 1999.

The following tables set out the high and low reported trading prices of the common shares on the NASDAQ Stock Market during the periods indicated.

Table of Contents

Annual High and Low Market Prices – Past Five Years

YEAR	ANNUAL HIGH		ANNUAL LOW
2017	$	5.10	$	2.67
2018	$	4.60	$	1.25
2019	$	2.75	$	1.32
2020	$	4.79	$	1.66
2021	$	3.50	$	0.94

Quarterly High and Low Market Prices – Past Two Years

YEAR	QUARTERLY PERIOD	HIGH SALES PRICE		LOW SALES PRICE
2020	1^stQuarter	$	4.09	$	1.66
	2^ndQuarter	$	4.79	$	1.98
	3^rdQuarter	$	3.75	$	2.29
	4^thQuarter	$	2.84	$	1.83

2021	1^stQuarter	$	3.50	$	2.14
	2^ndQuarter	$	2.87	$	1.42
	3^rdQuarter	$	2.27	$	1.25
	4^thQuarter	$	2.15	$	0.94

Monthly High and Low Market Prices – Most Recent Six Months

DATE	MONTHLY HIGH		MONTHLY LOW
October, 2021	$	2.15	$	1.75
November, 2021	$	1.90	$	1.40
December, 2021	$	1.57	$	0.94
January, 2022	$	1.79	$	1.18
February, 2022	$	1.84	$	1.2
March 29, 2022	$	2.1	$	1.20

ITEM 10. ADDITIONAL INFORMATION

Memorandum and Articles of Association

Bylaws and Articles of Incorporation

The Corporation’s Certificate of Continuation filed pursuant to the International Business Companies Act of the Commonwealth of The Bahamas, which we refer to as our articles of incorporation, are on file with the Acting Registrar General of the Commonwealth of The Bahamas under Corporation Number 175894 (B). Our articles of incorporation do not include a stated purpose and do not place any restrictions on the business that the Corporation may carry on.

Directors

A director of our Corporation need not be a shareholder. In order to serve as a director, a person must be a natural person at least 18 years of age, of sound mind and not bankrupt. Neither our articles of incorporation or by-laws impose any mandatory retirement requirements for directors.

Our bylaws authorizes the directors from time to time to determine the remuneration for their services. There is no requirement for an independent quorum.

A director who is a party to, or who is a director or officer of or has a material interest in any person who is a party to, a material contract or transaction or proposed material contract or transaction with our Corporation must disclose to the Corporation the nature and extent of his or her interest at the time and in the manner provided by the International Business Corporations Act. The International Business Corporations Act prohibits such a director from voting on any resolution to approve the contract or transaction unless the contract or transaction:

	•	is an arrangement by way of security for money lent to or obligations undertaken by the director for the benefit of the Corporation or an affiliate;

	•	relates primarily to his or her remuneration as a director, officer, employee or agent of the Corporation or an affiliate;

	•	is for indemnity or insurance for director’s liability as permitted by the Act; or

	•	is with an affiliate.

Our board of directors may, on behalf of the Corporation and without authorization of our shareholders:

	•	borrow money upon the credit of the Corporation;

	•	issue, reissue, sell or pledge debt obligations of the Corporation;

	•	give a guarantee on behalf of the Corporation to secure performance of an obligation of any person; and

	•	mortgage, hypothecate, pledge or otherwise create a security interest in all or any property of the Corporation, owned or subsequently acquired, to secure any obligation of the Corporation.

The International Business Corporations Act prohibits the giving of a guarantee to any shareholder, director, officer or employee of the Corporation or of an affiliated corporation or to an associate of any such person for any purpose or to any person for the purpose of or in connection with a purchase of a share issued or to be issued by the Corporation or its affiliates, where there are reasonable grounds for believing that the Corporation is or, after giving the guarantee, would be unable to pay its liabilities as they become due, or the realizable value of the Corporation’s assets in the form of assets pledged or encumbered to secure a guarantee, after giving the guarantee, would be less than the aggregate of the Corporation’s liabilities and stated capital of all classes.

These borrowing powers may be varied by the Corporation’s bylaws or its articles of incorporation. However, our bylaws and articles of incorporation do not contain any restrictions on or variations of these borrowing powers.

Common Shares

Our articles of incorporation authorize the issuance of an unlimited number of common shares. They do not authorize the issuance of any other class of shares.

The holders of the common shares of our Corporation are entitled to receive notice of and to attend all meetings of the shareholders of our Corporation and have one vote for each common share held at all meetings of the shareholders of our Corporation. Our directors are elected at each annual meeting of shareholders and do not stand for reelection at staggered intervals.

The holders of common shares are entitled to receive dividends and the Corporation will pay dividends, as and when declared by our board of directors, out of moneys properly applicable to the payment of dividends, in such amount and in such form as our board of directors may from time to time determine, and all dividends which our board of directors may declare on the common shares shall be declared and paid in equal amounts per share on all common shares at the time outstanding.

In the event of the dissolution, liquidation or winding-up of the Corporation, whether voluntary or involuntary, or any other distribution of assets of the Corporation among its shareholders for the purpose of winding up its affairs, the holders of the common shares will be entitled to receive the remaining property and assets of the Corporation.

There are no redemption provisions and no liability for further capital calls associated with the Corporation’s common stock.

Action Necessary to Change Rights Of Shareholders

In order to change the rights of our shareholders, we would need to amend our articles of incorporation to effect the change. Such an amendment would require the approval of holders of two-thirds of the shares cast at a duly called special meeting. For certain amendments such as those creating of a class of preferred shares, a shareholder is entitled to dissent in respect of such a resolution amending our articles and, if the resolution is adopted and the Corporation implements such changes, demand payment of the fair value of its shares.

Meetings of Shareholders

An annual meeting of shareholders is held each year for the purpose of considering the financial statements and reports, electing directors, appointing auditors and for the transaction of other business as may be brought before the meeting. The board of directors has the power to call a special meeting of shareholders at any time.

Notice of the time and place of each meeting of shareholders must be given not less than 21 days, nor more than 60 days, before the date of each meeting to each director, to the auditor and to each shareholder who at the close of business on the record date for notice is entered in the securities register as the holder of one or more shares carrying the right to vote at the meeting. Notice of meeting of shareholders called for any other purpose other than consideration of the minutes of an earlier meeting, financial statements and auditor’s report, election of directors and reappointment of the incumbent auditor, must state the nature of the business in sufficient detail to permit the shareholder to form a reasoned judgment on and must state the text of any special resolution or by-law to be submitted to the meeting.

The only persons entitled to be present at a meeting of shareholders are those entitled to vote, the directors of the Corporation and the auditor of the Corporation. Any other person may be admitted only on the invitation of the chairman of the meeting or with the consent of the meeting. In circumstances where a court orders a meeting of shareholders, the court may direct how the meeting may be held, including who may attend the meeting.

Limitations on Right To Own Securities

Neither the International Business Corporation Act nor our articles or by-laws limit the right of a nonresident to hold or vote our shares, as amended by the World Trade Organization Agreement Implementation Act.

	(a)	An acquisition of our shares if the acquisition were made in the ordinary course of that person’s business as a trader or dealer in securities;
	(b)	an acquisition of control of the Corporation in connection with the foreclosure of a security interest granted for a loan or other assistance and not for any purpose related to the provisions the Investment Act; and
	(c)	an acquisition of control of the Corporation by reason of an amalgamation, consolidation or corporate reorganization, following which the direct or indirect control in fact of the Corporation, through ownership of voting interests, remains unchanged.

Change of Control

There are no provisions of our bylaws or articles of incorporation that would have an effect of delaying, deferring or preventing a change in control of the Corporation and that would operate only with respect to a merger, acquisition or corporate restructuring involving the Corporation. Our bylaws do not contain a provision governing the ownership threshold above which shareholder ownership must be disclosed.

Material Contracts

The following is a summary of the material contracts to which the Corporation is a party, for the three years ended March 30, 2022.

The prospectus supplement and accompanying prospectus relates to the issuance and sale of up to $12,000,000 of our common stock, no par value per share, from time to time through our sales agent, Chardan Capital Markets, LLC, or Chardan. These sales, if any, will be made under an equity distribution agreement, dated February 5, 2016, between us and Chardan, which we refer to as the equity distribution agreement.

Issuance and sale of up to $12,000,000 of the company common stock prospectus.

Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made by any method permitted by law deemed to be an “at-the-market” offering as defined in Rule 415 under the Securities Act of 1933, as amended, which we refer to as the Securities Act, including sales made directly on The NASDAQ Capital Market, on any other existing trading market for our common stock or to or through a market maker or through an electronic communications network. If expressly authorized by us, Chardan may also sell our common stock in privately negotiated transactions. Chardan will act as sales agent on a commercially reasonable efforts basis, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of NASDAQ. There is no specific date on which the offering will end, there are no minimum sale requirements and there are no arrangements to place any of the proceeds of this offering in an escrow, trust or similar account.

Chardan will be entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds from the sale of our common stock pursuant to the equity distribution agreement. In connection with the sale of the common stock on our behalf, Chardan may, and will with respect to sales effected in an “at-the-market” offering, be deemed to be an “underwriter” within the meaning of the Securities Act, and the compensation of Chardan may be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Chardan against certain civil liabilities, including liabilities under the Securities Act.

Exchange Controls

The Bahamas has no system of exchange controls. There are no exchange restrictions on borrowing from foreign countries or on the remittance of dividends, interest, royalties and similar payments, management fees, loan repayments, settlement of trade debts or the repatriation of capital.

There are no limitations on the rights of non-Canadians to exercise voting rights on their shares of Nymox.

Taxation

U.S. Federal Income Tax Considerations for U.S. Persons

This section contains a summary of certain U.S. federal income tax considerations for U.S. Persons (as defined below) who hold common shares of Nymox. This summary is based upon the Internal Revenue Code of 1986, as amended (the “Code”), Treasury regulations, rulings of the Internal Revenue Service (the “IRS”), and judicial decisions in existence on the date hereof, all of which are subject to change. Any such change could apply retroactively and could have adverse consequences to Nymox and its shareholders. This summary is necessarily general and does not attempt to summarize all aspects of the federal tax laws (and does not attempt to summarize any state or local laws) that may affect an investor’s acquisition of an interest in Nymox. No ruling from the IRS will be requested and no assurance can be given that the IRS will agree with the tax consequences described in this summary.

For purposes of this discussion, the term “U.S. Person” means (a) an individual who is a citizen of the United States or who is resident in the United States for United States federal income tax purposes, (b) a corporation or a partnership that is organized under the laws of the United States or any state thereof, (c) an estate the income of which is subject to United States federal income taxation regardless of its source, or (d) a trust (i) that is subject to the supervision of a court within the United States and is subject to the control of one or more United States persons as described in the Code, or (ii) that has a valid election in effect under applicable Treasury regulations to be treated as a United States person. The term “U.S. Holder” means a shareholder of Nymox who is a U.S. Person. The term “foreign corporation” means an entity that is classified as a corporation for U.S. federal income tax purposes and that is not organized under the laws of the United States or any state thereof.

This summary does not discuss all United States federal income tax considerations that may be relevant to U.S. Holders in light of their particular circumstances or to certain holders that may be subject to special treatment under United States federal income tax law (for example, insurance companies, tax-exempt organizations, financial institutions, dealers in securities, persons who hold shares as part of a straddle, hedging, constructive sale, or conversion transaction, U.S. Holders whose functional currency is not the U.S. dollar, and U.S. Holders who acquired shares through exercise of employee stock options or otherwise as compensation for services). Furthermore, this summary does not address any aspects of state or local taxation.

The tax consequences of an investment in Nymox are complex and based on tax provisions that are subject to change. You are urged to consult with, and must depend upon, your own tax advisors with specific reference to your own tax situations as to the income and other tax consequences of an investment in Nymox.

Dividends and gains on sale. Except as described below with respect to the “passive foreign investment corporation” rules, dividends paid by Nymox to a U.S. Holder, without reduction for Canadian withholding taxes, will be included in the gross income of such U.S. Holder, as a dividend, to the extent paid out of current or accumulated earnings and profits, as determined under U.S. federal income tax. Such dividends will not be eligible for the dividend-received deduction generally allowed under the Code to dividend recipients that are U.S. corporations. The amount of any distribution in excess of Nymox’s current and accumulated earnings and profits will first be applied to reduce the U.S. Holder’s tax basis in its Nymox common shares, and any amount in excess of tax basis will be treated as gain from the sale or exchange of the common shares. A dividend paid by Nymox generally will be taxed at the preferential tax rates applicable to long-term capital gains (where the maximum federal rate is currently 20%) if (a) Nymox is a “qualified foreign corporation” as defined in Section 1(h)(11) of the Code, (a “QFC”), (b) the U.S. Holder receiving such dividend is an individual, estate, or trust, and (c) such dividend is paid on common shares that have been held by such U.S. Holder for at least 61 days during the 121-day period beginning 60 days before the “ex-dividend date” (i.e., the first date that a purchaser of such common shares will not be entitled to receive such dividend). Nymox currently meets the definition of a QFC because its common shares are readily tradable on the Nasdaq Stock Market, an established securities market in the United States, provided that Nymox is not a “passive foreign investment corporation” (as described below) for the taxable year during which Nymox pays a dividend or for the preceding taxable year. If Nymox were to be delisted from the Nasdaq Stock Market, it is not clear whether Nymox would meet the definition of a QFC. If Nymox is not a QFC, a dividend paid by Nymox to a U.S. Holder that is an individual, estate, or trust generally will be taxed at ordinary income tax rates (and not at the preferential tax rates applicable to long-term capital gains). The dividend rules are complex, and each U.S. Holder should consult its own financial advisor, legal counsel, or accountant regarding the dividend rules.

Except as described below with respect to the “passive foreign investment corporation” rules, any gain recognized by a U.S. Holder on a sale or exchange of Nymox common shares (or on a distribution treated as a sale or exchange) generally will be treated as capital gain. Capital gains of corporations are taxable at the same rate as ordinary income. With respect to non-corporate taxpayers, the excess of net long-term capital gain over net short term capital loss may be taxed at a substantially lower rate than is ordinary income. A capital gain or loss is long-term if the asset has been held for more than one year and short-term if held for one year or less. In addition, the distinction between capital gain or loss and ordinary income or loss is relevant for purposes of limitations on the deductibility of capital losses.

A U.S. Holder generally may claim a credit against its U.S. federal income tax liability for Canadian income tax withheld from dividends received on Nymox common shares. The amount of this credit is subject to several limitations under the Code.

Controlled foreign corporation rules. A foreign corporation generally is classified as a “controlled foreign corporation” (a “CFC”) if more than 50% of the corporation’s shares (by vote or value) are owned, directly or indirectly, by “10% U.S. Shareholders”. For this purpose, a “10% U.S. Shareholder” is a U.S. Person that owns, directly or indirectly, shares possessing 10% or more of the voting power in the foreign corporation. Nymox believes that it is not a CFC at the present time. If Nymox were a CFC, each 10% U.S. Shareholder that owns, directly or indirectly through foreign entities, an interest in Nymox generally would be required to include in its gross income for U.S. federal income tax purposes a pro-rata share of any “Subpart F” income earned by Nymox, whether or not such income is distributed by Nymox. Subpart F income generally includes interest, dividends, royalties, gain on the sale of stock or securities and certain other categories of income.

Passive foreign investment corporation rules. In general, a foreign corporation is a “passive foreign investment corporation” (a “PFIC”) during a taxable year if 75% or more of its gross income for the taxable year constitutes “passive income” or if 50% or more of its assets (by average fair market value) held during the taxable year produce, or are held for the production of, passive income. In general, any U.S. Person that owns, directly or indirectly, an interest in a foreign corporation will be subject to an interest charge (in addition to regular U.S. federal income tax) upon the disposition by the U.S. Person of, or receipt by the U.S. Person of “excess distributions” with respect to, any shares of the foreign corporation if: (i) the foreign corporation is a PFIC during the taxable year in which such income is realized by the U.S. Person; or (ii) the foreign corporation was a PFIC during any prior taxable year that is included in whole or in part in the U.S. Person’s “holding period” (within the meaning of Section 1223 of the Code) with respect to its interest in the shares of the foreign corporation. Furthermore, the U.S. Person’s share of such gain or “excess distribution” will be taxable as ordinary income. There exist several other adverse tax consequences that may apply to any U.S. Person that owns, directly or indirectly, an interest in a PFIC.

A U.S. Person that owns, directly or indirectly, an interest in a PFIC can elect to treat such PFIC as a “qualified electing fund” (a “QEF”) with respect to the U.S. Person. In general, the effect of a QEF election with respect to a PFIC is that, beginning with the first taxable year to which the election applies and in all succeeding taxable years during which the foreign corporation is a PFIC, the U.S. Person is required to include in its income its share of the ordinary earnings and net capital gains of the PFIC. The U.S. Person is not taxable with respect to any distribution by the PFIC from earnings that have been included previously in the U.S. Person’s income under the QEF provisions. If the QEF election is made with respect to the first taxable year in which a U.S. Person owns, directly or indirectly, an interest in the particular PFIC, the adverse tax consequences described in the immediately preceding paragraph (including the interest charge and the treatment of gains as ordinary income) would not apply to the U.S. Person’s interest in that PFIC. In order to make a QEF election, a U.S. Person is required to provide to the IRS certain information furnished by the PFIC.

Nymox believes that it has not been a PFIC during any taxable year ending on or before December 31, 2014. There can be no assurance that Nymox will not be a PFIC during its current taxable year. Because PFIC classification cannot be determined until the close of a taxable year, is determined annually, and depends on the application of complex rules which are subject to differing interpretations, there can be no assurance that Nymox has never been and will not become a PFIC for any taxable year during which U.S. Holders hold Nymox common stock. Nymox intends to notify its U.S. Holders within 45 days after the end of any taxable year for which Nymox believes it might be a PFIC. Nymox has further undertaken (i) to provide its U.S. Holders with timely and accurate information as to its status as a PFIC and the manner in which the QEF election can be made and (ii) to comply with all record-keeping, reporting and other requirements so that the U.S. Holders, at their option, may make a QEF election.

Each U.S. Person who owns, directly or indirectly, common shares of Nymox is urged to consult its own tax advisor with respect to the advantages and disadvantages of making a QEF election with respect to Nymox.

Information Reporting and Backup withholding. Information reporting to the IRS may be required with respect to payments of dividends on the Nymox common shares to U.S. Holders, and with respect to proceeds received by U.S. Holders on the sale of Nymox common shares. A U.S. Holder may be subject to backup withholding with respect to dividends received with respect to Nymox common shares, or proceeds received on the sale of Nymox common shares through a broker, unless the U.S. Holder (i) demonstrates that it qualifies for an applicable exemption (such as the exemption for holders that are corporations), or (ii) provides a taxpayer identification number and complies with certain other requirements. Any amount withheld from payment to a U.S. Holder under the backup withholding rules generally will be allowed as credit against the U.S. Holder’s U.S. federal income tax liability, if any, and may entitle the U.S. Holder to a refund, provided that the required information is furnished to the IRS.

In addition, certain categories of U.S. Holders that hold certain “foreign financial assets” (which may include Nymox common shares), over a certain threshold, must file IRS Form 8938 to report information relating to such assets, subject to certain exceptions. Each U.S. Holder should consult its own financial advisor, legal counsel, or accountant regarding the application of these information reporting and backup withholding rules to it.

Medicare Contribution Tax. Certain U.S. Holders who are individuals, estates or trusts are required to pay up to an additional 3.8% tax on, among other things, dividends and capital gains. Each U.S. Holder should consult its own financial advisor, legal counsel or accountant regarding the possible application of this additional tax to income earned with respect to Nymox common shares.

Canadian Federal Income Taxation

The following summary describes the principal Canadian federal tax considerations generally applicable to a shareholder who holds as beneficial owner common shares of Nymox and who, at all relevant times, for purposes of the Income Tax Act (Canada) and the Income Tax Regulations (collectively, the “Tax Act”), (1) holds the common shares of Nymox as capital property, (2) deals at arm’s length with Nymox , (3) is not affiliated with Nymox, and (4) has not entered into, with respect to their common shares of Nymox, a “derivative forward agreement” as that term is defined in the Tax Act (a “Holder”). Generally, the common shares of Nymox will be capital property to a Holder provided the Holder does not acquire or hold their common shares of Nymox in the course of carrying on a business or provided the Holder has not acquired their common shares of Nymox as part of an adventure in the nature of trade.

This summary is based on the current provisions of the Tax Act, and an understanding of the current administrative and assessing practices and policies of the Canada Revenue Agency published in writing prior to the date hereof. This summary takes into account all specific proposals to amend the Tax Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date hereof (the “Proposed Amendments”) and assumes that all Proposed Amendments will be enacted in the form proposed. However, no assurances can be given that the Proposed Amendments will be enacted as proposed, or at all. This summary does not otherwise take into account or anticipate any changes in law or administrative policy or assessing practice whether by legislative, administrative or judicial action nor does it take into account tax legislation or considerations of any province, territory or foreign jurisdiction, which may differ from those discussed herein. This summary is of a general nature only and is not, and is not intended to be, legal or tax advice to any particular Holder. This summary is not exhaustive of all possible Canadian federal income tax considerations. Accordingly, Holders should consult their own tax advisors having regard to their own particular circumstances.

Generally, for purposes of the Tax Act, all amounts relating to the acquisition, holding or disposition of common shares of Nymox must be converted into Canadian dollars based on exchange rates as determined in accordance with the Tax Act. The amount of dividends required to be included in the income of, and capital gains or capital losses realized by, a Holder may be affected by fluctuations in the Canadian / U.S. dollar exchange rate.

Canadian Resident Holders

The following portion of the summary is generally applicable to a Holder who, at all relevant times, for purposes of the Tax Act, is, or is deemed to be resident in Canada (a “Resident Holder”). Certain Resident Holders may be entitled to make or may have already made the irrevocable election permitted by subsection 39(4) of the Tax Act the effect of which may be to deem to be capital property any common shares of Nymox (and all other “Canadian securities”, as defined in the Tax Act) owned by such Resident Holder in the taxation year in which the election is made and in all subsequent taxation years. Resident Holders whose common shares of Nymox might not otherwise be considered to be capital property should consult their own tax advisors concerning this election. This portion of the summary is not applicable to (i) a Holder that is a “specified financial institution” , (ii) a Holder an interest in which is a “tax shelter investment”, (iii) a Holder that is, for purposes of certain rules (referred to as the mark-to-market rules) applicable to securities held by financial institutions, a “financial institution” , or (iv) a Holder that reports its “Canadian tax results” in a currency other than Canadian currency, or (v) a Holder that is a corporation and is, or becomes as part of a transaction or event or series of transactions or events that includes the acquisition of common shares of Nymox, controlled by a non-resident corporation for the purposes of the foreign affiliate dumping rules in proposed section 212.3 of the Tax Act , each as defined in the Tax Act. Such Holders should consult their own tax advisors.

Dividends

A Resident Holder will be required to include in computing its income for a taxation year any dividends received (or deemed to be received) on the common shares of Nymox. In the case of a Resident Holder that is an individual (other than certain trusts), such dividends will be subject to the gross-up and dividend tax credit rules applicable to taxable dividends received from taxable Canadian corporations, including the enhanced gross-up and dividend tax credit applicable to any dividends designated by Nymox as an eligible dividend in accordance with the provisions of the Tax Act. A dividend received (or deemed to be received) by a Resident Holder that is a corporation will generally be deductible in computing the corporation’s taxable income.

A Resident Holder that is “private corporation”, as defined in the Tax Act, or any other corporation controlled, whether because of a beneficial interest in one or more trusts or otherwise, by or for the benefit of an individual (other than a trust) or a related group of individuals (other than trusts), will generally be liable to pay a refundable tax of 33 1/3 % under Part IV of the Tax Act on dividends received (or deemed to be received) on the common shares of Nymox to the extent such dividends are deductible in computing the Resident Holder’s taxable income for the taxation year.

Dispositions

Generally, on a disposition or deemed disposition of a common share of Nymox, the Resident Holder will realize a capital gain (or capital loss) equal to the amount, if any, by which the proceeds of disposition, net of any reasonable costs of disposition, exceed (or are less than) the adjusted cost base to the Resident Holder of the common share of Nymox immediately before the disposition or deemed disposition.

The adjusted cost base to the Resident Holder of a common share of Nymox will be determined by averaging the cost of such common share of Nymox with the adjusted cost base of all other common shares of Nymox owned by the Resident Holder as capital property at that time, if any.

Generally, a Resident Holder is required to include in computing its income for a taxation year one-half of the amount of any capital gain (a “taxable capital gain”) realized in the year. Subject to and in accordance with the provisions of the Tax Act, a Resident Holder is required to deduct one-half of the amount of any capital loss (an “allowable capital loss”) realized in a taxation year from taxable capital gains realized by the Resident Holder in the year and allowable capital losses in excess of taxable capital gains for the year may be carried back and deducted in any of the three preceding taxation years or carried forward and deducted in any subsequent taxation year against net taxable capital gains realized in such years.

The amount of any capital loss realized by a Resident Holder that is a corporation on the disposition of a common share of Nymox may be reduced by the amount of any dividends received (or deemed to be received) by the Resident Holder on a common share of Nymox to the extent and under the circumstances prescribed by the Tax Act. Similar rules may apply where a common share of Nymox is owned by a partnership or trust of which a corporation, trust or partnership is a member or beneficiary. Such Resident Holders should consult their own tax advisors.

Holders Not Resident in Canada

The following portion of the summary is generally applicable to a Holder who, at all relevant times, for purposes of the Tax Act, is not, and is not deemed to be,, resident in Canada and does not use or hold, and is not deemed to use or hold, common shares of Nymox in a business carried on in Canada (a “Non-Resident Holder”). Special rules, which are not discussed in this summary, may apply to a holder that is not resident in Canada that is an insurance business in Canada and elsewhere.

Dividends

Dividends paid or credited on the common shares of Nymox or deemed to be paid or credited on the common shares of Nymox will be subject to Canadian withholding tax at the rate of 25%, subject to any reduction in the rate of withholding to which the Non-Resident Holder is entitled under any applicable income tax convention. . For example, under the Canada-United States Tax Convention (1980), as amended (the “Canada-U.S. Tax Treaty”), where dividends on the common shares of Nymox are considered to be paid to or derived by a Non-Resident Holder that is the beneficial owner of the dividends and is a U.S. resident for the purposes of, and is entitled to benefits of, the Canada-U.S. Tax Treaty, the applicable rate of Canadian withholding tax is generally reduced to 15%.

Dispositions

A Non-Resident Holder will not be subject to tax under the Tax Act on any capital gain realized on the disposition or deemed disposition of common shares of Nymox, unless the common shares of Nymox are “taxable Canadian property” to the NonResident Holder for purposes of the Tax Act and the Non-Resident Holder is not entitled to relief under an applicable income tax convention between Canada and the country in which the Non-Resident Holder is resident. Generally, the common shares of Nymox will not constitute taxable Canadian property to a Non-Resident Holder at a particular time provided that the common shares of Nymox are listed at that time on a designated stock exchange (which includes the NASDAQ), unless at any particular time during the 60-month period that ends at that time (i) one or any combination of (a) the Non-Resident Holder, (b) persons with whom the Non-Resident Holder does not deal with at arm’s length, and (c) partnerships in which the Non-Resident Holder or a person described in (b) holds a membership interest directly or indirectly through one or more partnerships, has owned 25% or more of the issued shares of any class or series of the capital stock of Nymox, and (ii) more than 50% of the fair market value of the common shares of Nymox was derived directly or indirectly from one or any combination of: (i) real or immovable properties situated in Canada, (ii) “Canadian resource properties” (as defined in the Tax Act), (iii) “timber resource properties” (as defined in the Tax Act), and (iv) options in respect of, or interests in, or for civil law rights in, property in any of the foregoing whether or not the property exists. Notwithstanding the foregoing, in certain circumstances set out in the Tax Act, common shares of Nymox could be deemed to be taxable Canadian property NonResident Holders whose common shares of Nymox may constitute taxable Canadian property should consult their own tax advisors.

Documents on Display

Nymox is subject to the informational requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In accordance with these requirements, the Corporation files reports and other information with the Securities and Exchange Commission. These materials, including this Annual Report on Form 20-F and the exhibits hereto, may be inspected and copied at the Commission’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Copies of the materials may be obtained from the Commission’s Public Reference Room at prescribed rates. Information on the operation of the Public Reference Room may be obtained by calling the Commission at 1-800-SEC-0330. The Commission maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers, including Nymox, that file electronically with the Commission.

We are required to file reports and other information with the securities commissions in all provinces of Canada. You also are invited to read and copy any reports, statements or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval (“SEDAR”) (http://www.sedar.com), the Canadian equivalent of the SEC’s electronic document gathering and retrieval system. This material includes our Management Information Circular for the most recent annual meeting, which provides information including directors’ and officers’, remuneration and indebtedness, principal holders of securities and securities authorized for issuance under equity compensation plans. Additional financial information is provided in our annual financial statements and our Management’s Discussion and Analysis relating to these statements. These documents are also accessible on SEDAR (www.sedar.com).

We will provide without charge to each person, including any beneficial owner, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this Annual Report on Form 20-F (not including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address: Nymox Pharmaceutical Corporation, Bay & Deveaux Sts., Nassau The Bahamas, Attention: Investor Relations. Telephone (800) 936-9669. Facsimile (514) 332-2227 EMAIL: info@nymox.com

ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Capital disclosures

The Corporation defines capital as total equity. To fund its activities, the Corporation has followed an approach that relies almost exclusively on the issuance of common shares and, during 2010, entered into a collaboration agreement. Since inception, the Corporation has financed its liquidity needs primarily through private placements and, since 2003, through a financing agreement with an investment company that has been replaced annually by a new agreement with the same purchaser (see note 10 - Common Stock Private Purchase Agreement of the Consolidated Financial Statements).

The Corporation’s ability to raise capital through the Agreement and other sources of financing will be impacted by the market price and trading volumes of its common shares. The results of the NX02-0017 and NX02-0018 clinical trials may adversely affect the Corporation’s ability to raise capital on a timely basis, requiring the Corporation to reduce its cash requirements by eliminating or deferring spending on research, development and corporate activities. In addition, other sources of financing may not be available or may be available only at a price or on terms that are not favorable to the Corporation. The capital management objectives remain the same as for the previous fiscal year. When possible, the Corporation tries to optimize its liquidity needs by non-dilutive sources, including sales, collaboration agreements, research tax credits and interest income. The Corporation’s general policy on dividends is to retain cash to keep funds available to finance its research and development and operating expenses.

Other than the financing discussed above, the Corporation does not have arranged sources of financing. See Note 10 to the consolidated financial statements.

The Corporation is not subject to any capital requirements imposed by external parties other than the Nasdaq Capital Market requirements related to the Listing Rules. Failure to meet the listing requirements may lead to delisting from the Nasdaq Capital Market in which case the Corporation will consider an alternate trading platform for its common shares.

Financial risk management

This section provides disclosures relating to the nature and extent of the Corporation’s exposure to risks arising from financial instruments, including foreign currency risk, credit risk, interest rate risk and liquidity risk, and to how the Corporation manages those risks.

Foreign currency risk

The Corporation uses the US dollar as its measurement currency because a substantial portion of revenues, expenses, assets and liabilities of its US and Canadian operations are denominated in US dollars. The Corporation’s equity financing facility is also in US dollars. Foreign currency risk is limited to the portion of the Corporation’s business transactions denominated in currencies other than the US dollar. The Canadian operation has transactions denominated in Canadian dollars, principally relating to salaries and rent. Additional variability arises from the translation of monetary assets and liabilities denominated in currencies other than the US dollar at each statement of financial position date. Fluctuations in the currency used for the payment of the Corporation’s expenses denominated in currencies other than the US dollar (primarily Canadian dollars) could cause unanticipated fluctuations in the Corporation’s operating results, but would not impair or enhance its ability to pay its Canadian dollar denominated obligations. The Corporation’s objective in managing its foreign currency risk is to minimize its net exposures to foreign currency cash flows by transacting with parties in US dollars to the maximum extent possible. The Corporation does not engage in the use of derivative financial instruments to manage its currency exposures.

Approximately 97% of expenses that occurred during the year ended December 31, 2021 (2020 - 97%; 2019 - 98%) were denominated in US dollars. Foreign exchange fluctuations had no meaningful impact on the Corporation’s results in 2021, 2020 or 2019.

The following table provides significant items exposed to foreign exchange:

	December 31,			December 31,			December 31,
CA$	2021			2020			2019
Cash	$	84,856		$	59,228		$	78,994
Trade accounts receivable and other receivables		17,361			26,036			18,092
Trade accounts payable and accrued liabilities		(173,244	)		(169,717	)		(247,071	)
Total	$	(71,027	)	$	(84,453	)	$	(149,985	)

The following exchange rates were applied for the years ended December 31, 2021, 2020 and 2019:

Description	Average rate (twelve months)		Reporting date rate
US$ - CA$ - December 31, 2021		1.2535		1.2678
US$ - CA$ - December 31, 2020		1.2808		1.2732
US$ - CA$ - December 31, 2019		1.3269		1.2988

Based on the Corporation’s foreign currency exposures noted above, varying the above foreign exchange rates to reflect a 5% strengthening of the US dollar against the Canadian dollar would have decreased the net loss for the year ended December 31, 2021 by approximately $17,653, assuming that all other variables remained constant.

An assumed 5% weakening of the US dollar against the Canadian dollar would have had an equal but opposite effect on the amount shown above, on the basis that all other variables remained constant.

Credit risk

Credit risk results from the possibility that a loss may occur from the failure of another party to perform according to the terms of the contract. Financial instruments that potentially subject the Corporation to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is maintained with high-credit quality financial institutions. For trade accounts receivable, the Corporation performs periodic credit evaluations and typically does not require collateral. Allowances are maintained for potential credit losses consistent with the credit risk, historical trends, general economic conditions and other information.

The Corporation has a limited number of customers. Included in the consolidated statement of financial position are trade accounts receivable of $0 (December 31, 2020 - $0), all of which were aged under 45 days. No bad debt expense on trade accounts receivable was recorded for the year ended December 31, 2021, nor for the year ended December 31, 2020.

At December 31, 2021, the Corporation’s maximum credit exposure corresponded to the carrying amount of cash, trade accounts receivable and other receivables.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Cash bears interest at a variable rate. Trade accounts receivable, other receivables, trade accounts payable and accrued liabilities bear no interest. The Corporation has no other interest-bearing financial instruments.

Based on the value of variable interest-bearing cash during the year ended December 31, 2021, an assumed 0.5% increase or 0.5% decrease in interest rates during such period would have had no significant effect on the net loss.

Liquidity risk

Liquidity risk is the risk that the Corporation will not be able to meet its financial obligations as they fall due. The Corporation manages liquidity risk through the management of its capital structure, as outlined in note 23 - Capital disclosures. The Corporation does not have an operating credit facility and has historically financed its activities primarily through an equity financing agreement with an investment company, as described in note 10 - Common Stock Private Purchase Agreement.

The Corporation’s ability to raise capital through other sources of financing will be impacted by the market price and trading volumes of its common shares. The results of the NX02-0017 and NX02-0018 clinical trials may adversely affect the Corporation’s ability to raise capital on a timely basis, requiring the Corporation to reduce its cash requirements by eliminating or deferring spending on research, development and corporate activities. In addition, other sources of financing may not be available or may be available only at a price or on terms that are not favorable to the Corporation.

In addition to financing operations through the issuance of equity, the Corporation may also secure additional funding through the issuance of debt, licensing or partnering products in development, increasing revenue from our products, or realizing on intellectual property and other assets. There can be no assurances that the Corporation will be successful in realizing on any such potential opportunities for additional funding at a price or on terms that are favorable to the Corporation.

The following are the contractual maturities of financial liabilities:

Trade accounts payable and accrued liabilities:	Carrying Amount		Less than 1 year		1 year to 5 years
December 31, 2021	$	1,948,812	$	1,557,353	$	391,459
December 31, 2020	$	2,198,266	$	1,830,213	$	368,053
December 31, 2019	$	2,041,039	$	2,038,293		2,746

ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

None.

ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

None.

ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

None.

ITEM 15. CONTROLS AND PROCEDURES

(a) Disclosure Controls and Procedures. In accordance with Rule 13a-15(b) of the Exchange Act, the Corporation’s management, including the Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of the design and operation of the Corporation’s disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report on Form 20-F and concluded that the disclosure controls and procedures were effective as of December 31, 2021.

The Corporation’s management has concluded that the Consolidated Financial Statements as of and for the year ended December 31, 2021 present fairly, in all material respects, the Corporation’s financial position, results of operations and cash flows for the periods disclosed in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.

TPS THAYER has issued its report dated March 30, 2022, which expressed an unqualified opinion on those Consolidated Financial Statements.

(b) Management’s Annual Report on Internal Control over Financial Reporting. Management is responsible for establishing and maintaining effective internal control over financial reporting as defined in Rules 13a-15(f) under the Exchange Act. The Corporation’s internal control over financial reporting is designed to provide reasonable assurance to management and our board of directors regarding the preparation and fair presentation of published financial statements.

The Corporation’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Corporation; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Corporation are being made only in accordance with authorizations of management and directors of the Corporation; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Corporation’s assets that could have a material effect on the financial statements.

Under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, management conducted an evaluation of the effectiveness of our internal control over financial reporting, as of December 31, 2021, based on the framework set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on its evaluation under this framework, the Chief Executive Officer and the Chief Financial Officer concluded that our internal control over financial reporting was effective as of December 31, 2021.

TPS THAYER’s attestation report on the effectiveness of the Corporation’s internal control over financial reporting is included in the financial statements which appear in this annual report.

(c) Attestation Report of the Registered Public Accounting Firm. TPS THAYER’s attestation report on the effectiveness of the Corporation’s internal control over financial reporting is included in Item 8. Financial Information.

(d) Changes in Internal Control over Financial Reporting

We have made significant improvements in Internal Controls over Financial Reporting during year 2017.

Management believes that proper segregation of duties is critical to a properly designed and operating internal control environment for financial reporting. The Corporation developed a remediation plan, with oversight from the Audit Committee, to remediate the following material weaknesses in internal controls over financial reporting, first identified in 2015:

The Corporation did not employ a sufficient complement of finance and accounting personnel to ensure that there was proper segregation of duties related to certain processes, primarily impacting the expenditures/disbursements processes and information technology general controls (“ITGC”) and sufficient compensating controls did not exist in these areas before year 2017.

The Corporation’s remediation plan included hiring an external accounting expert, functioning in a Controller role, at the beginning of 2017 to assist in the accounting of non-routine complex accounting matters and to enhance oversight of the financial reporting process. The accounting system was transferred to a new general ledger software system on a secure cloud platform. Additionally, we contracted with a Managed Service Provider to maintain our IT infrastructure. These changes allowed for proper segregation of duties and strengthened the controls related to the expenditures/disbursements approval process, financial statement review and information technology general controls (“ITGC”). This remediation plan was implemented and functioning as of September 30, 2017.

Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. See “Risk Factors”.

Item 16. RESERVED

Item 16A. AUDIT COMMITTEE FINANCIAL EXPERT

Our board of directors has determined that Richard Cutler, Esq., the Chairman of our Audit Committee, is an audit committee financial expert and is an independent director under the applicable listing rules of the Nasdaq Stock Market.

Item 16B. CODE OF ETHICS

We have adopted a code of ethics that is applicable to our officers, directors and employees in general and our principal executive officer, principal financial officer, principal accounting officer or controller and persons performing similar functions in particular. The code of ethics can be found on our website, www.nymox.com.

Item 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES

Our principal independent auditor is TPS THAYER, CPA.

Fees and Services

For the years ended December 31, 2021 and 2020 audited by TPS Thayer, 2019 audited by Thayer O’Neal Company, LLC, for professional services, the following fees:

Description	US 2021		US 2020		US 2019

Audit fees	$	172,500	$	172,000	$	172,000
Audit related fees		5,000		12,000		-
Tax fees		8,000		8,000		8,000
All other fees		-		-		-
Total	$	185,000	$	192,000	$	180,000

Audit Fees consisted of professional services rendered for the annual audit of the Corporation’s consolidated financial statements, the quarterly reviews of the Corporation’s interim financial statements, consultation concerning financial reporting and accounting standards, and services provided in connection with statutory and regulatory filings or engagements. The fees in 2021 also include fees for the audit of the effectiveness of the Corporation’s internal control over financial reporting which was required as the Company became an accelerated filer under SEC regulations for 2021 with more than $75 million in public float.

Audit-Related Fees consisted of comfort letter services rendered in connection with the Corporation’s financial documents.

Tax Fees consisted of services rendered in connection with the preparation of tax returns of the Corporation and its subsidiaries and general tax advice.

All Other Fees – there were no other professional services rendered during the years ended December 31, 2021 , 2020 and 2019.

Policy on Pre-Approval of Audit and Non-Audit Services of Independent Auditors

Our Audit Committee is responsible for the oversight of our independent auditor’s work. Our Audit Committee’s policy is to pre-approve all audit and non-audit services provided by TPS THAYER. These services may include audit services, audit-related services, tax services and other services. The Audit Committee appoints the auditors and oversees and fixes the compensation for all such services. TPS THAYER and our management report to the Audit Committee regarding the extent of services actually provided in accordance with the applicable pre-approval, and regarding the fees for the services performed. The Audit Committee approved 100% of the fees listed on the table above.

ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

Not applicable.

ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

None.

ITEM 16F. CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT

On July 15, 2015, the Board of Directors (the “Board”) of Nymox Pharmaceutical Corporation (the “Company”) approved the dismissal of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm.

The audit reports of KPMG on the Company’s financial statements as of and for the years ended December 31, 2014 and 2013 did not contain any adverse opinion or disclaimer of opinion nor were they qualified or modified as to uncertainty, audit scope or accounting principle, except as follows:

KPMG’s report on the consolidated financial statements of the Company as of and for the years ended December 31, 2014 and 2013 contained an explanatory paragraph that states that the failure of two Phase 3 studies of NX-1207 materially affects Nymox Pharmaceutical Corporation’s current ability to fund its operations, meet its cash flow requirements, realize its assets and discharge its obligations, and casts substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.

The audit reports of KPMG on the effectiveness of internal control over financial reporting as of December 31, 2013 did not contain any adverse opinion or disclaimer of opinion nor was it qualified or modified as to uncertainty, audit scope or accounting principle. The audit reports of KPMG on the effectiveness of internal control over financial reporting as of December 31, 2014 reflected the following material weakness:

KPMG’s report indicates that the Company did not maintain effective internal control over financial reporting as of December 31, 2014 because of the effect of a material weakness on the achievement of the objectives of the control criteria and contains an explanatory paragraph that states that the Company did not employ a sufficient complement of finance and accounting personnel to ensure that there was a proper segregation of incompatible duties relating to certain processes, primarily impacting the expenditures/disbursements processes and information technology controls, and sufficient compensating controls did not exist in these areas.

During the years ended December 31, 2014 and 2013 and through the subsequent interim period to July 15, 2015, the date of KPMG’s dismissal, there were no: (i) disagreements with KPMG on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the their satisfaction, would have caused them to make reference in connection with their opinion to the subject matter of the disagreements, or (2) reportable events, except that KPMG advised the Company of the following material weakness: the Company did not employ a sufficient complement of finance and accounting personnel to ensure that there was a proper segregation of incompatible duties relating to certain processes, primarily impacting the expenditures/disbursements processes and information technology controls, and sufficient compensating controls did not exist in these areas.

On July 15, 2015, the Board approved the engagement of Cutler & Co., LLC (“Cutler”) to serve as the Company’s new independent registered public accounting firm. Prior to the date of Cutler’s engagement, the Company has not consulted with Cutler regarding (i) the application of accounting principles to a specific completed or contemplated transaction, (ii) the type of audit opinion that might be rendered on the Company’s financial statements and neither a written report was provided to the registrant nor oral advice was provided that the new accountant concluded was an important factor considered by the registrant in reaching a decision as to the accounting, auditing or financial reporting issue; or (iii) any matter that was either the subject of a disagreement.

On December 15, 2015, the Board of Directors (the “Board”) of Nymox Pharmaceutical Corporation (the “Company”) was notified by Cutler & Co., LLC (“Cutler”) that Cutler had filed for deregistering with the PCAOB and was transferring its foreign issuers to Thayer O’Neal Company, LLC (“ThayerONeal”). Accordingly Cutler resigned as the Registrant’s independent registered public accounting firm.

The review of Cutler & Co on the Company’s financial statements as of and for the quarter ended June 30, 2015 resulted in no: (i) disagreements with Cutler & Co on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the their satisfaction, would have caused them to make reference in connection with their opinion to the subject matter of the disagreements, or (2) reportable events, except that Cutler & Co advised the Company of the following material weakness: the Company did not employ a sufficient complement of finance and accounting personnel to ensure that there was a proper segregation of incompatible duties relating to certain processes, primarily impacting the expenditures/disbursements processes and information technology controls, and sufficient compensating controls did not exist in these areas.

On December 16, 2015, the Board approved the engagement of ThayerONeal to serve as the Company’s new independent registered public accounting firm. Prior to the date of ThayerONeal’s engagement, the Company has not consulted with ThayerONeal regarding (i) the application of accounting principles to a specific completed or contemplated transaction, other than that noted below, (ii) the type of audit opinion that might be rendered on the Company’s financial statements and neither a written report was provided to the registrant nor oral advice was provided that the new accounting firm concluded was an important factor considered by the registrant in reaching a decision as to the accounting, auditing or financial reporting; or (iii) any matter that was either the subject of a disagreement.

With respect to item (i) in the preceding paragraph the Company engaged a specialist to value share based compensation expense related to the issuance of options and the modification of those options associated with an employment agreement with an officer of the Company at the request of KPMG, the independent registered accounting firm which preceded the appointment of Cutler & Co. In connection with that engagement, ThayerONeal has reviewed and tested the accounting model created by the specialist for future reliance thereon and has provided comments to management concerning that model.

On October 13, 2020, Nymox Pharmaceutical Corporation (the “Company”) dismissed Thayer O’Neal Company, LLC as its independent registered public accounting firm. The reports of Thayer O’Neal Company, LLC regarding the Company’s financial statements for the fiscal years ended December 31,2019, 2018, and 2017 did not contain an adverse opinion or disclaimer of opinion and were not modified as to uncertainty, audit scope, or accounting principles, except each report did contain an explanatory paragraph related to the Company’s ability to continue as a going concern.

Effective October 13, 2020, the Company engaged TPS Thayer, LLC Certified Public Accountants (“TPS”) as the Company’s new independent registered public accounting firm. During the two most recent fiscal years and through March 30, 2022, the Company had not consulted with TPS regarding any of the following:

The application of accounting principles to a specific transaction, either completed or proposed; The type of audit opinion that might be rendered on the Company’s financial statements, and none of the following was provided to the Company: (a) a written report, or (b) oral advice that TPS concluded was an important factor considered by the Company in reaching a decision as to accounting, auditing or financial reporting issue; or Any matter that was subject of a disagreement, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K.

ITEM 16G. CORPORATE GOVERNANCE

The Corporation is listed on the Nasdaq Stock Market. The Corporation complies with all the Nasdaq Stock Market corporate governance requirements.

ITEM 16H. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 17. FINANCIAL STATEMENTS

Not applicable.

ITEM 18. FINANCIAL STATEMENTS

The financial statements for the three years ended December 31, 2021, 2020 and 2019 are included in Item 8 of this report and are incorporated by reference in this item.

ITEM 19. EXHIBITS

The following exhibits are included with or incorporated by reference into this report:

Exhibit
No.		Description
1(a)		Articles of Incorporation, as amended. (incorporated by reference to Exhibit 3.1 to the Corporation’s Form 20-F filed with the Commission December 9, 1996)
1(b)		Bylaws of the Corporation (incorporated by reference to Exhibit 3.2 to the Corporation’s Form 20-F filed with the Commission December 9, 1996)
4(a)		Memorandum of Agreement between Paul Averback and the Corporation (incorporated by reference to Exhibit 10.1 to the Corporation’s Form 20-F filed with the Commission December 9, 1996)
4(b)		Share Option Plan of the Corporation (incorporated by reference to Exhibit 10.2 to the Corporation’s Form 20-F filed with the Commission December 9, 1996)
4(c)		Research and License Agreement between the Massachusetts General Hospital Corporation and the Corporation (incorporated by reference to Exhibit 10.3 to the Corporation’s Form 20-F filed with the Commission December 9, 1996)
4(d)		Research and License Amendment between the Massachusetts General Hospital Corporation and the Corporation (incorporated by reference to Exhibit 10.5 to the Corporation’s Form 20-F filed with the Commission February 21, 1997)
4(e)		Common Stock Purchase Agreement between Nymox Pharmaceutical Corporation and Jaspas Investments Limited dated November 1, 1999 (incorporated by reference to Exhibit 2.0 to the Corporation’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(f)		Registration Rights Agreement between Nymox Pharmaceutical Corporation and Jaspas Investments Limited dated November 1, 1999 (incorporated by reference to Exhibit 2.1 to the Corporation’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(g)		Escrow Agreement among Nymox Pharmaceutical Corporation, Jaspas Investments Limited and Epstein, Becker & Green, P.C. dated November 1, 1999 (incorporated by reference to Exhibit 2.2 to the Corporation’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(h)		Stock Purchase Warrant to purchase common shares issued to Jaspas Investments Limited dated November 1, 1999 (incorporated by reference to Exhibit 2.3 to the Corporation’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(i)		Research and License Agreement between the Rhode Island Hospital Corporation and the Corporation dated May 14, 1999 (incorporated by reference to Exhibit 10.10 to the Corporation’s Form 20-F filed with the Commission May 15, 2000).
4(j)		Research and License Amendment between the Rhode Island Hospital Corporation and the Corporation dated November 19, 2001 (incorporated by reference to Exhibit 10.10 to the Corporation’s Form 20-F filed with the Commission June 28, 2002).
4(s)		Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments, Ltd. dated November 1, 2010. (incorporated by reference to Exhibit 4(s) to the Corporation’s Amendment No.1 to 20-F Report filed with the Commission on June 3, 2011).
4(t)*		License and Collaboration Agreement between Nymox Pharmaceutical Corporation and Recordati Ireland Ltd. dated December 16, 2010. (incorporated by reference to Exhibit 4(t) to the Corporation’s Amendment No.1 to 20-F Report filed with the Commission on June 3, 2011)
4(u)		Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments, Ltd. dated November 1, 2011. (incorporated by reference to Exhibit 4(u) to the Corporation’s 6-K Report filed with the Commission on March 15, 2012).
4(v)		Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments, Ltd. dated November 1, 2012. (incorporated by reference to Exhibit 4(v) to the Corporation’s 6-K Report filed with the Commission on March 15, 2013).
4(w)		Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments, Ltd. dated November 1, 2013.
4(x)		6% Secured Convertible Note between Nymox Pharmaceutical Corporation and Cantone Asset Management, LLC dated December 16, 2014. (filed herewith).
4(y)		Response Letter from KPMG in the Corporation’s 6-K dated July 16, 2015 (Incorporated by reference herewith)
8		List of Subsidiaries of Nymox Pharmaceutical Corporation (incorporated by reference to Exhibit 8 to the Corporation’s Form 20-F filed with the Commission June 30, 2004)
11		Code of Business Conduct for the Officers, Directors and Employees of Nymox Pharmaceutical Corporation (incorporated by reference to Exhibit 11 to the Corporation’s Form 20-F filed with the Commission June 30, 2004)
12(a)		Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a)
12(b)		Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a)
13(a)		Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
13(b)		Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

________

* Portions of this exhibit have been omitted pursuant to a confidential treatment request. Omitted portions have been filed separately with the SEC.

SIGNATURES

The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.

		NYMOX PHARMACEUTICAL CORPORATION
		(Registrant)

Date: March 30, 2022		/s/ Paul Averback
		Paul Averback,
		Title: President and Chief Executive Officer

EXHIBIT INDEX - NYMOX PHARMACEUTICAL CORPORATION Form 20-F Annual Report

Exhibit
No.		Description
1(a)		Articles of Incorporation, as amended. (incorporated by reference to Exhibit 3.1 to the Corporation’s Form 20-F filed with the Commission December 9, 1996)
1(b)		Bylaws of the Corporation (incorporated by reference to Exhibit 3.2 to the Corporation’s Form 20-F filed with the Commission December 9, 1996)
4(a)		Memorandum of Agreement between Paul Averback and the Corporation (incorporated by reference to Exhibit 10.1 to the Corporation’s Form 20-F filed with the Commission December 9, 1996)
4(b)		Share Option Plan of the Corporation (incorporated by reference to Exhibit 10.2 to the Corporation’s Form 20-F filed with the Commission December 9, 1996)
4(c)		Research and License Agreement between the Massachusetts General Hospital Corporation and the Corporation (incorporated by reference to Exhibit 10.3 to the Corporation’s Form 20-F filed with the Commission December 9, 1996)
4(d)		Research and License Amendment between the Massachusetts General Hospital Corporation and the Corporation (incorporated by reference to Exhibit 10.5 to the Corporation’s Form 20-F filed with the Commission February 21, 1997)
4(e)		Common Stock Purchase Agreement between Nymox Pharmaceutical Corporation and Jaspas Investments Limited dated November 1, 1999 (incorporated by reference to Exhibit 2.0 to the Corporation’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(f)		Registration Rights Agreement between Nymox Pharmaceutical Corporation and Jaspas Investments Limited dated November 1, 1999 (incorporated by reference to Exhibit 2.1 to the Corporation’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(g)		Escrow Agreement among Nymox Pharmaceutical Corporation, Jaspas Investments Limited and Epstein, Becker & Green, P.C. dated November 1, 1999 (incorporated by reference to Exhibit 2.2 to the Corporation’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(h)		Stock Purchase Warrant to purchase common shares issued to Jaspas Investments Limited dated November 1, 1999 (incorporated by reference to Exhibit 2.3 to the Corporation’s Form F-1 Registration Statement filed with the Commission February 29, 2000)
4(i)		Research and License Agreement between the Rhode Island Hospital Corporation and the Corporation dated May 14, 1999 (incorporated by reference to Exhibit 10.10 to the Corporation’s Form 20-F filed with the Commission May 15, 2000).
4(j)		Research and License Amendment between the Rhode Island Hospital Corporation and the Corporation dated November 19, 2001 (incorporated by reference to Exhibit 10.10 to the Corporation’s Form 20-F filed with the Commission June 28, 2002).
4(s)		Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments, Ltd. dated November 1, 2010. (incorporated by reference to Exhibit 4(s) to the Corporation’s Amendment No.1 to 20-F Report filed with the Commission on June 3, 2011).
4(t)*		License and Collaboration Agreement between Nymox Pharmaceutical Corporation and Recordati Ireland Ltd. dated December 16, 2010. (incorporated by reference to Exhibit 4(t) to the Corporation’s Amendment No.1 to 20-F Report filed with the Commission on June 3, 2011)
4(u)		Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments, Ltd. dated November 1, 2011. (incorporated by reference to Exhibit 4(u) to the Corporation’s 6-K Report filed with the Commission on March 15, 2012).
4(v)		Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments, Ltd. dated November 1, 2012. (incorporated by reference to Exhibit 4(v) to the Corporation’s 6-K Report filed with the Commission on March 15, 2013).
4(w)		Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments, Ltd. dated November 1, 2013.
4(x)		6% Secured Convertible Note between Nymox Pharmaceutical Corporation and Cantone Asset Management, LLC dated December 16, 2014. (filed herewith).
4(y)		Response Letter from KPMG in the Corporation’s 6-K dated July 16, 2015 (Incorporated by reference herewith)
8		List of Subsidiaries of Nymox Pharmaceutical Corporation (incorporated by reference to Exhibit 8 to the Corporation’s Form 20-F filed with the Commission June 30, 2004)
11		Code of Business Conduct for the Officers, Directors and Employees of Nymox Pharmaceutical Corporation (incorporated by reference to Exhibit 11 to the Corporation’s Form 20-F filed with the Commission June 30, 2004)
12(a)		Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a)
12(b)		Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a)
13(a)		Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
13(b)		Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

__________

* Portions of this exhibit have been omitted pursuant to a confidential treatment request. Omitted portions have been filed separately with the SEC.

EX-12.A 2 nymox_ex12a.htm CERTIFICATION nymox_ex12a.htm

EXHIBIT 12 (a)

CERTIFICATION

I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that:

1.	I have reviewed this annual report for the period ended December 31, 2021 of Nymox Pharmaceutical Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

4.	The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a – 15(e) and 15d – 15(e)), and internal control over financial reporting (as defined in the Exchange Act Rules 13a–15(f) and 15d–15(f)) for the company based on the COSO 1992 framework and we have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with international financial reporting standards;

	c)	evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

5.	The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent function):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

Date: March 30, 2022

By:	/s/ Paul Averback, MD
	Paul Averback, MD
	President and Chief Executive Officer
	Nymox Pharmaceutical Corporation

EX-12.B 3 nymox_ex12b.htm CERTIFICATION nymox_ex12b.htm

EXHIBIT 12 (b)

CERTIFICATION

I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that:

1.	I have reviewed this annual report for the period ended December 31, 2021 of Nymox Pharmaceutical Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

4.	The company s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a 15(e) and 15d 15(e)), and internal control over financial reporting (as defined in the Exchange Act Rules 13a 15(f) and 15d 15(f)) for the company based on the COSO 1992 framework and we have:

	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with international financial reporting standards;

	c)	evaluated the effectiveness of the company s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	disclosed in this report any change in the company s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company s internal control over financial reporting; and

5.	The company s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company s auditors and the audit committee of the company s board of directors (or persons performing the equivalent function):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the company s internal control over financial reporting.

Date: March 30, 2022

By:	/s/ Erik Danielsen
	Erik Danielsen
	Chief Financial Officer Nymox Pharmaceutical Corporation

EX-13.A 4 nymox_ex13a.htm CERTIFICATION nymox_ex13a.htm

EXHIBIT 13 (a)

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December 31, 2021 of Nymox Pharmaceutical Corporation and filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Nymox Pharmaceutical Corporation

Date: March 30, 2022

By:	/s/ Paul Averback, MD
	Paul Averback, MD
	President and Chief Executive Officer
	Nymox Pharmaceutical Corporation

EX-13.B 5 nymox_ex13b.htm CERTIFICATION nymox_ex13b.htm

EXHIBIT 13 (b)

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December 31, 2021 of Nymox Pharmaceutical Corporation and filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Nymox Pharmaceutical Corporation

Date: March 30, 2022

By:	/s/ Erik Danielsen
	Erik Danielsen
	Chief Financial Officer
	Nymox Pharmaceutical Corporation

EX-101.SCH 6 nymox-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - Consolidated Statements of Financial Position link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - Consolidated Statements of Financial Position (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - Consolidated Statements of Cash Flow link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - Consolidated Statements of Changes in Equity link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - BUSINESS ACTIVITIES AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - GOING CONCERN CONSIDERATIONS link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - SIGNIFICANT ESTIMATES link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - NEW ACCOUNTING STANDARDS AND INTERPRETATIONS link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - OPERATING LEASES AND COMMITMENTS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - SHARE CAPITAL link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - STOCK OPTIONS link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - SHARE BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - WARRANTS link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - FINANCE INCOME AND FINANCE COSTS link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - SEGMENT DISCLOSURES link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - PERSONNEL EXPENSES link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - CAPITAL DISCLOSURES AND FINANCIAL RISK link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - FOREIGN EXCHANGE RISK link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - CREDIT RISK link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - INTEREST RATE RISK link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - LIQUIDITY RISK link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000037 - Disclosure - NEW ACCOUNTING STANDARDS AND INTERPRETATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 000038 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 000039 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 000040 - Disclosure - OPERATING LEASES AND COMMITMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000041 - Disclosure - SHARE CAPITAL (Tables) link:presentationLink link:calculationLink link:definitionLink 000042 - Disclosure - STOCK OPTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 000043 - Disclosure - SHARE BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 000044 - Disclosure - WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000045 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 000046 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 000047 - Disclosure - FINANCE INCOME AND FINANCE COSTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000048 - Disclosure - SEGMENT DISCLOSURES (Tables) link:presentationLink link:calculationLink link:definitionLink 000049 - Disclosure - CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 000050 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 000051 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 000052 - Disclosure - PERSONNEL EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 000053 - Disclosure - LIQUIDITY RISK (Tables) link:presentationLink link:calculationLink link:definitionLink 000054 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 000055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000056 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 000057 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000058 - Disclosure - INTANGIBLE ASSETS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000059 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 000060 - Disclosure - INTEREST RATE RISK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000061 - Disclosure - CREDIT RISK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000062 - Disclosure - FOREIGN EXCHANGE RISK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000063 - Disclosure - CAPITAL DISCLOSURES AND FINANCIAL RISK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000064 - Disclosure - OPERATING LEASES AND COMMITMENT (Details) link:presentationLink link:calculationLink link:definitionLink 000065 - Disclosure - OPERATING LEASES AND COMMITMENT (Details 1) link:presentationLink link:calculationLink link:definitionLink 000066 - Disclosure - OPERATING LEASES AND COMMITMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000067 - Disclosure - Operating leases and other commitment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000068 - Disclosure - SHARE CAPITAL (Details) link:presentationLink link:calculationLink link:definitionLink 000069 - Disclosure - Share capital (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000070 - Disclosure - STOCK OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 000071 - Disclosure - STOCK OPTIONS (Details 1) link:presentationLink link:calculationLink link:definitionLink 000072 - Disclosure - STOCK OPTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000073 - Disclosure - SHARE BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 000074 - Disclosure - SHARE BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000075 - Disclosure - WARRANTS (Details) link:presentationLink link:calculationLink link:definitionLink 000076 - Disclosure - WARRANTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000077 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 000078 - Disclosure - INCOME TAXES (Details 1) link:presentationLink link:calculationLink link:definitionLink 000079 - Disclosure - INCOME TAXES (Details 2) link:presentationLink link:calculationLink link:definitionLink 000080 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000081 - Disclosure - EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 000082 - Disclosure - FINANCE INCOME AND FINANCE COSTS (Details) link:presentationLink link:calculationLink link:definitionLink 000083 - Disclosure - SEGMENT DISCLOSURES (Details) link:presentationLink link:calculationLink link:definitionLink 000084 - Disclosure - CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 000085 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 000086 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000087 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 000088 - Disclosure - PERSONNEL EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 000089 - Disclosure - PERSONNEL EXPENSES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000090 - Disclosure - LIQUIDITY RISK (Details) link:presentationLink link:calculationLink link:definitionLink 000091 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 nymox-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Voluntary Filers Current Fiscal Year End Date Entity Well Known Seasoned Issuer Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Annual Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Address Address Line 1 Entity Address City Or Town Entity Address Country City Area Code Auditor Name Auditor Location Local Phone Number Security 12b Title Security Exchange Name No Trading Symbol Flag Entity Interactive Data Current Document Shell Company Report Document Registration Statement Contact Personnel Email Address Entity Other Identification Type Document Accounting Standard Auditor Firm Id Icfr Auditor Attestation Flag Contact Personnel Name Entity Addresses Address Type [Axis] Business Contact [Member] Consolidated Statements of Comprehensive Loss Sales of goods Total revenue [Revenue] Cost of goods sold and operating Expenses Cost of goods sold Research and development General and administrative Total operating expenses [Expenses, by nature] Loss from operations [Profit (loss) from operating activities] Finance income Finance costs Operating lease interest expense Loss before income taxes [Profit (loss) before tax] Income tax provision (recovery) Net loss Net Loss attributable to Nymox share holders Basic and diluted loss per share Weighted average number of common shares outstanding Consolidated Statements of Financial Position ASSETS Current assets Cash Accounts receivable Other receivables Inventory Security deposit Prepaid expenses and other current assets Total current assets [Current assets] Property and equipment Operating lease right-of-use asset, net Total assets [Assets] Current liabilities Accounts payable and accrued liabilities Operating lease liability due within one year Total current liabilities [Current liabilities] Long term operating lease liability Total liabilities [Liabilities] Equity Share capital - unlimited authorized shares at no par value.85,546, 77,961 and 71,218 shares outstanding at December 31, 2021, 2020 and 2019, respectively Share capital subscription receivable Additional paid-in capital [Additional paid-in capital] Accumulated deficit Total Stockholders' equity (deficit) [Equity] Total liabilities and stockholders' equity [Equity and liabilities] Share capital, shares outstanding Consolidated Statements of Cash Flow Net loss Depreciation Stock-based compensation Issued stock for service fee Amortization and others Changes in non-cash operating balances: Accounts receivable and other receivables Security deposit [Security deposit] Prepaid expense Inventory [Inventory] Employee deposit of overpayment Accounts payable and accrued liabilities [Accounts payable and accrued liabilities] Net cash used in operating activities [Cash flows from (used in) operating activities] Purchase of property and equipment Net cash flows used in investing activities [Cash flows from (used in) investing activities] Proceeds from the issuance of share capital Repayment of operating lease and financing obligation [Repayment of operating lease and financing obligation] Net cash provided from financing activities [Cash flows from (used in) financing activities] Net (decrease) increase in cash and cash equivalents [Increase (decrease) in cash and cash equivalents after effect of exchange rate changes] CASH AT BANK Beginning of year [Cash and cash equivalents] End of year SUPPLEMENTAL DISCLOSURE Income taxes paid Interest paid NON-CASH INVESTING AND FINANCING ACTIVITIES Shares and warrants issued on connection with convertible notes Consolidated Statements of Changes in Equity Statement [Table] Statement [Line Items] Components Of Equity [Axis] Common Shares Subscriptions Additional paid-in capital [Additional paid-in capital 1] Retained Earnings (Accumulated Deficit) Balance, shares [Number of shares issued] Balance, amount Lease adoption prior year cumulative effect Shares issuance for cash and subscriptions, shares Shares issuance for cash and subscriptions, amount Warrant issued Stock-based compensation and service fee, shares Stock-based compensation and service fee, amount Net loss [Net loss] Balance, shares Balance, amount BUSINESS ACTIVITIES AND BASIS OF PRESENTATION NOTE 1 - BUSINESS ACTIVITIES AND BASIS OF PRESENTATION GOING CONCERN CONSIDERATIONS NOTE 2 - GOING CONCERN CONSIDERATIONS SIGNIFICANT ESTIMATES NOTE 3 - SIGNIFICANT ESTIMATES SIGNIFICANT ACCOUNTING POLICIES NOTE 4 - SIGNIFICANT ACCOUNTING POLICIES NEW ACCOUNTING STANDARDS AND INTERPRETATIONS NOTE 5 - NEW ACCOUNTING STANDARDS AND INTERPRETATIONS PROPERTY AND EQUIPMENT NOTE 6 - PROPERTY AND EQUIPMENT INTANGIBLE ASSETS NOTE 7 - INTANGIBLE ASSETS ACCOUNTS PAYABLE AND ACCRUED LIABILITIES NOTE 8 - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES OPERATING LEASES AND COMMITMENTS NOTE 9 - OPERATING LEASES AND COMMITMENTS SHARE CAPITAL NOTE 10 - SHARE CAPITAL STOCK OPTIONS NOTE 11 - STOCK OPTIONS SHARE BASED COMPENSATION NOTE 12 - SHARE BASED COMPENSATION WARRANTS NOTE 13 - WARRANTS INCOME TAXES NOTE 14 - INCOME TAXES EARNINGS PER SHARE NOTE 15 - EARNINGS PER SHARE FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES NOTE 16 - FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES FINANCE INCOME AND FINANCE COSTS NOTE 17 - FINANCE INCOME AND FINANCE COSTS SEGMENT DISCLOSURES NOTE 18 - SEGMENT DISCLOSURES CONCENTRATIONS NOTE 19 - CONCENTRATIONS RELATED PARTY TRANSACTIONS NOTE 20 - RELATED PARTY TRANSACTIONS RESEARCH AND DEVELOPMENT EXPENSES NOTE 21 - RESEARCH AND DEVELOPMENT EXPENSES PERSONNEL EXPENSES NOTE 22 - PERSONNEL EXPENSES CAPITAL DISCLOSURES AND FINANCIAL RISK NOTE 23 - CAPITAL DISCLOSURES AND FINANCIAL RISK FOREIGN EXCHANGE RISK NOTE 24 - FOREIGN EXCHANGE RISK CREDIT RISK EX-101.CAL 8 nymox-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 nymox-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 nymox-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover	12 Months Ended
Cover	Dec. 31, 2021 shares
Document Information Line Items
Entity Registrant Name	NYMOX PHARMACEUTICAL CORPORATION
Entity Central Index Key	0001018735
Document Type	20-F
Amendment Flag	false
Entity Voluntary Filers	No
Current Fiscal Year End Date	--12-31
Entity Well Known Seasoned Issuer	No
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Dec. 31, 2021
Entity Filer Category	Accelerated Filer
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding	85,545,875
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-12033
Entity Incorporation State Country Code	C5
Entity Address Address Line 1	Bay & Deveaux Streets
Entity Address City Or Town	Nassau
Entity Address Country	BS
Auditor Name	TPS Thayer, LLC
Auditor Location	Sugar Land, Texas
Security 12b Title	Common Stock
Security Exchange Name	NASDAQ
No Trading Symbol Flag	true
Entity Interactive Data Current	Yes
Document Shell Company Report	false
Document Registration Statement	false
Entity Other Identification Type	Erik Danielsen
Document Accounting Standard	International Financial Reporting Standards
Auditor Firm Id	6706
Icfr Auditor Attestation Flag	false
Business Contact [Member]
Document Information Line Items
City Area Code	800
Local Phone Number	936-9669
Contact Personnel Email Address	edanielsen@nymox.com
Contact Personnel Name	Erik Danielsen

XML 12 R2.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Consolidated Statements of Comprehensive Loss
Sales of goods	$ 0	$ 5	$ 116
Total revenue	0	5	116
Cost of goods sold and operating Expenses
Cost of goods sold	0	4	58
Research and development	6,658	8,120	7,377
General and administrative	5,846	3,601	6,006
Total operating expenses	12,504	11,725	13,441
Loss from operations	(12,504)	(11,720)	(13,325)
Finance income	6	24	201
Finance costs	(20)	(30)	(18)
Operating lease interest expense	(19)	(12)	(20)
Loss before income taxes	(33)	(18)	(163)
Income tax provision (recovery)	0	0	0
Net loss	(12,537)	(11,738)	(13,162)
Net Loss attributable to Nymox share holders	$ (12,537)	$ (11,738)	$ (13,162)
Basic and diluted loss per share	$ (0.15)	$ (0.16)	$ (0.19)
Weighted average number of common shares outstanding	81,976	73,823	68,845

XML 13 R3.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash	$ 830	$ 3,611	$ 5,239
Accounts receivable	0	0	4
Other receivables	13	20	14
Inventory	34	34	23
Security deposit	28	28	28
Prepaid expenses and other current assets	132	200	20
Total current assets	1,037	3,893	5,328
Property and equipment	22	28	25
Operating lease right-of-use asset, net	384	422	136
Total assets	1,443	4,343	5,489
Current liabilities
Accounts payable and accrued liabilities	1,558	1,772	1,894
Operating lease liability due within one year	228	193	144
Total current liabilities	1,786	1,965	2,038
Long term operating lease liability	163	233	3
Total liabilities	1,949	2,198	2,041
Equity
Share capital - unlimited authorized shares at no par value.85,546, 77,961 and 71,218 shares outstanding at December 31, 2021, 2020 and 2019, respectively	165,061	151,722	136,554
Share capital subscription receivable	(589)	(589)	(589)
Additional paid-in capital	27,584	31,037	35,770
Accumulated deficit	(192,562)	(180,025)	(168,287)
Total Stockholders' equity (deficit)	(506)	2,145	3,448
Total liabilities and stockholders' equity	$ 1,443	$ 4,343	$ 5,489

XML 14 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Financial Position (Parenthetical) - shares shares in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Consolidated Statements of Financial Position
Share capital, shares outstanding	85,546	77,961	71,218

XML 15 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flow - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Consolidated Statements of Cash Flow
Net loss	$ (12,537)	$ (11,738)	$ (13,162)
Depreciation	12	9	9
Stock-based compensation	2,603	1,748	3,011
Issued stock for service fee	0	0	1,330
Amortization and others	242	258	556
Changes in non-cash operating balances:
Accounts receivable and other receivables	7	(1)	(4)
Security deposit	0	0	12
Prepaid expense	68	(180)	(18)
Inventory	0	(11)	17
Employee deposit of overpayment	(50)	50	0
Accounts payable and accrued liabilities	(165)	(172)	(819)
Net cash used in operating activities	(9,820)	(10,037)	(7,430)
Purchase of property and equipment	(6)	(13)	0
Net cash flows used in investing activities	(6)	(13)	0
Proceeds from the issuance of share capital	7,283	8,687	5,000
Repayment of operating lease and financing obligation	238	265	277
Net cash provided from financing activities	7,045	8,422	4,723
Net (decrease) increase in cash and cash equivalents	(2,781)	(1,628)	(2,707)
CASH AT BANK
Beginning of year	3,611	5,239	7,946
End of year	830	3,611	5,239
SUPPLEMENTAL DISCLOSURE
Income taxes paid	0	0	0
Interest paid	0	0	0
NON-CASH INVESTING AND FINANCING ACTIVITIES
Shares and warrants issued on connection with convertible notes	$ 0	$ 0	$ 0

XML 16 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Changes in Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Shares	Subscriptions	Additional paid-in capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2018		64,676
Balance, amount at Dec. 31, 2018	$ 7,002	$ 126,684	$ (868)	$ 36,299	$ (155,113)
Statement [Line Items]
Lease adoption prior year cumulative effect	(12)				(12)
Shares issuance for cash and subscriptions, shares		2,542
Shares issuance for cash and subscriptions, amount	5,079	$ 4,800	279
Warrant issued	200	$ 0		200	0
Stock-based compensation and service fee, shares		4,000
Stock-based compensation and service fee, amount	4,341	$ 5,070	0	(729)	0
Net loss	(13,162)	$ 0	0	0	(13,162)
Balance, shares at Dec. 31, 2019		71,218
Balance, amount at Dec. 31, 2019	3,448	$ 136,554	(589)	35,770	(168,287)
Statement [Line Items]
Shares issuance for cash and subscriptions, shares		3,743
Shares issuance for cash and subscriptions, amount	8,687	$ 9,388	0	(701)	0
Stock-based compensation and service fee, shares		3,000
Stock-based compensation and service fee, amount	1,748	$ 5,780	0	(4,032)	0
Net loss	(11,738)	$ 0	0	0	(11,738)
Balance, shares at Dec. 31, 2020		77,961
Balance, amount at Dec. 31, 2020	2,145	$ 151,722	(589)	31,037	(180,025)
Statement [Line Items]
Shares issuance for cash and subscriptions, shares		3,670
Shares issuance for cash and subscriptions, amount	6,953	$ 7,670	0	(717)	0
Warrant issued	330			330
Stock-based compensation and service fee, shares		3,915
Stock-based compensation and service fee, amount	2,603	$ 5,669	0	(3,066)	0
Net loss	(12,537)	$ 0	0	0	(12,537)
Balance, shares at Dec. 31, 2021		85,546
Balance, amount at Dec. 31, 2021	$ (506)	$ 165,061	$ (589)	$ 27,584	$ (192,562)

XML 17 R7.htm IDEA: XBRL DOCUMENT

BUSINESS ACTIVITIES AND BASIS OF PRESENTATION

12 Months Ended

Dec. 31, 2021

NOTE 1 - BUSINESS ACTIVITIES AND BASIS OF PRESENTATION

NOTE 1 – BUSINESS ACTIVITIES AND BASIS OF PRESENTATION

Statement of Compliance

The consolidated financial statements were authorized for issue by the Audit Committee of the Corporation’s Board of Directors on March 30, 2022.

Basis of measurement

The consolidated financial statements have been prepared on a going concern and on the historical cost basis.

Functional and presentation currency

These consolidated financial statements are presented in United States dollars, which is the Corporation and its subsidiaries’ functional currency.

Use of estimates and judgments

Judgments in applying accounting policies

The use of the going concern basis (Note 2)

Contingent liability

Assessing the recognition of contingent liabilities requires judgment in evaluating whether it is probable that economic benefits will be required to settle matters subject to litigation .

Stock options and warrants

There is estimation uncertainty with respect to selecting inputs to the Binomial pricing model used to determine the fair value of the stock options and warrants (Note 11).

The above estimates and assumptions are reviewed regularly. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

XML 18 R8.htm IDEA: XBRL DOCUMENT

GOING CONCERN CONSIDERATIONS

12 Months Ended

Dec. 31, 2021

GOING CONCERN CONSIDERATIONS

NOTE 2 - GOING CONCERN CONSIDERATIONS

NOTE 2 – GOING CONCERN CONSIDERATIONS

XML 19 R9.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ESTIMATES

12 Months Ended

Dec. 31, 2021

SIGNIFICANT ESTIMATES

NOTE 3 - SIGNIFICANT ESTIMATES

NOTE 3 – SIGNIFICANT ESTIMATES

XML 20 R10.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2021

SIGNIFICANT ACCOUNTING POLICIES

NOTE 4 - SIGNIFICANT ACCOUNTING POLICIES

NOTE 4 – SIGNIFICANT ACCOUNTING POLICIES

The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.

Consolidation

-	power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee);

-	exposure, or rights, to variable returns from its involvement with the investee; and

-	The ability to use its power over the investee to affect its returns.

All intra-group transactions, balances, income, expenses and unrealized gains and losses on transactions between Group companies are eliminated in full.

Financial instruments

Financial assets

Financial liabilities

Share capital

Common shares are classified as equity. Incremental costs attributable to the issuance of common shares are recognized as an increase to deficit.

Accounts receivable

Inventory

Property and equipment

The estimated useful lives for the current and comparative periods are represented by the following estimated useful lives:

Asset Classification		Useful life

Laboratory equipment		5 years
Computer equipment		3 years
Office equipment and fixtures		5 years

Depreciation methods, useful lives and residual values are reviewed on an ongoing basis and adjusted if appropriate.

Research and development expenditures

Amortization

Amortization is calculated on the cost of the asset, less its residual value. Amortization methods, useful lives and residual values are reviewed on an ongoing basis and adjusted if appropriate.

Impairment

Indefinite lived intangibles are subject an assessment for impairment at each reporting date.

Financial assets impairment

Non-financial assets impairment

Revenue recognition

Upfront payments

Milestone payments

Revenue subject to the achievement of milestones is recognized only when the specified events have occurred, and collectability is reasonably assured.

The company does not have any upfront payments, milestone payments or license revenue for the years ended December 31, 2021, 2020 and 2019.

IFRS 15, Revenue from Contracts with Customers

The Corporation has adopted this standard in these financial statements yet determined that there is no impact on reported results of operations from its implementation.

Sale of goods

Foreign currency

Foreign exchange loss and gain are reported on a net basis, within finance costs or finance income.

Research tax credits

Stock-based compensation

Employee benefits

Short-term employee benefits obligations are measured on an undiscounted basis and are expensed as the related service is provided.

Operating leases

Income taxes

Earnings per share

Provisions

Onerous contracts

Reclassification

XML 21 R11.htm IDEA: XBRL DOCUMENT

NEW ACCOUNTING STANDARDS AND INTERPRETATIONS

12 Months Ended

Dec. 31, 2021

NEW ACCOUNTING STANDARDS AND INTERPRETATIONS

NOTE 5 - NEW ACCOUNTING STANDARDS AND INTERPRETATIONS

NOTE 5 – NEW ACCOUNTING STANDARDS AND INTERPRETATIONS

Standards, amendments and improvements to the approved accounting standards that are not yet effective for CFY’ 2021.

The following standards, amendments and improvements to the approved accounting standards would be effective from the dates mentioned below against the respective standard or interpretation:

Standard or Interpretation		IASB Effective Date (Annual periods beginning on or after)
IFRS 03	Reference to Conceptual Framework (Amendments)	01 January 2022
IFRS 09	Financial Instruments – Fees in the ‘10 percent’ test for derecognition of financial liabilities	01 January 2022
IFRS 10/IAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendment)	Not Yet Finalized
IAS 01	Classification of Liabilities as Current or Non-current liabilities (Amendments)	01 January 2022*
IAS 16	Proceeds before Intended Use (Amendments)	01 January 2022
IAS 37	Onerous Contracts – Costs of Fulfilling a Contract (Amendments)	01 January 2022

*The IASB has issued an exposure draft proposing to defer the effective date of the Amendments to IAS 01 to 01 January 2023.

The above standards and amendments are not expected to have any material impact on the Company’s unconsolidated financial statements in the period of initial application.

XML 22 R12.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT

12 Months Ended

Dec. 31, 2021

PROPERTY AND EQUIPMENT

NOTE 6 - PROPERTY AND EQUIPMENT

NOTE 6 – PROPERTY AND EQUIPMENT

The carrying value of property and equipment included the following changes for the years ended December 31, 2021, 2020 and 2019:

In Thousands of US Dollars
	Laboratory Equipment		Computer Equipment		Office Equipment		Total
Cost
Balance at January 1, 2019	$	418	$	43	$	113	$	574
Additions		–		–		–		–
Disposals		–		–		–		–
Balance at December 31, 2019		418	$	43	$	113	$	574
Additions		–		13		–		13
Disposals		–		–		–		–
Balance at December 31, 2020		418	$	56	$	113	$	587
Additions		–		3		3		6
Disposals		–		–		–		–
Balance at December 31, 2021	$	418	$	59	$	116	$	593

Accumulated depreciation
Balance at January1, 2019		418		33		90	$	541
Depreciation for the year		–		4		5		9
Disposals		–		–		–		–
Balance at December 31, 2019	$	418	$	37	$	95	$	550
Depreciation for the year		–		4		5		9
Disposals		–		–		–		–
Balance at December 31, 2020		418	$	41	$	100	$	559
Depreciation for the year		–		7		5		12
Disposals		–		–		–		–
Balance at December 31, 2021	$	418	$	48	$	105	$	571
Carrying amounts
At December 31, 2019	$	-	$	6	$	19	$	25
At December 31, 2020	$	-	$	15	$	13	$	28
At December 31, 2021	$	-	$	11	$	11	$	22

The depreciation expense of property and equipment amounts to $12,357, $9,236 and $8,684 for the years ended December 31, 2021, 2020 and 2019, respectively. .

XML 23 R13.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2021

INTANGIBLE ASSETS

NOTE 7 - INTANGIBLE ASSETS

NOTE 7 – INTANGIBLE ASSETS

XML 24 R14.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

12 Months Ended

Dec. 31, 2021

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE 8 - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

NOTE 8 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities as of December 31, 2021, 2020 and 2019, consisted of the following:

In Thousands of US Dollars
Description	2021		2020		2019
Accounts payable	$	1,273	$	1,403	$	1,629
Accrued liabilities:
Payroll related liabilities		262		245		225
Other accrued liabilities		23		74		40
Deposit		-		50		-
Total accounts payable and accrued liabilities	$	1,558	$	1,772	$	1,894

XML 25 R15.htm IDEA: XBRL DOCUMENT

OPERATING LEASES AND COMMITMENTS

12 Months Ended

Dec. 31, 2021

OPERATING LEASES AND COMMITMENTS

NOTE 9 - OPERATING LEASES AND COMMITMENTS

NOTE 9 – OPERATING LEASES AND COMMITMENTS

Table of Contents

The following table provides the changes in the Corporation’s operating lease right-of-use assets for the year ended December 31, 2021, 2020 and 2019 respectively:

In Thousands of US Dollars
	Operation lease right-of-use asset
Balances as of January 1, 2021	$	422
Renewed office lease		184
Accumulated amortization		(222	)
Balances as of December 31, 2021	$	384

In Thousands of US Dollars
	Operation lease right-of-use asset
Balances as of January 1, 2020	$	136
Renewed office lease		533
Accumulated amortization		(247	)
Balances as of December 31, 2020	$	422

In Thousands of US Dollars
	Operation lease right-of-use asset
Balances as of January 1, 2019	$	393
Accumulated amortization		(247	)
Other		(4	)
Balances as of December 31, 2019	$	136

Table of Contents

The following table provides the changes in the Corporation’s operating lease liability for the year ended December 31, 2021, 2020 and 2019 respectively:

In Thousands of US Dollars
	Total
Balances as of January 1, 2021	$	426
Renewed office lease		184
Repayments of lease liability		(238	)
Other		19
Balances as of December 31, 2021	$	391
Lease liability due within one year	$	228
Lease liability long term	$	163

In Thousands of US Dollars
	Total
Balances as of January 1, 2020	$	147
Renewed office lease		533
Repayments of lease liability		(265	)
Other		11
Balances as of December 31, 2020	$	426
Lease liability due within one year	$	193
Lease liability long term	$	233

In Thousands of US Dollars
	Total
Balances as of January 1, 2019	$	405
Repayments of lease liability		(277	)
Other		19
Balances as of December 31, 2019	$	147
Lease liability due within one year	$	144
Lease liability long term	$	3

XML 26 R16.htm IDEA: XBRL DOCUMENT

SHARE CAPITAL

12 Months Ended

Dec. 31, 2021

SHARE CAPITAL

NOTE 10 - SHARE CAPITAL

NOTE 10 – SHARE CAPITAL

Common shares authorized, issued and related contributed capital by controlling shareholders as of December 31, 2021, 2020 and 2019 were as follows

In Thousands of US Dollars and shares
Description	2021		2020		2019
Authorized:
An unlimited number of common shares, at no par value
Issued, outstanding:
Number of common shares		85,546		77,961		71,218
Dollars	$	165,061	$	151,722	$	136,554

Common Stock

XML 27 R17.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS

12 Months Ended

Dec. 31, 2021

STOCK OPTIONS

NOTE 11 - STOCK OPTIONS

NOTE 11 – STOCK OPTIONS

	Options outstanding
	Number			Weighted average exercise price		Weighted average remaining contractual life (in years)
Outstanding January 1, 2019		5,740,000		$	1.76		6.37
Expired		(10,000	)		3.43		-
Granted		360,000			2.08		9.26
Outstanding December 31, 2019		6,090,000		$	1.78		5.61
Expired		-			-		-
Granted		410,000			2.34		8.94
Outstanding December 31, 2020		6,500,000		$	1.81		4.87
Expired		(200,000	)		1.81		-
Not vested
Granted		128,000			1.77		9.48
Outstanding December 31, 2021		6,428,000		$	1.81		3.86
Options exercisable		6,348,833		$	1.80		3.80

The fair value of the options granted during the years ended December 31, 2021, 2020 and 2019, was determined using the Binomial Option pricing model using the following weighted average assumptions:

Description	2021			2020			2019
Share price	$	1.75~1.83		$	1.81~2.86			$	2.08
Exercise price	$	1.75~1.83		$	1.81~2.86			$	2.08
Risk-free interest rate		1.60%~1.64	%		1.12%~1.67	%			2.48	%
Expected volatility		107.05%~107.47	%		81.34%~106.56	%			105.36	%
Expected option life in years		10.	Yrs		4~10	Yrs			10	Yrs
Expected dividend yield		-			-				-

XML 28 R18.htm IDEA: XBRL DOCUMENT

SHARE BASED COMPENSATION

12 Months Ended

Dec. 31, 2021

SHARE BASED COMPENSATION

NOTE 12 - SHARE BASED COMPENSATION

NOTE 12 - SHARE BASED COMPENSATION

In Thousands of US Dollars
Functional Expense Category	2021		2020		2019
General and administrative expense	$	2,124	$	702	$	1,839
Research and development expense		479		1,046		1,172
Total	$	2,603	$	1,748	$	3,011

XML 29 R19.htm IDEA: XBRL DOCUMENT

WARRANTS

12 Months Ended

Dec. 31, 2021

WARRANTS

NOTE 13 - WARRANTS

NOTE 13 - WARRANTS

A detail of warrant activity for the years ended December 31, 2021, 2020 and 2019 is as follows:

Description	Number		Weighted average exercise price		Weighted average remaining contractual life (in years)
Outstanding 1-Jan-19		-	$	-		-
Exercised		-		-		-
Granted		2,500,000-		8.00		-
Expired		-		-		-
Cancelled		-		-		-
Outstanding 31-Dec-19		2,500,000	$	8.00		4.04
Exercised		-		-		-
Granted						-
Expired		-		-		-
Cancelled		-		-		-
Outstanding 31-Dec-20		2,500,000	$	8.00		3.04
Exercised		-		-		-
Granted		2,018,348		2.50		-
Expired		-		-		-
Cancelled		-		-		-
Outstanding 31-Dec-21		4,518,348	$	5.54		3.07

XML 30 R20.htm IDEA: XBRL DOCUMENT

INCOME TAXES

12 Months Ended

Dec. 31, 2021

INCOME TAXES

NOTE 14 - INCOME TAXES

NOTE 14 - INCOME TAXES

Nymox recognized no provision (recovery) for federal income taxes for the years ended December 31, 2021, 2020 and 2019.

Table of Contents

The following table is a reconciliation of effective tax rate:

In Thousands of US Dollars
Description	2021			2020			2019
Net loss for the year, before income taxes	$	(12,537	)	$	(11,738	)	$	(13,162	)
Net loss attributable to the Bahamas		(11,781	)		(11,012	)		(12,841	)
Net loss attributable the United States		(756	)		(725	)		(321	)
Domestic tax rate applicable to the Corporation		21	%		21	%		21	%
Income taxes at domestic tax statutory rate		(159	)		(152	)		(67	)
Change in valuation allowance		159			152			67
Deferred tax provision (recovery)	$	-		$	-		$	-

As of December 31, 2021, 2020 and 2019, deferred tax assets not recognized were as follows:

In Thousands of US Dollars
Description	2021		2020		2019
Tax loss carry forward	$	1,404	$	1,386	$	1,402
Patents capitalized and amortized for tax purposes		0		0		0
Unrecognized deferred tax assets	$	1,404	$	1.386	$	1,402

The amount of net operating loss carryforwards for US Federal income tax purposes by year of origination and expiration is detailed below:

In Thousands of US Dollars
Year Originated	Year of Expiration	Amount		Year Originated	Year of Expiration	Amount
2002	2022		522	2012	2032		177
2003	2023		564	2013	2033		121
2004	2024		353	2014	2034		70
2005	2025		264	2015	2035		127
2006	2026		355	2016	2036		147
2007	2027		373	2017	2037		140
2008	2028		.351	2018	2038		194
2009	2029		86	2019	2039		337
2010	2030		541	2020	2040		732
2011	2031		480	2021	2041		753

		Total				$	6,687

XML 31 R21.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE

12 Months Ended

Dec. 31, 2021

EARNINGS PER SHARE

NOTE 15 - EARNINGS PER SHARE

NOTE 15 - EARNINGS PER SHARE

Weighted average number of common shares outstanding:

In Thousands of Shares
Description	2021		2020		2019
Issued common shares at January 1		77,961		71,218		64,676
Effect of shares issued		4,015		2,605		4,169
Weighted average number of common shares outstanding at December 31		81,976		73,823		68,845

XML 32 R22.htm IDEA: XBRL DOCUMENT

FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES

12 Months Ended

Dec. 31, 2021

FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES

NOTE 16 - FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES

NOTE 16 - FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES

XML 33 R23.htm IDEA: XBRL DOCUMENT

FINANCE INCOME AND FINANCE COSTS

12 Months Ended

Dec. 31, 2021

FINANCE INCOME AND FINANCE COSTS

NOTE 17 - FINANCE INCOME AND FINANCE COSTS

NOTE 17 – FINANCE INCOME AND FINANCE COSTS

Finance income and finance costs for the years ended December 31, 2021, 2020 and 2019, are detailed below:

In Thousands of US Dollars
Description	2021			2020			2019

Interest income	$	8		$	27		$	213
Net foreign exchange gain(loss)		(2	)		(3	)		(12	)
Finance income		6			24			201
Interest and bank charges		(20	)		(30	)		(18	)
Financial costs		(20	)		(30	)		(18	)
Operating lease interest expense		(19	)		(12	)		(20	)
Total finance income and costs	$	(33	)	$	(18	)	$	163

XML 34 R24.htm IDEA: XBRL DOCUMENT

SEGMENT DISCLOSURES

12 Months Ended

Dec. 31, 2021

SEGMENT DISCLOSURES

NOTE 18 - SEGMENT DISCLOSURES

NOTE 18 - SEGMENT DISCLOSURES

The Corporation operates in one reportable segment, which is the Corporation’s strategic business unit -the research and development of products for the aging population.

Information regarding the geographic reportable segment is as follows:

In Thousands of US Dollars
Description	Canada		United States		Europe
Revenues
2021	$	-	$	-	$	-
2020	$	-	$	3	$	2
2019	$	1	$	91	$	24
Property and equipment
December 31, 2021	$	10	$	12	$	–
December 31, 2020	$	9	$	19	$	–
December 31, 2019	$	–	$	25	$	–

Revenues are attributed to geographic locations based on location of customers. Property and equipment is attributed to geographic locations based on its physical location.

XML 35 R25.htm IDEA: XBRL DOCUMENT

CONCENTRATIONS

12 Months Ended

Dec. 31, 2021

CONCENTRATIONS

NOTE 19 - CONCENTRATIONS

NOTE 19 - CONCENTRATIONS

Major customers

Customers that accounted for greater than 10% of revenues from sales of goods in any of the last three years were as follows:

In Thousands of US Dollars
Description	2021		2020		2019
Customer A	$	-	$	-	$	23
Customer B	$	-	$	2	$	-
Customer C	$	-	$	-	$	36

XML 36 R26.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

12 Months Ended

Dec. 31, 2021

RELATED PARTY TRANSACTIONS

NOTE 20 - RELATED PARTY TRANSACTIONS

NOTE 20- RELATED PARTY TRANSACTIONS

Executive officers and directors participate in the Corporation’s stock option plan. Executive officers are covered under the Corporation’s health plan.

Table of Contents

Key management personnel compensation is comprised of:

In Thousands of US Dollars
Description	2021		2020		2019
Salary and Compensation	$	750	$	-	$	-
Short-term employee benefits		14		2		2
Stock-based compensation		2,227		1,404		2,998
Total	$	2,991	$	1,406	$	3,000

The above honorariums payment to directors and professional service fee paid to officers’ related party are part of the company’s G&A expense.

XML 37 R27.htm IDEA: XBRL DOCUMENT

RESEARCH AND DEVELOPMENT EXPENSES

12 Months Ended

Dec. 31, 2021

RESEARCH AND DEVELOPMENT EXPENSES

NOTE 21 - RESEARCH AND DEVELOPMENT EXPENSES

NOTE 21 – RESEARCH AND DEVELOPMENT EXPENSES

Research and development expenses, excluding stock-based compensation, depreciation and lease amortization expenses, allocated to our major research and development programs are as follows:

In Thousands of US Dollars
	For the Year Ended December 31,
Research and Development Program	2021		2020		2019
Research and Development Program	$	-	$	-	$	4
Alzheimer’s Disease: Therapeutics		4		-		4
Anti-Infectives		-		4		4
BPH (Enlarged Prostate) and Prostate Cancer Therapeutics	5,944			7,162		5,932
Tobacco Exposure Tests: NicAlert™ and TobacAlert™		1		1		18
Total	$	5,949	$	7,167	$	5,962

XML 38 R28.htm IDEA: XBRL DOCUMENT

PERSONNEL EXPENSES

12 Months Ended

Dec. 31, 2021

PERSONNEL EXPENSES

NOTE 22 - PERSONNEL EXPENSES

NOTE 22 - PERSONNEL EXPENSES

A detailed analysis of employee personnel related expenses for the years ended December 31, 2021, 2020 and 2019 is provided below:

In Thousands of US Dollars
Description	2021		2020		2019
Salaries and compensation	$	1,419	$	659	$	689
Employer contributions		49		51		54
Short-term employee benefits		70		18		16
Stock-based compensation		2,227		1,417		3,011
Total	$	3,765	$	2,145	$	3,770

XML 39 R29.htm IDEA: XBRL DOCUMENT

CAPITAL DISCLOSURES AND FINANCIAL RISK

12 Months Ended

Dec. 31, 2021

CAPITAL DISCLOSURES AND FINANCIAL RISK

NOTE 23 - CAPITAL DISCLOSURES AND FINANCIAL RISK

NOTE 23 - CAPITAL DISCLOSURES AND FINANCIAL RISK

XML 40 R30.htm IDEA: XBRL DOCUMENT

FOREIGN EXCHANGE RISK

12 Months Ended

Dec. 31, 2021

FOREIGN EXCHANGE RISK

NOTE 24 - FOREIGN EXCHANGE RISK

NOTE 24 - FOREIGN EXCHANGE RISK

We have no significant items exposed to foreign exchange.

An assumed 5% weakening of the US dollar against the Canadian dollar would have had an equal but opposite effect on the amount shown above, on the basis that all other variables remained constant.

XML 41 R31.htm IDEA: XBRL DOCUMENT

CREDIT RISK

12 Months Ended

Dec. 31, 2021

CREDIT RISK

NOTE 25 - CREDIT RISK

NOTE 25 - CREDIT RISK

At December 31, 2021, the Corporation’s maximum credit exposure corresponded to the carrying amount of cash, and other receivables.

XML 42 R32.htm IDEA: XBRL DOCUMENT

INTEREST RATE RISK

12 Months Ended

Dec. 31, 2021

INTEREST RATE RISK

NOTE 26 - INTEREST RATE RISK

NOTE 26 - INTEREST RATE RISK

XML 43 R33.htm IDEA: XBRL DOCUMENT

LIQUIDITY RISK

12 Months Ended

Dec. 31, 2021

LIQUIDITY RISK

NOTE 27 - LIQUIDITY RISK

NOTE 27 - LIQUIDITY RISK

The following are the contractual maturities of financial liabilities:

In Thousands of US Dollars
Description	Carrying Amount		Less than 1 year		1 year to 5 years
Accounts payable and accrued liabilities
December 31, 2021	$	1,949	$	1,786	$	163
December 31, 2020	$	2,198	$	1,965	$	233

XML 44 R34.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2021

SUBSEQUENT EVENTS

NOTE 28 - SUBSEQUENT EVENTS

NOTE 28 - SUBSEQUENT EVENTS

XML 45 R35.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2021

SIGNIFICANT ACCOUNTING POLICIES (Policies)

Consolidation

-	power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee);

-	exposure, or rights, to variable returns from its involvement with the investee; and

-	The ability to use its power over the investee to affect its returns.

All intra-group transactions, balances, income, expenses and unrealized gains and losses on transactions between Group companies are eliminated in full.

Financial instruments

Financial assets

Financial liabilities

Share capital

Common shares are classified as equity. Incremental costs attributable to the issuance of common shares are recognized as an increase to deficit.

Account Receivable

Inventories

Property and equipment

The estimated useful lives for the current and comparative periods are represented by the following estimated useful lives:

Asset Classification		Useful life

Laboratory equipment		5 years
Computer equipment		3 years
Office equipment and fixtures		5 years

Depreciation methods, useful lives and residual values are reviewed on an ongoing basis and adjusted if appropriate.

Research and development expenditures

Amortization

Amortization is calculated on the cost of the asset, less its residual value. Amortization methods, useful lives and residual values are reviewed on an ongoing basis and adjusted if appropriate.

Impairment

Indefinite lived intangibles are subject an assessment for impairment at each reporting date.

Financial assets impairment

Non-financial assets impairment

Revenue recognitions

Upfront payments

Milestone payments

Revenue subject to the achievement of milestones is recognized only when the specified events have occurred, and collectability is reasonably assured.

The company does not have any upfront payments, milestone payments or license revenue for the years ended December 31, 2021, 2020 and 2019.

IFRS 15, Revenue from Contracts with Customers

The Corporation has adopted this standard in these financial statements yet determined that there is no impact on reported results of operations from its implementation.

Sale of goods

Foreign currency

Foreign exchange loss and gain are reported on a net basis, within finance costs or finance income.

Research tax credits

Stock-based compensation

Employee benefits

Short-term employee benefits obligations are measured on an undiscounted basis and are expensed as the related service is provided.

XML 46 R36.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Property and equipment estimated useful lives

Asset Classification		Useful life

Laboratory equipment		5 years
Computer equipment		3 years
Office equipment and fixtures		5 years

XML 47 R37.htm IDEA: XBRL DOCUMENT

NEW ACCOUNTING STANDARDS AND INTERPRETATIONS (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of accounting standards

Standard or Interpretation		IASB Effective Date (Annual periods beginning on or after)
IFRS 03	Reference to Conceptual Framework (Amendments)	01 January 2022
IFRS 09	Financial Instruments – Fees in the ‘10 percent’ test for derecognition of financial liabilities	01 January 2022
IFRS 10/IAS 28	Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendment)	Not Yet Finalized
IAS 01	Classification of Liabilities as Current or Non-current liabilities (Amendments)	01 January 2022*
IAS 16	Proceeds before Intended Use (Amendments)	01 January 2022
IAS 37	Onerous Contracts – Costs of Fulfilling a Contract (Amendments)	01 January 2022

XML 48 R38.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of property and equipment

In Thousands of US Dollars
	Laboratory Equipment		Computer Equipment		Office Equipment		Total
Cost
Balance at January 1, 2019	$	418	$	43	$	113	$	574
Additions		–		–		–		–
Disposals		–		–		–		–
Balance at December 31, 2019		418	$	43	$	113	$	574
Additions		–		13		–		13
Disposals		–		–		–		–
Balance at December 31, 2020		418	$	56	$	113	$	587
Additions		–		3		3		6
Disposals		–		–		–		–
Balance at December 31, 2021	$	418	$	59	$	116	$	593

Accumulated depreciation
Balance at January1, 2019		418		33		90	$	541
Depreciation for the year		–		4		5		9
Disposals		–		–		–		–
Balance at December 31, 2019	$	418	$	37	$	95	$	550
Depreciation for the year		–		4		5		9
Disposals		–		–		–		–
Balance at December 31, 2020		418	$	41	$	100	$	559
Depreciation for the year		–		7		5		12
Disposals		–		–		–		–
Balance at December 31, 2021	$	418	$	48	$	105	$	571
Carrying amounts
At December 31, 2019	$	-	$	6	$	19	$	25
At December 31, 2020	$	-	$	15	$	13	$	28
At December 31, 2021	$	-	$	11	$	11	$	22

XML 49 R39.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

In Thousands of US Dollars
Description	2021		2020		2019
Accounts payable	$	1,273	$	1,403	$	1,629
Accrued liabilities:
Payroll related liabilities		262		245		225
Other accrued liabilities		23		74		40
Deposit		-		50		-
Total accounts payable and accrued liabilities	$	1,558	$	1,772	$	1,894

XML 50 R40.htm IDEA: XBRL DOCUMENT

OPERATING LEASES AND COMMITMENTS (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Operating lease right-of-use assets

In Thousands of US Dollars
	Operation lease right-of-use asset
Balances as of January 1, 2021	$	422
Renewed office lease		184
Accumulated amortization		(222	)
Balances as of December 31, 2021	$	384

In Thousands of US Dollars
	Operation lease right-of-use asset
Balances as of January 1, 2019	$	393
Accumulated amortization		(247	)
Other		(4	)
Balances as of December 31, 2019	$	136

Summary of operating lease liability

In Thousands of US Dollars
	Operation lease right-of-use asset
Balances as of January 1, 2020	$	136
Renewed office lease		533
Accumulated amortization		(247	)
Balances as of December 31, 2020	$	422

In Thousands of US Dollars
	Total
Balances as of January 1, 2021	$	426
Renewed office lease		184
Repayments of lease liability		(238	)
Other		19
Balances as of December 31, 2021	$	391
Lease liability due within one year	$	228
Lease liability long term	$	163

Summary of lease liability

In Thousands of US Dollars
	Total
Balances as of January 1, 2020	$	147
Renewed office lease		533
Repayments of lease liability		(265	)
Other		11
Balances as of December 31, 2020	$	426
Lease liability due within one year	$	193
Lease liability long term	$	233

In Thousands of US Dollars
	Total
Balances as of January 1, 2019	$	405
Repayments of lease liability		(277	)
Other		19
Balances as of December 31, 2019	$	147
Lease liability due within one year	$	144
Lease liability long term	$	3

XML 51 R41.htm IDEA: XBRL DOCUMENT

SHARE CAPITAL (Tables)

12 Months Ended

Dec. 31, 2021

SHARE CAPITAL (Tables)

Summary of Common shares authorized, issued and related contributed capital by controlling shareholders

In Thousands of US Dollars and shares
Description	2021		2020		2019
Authorized:
An unlimited number of common shares, at no par value
Issued, outstanding:
Number of common shares		85,546		77,961		71,218
Dollars	$	165,061	$	151,722	$	136,554

XML 52 R42.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS (Tables)

12 Months Ended

Dec. 31, 2021

STOCK OPTIONS (Tables)

Summary of Stock option award

	Options outstanding
	Number			Weighted average exercise price		Weighted average remaining contractual life (in years)
Outstanding January 1, 2019		5,740,000		$	1.76		6.37
Expired		(10,000	)		3.43		-
Granted		360,000			2.08		9.26
Outstanding December 31, 2019		6,090,000		$	1.78		5.61
Expired		-			-		-
Granted		410,000			2.34		8.94
Outstanding December 31, 2020		6,500,000		$	1.81		4.87
Expired		(200,000	)		1.81		-
Not vested
Granted		128,000			1.77		9.48
Outstanding December 31, 2021		6,428,000		$	1.81		3.86
Options exercisable		6,348,833		$	1.80		3.80

Summary of Fair value of the options granted

Description	2021			2020			2019
Share price	$	1.75~1.83		$	1.81~2.86			$	2.08
Exercise price	$	1.75~1.83		$	1.81~2.86			$	2.08
Risk-free interest rate		1.60%~1.64	%		1.12%~1.67	%			2.48	%
Expected volatility		107.05%~107.47	%		81.34%~106.56	%			105.36	%
Expected option life in years		10.	Yrs		4~10	Yrs			10	Yrs
Expected dividend yield		-			-				-

XML 53 R43.htm IDEA: XBRL DOCUMENT

SHARE BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2021

Summary of stock option-based compensation expense

In Thousands of US Dollars
Functional Expense Category	2021		2020		2019
General and administrative expense	$	2,124	$	702	$	1,839
Research and development expense		479		1,046		1,172
Total	$	2,603	$	1,748	$	3,011

XML 54 R44.htm IDEA: XBRL DOCUMENT

WARRANTS (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Warrants outstanding

Description	Number		Weighted average exercise price		Weighted average remaining contractual life (in years)
Outstanding 1-Jan-19		-	$	-		-
Exercised		-		-		-
Granted		2,500,000-		8.00		-
Expired		-		-		-
Cancelled		-		-		-
Outstanding 31-Dec-19		2,500,000	$	8.00		4.04
Exercised		-		-		-
Granted						-
Expired		-		-		-
Cancelled		-		-		-
Outstanding 31-Dec-20		2,500,000	$	8.00		3.04
Exercised		-		-		-
Granted		2,018,348		2.50		-
Expired		-		-		-
Cancelled		-		-		-
Outstanding 31-Dec-21		4,518,348	$	5.54		3.07

XML 55 R45.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Effective tax rate

In Thousands of US Dollars
Description	2021			2020			2019
Net loss for the year, before income taxes	$	(12,537	)	$	(11,738	)	$	(13,162	)
Net loss attributable to the Bahamas		(11,781	)		(11,012	)		(12,841	)
Net loss attributable the United States		(756	)		(725	)		(321	)
Domestic tax rate applicable to the Corporation		21	%		21	%		21	%
Income taxes at domestic tax statutory rate		(159	)		(152	)		(67	)
Change in valuation allowance		159			152			67
Deferred tax provision (recovery)	$	-		$	-		$	-

Summary of Unrecognized deferred tax assets

In Thousands of US Dollars
Description	2021		2020		2019
Tax loss carry forward	$	1,404	$	1,386	$	1,402
Patents capitalized and amortized for tax purposes		0		0		0
Unrecognized deferred tax assets	$	1,404	$	1.386	$	1,402

Summary of Net operating loss carryforwards for origination and expiration

In Thousands of US Dollars
Year Originated	Year of Expiration	Amount		Year Originated	Year of Expiration	Amount
2002	2022		522	2012	2032		177
2003	2023		564	2013	2033		121
2004	2024		353	2014	2034		70
2005	2025		264	2015	2035		127
2006	2026		355	2016	2036		147
2007	2027		373	2017	2037		140
2008	2028		.351	2018	2038		194
2009	2029		86	2019	2039		337
2010	2030		541	2020	2040		732
2011	2031		480	2021	2041		753

		Total				$	6,687

XML 56 R46.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2021

EARNINGS PER SHARE (Tables)

Schedule of weighted average number of share

In Thousands of Shares
Description	2021		2020		2019
Issued common shares at January 1		77,961		71,218		64,676
Effect of shares issued		4,015		2,605		4,169
Weighted average number of common shares outstanding at December 31		81,976		73,823		68,845

XML 57 R47.htm IDEA: XBRL DOCUMENT

FINANCE INCOME AND FINANCE COSTS (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Finance income and finance cots

In Thousands of US Dollars
Description	2021			2020			2019

Interest income	$	8		$	27		$	213
Net foreign exchange gain(loss)		(2	)		(3	)		(12	)
Finance income		6			24			201
Interest and bank charges		(20	)		(30	)		(18	)
Financial costs		(20	)		(30	)		(18	)
Operating lease interest expense		(19	)		(12	)		(20	)
Total finance income and costs	$	(33	)	$	(18	)	$	163

XML 58 R48.htm IDEA: XBRL DOCUMENT

SEGMENT DISCLOSURES (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Geographic reportable segment

In Thousands of US Dollars
Description	Canada		United States		Europe
Revenues
2021	$	-	$	-	$	-
2020	$	-	$	3	$	2
2019	$	1	$	91	$	24
Property and equipment
December 31, 2021	$	10	$	12	$	–
December 31, 2020	$	9	$	19	$	–
December 31, 2019	$	–	$	25	$	–

XML 59 R49.htm IDEA: XBRL DOCUMENT

CONCENTRATIONS (Tables)

12 Months Ended

Dec. 31, 2021

Summary of revenues from sales

In Thousands of US Dollars
Description	2021		2020		2019
Customer A	$	-	$	-	$	23
Customer B	$	-	$	2	$	-
Customer C	$	-	$	-	$	36

XML 60 R50.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Tables)

12 Months Ended

Dec. 31, 2021

NOTE 20 - RELATED PARTY TRANSACTIONS

In Thousands of US Dollars
Description	2021		2020		2019
Salary and Compensation	$	750	$	-	$	-
Short-term employee benefits		14		2		2
Stock-based compensation		2,227		1,404		2,998
Total	$	2,991	$	1,406	$	3,000

XML 61 R51.htm IDEA: XBRL DOCUMENT

RESEARCH AND DEVELOPMENT EXPENSES (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Research and development expenses

In Thousands of US Dollars
	For the Year Ended December 31,
Research and Development Program	2021		2020		2019
Research and Development Program	$	-	$	-	$	4
Alzheimer’s Disease: Therapeutics		4		-		4
Anti-Infectives		-		4		4
BPH (Enlarged Prostate) and Prostate Cancer Therapeutics	5,944			7,162		5,932
Tobacco Exposure Tests: NicAlert™ and TobacAlert™		1		1		18
Total	$	5,949	$	7,167	$	5,962

XML 62 R52.htm IDEA: XBRL DOCUMENT

PERSONNEL EXPENSES (Tables)

12 Months Ended

Dec. 31, 2021

Summary of personnel related expenses

In Thousands of US Dollars
Description	2021		2020		2019
Salaries and compensation	$	1,419	$	659	$	689
Employer contributions		49		51		54
Short-term employee benefits		70		18		16
Stock-based compensation		2,227		1,417		3,011
Total	$	3,765	$	2,145	$	3,770

XML 63 R53.htm IDEA: XBRL DOCUMENT

LIQUIDITY RISK (Tables)

12 Months Ended

Dec. 31, 2021

Summary of Contractual maturities of financial liabilities

In Thousands of US Dollars
Description	Carrying Amount		Less than 1 year		1 year to 5 years
Accounts payable and accrued liabilities
December 31, 2021	$	1,949	$	1,786	$	163
December 31, 2020	$	2,198	$	1,965	$	233

XML 64 R54.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details)	12 Months Ended
SIGNIFICANT ACCOUNTING POLICIES (Details)	Dec. 31, 2021
Laboratory Equipment [Member]
Statement [Line Items]
Property and equipment estimated useful lives	5
Computer Equipment [member]
Statement [Line Items]
Property and equipment estimated useful lives	3
Office Equipment And Fixtures [Member]
Statement [Line Items]
Property and equipment estimated useful lives	5

XML 65 R55.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Accounts receivable	$ 0	$ 0	$ 4,000
January 1, 2019 [Member]
Statement [Line Items]
Immaterial cumulative adjustment	$ 11,667	$ 11,667

XML 66 R56.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Beginning balance	$ 587,000	$ 574,000	$ 574,000
Additions	6,000	13,000
Disposals		0	0
Ending balance	593,000	587,000	574,000
Accumulated depreciation, beginning balance	559,000	550,000	418,000
Accumulated depreciation, depreciation for the year	12,000	9,000	9,000
Accumulated depreciation, Disposals for the year	0	0	0
Accumulated depreciation, ending balance	571,000	559,000	550,000
Carrying value of property and equipment	22,000		25,000
Office equipment [member]
Statement [Line Items]
Beginning balance	113,000	113,000	113,000
Additions	3,000	3,000	0
Ending balance	116,000	113,000	113,000
Accumulated depreciation, beginning balance	100,000	95,000	90,000
Accumulated depreciation, depreciation for the year	5,000		5,000
Accumulated depreciation, Disposals for the year	0	0	0
Accumulated depreciation, ending balance	105,000	100,000	95,000
Carrying value of property and equipment	11,000	13,000	19,000
Laboratory Equipment [Member]
Statement [Line Items]
Beginning balance	418,000	418,000	418,000
Ending balance	418,000	418,000	418,000
Accumulated depreciation, beginning balance	418,000	418,000
Accumulated depreciation, ending balance	418,000	418,000	418,000
Accumulated depreciation, Disposals for the year	0	0	0
Computer equipment [member]
Statement [Line Items]
Beginning balance	56,000	43,000	43,000
Additions	3,000	13,000
Ending balance	59,000	56,000	43,000
Accumulated depreciation, beginning balance	41,000	37,000	33,000
Accumulated depreciation, depreciation for the year	7,000	4,000	4,000
Accumulated depreciation, Disposals for the year	0	0	0
Accumulated depreciation, ending balance	48,000	41,000	37,000
Carrying value of property and equipment	$ 11,000	$ 15,000	$ 6,000

XML 67 R57.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
PROPERTY AND EQUIPMENT (Details)
Depreciation expense of property and equipment	$ 12,357	$ 9,236	$ 8,684

XML 68 R58.htm IDEA: XBRL DOCUMENT

INTANGIBLE ASSETS (Details Narrative) - Intellectual Property Rights [Member] - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Intangible assets	$ 2,222,661	$ 2,222,661	$ 2,222,661
Accumulated amortization	$ 2,222,661	$ 2,222,661	$ 2,222,661

XML 69 R59.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounts payable	$ 1,273	$ 1,403	$ 1,629
Payroll related liabilities	262	245	225
Other accrued liabilities	23	74	40
Deposit	0	50	0
Total accounts payable and accrued liabilities	$ 1,558	$ 1,772	$ 1,894

XML 70 R60.htm IDEA: XBRL DOCUMENT

INTEREST RATE RISK (Details Narrative)	12 Months Ended
INTEREST RATE RISK (Details Narrative)	Dec. 31, 2021
Increase decrease interest rates percentage description	Based on the value of variable interest-bearing cash during the year ended December 31, 2021, an assumed 0.5% increase or 0.5% decrease in interest rates during such period would have had no significant effect on the net loss.

XML 71 R61.htm IDEA: XBRL DOCUMENT

CREDIT RISK (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Trade accounts receivable	$ 0	$ 0	$ 4,368

XML 72 R62.htm IDEA: XBRL DOCUMENT

FOREIGN EXCHANGE RISK (Details Narrative)	12 Months Ended
FOREIGN EXCHANGE RISK (Details Narrative)	Dec. 31, 2019
Description of functional currency exposures	foreign currency exposures, varying the above foreign exchange rates to reflect a 5% strengthening of the US dollar would have decreased the net loss for the year ended December 31, 2021 by approximately $17,653, assuming that all other variables remained constant.

XML 73 R63.htm IDEA: XBRL DOCUMENT

CAPITAL DISCLOSURES AND FINANCIAL RISK (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Denominated percentages of expenses	97.00%	97.00%	98.00%
Private Placements [Member]
Statement [Line Items]
Common shares issued	3,669,724
Warrants to purchase up shares of common stock	2,018,348
Warrant Excise	$ 2.50
Share Capital Before Various Fee Charges	$ 8,000,000
Corporation Raised a Total Share Capital	$ 681,652

XML 74 R64.htm IDEA: XBRL DOCUMENT

OPERATING LEASES AND COMMITMENT (Details) - USD ($)	12 Months Ended
OPERATING LEASES AND COMMITMENT (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Begininng balance	$ 442,000	$ 136,000	$ 393,000
Renewed office lease	184,000	533,000
Renewed office lease	184,000		(247,000)
Accumulated amortization	(222,000)	(247,000)	(4,000)
Ending balance	$ 384,000	$ 422,000	$ 136,000

XML 75 R65.htm IDEA: XBRL DOCUMENT

OPERATING LEASES AND COMMITMENT (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Beginning balance	$ 426	$ 147	$ 405
Renewed office lease	184		(247)
Renewed office lease	184	533
Repayments of lease liability	(238)	(265)	(277)
Other	19	11	19
Ending balance	391	426	147
Lease liability due within one year	228	193	144
Lease liability long term	$ 163	$ 233	$ 3

XML 76 R66.htm IDEA: XBRL DOCUMENT

OPERATING LEASES AND COMMITMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Operating lease liability	$ 391,459	$ 425,620	$ 147,036
Future payment amount	$ 409,279	454,092	$ 151,805
Average remaining years	1 year 8 months 16 days
January 1, 2019 [Member]
Statement [Line Items]
Average remaining years	1 year 8 months 15 days
Immaterial cumulative adjustment	$ 11,667	11,667
Discount rate description	Ranges from 5.00% to 7.03%
August, 2021 [Member]
Statement [Line Items]
Operating lease liability	$ 184,000
Operating lease assets and liability		$ 390,000
Lease expiry date	Jul. 31, 2023

XML 77 R67.htm IDEA: XBRL DOCUMENT

Operating leases and other commitment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Average remaining years	1 year 8 months 16 days
Operating lease liability	$ 391,459	$ 425,620	$ 147,036
January 1, 2019 [Member]
Statement [Line Items]
Immaterial cumulative adjustment	$ 11,667
Average remaining years	1 year 8 months 15 days
August, 2021 [Member]
Statement [Line Items]
Operating lease liability	$ 184,000

XML 78 R68.htm IDEA: XBRL DOCUMENT

SHARE CAPITAL (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Share capital, shares outstanding	85,546,000	77,961,000	71,218,000
Number of common shares, value	$ 165,061	$ 151,722	$ 136,554
Stock Option [Member]
Statement [Line Items]
Weighted average exercise price, Beginning	$ 1.76	$ 1.81	$ 1.78
Expired / Cancelled	200,000	0	(10,000)
Weighted average remaining contractual life (in years), Ending	3 years 10 months 9 days
Weighted average remaining contractual life options exercisable (in years)	3 years 9 months 18 days
Weighted average remaining contractual life (in years), Granted	9 years 5 months 23 days	8 years 11 months 8 days	9 years 3 months 3 days

XML 79 R69.htm IDEA: XBRL DOCUMENT

Share capital (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended	6 Months Ended	12 Months Ended
Share capital (Details Narrative) - USD ($)	Apr. 30, 2021	Apr. 28, 2021	Mar. 31, 2019	Jun. 30, 2021	Dec. 31, 2021
Statement [Line Items]
Warrant value			$ 200,000	$ 330,277	$ 220,457
Warrants issued					183,486
Private Placements [Member]
Statement [Line Items]
Warrant value		$ 8,000,000	$ 200,000	$ 330,277
Warrants issued		1,834,862	2,500,000	1,834,862
Exercise price or warrants	$ 2.50	$ 2.50
Common stock shares issued	183,486	3,669,724
Proceed from private placement	$7,318,348.46

XML 80 R70.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS (Details) - Stock Option [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Number of outstanding balance, Beginning	6,500,000	6,090,000	5,740,000
Expired	200,000	0	(10,000)
Granted	128,000	410,000	360,000
Number of outstanding balance, Ending	6,428,000	6,500,000	6,090,000
Options exercisable	6,348,833	0	0
Weighted average exercise price, Beginning	$ 1.76	$ 1.81	$ 1.78
Weighted average exercise price, Expired	1.81	0	3.43
Weighted average exercise price, Granted	1.77	2.34	2.08
Weighted average exercise price, Ending	1.81	1.81	1.78
Weighted average exercise price, Options exercisable	$ 1.80	$ 0	$ 0
Weighted average remaining contractual life (in years)		5 years 7 months 10 days	6 years 4 months 13 days
Weighted average remaining contractual life (in years), Granted	9 years 5 months 23 days	8 years 11 months 8 days	9 years 3 months 3 days
Weighted average remaining contractual life options outstanding	4 years 10 months 13 days	4 years 10 months 13 days	5 years 7 months 9 days
Weighted average remaining contractual life options exercisable (in years)	3 years 9 months 18 days

XML 81 R71.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS (Details 1) - $ / shares	12 Months Ended
STOCK OPTIONS (Details 1) - $ / shares	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Share price			$ 2.08
Exercise price			$ 2.08
Risk-free interest rate			2.48%
Expected volatility			105.36%
Expected option life in years			10 years
Expected dividend yield	0.00%	0.00%	0.00%
Minimum [Member]
Statement [Line Items]
Share price	$ 1.75	$ 1.81
Exercise price	$ 1.75	$ 1.81
Risk-free interest rate	1.60%	1.12%
Expected volatility	107.05%	81.34%
Expected option life in years		4 years
Maximum [Member]
Statement [Line Items]
Share price	$ 1.83	$ 2.86
Exercise price	$ 1.83	$ 2.86
Risk-free interest rate	1.64%	1.67%
Expected volatility	107.47%	106.56%
Expected option life in years	10 years	10 years

XML 82 R72.htm IDEA: XBRL DOCUMENT

STOCK OPTIONS (Details Narrative) - $ / shares	12 Months Ended
STOCK OPTIONS (Details Narrative) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Stock option plan, description	The maximum number of shares which may be optioned under the stock option plan is 15,000,000. The maximum number of shares which may be optioned to any one individual is 15% of the total issued and outstanding common shares. Options under the Plan expire up to ten years after the grant date and vest either immediately or over periods up to six years and are equity-settled.
Stock option granted	1,072,000
Weighted average grant-date fair value	$ 1.68	$ 2.09

XML 83 R73.htm IDEA: XBRL DOCUMENT

SHARE BASED COMPENSATION (Details) - USD ($) $ in Thousands	12 Months Ended
SHARE BASED COMPENSATION (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Research and development expense	$ 6,658	$ 8,120	$ 7,377
Stock Option [Member]
Statement [Line Items]
General and administrative expense	2,124	702	1,839
Research and development expense	479	1,046	1,172
Total	$ 2,603	$ 1,748	$ 3,011

XML 84 R74.htm IDEA: XBRL DOCUMENT

SHARE BASED COMPENSATION (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
SHARE BASED COMPENSATION (Details Narrative) - USD ($)	Jul. 31, 2015	Dec. 31, 2021	Jul. 17, 2015
Statement [Line Items]
Shares based compensation recognized expense		$ 657,838
Shares based compensation unrecognized compensation		$ 86,749
Fair value per share		$ 2.50
Dr. Averback [Member]
Statement [Line Items]
Restricted shares granted	3,000,000
equity compensation reward		$ 750,000
Restricted shares granted monthly	250,000
Total rerestricted shares granted			21,000,000
Proceeds from issuance of shares	$ 8,000,000
Fair value per share			$ 1.36

XML 85 R75.htm IDEA: XBRL DOCUMENT

WARRANTS (Details) - Warrants [Member] - $ / shares	12 Months Ended
WARRANTS (Details) - Warrants [Member] - $ / shares	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Number of outstanding balance, Beginning	2,500,000	2,500,000
Granted	2,018,348		2,500,000
Number of outstanding balance, Ending	4,518,348	2,500,000	2,500,000
Weighted average exercise price, Beginning	$ 8.00	$ 8.00
Weighted average exercise price, Ending	$ 5.54	$ 8.00	$ 8.00
Weighted average remaining contractual life (in years)	4.04		1.31 years

XML 86 R76.htm IDEA: XBRL DOCUMENT

WARRANTS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
WARRANTS (Details Narrative) - USD ($)	Apr. 28, 2021	Mar. 31, 2019	Jun. 30, 2021	Dec. 31, 2021
Statement [Line Items]
Warrants issued				183,486
Warrant exercise price per share				$ 2.50
Warrant value		$ 200,000	$ 330,277	$ 220,457
Private Placements [Member]
Statement [Line Items]
Warrants issued	1,834,862	2,500,000	1,834,862
Warrant exercise price per share		$ 8.00	$ 2.50
Warrant value	$ 8,000,000	$ 200,000	$ 330,277

XML 87 R77.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Net loss for the year, before income taxes	$ (12,537)	$ (11,738)	$ (13,162)
Domestic tax rate applicable to the Corporation	21.00%	21.00%	21.00%
Income taxes at domestic tax statutory rate	$ (159)	$ (152)	$ (67)
Change in valuation allowance	159	152	67
Deferred tax provision (recovery)	0	0	0
Bahamas [Member]
Statement [Line Items]
Net loss for the year, before income taxes	(11,781)	(11,012)	(12,841)
United States [Member]
Statement [Line Items]
Net loss for the year, before income taxes	$ (756)	$ (725)	$ (321)

XML 88 R78.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Tax loss carry forward	$ 1,404,000	$ 1,386,000	$ 1,402,000
Patents capitalized and amortized for tax purposes	0	0	0
Unrecognized deferred tax assets	$ 1,404,000	$ 1,386	$ 1,402,000

XML 89 R79.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details 2)	12 Months Ended
INCOME TAXES (Details 2)	Dec. 31, 2021 USD ($)
Statement [Line Items]
Net operating loss carryforwards	$ 6,687,000
2020 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 732,000
Year Originated	2020
Year of Expiration	2040
2009 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 86,000
Year Originated	2009
Year of Expiration	2029
2001 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 664,000
Year Originated	2001
Year of Expiration	2021
2002 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 522,000
Year Originated	2002
Year of Expiration	2022
2010 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 541,000
Year Originated	2010
Year of Expiration	2030
2011 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 480,000
Year Originated	2011
Year of Expiration	2031
2012 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 177,000
Year Originated	2012
Year of Expiration	2032
2013 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 121,000
Year Originated	2013
Year of Expiration	2033
2014 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 70,000
Year Originated	2014
Year of Expiration	2034
2015 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 127,000
Year Originated	2015
Year of Expiration	2035
2016 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 147,000
Year Originated	2016
Year of Expiration	2036
2017 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 140,000
Year Originated	2017
Year of Expiration	2037
2018 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 194,000
Year Originated	2018
Year of Expiration	2038
2019 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 337,000
Year Originated	2019
Year of Expiration	2039
2003 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 564,000
Year Originated	2003
Year of Expiration	2023
2004 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 353,000
Year Originated	2004
Year of Expiration	2024
2005 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 264,000
Year Originated	2005
Year of Expiration	2025
2006 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 355,000
Year Originated	2006
Year of Expiration	2026
2007 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 373,000
Year Originated	2007
Year of Expiration	2027
2008 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 351,000
Year Originated	2008
Year of Expiration	2028
2021 [Member]
Statement [Line Items]
Net operating loss carryforwards	$ 753,000
Year Originated	2021
Year of Expiration	2041

XML 90 R80.htm IDEA: XBRL DOCUMENT

INCOME TAXES (Details Narrative)	Dec. 31, 2015 USD ($)
Canadian research tax credit carryforwards	$ 1,686,270
Canadian loss carryforwards	$ 55,850,632

XML 91 R81.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Details) - shares shares in Thousands	12 Months Ended
EARNINGS PER SHARE (Details) - shares shares in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Issued common shares at January 1	77,961	71,218	64,676
Effect of shares issued	4,015	2,605	4,169
Weighted average number of common shares outstanding at December 31	81,976	73,823	68,845

XML 92 R82.htm IDEA: XBRL DOCUMENT

FINANCE INCOME AND FINANCE COSTS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Interest income	$ 8	$ 27	$ 213
Net foreign exchange gain(loss)	(2)	(3)	(12)
Finance income	6	24	201
Interest and bank charges	20	30	18
Finance costs	(20)	(30)	(18)
Operation lease interest expense	(19)	(12)	(20)
Total finance income and costs	$ (33)	$ (18)	$ 163

XML 93 R83.htm IDEA: XBRL DOCUMENT

SEGMENT DISCLOSURES (Details) - USD ($)	12 Months Ended
SEGMENT DISCLOSURES (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Revenue	$ 0	$ 5,000	$ 116,000
Property and equipment	22,000	28,000	25,000
United States [Member]
Statement [Line Items]
Revenue	0	3,000	91,000
Property and equipment	12,000	19,000	25,000
Europe [Member]
Statement [Line Items]
Revenue	0	2,000	24,000
Property and equipment		0	0
Canada [Member]
Statement [Line Items]
Revenue	0	0	1,000
Property and equipment	$ 10,000	$ 9,000	$ 0

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 28
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2021-03-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 23
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2021-03-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 32
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard
-URIDate 2021-03-24

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 33
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2021-03-24

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2021-01-01
-Paragraph 34
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard
-URIDate 2021-03-24

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 82
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2021-03-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard
-URIDate 2021-03-24

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2021-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard
-URIDate 2021-03-24

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2021-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2021-03-24

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2021-03-24

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2021-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2021-03-24

+ Details

XML 94 R84.htm IDEA: XBRL DOCUMENT

CONCENTRATIONS (Details) - USD ($)	12 Months Ended
CONCENTRATIONS (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Revenue From Sale Of Goods	$ 0	$ 5,000	$ 116,000
Subscriptions
Statement [Line Items]
Revenue From Sale Of Goods	0
Customer B [Member]
Statement [Line Items]
Revenue From Sale Of Goods	0	2,000	0
Customer C [Member]
Statement [Line Items]
Revenue From Sale Of Goods	$ 0	0	36,000
Customer A
Statement [Line Items]
Revenue From Sale Of Goods		$ 0	$ 23,000

XML 95 R85.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details) - Officers And Directors [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Salaries	$ 750	$ 0	$ 0
Short-term employee benefits	14	2	2
Stock-based compensation	2,227	1,404	2,998
Total	$ 2,991	$ 1,406	$ 3,000

XML 96 R86.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Chief Financial Officers [Member]
Statement [Line Items]
Amounts paid contract for services	$ 580,000	$ 535,000	$ 480,000
Corporate Legal Counsel [Member]
Statement [Line Items]
Amounts paid contract for services	435,289	324,767	289,992
Independent Directors [Member]
Statement [Line Items]
Total honorariums	$ 0	$ 26,000	$ 0
Restricted shares of common shares	900,000

XML 97 R87.htm IDEA: XBRL DOCUMENT

RESEARCH AND DEVELOPMENT EXPENSES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Research and development expenses	$ 5,949	$ 7,167	$ 5,962
Alzheimer's Disease Therapeutics [Member]
Statement [Line Items]
Research and development expenses	4	0	4
Anti-Infectives [Member]
Statement [Line Items]
Research and development expenses	0	4	4
BPH (Enlarged Prostate) and Prostate Cancer Therapeutics [Member]
Statement [Line Items]
Research and development expenses	5,944	7,162	5,932
Tobacco Exposure Tests [Member]
Statement [Line Items]
Research and development expenses	1	1	18
Research and Development Program [Member]
Statement [Line Items]
Research and development expenses	$ 0	$ 0	$ 4

XML 98 R88.htm IDEA: XBRL DOCUMENT

PERSONNEL EXPENSES (Details) - USD ($) $ in Thousands	12 Months Ended
PERSONNEL EXPENSES (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Salaries	$ 1,419	$ 659	$ 689
Employer contributions	49	51	54
Short-term employee benefits	70	18	16
Stock-based compensation	2,227	1,417	3,011
Total	$ 3,765	$ 2,145	$ 3,770

XML 99 R89.htm IDEA: XBRL DOCUMENT

PERSONNEL EXPENSES (Details Narrative) - USD ($)	12 Months Ended
PERSONNEL EXPENSES (Details Narrative) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Salaries	$ 1,419,000	$ 659,000	$ 689,000
Stock-based compensation	2,227,000	1,417,000	3,011,000
General and Adminstrative [Member]
Statement [Line Items]
Salaries	874,000	98,000	90,000
Stock-based compensation	$ 1,897,000	$ 702,000	$ 1,839,000

XML 100 R90.htm IDEA: XBRL DOCUMENT

LIQUIDITY RISK (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Statement [Line Items]
Trade accounts payable and accrued liabilities	$ 1,558	$ 1,772	$ 1,894
Less than 1 year [Member]
Statement [Line Items]
Trade accounts payable and accrued liabilities	1,786	1,965
1 year to 5 years [Member]
Statement [Line Items]
Trade accounts payable and accrued liabilities	163	233
Carrying amount [member]
Statement [Line Items]
Trade accounts payable and accrued liabilities	$ 1,949	$ 2,198

XML 101 R91.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Mar. 22, 2022	Mar. 18, 2022	Dec. 31, 2021
Statement [Line Items]
Issuance and sale of common stock per share			$ 2.50
Subsequent Event [Member]
Statement [Line Items]
Warrants to purchase shares of common stock	193,939
Warrants to purchase shares of common stock exercise price	$ 2.06
Offering and concurrent private placement of warrants expired	five-year	five (5) years
Offering and concurrent private placement of warrants		3,878,789
Exercise price		$ 2.00
Issuance and sale of common stock		3,878,789
Issuance and sale of common stock per share		$ 1.65
Gross proceeds before deducting placement agent fees and various expenses	$ 6.4
Subsequent Event [Member] \| James G. Robinson [Member]
Statement [Line Items]
Warrants to purchase shares of common stock		1,151,515
Purchased offering shares		1,151,515

XML 102 nymox_20f_htm.xml IDEA: XBRL DOCUMENT 0001018735 2021-01-01 2021-12-31 0001018735 nymox:SubsequentEventsMember nymox:JamesGRobinsonMember 2022-03-18 0001018735 nymox:SubsequentEventsMember 2022-03-18 0001018735 nymox:SubsequentEventsMember 2022-03-01 2022-03-18 0001018735 nymox:SubsequentEventsMember 2022-03-01 2022-03-22 0001018735 nymox:SubsequentEventsMember 2022-03-22 0001018735 nymox:OneyearToFiveYearsMember 2020-12-31 0001018735 nymox:OneyearToFiveYearsMember 2021-12-31 0001018735 nymox:LessThanOneYearMember 2020-12-31 0001018735 nymox:LessThanOneYearMember 2021-12-31 0001018735 nymox:CarryingAmountsMember 2020-12-31 0001018735 nymox:CarryingAmountsMember 2021-12-31 0001018735 nymox:GeneralandAdminstrativeMember 2020-01-01 2020-12-31 0001018735 nymox:GeneralandAdminstrativeMember 2019-01-01 2019-12-31 0001018735 nymox:GeneralandAdminstrativeMember 2021-01-01 2021-12-31 0001018735 nymox:TobaccoExposureTestsMember 2020-01-01 2020-12-31 0001018735 nymox:TobaccoExposureTestsMember 2021-01-01 2021-12-31 0001018735 nymox:TobaccoExposureTestsMember 2019-01-01 2019-12-31 0001018735 nymox:BPHEnlargedProstateAndProstateCancerTherapeuticsMember 2020-01-01 2020-12-31 0001018735 nymox:BPHEnlargedProstateAndProstateCancerTherapeuticsMember 2021-01-01 2021-12-31 0001018735 nymox:BPHEnlargedProstateAndProstateCancerTherapeuticsMember 2019-01-01 2019-12-31 0001018735 nymox:AntiInfectivesMember 2020-01-01 2020-12-31 0001018735 nymox:AntiInfectivesMember 2019-01-01 2019-12-31 0001018735 nymox:AntiInfectivesMember 2021-01-01 2021-12-31 0001018735 nymox:AlzheimersDiseaseTherapeuticsMember 2020-01-01 2020-12-31 0001018735 nymox:AlzheimersDiseaseTherapeuticsMember 2021-01-01 2021-12-31 0001018735 nymox:AlzheimersDiseaseTherapeuticsMember 2019-01-01 2019-12-31 0001018735 nymox:ResearchAndDevelopmentProgramMember 2020-01-01 2020-12-31 0001018735 nymox:ResearchAndDevelopmentProgramMember 2021-01-01 2021-12-31 0001018735 nymox:ResearchAndDevelopmentProgramMember 2019-01-01 2019-12-31 0001018735 nymox:IndependentDirectorsMember 2020-01-01 2020-12-31 0001018735 nymox:IndependentDirectorsMember 2021-01-01 2021-12-31 0001018735 nymox:IndependentDirectorsMember 2019-01-01 2019-12-31 0001018735 nymox:CorporateLegalCounselMember 2020-12-31 0001018735 nymox:CorporateLegalCounselMember 2021-12-31 0001018735 nymox:CorporateLegalCounselMember 2019-12-31 0001018735 nymox:ChiefFinancialOfficersMember 2020-12-31 0001018735 nymox:ChiefFinancialOfficersMember 2021-12-31 0001018735 nymox:ChiefFinancialOfficersMember 2019-12-31 0001018735 nymox:OfficersAndDirectorsMember 2020-01-01 2020-12-31 0001018735 nymox:OfficersAndDirectorsMember 2021-01-01 2021-12-31 0001018735 nymox:OfficersAndDirectorsMember 2019-01-01 2019-12-31 0001018735 nymox:CustomerCMember 2019-01-01 2019-12-31 0001018735 nymox:CustomerCMember 2020-01-01 2020-12-31 0001018735 nymox:CustomerBMember 2019-01-01 2019-12-31 0001018735 nymox:CustomerBMember 2020-01-01 2020-12-31 0001018735 nymox:CustomerAMember 2019-01-01 2019-12-31 0001018735 nymox:CustomerAMember 2020-01-01 2020-12-31 0001018735 nymox:ShareSubscriptionsPremiumMember 2021-01-01 2021-12-31 0001018735 nymox:CustomerCMember 2021-01-01 2021-12-31 0001018735 nymox:CustomerBMember 2021-01-01 2021-12-31 0001018735 nymox:GeographicalAreasEuropeMember 2019-01-01 2019-12-31 0001018735 nymox:GeographicalAreasEuropeMember 2020-01-01 2020-12-31 0001018735 nymox:GeographicalAreasEuropeMember 2021-01-01 2021-12-31 0001018735 nymox:GeographicalAreasEuropeMember 2020-12-31 0001018735 nymox:GeographicalAreasUnitedStatesMember 2020-12-31 0001018735 nymox:GeographicalAreasCanadaMember 2019-01-01 2019-12-31 0001018735 nymox:GeographicalAreasCanadaMember 2020-01-01 2020-12-31 0001018735 nymox:GeographicalAreasCanadaMember 2021-01-01 2021-12-31 0001018735 nymox:GeographicalAreasCanadaMember 2020-12-31 0001018735 nymox:GeographicalAreasCanadaMember 2021-12-31 0001018735 nymox:GeographicalAreasCanadaMember 2019-12-31 0001018735 nymox:GeographicalAreasEuropeMember 2019-12-31 0001018735 nymox:GeographicalAreasUnitedStatesMember 2021-12-31 0001018735 nymox:GeographicalAreasUnitedStatesMember 2019-12-31 0001018735 nymox:GeographicalAreasUnitedStatesMember 2021-01-01 2021-12-31 0001018735 nymox:GeographicalAreasUnitedStatesMember 2020-01-01 2020-12-31 0001018735 nymox:GeographicalAreasUnitedStatesMember 2019-01-01 2019-12-31 0001018735 2015-12-31 0001018735 nymox:TwoThousandTwentyoneMember 2021-12-31 0001018735 nymox:TwoHundredNineteenMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredEighteenMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredSeventeenMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredSixteenMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredFifteenMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredFourteenMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredThirteenMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredTwelveMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredElevenMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredTenMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredZeroEightMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredZeroSevenMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredZeroSixMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredZeroFiveMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredZeroFourMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredZeroThreeMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredZeroTwoMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredZeroOneMember 2021-01-01 2021-12-31 0001018735 nymox:TwoThousandNineMember 2021-01-01 2021-12-31 0001018735 nymox:TwoThousandTwentyoneMember 2021-01-01 2021-12-31 0001018735 nymox:TwoThousandTwentyMember 2021-01-01 2021-12-31 0001018735 nymox:TweentyHundredZeroEightMember 2021-12-31 0001018735 nymox:TweentyHundredZeroSevenMember 2021-12-31 0001018735 nymox:TweentyHundredZeroSixMember 2021-12-31 0001018735 nymox:TweentyHundredZeroFiveMember 2021-12-31 0001018735 nymox:TweentyHundredZeroFourMember 2021-12-31 0001018735 nymox:TweentyHundredZeroThreeMember 2021-12-31 0001018735 nymox:TwoHundredNineteenMember 2021-12-31 0001018735 nymox:TweentyHundredEighteenMember 2021-12-31 0001018735 nymox:TweentyHundredSeventeenMember 2021-12-31 0001018735 nymox:TweentyHundredSixteenMember 2021-12-31 0001018735 nymox:TweentyHundredFifteenMember 2021-12-31 0001018735 nymox:TweentyHundredFourteenMember 2021-12-31 0001018735 nymox:TweentyHundredThirteenMember 2021-12-31 0001018735 nymox:TweentyHundredTwelveMember 2021-12-31 0001018735 nymox:TweentyHundredElevenMember 2021-12-31 0001018735 nymox:TweentyHundredTenMember 2021-12-31 0001018735 nymox:TweentyHundredZeroTwoMember 2021-12-31 0001018735 nymox:TweentyHundredZeroOneMember 2021-12-31 0001018735 nymox:TwoThousandNineMember 2021-12-31 0001018735 nymox:TwoThousandTwentyMember 2021-12-31 0001018735 nymox:UnitedStatesMember 2020-01-01 2020-12-31 0001018735 nymox:UnitedStatesMember 2021-01-01 2021-12-31 0001018735 nymox:UnitedStatesMember 2019-01-01 2019-12-31 0001018735 nymox:BahamasMember 2020-01-01 2020-12-31 0001018735 nymox:BahamasMember 2021-01-01 2021-12-31 0001018735 nymox:BahamasMember 2019-01-01 2019-12-31 0001018735 2021-01-01 2021-06-30 0001018735 nymox:PrivatePlacementsMember 2021-01-01 2021-06-30 0001018735 2019-01-01 2019-03-31 0001018735 nymox:PrivatePlacementsMember 2019-01-01 2019-03-31 0001018735 nymox:PrivatePlacementsMember 2019-03-31 0001018735 nymox:PrivatePlacementsMember 2021-06-30 0001018735 nymox:WarrantsMember 2019-01-01 2019-12-31 0001018735 nymox:WarrantsMember 2020-01-01 2020-12-31 0001018735 nymox:WarrantsMember 2021-01-01 2021-12-31 0001018735 nymox:DrAverbackMember 2015-07-17 0001018735 nymox:DrAverbackMember 2021-01-01 2021-12-31 0001018735 nymox:DrAverbackMember 2015-07-01 2015-07-31 0001018735 nymox:MaximumsMember 2021-01-01 2021-12-31 0001018735 nymox:MaximumsMember 2020-01-01 2020-12-31 0001018735 nymox:MinimumsMember 2020-01-01 2020-12-31 0001018735 nymox:MinimumsMember 2021-01-01 2021-12-31 0001018735 nymox:StockOptionsMember 2019-01-01 2019-12-31 0001018735 nymox:StockOptionsMember 2020-01-01 2020-12-31 0001018735 nymox:PrivatePlacementsMember 2021-04-30 0001018735 nymox:PrivatePlacementsMember 2021-04-01 2021-04-30 0001018735 nymox:PrivatePlacementsMember 2021-04-28 0001018735 nymox:PrivatePlacementsMember 2021-04-01 2021-04-28 0001018735 nymox:StockOptionsMember 2021-01-01 2021-12-31 0001018735 nymox:AugustTwoZeroTwoOneMember 2021-12-31 0001018735 nymox:JanuaryOneTwoZeroOneNineMember 2021-01-01 2021-12-31 0001018735 nymox:JanuaryOneTwoZeroOneNineMember 2020-12-31 0001018735 nymox:AugustTwoZeroTwoOneMember 2021-01-01 2021-12-31 0001018735 nymox:AugustTwoZeroTwoOneMember 2020-12-31 0001018735 nymox:PrivatePlacementsMember 2021-01-01 2021-12-31 0001018735 nymox:IntellectualPropertyRightsMember 2021-01-01 2021-12-31 0001018735 nymox:IntellectualPropertyRightsMember 2019-01-01 2019-12-31 0001018735 nymox:IntellectualPropertyRightsMember 2020-01-01 2020-12-31 0001018735 nymox:IntellectualPropertyRightsMember 2021-12-31 0001018735 nymox:IntellectualPropertyRightsMember 2019-12-31 0001018735 nymox:IntellectualPropertyRightsMember 2020-12-31 0001018735 nymox:OfficeEquipmentsMember 2019-12-31 0001018735 nymox:OfficeEquipmentsMember 2021-12-31 0001018735 nymox:OfficeEquipmentsMember 2019-01-01 2019-12-31 0001018735 nymox:OfficeEquipmentsMember 2020-01-01 2020-12-31 0001018735 nymox:OfficeEquipmentsMember 2021-01-01 2021-12-31 0001018735 nymox:OfficeEquipmentsMember 2018-12-31 0001018735 nymox:OfficeEquipmentsMember 2020-12-31 0001018735 nymox:ComputerEquipmentsMember 2021-12-31 0001018735 nymox:ComputerEquipmentsMember 2019-01-01 2019-12-31 0001018735 nymox:ComputerEquipmentsMember 2021-01-01 2021-12-31 0001018735 nymox:ComputerEquipmentsMember 2020-01-01 2020-12-31 0001018735 nymox:ComputerEquipmentsMember 2018-12-31 0001018735 nymox:ComputerEquipmentsMember 2020-12-31 0001018735 nymox:ComputerEquipmentsMember 2019-12-31 0001018735 nymox:LaboratoryEquipmentMember 2021-12-31 0001018735 nymox:LaboratoryEquipmentMember 2019-01-01 2019-12-31 0001018735 nymox:LaboratoryEquipmentMember 2020-01-01 2020-12-31 0001018735 nymox:LaboratoryEquipmentMember 2019-12-31 0001018735 nymox:LaboratoryEquipmentMember 2020-12-31 0001018735 nymox:LaboratoryEquipmentMember 2018-12-31 0001018735 nymox:JanuaryOneTwoZeroOneNineMember 2021-12-31 0001018735 nymox:OfficeEquipmentAndFixturesMember 2021-01-01 2021-12-31 0001018735 nymox:ComputerEquipmentOneMember 2021-01-01 2021-12-31 0001018735 nymox:LaboratoryEquipmentMember 2021-01-01 2021-12-31 0001018735 nymox:RetainedEarningsAccumulatedDeficitMember 2021-12-31 0001018735 nymox:AdditionalPaidinCapitalOneMember 2021-12-31 0001018735 nymox:ShareSubscriptionsPremiumsMember 2021-12-31 0001018735 nymox:CommonStockMember 2021-12-31 0001018735 nymox:RetainedEarningsAccumulatedDeficitMember 2021-01-01 2021-12-31 0001018735 nymox:AdditionalPaidinCapitalOneMember 2021-01-01 2021-12-31 0001018735 nymox:ShareSubscriptionsPremiumsMember 2021-01-01 2021-12-31 0001018735 nymox:CommonStockMember 2021-01-01 2021-12-31 0001018735 nymox:RetainedEarningsAccumulatedDeficitMember 2020-12-31 0001018735 nymox:AdditionalPaidinCapitalOneMember 2020-12-31 0001018735 nymox:ShareSubscriptionsPremiumsMember 2020-12-31 0001018735 nymox:CommonStockMember 2020-12-31 0001018735 nymox:RetainedEarningsAccumulatedDeficitMember 2020-01-01 2020-12-31 0001018735 nymox:AdditionalPaidinCapitalOneMember 2020-01-01 2020-12-31 0001018735 nymox:ShareSubscriptionsPremiumsMember 2020-01-01 2020-12-31 0001018735 nymox:CommonStockMember 2020-01-01 2020-12-31 0001018735 nymox:RetainedEarningsAccumulatedDeficitMember 2019-12-31 0001018735 nymox:AdditionalPaidinCapitalOneMember 2019-12-31 0001018735 nymox:ShareSubscriptionsPremiumsMember 2019-12-31 0001018735 nymox:CommonStockMember 2019-12-31 0001018735 nymox:AdditionalPaidinCapitalOneMember 2019-01-01 2019-12-31 0001018735 nymox:ShareSubscriptionsPremiumsMember 2019-01-01 2019-12-31 0001018735 nymox:CommonStockMember 2019-01-01 2019-12-31 0001018735 nymox:RetainedEarningsAccumulatedDeficitMember 2019-01-01 2019-12-31 0001018735 nymox:RetainedEarningsAccumulatedDeficitMember 2018-12-31 0001018735 nymox:AdditionalPaidinCapitalOneMember 2018-12-31 0001018735 nymox:ShareSubscriptionsPremiumsMember 2018-12-31 0001018735 nymox:CommonStockMember 2018-12-31 0001018735 2018-12-31 0001018735 2019-12-31 0001018735 2020-12-31 0001018735 2019-01-01 2019-12-31 0001018735 2020-01-01 2020-12-31 0001018735 2021-12-31 0001018735 dei:BusinessContactMember 2021-01-01 2021-12-31 iso4217:USD shares iso4217:USD shares pure 0001018735 false --12-31 false FY 2021 true Erik Danielsen 0 0 550000 0 0 0

418000

0 0 0 418000 0 0 0

3000

0 0 0

2222661

442000 136000

390000

P1Y8M16D 2023-07-31 11667 Ranges from 5.00% to 7.03% 6500000 6090000 0 0 0 0 1.81 1.78 0 0 P5Y7M10D P4Y10M13D 0 0 0 2500000 2500000 8.00 8.00 4.04 1.31 years 200000 330277 664000 2001 2021

20-F false true 2021-12-31 false false 001-12033 NYMOX PHARMACEUTICAL CORPORATION C5 Bay & Deveaux Streets Nassau BS Erik Danielsen 800 936-9669 edanielsen@nymox.com Common Stock NASDAQ 85545875 No No Yes Yes Accelerated Filer International Financial Reporting Standards false false TPS Thayer, LLC 6706 Sugar Land, Texas

5000

116000

5000

116000

4000

58000

6658000

8120000

7377000

5846000

3601000

6006000

12504000

11725000

13441000

-12504000

-11720000

-13325000

6000

24000

201000

-20000 -30000 -18000 -19000 -12000 -20000

-33000

-18000

-163000

0 0 0

-12537000

-11738000

-13162000

-12537000

-11738000

-13162000

-0.15

-0.16

-0.19

81976000

73823000

68845000

830000

3611000

5239000

0 0 4000

13000

20000

14000

34000

23000

28000 28000 28000

132000

200000

20000

1037000

3893000

5328000

22000

28000

25000

384000 422000 136000

1443000

4343000

5489000

1558000 1772000 1894000 228000 193000 144000

1786000

1965000

2038000

163000 233000 3000

1949000

2198000

2041000

165061000

151722000

136554000

-589000 -589000 -589000

27584000

31037000

35770000

-192562000

-180025000

-168287000

-506000

2145000

3448000

1443000

4343000

5489000

-12537000

-11738000

-13162000

12000 9000 9000

2603000

1748000

3011000

0 0 1330000 242000 258000 556000 7000 -1000 -4000 0 0 12000 68000 -180000 -18000 0 -11000 17000 -50000 50000 0 -165000 -172000 -819000

-9820000

-10037000

-7430000

-6000 -13000 0

-6000

-13000

7283000

8687000

5000000

-238000 -265000 -277000

7045000

8422000

4723000

-2781000

-1628000

-2707000

3611000

5239000

7946000

830000

3611000

5239000

0 0 0 0 0 0

64676000

126684000

-868000

36299000

-155113000

7002000

-12000 -12000 2542000 4800000 279000 5079000 0 200000 0 200000 4000000 5070000 0 -729000 0 4341000 0 0 0 -13162000 -13162000

71218000

136554000

-589000

35770000

-168287000

3448000

3743000 9388000 0 -701000 0 8687000 3000000 5780000 0 -4032000 0 1748000 0 0 0 -11738000 -11738000

77961000

151722000

-589000

31037000

-180025000

2145000

3670000 7670000 0 -717000 0 6953000 330000 330000 3915000 5669000 0 -3066000 0 2603000 0 0 0 -12537000 -12537000

85546000

165061000

-589000

27584000

-192562000

-506000

NOTE 1 – BUSINESS ACTIVITIES AND BASIS OF PRESENTATION Nymox Pharmaceutical Corporation is a company which re-domiciled from Canada to the Commonwealth of The Bahamas in 2015 and is incorporated under the International Business Companies Act of the Commonwealth of The Bahamas. Nymox Pharmaceutical Corporation including its whole owned subsidiaries, Nymox Corporation, a Delaware Corporation, and Serex Inc. of New Jersey (together referred to as the “Corporation”), is a biopharmaceutical corporation, which specializes in the research and development of products for the aging population. The head office of the Corporation is located at Bay & Deveaux Sts., 2nd Floor, Nassau, The Bahamas. The Corporation currently markets NicAlertTM and TobacAlertTM, tests that use urine or saliva to detect use of tobacco products. Since 1989, the Corporation’s activities and resources have been primarily focused on developing certain pharmaceutical technologies. Since 2002, the Corporation has been developing its novel proprietary drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and, since 2012, for the treatment of low-grade localized prostate cancer. The Corporation also has an extensive patent portfolio covering its marketed products, its investigational drug as well as other therapeutic and diagnostic indications. Statement of ComplianceThe consolidated financial statements of the Corporation have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and its interpretations as issued by the International Accounting Standards Board (“IASB”). The consolidated financial statements were authorized for issue by the Audit Committee of the Corporation’s Board of Directors on March 30, 2022. Basis of measurementThe consolidated financial statements have been prepared on a going concern and on the historical cost basis. Functional and presentation currencyThese consolidated financial statements are presented in United States dollars, which is the Corporation and its subsidiaries’ functional currency. Use of estimates and judgmentsThe preparation of the consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Information about critical judgments in applying accounting policies and assumption and estimation uncertainties that have the most significant effect on the amounts recognized in the consolidated financial statements is noted below: Judgments in applying accounting policiesThe use of the going concern basis (Note 2) Contingent liabilityAssessing the recognition of contingent liabilities requires judgment in evaluating whether it is probable that economic benefits will be required to settle matters subject to litigation . Stock options and warrants There is estimation uncertainty with respect to selecting inputs to the Binomial pricing model used to determine the fair value of the stock options and warrants (Note 11). Other areas of judgment and uncertainty relate to deferred tax assets. Reported amounts and note disclosure reflect the overall economic conditions that are most likely to occur and anticipated measures management intends to take. Actual results could differ from those estimates. The above estimates and assumptions are reviewed regularly. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. NOTE 2 – GOING CONCERN CONSIDERATIONS The Corporation is subject to a number of risks, including the successful development and marketing of its technologies the ability to raise financing to pursue the development of its operations. The Corporation depends on private placements and other types of financing as well as collaboration agreements, to fund its operations, achieve its business plan and the realization of its assets and liabilities in the normal course of operations. The failure of the two Phase 3 studies of NX-1207 for BPH materially affects the Corporation’s current ability to fund its operations, meet its cash flow requirements, realize its assets and discharge its obligations. Management believes that current cash balances as of December 31, 2021 will not be sufficient to finance all of its planned business operations and research and development programs over the next year. However, the Corporation’s primary sources of financing since 2003 has been the Common Stock Private Purchase Agreement If necessary, the Corporation intends to seek additional equity or finance through the existing private placements and/or other sources of capital in order to fund these operations and activities over the next year. Considering recent developments and the need for additional financing, there exists a material uncertainty that casts substantial doubt about the Corporation’s ability to continue as a going concern. These financial statements do not reflect adjustments that would be necessary if the going concern assumption was not appropriate. If the going concern assumption is not appropriate, then adjustments may be necessary to the carrying value and classification of assets and liabilities and reported results of operations and such adjustments could be material. NOTE 3 – SIGNIFICANT ESTIMATES Significant estimates applied in the preparation of these financial statements include the estimated useful lives of property and equipment, share volatility and estimated life of options and warrants in determining their fair value as well as the expected potential for the realization of deferred tax assets in determining the amount of the valuation allowance thereto. NOTE 4 – SIGNIFICANT ACCOUNTING POLICIES The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements. Consolidation The consolidated financial statements of the Corporation include the accounts of its subsidiaries. Subsidiaries are those entities over which the Group has control. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">-</td><td style="vertical-align:top;">power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee);</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">-</td><td style="vertical-align:top;">exposure, or rights, to variable returns from its involvement with the investee; and</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">-</td><td style="vertical-align:top;">The ability to use its power over the investee to affect its returns.</td></tr></tbody></table>Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date, irrespective of the extent of any non-controlling interest. The excess of the cost of acquisition is recorded as goodwill. If the cost of acquisition is less than fair value of the net assets of the subsidiary acquired, the difference is recognized directly in the consolidated statement of profit or loss. The assets, liabilities, income and expenses of subsidiary companies are consolidated on a line by line basis and the carrying value of investments held by the Holding Company is eliminated against the subsidiaries’ shareholders’ equity in the consolidated financial statements. All intra-group transactions, balances, income, expenses and unrealized gains and losses on transactions between Group companies are eliminated in full. Subsidiaries have same reporting period as that of the Holding Company. The accounting policies of subsidiaries have been same with the holding parent company. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Intercompany balances and transactions have been eliminated on consolidation. Financial instruments The Corporation has classified its cash, trade accounts receivable and other receivables as “loans and receivables”, and its trade accounts payable, accrued liabilities, “other financial liabilities”. The Corporation must classify the fair value measurements of financial instruments according to a three-level hierarchy, based on the type of inputs used in making these measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. Financial assetsThe Corporation initially recognizes receivables on the date that they are originated. Receivables are financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, loans and receivables are measured at amortized cost using the effective interest method, less any impairment losses. The Corporation derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Financial assets and liabilities are offset, and the net amount presented in the consolidated statements of financial position when, and only when, the Corporation has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Financial liabilitiesThe Corporation initially recognizes other financial liabilities on the trade date at which the Corporation becomes a party to the contractual provisions of the instrument. Other financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method. The Corporation derecognizes a financial liability when its contractual obligations are discharged, cancelled or expired. Interest, losses and gains relating to a financial liability are recognized in the statement of operations and comprehensive loss. IFRS 9 – Financial Instruments (“IFRS 9”) ultimately replaces IAS 39 – Financial Instruments: Recognition and Measurement (“IAS 39”), with the objective of improving and simplifying the reporting for financial instruments. In July 2014, the IASB issued the final version of IFRS 9, Financial Instruments (IFRS 9). IFRS 9 supersedes IAS 39, IFRIC 9 and earlier versions of IFRS 9. This standard provides guidance on the classification and measurement of financial liabilities and the presentation of gains and losses on financial liabilities designated at fair value through profit and loss. When an entity elects to measure a financial liability at fair value, gains or losses due to changes in the credit risk of the instrument must be recognized in other comprehensive income. This standard was effective for annual periods beginning on or after January 1, 2018 with earlier adoption permitted. The Corporation has implemented this standard yet there is no impact of the adoption of this standard on its consolidated financial statements. Share capitalCommon shares are classified as equity. Incremental costs attributable to the issuance of common shares are recognized as an increase to deficit. Accounts receivable Accounts receivable consists of trade receivables. Sales allowance for expected credit losses is recorded against trade receivables and is based on historical experience. The company has zero, zero and $4,000 trade receivables as of December 31, 2021, 2020 and 2019, respectively and no sales allowance was recorded during those three years. Inventory Inventory consists primarily of finished goods held for sale and materials and are carried at the lower of first-in, first-out cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less selling expenses. Property and equipmentProperty and equipment are measured at cost, less accumulated depreciation and accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. When parts of an item of property and equipment have significantly different useful lives, they are accounted for as separate items (major components) of property and equipment. Gains and losses on disposal of an item of property and equipment are recognized as the difference in the proceeds from disposal and the carrying amount of property and equipment. The cost of replacing a part of an item of property and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Corporation, and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of property and equipment are recognized in the statement of operations and comprehensive loss. Depreciation is calculated on the depreciable amount, which is the cost of an asset less its residual value. Depreciation is recognized on a straight-line basis over the estimated useful lives of each component of an item of property and equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are represented by the following estimated useful lives: <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Asset Classification</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:10%;vertical-align:bottom;">Useful life</td></tr><tr style="height:15px"><td/><td/><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Laboratory equipment</td><td> </td><td style="vertical-align:bottom;">5 years</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Computer equipment</td><td> </td><td style="vertical-align:bottom;">3 years</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Office equipment and fixtures</td><td> </td><td style="vertical-align:bottom;">5 years</td></tr></tbody></table> Depreciation methods, useful lives and residual values are reviewed on an ongoing basis and adjusted if appropriate.Research and development expendituresExpenditures on research activities, net of research tax credits, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, as well as demonstrating product efficacy and regulatory compliance prior to launch, are expensed in the statement of comprehensive earnings (loss) as incurred. Development activities, net of research tax credits, involve a plan or design to produce new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically, and commercially feasible, future economic benefits are probable, and the Corporation intends to and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are recognized in research and development expenses as incurred. AmortizationAmortization is calculated on the cost of the asset, less its residual value. Amortization methods, useful lives and residual values are reviewed on an ongoing basis and adjusted if appropriate. Impairment Indefinite lived intangibles are subject an assessment for impairment at each reporting date. Financial assets impairmentFinancial assets are assessed at each reporting date to determine whether there is objective evidence that they are impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, restructuring of an amount due to the Corporation on terms that the Corporation would not consider otherwise, and indications that a debtor or issuer will enter bankruptcy. In assessing impairment, the Corporation uses historical trends of the probability of default, timing of recoveries and the amount of loss incurred, adjusted for management’s judgment as to whether current economic and credit conditions are such that the actual losses are likely to be greater or less than suggested by historical trends. An impairment loss in respect of a financial asset measured at amortized cost is calculated and recognized for the amount by which the asset’s carrying amount exceeds the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed. Non-financial assets impairmentThe carrying amounts of the Corporation’s non-financial assets, including property and equipment, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the “cash-generating unit, CGU or segment”). The Corporation’s corporate assets do not generate separate cash inflows. If there is an indication that a corporate asset may be impaired, then the recoverable amount is determined for the CGU to which the corporate asset belongs. An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses recognized in respect of CGUs are allocated to reduce the carrying amounts of the assets in the CGU on a pro rata basis. Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized.Revenue recognitionRevenue from product sales is recognized when the product has been delivered and obligations as defined in the agreement are performed. Collaboration agreements that include multiple deliverables are considered to be multiple-element arrangements. Under this type of arrangement, the identification of separate units of accounting is required and revenue is allocated among the separate units based on their relative fair values. Payments received under a collaboration agreement may include upfront payments, milestone payments, sale of goods, royalties and license fees. Revenue for each unit of accounting is recorded as described below: Upfront paymentsUpfront payments are deferred and recognized as revenue on a systematic basis over the estimated service period. Changes in estimates are recognized prospectively when changes to the expected term are determined. Milestone paymentsRevenue subject to the achievement of milestones is recognized only when the specified events have occurred, and collectability is reasonably assured. Specifically, the criteria for recognizing milestone payments are that (i) the milestone is substantive in nature, (ii) the achievement was not reasonably assured at the inception of the agreement, and (iii) the Corporation has no further involvement or obligation to perform associated with the achievement of the milestone, as defined in the related collaboration arrangement. The company does not have any upfront payments, milestone payments or license revenue for the years ended December 31, 2021, 2020 and 2019. IFRS 15, Revenue from Contracts with CustomersIn May 2014, the IASB issued IFRS 15, Revenue from Contracts with Customers, which establishes principles for reporting the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. It provides a single model in order to depict the transfer of promised goods or services to customers. IFRS 15 supersedes the following standards: IAS 11, Construction Contracts, IAS 18, Revenue, IFRIC 13, Customer Loyalty Programs, IFRIC 15, Agreements for the Construction of Real Estate, IFRIC 18, Transfers of Assets from Customers, and SIC-31, Revenue – Barter Transactions Involving Advertising Service. The core principle of IFRS 15 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. IFRS 15 also includes a cohesive set of disclosure requirements that would result in an entity providing comprehensive information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts with customers. The Corporation has adopted this standard in these financial statements yet determined that there is no impact on reported results of operations from its implementation. Sale of goodsRevenue from the sale of goods is recognized when the Corporation has transferred to the buyer the significant risks and rewards of ownership of the goods, there is no continuing management involvement with the goods, and the amount of revenue can be measured reliably. Foreign currencyMonetary assets and liabilities of the Corporation’s Canadian and US subsidiaries denominated in currencies other than the US dollar are translated at the rates of exchange at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Income and expenses denominated in foreign currencies are translated at the average rate prevailing during the year.Foreign exchange loss and gain are reported on a net basis, within finance costs or finance income.Research tax creditsUntil the corporation re-domiciled from Canada to the commonwealth of Bahamas in 2015, it is entitled to scientific research and experimental development tax credits (“research tax credits”) granted by the Canadian federal government and the government of the province of Québec. Federal research tax credits, which are non-refundable, are earned on qualified research and development expenditures and can only be used to offset federal income taxes otherwise payable. Provincial research tax credits, which are refundable, are earned on qualified research and development expenditures incurred in the province of Québec. These research tax credits are recognized as a reduction of research and development expenditures in the period in which they become receivable, provided that there is reasonable assurance that they will be received. Stock-based compensationThe grant date fair value of stock-based compensation awards granted to employees, consultants and directors is recognized as an expense, with a corresponding increase in equity, over the period that the employees, consultants or directors unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service at the vesting date. The fair value of the stock options is measured using the binomial pricing model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historic volatility), weighted average expected life of the instruments (based on historical experience and general option holder behavior), expected dividends, and the risk-free interest rate (based on government bonds). Service conditions attached to the transactions are not taken into account in determining fair value.Share based payment arrangements in which the Corporation receives goods or services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions. Employee benefitsShort-term employee benefits obligations are measured on an undiscounted basis and are expensed as the related service is provided. In addition to their salaries, employees of the Corporation are covered by a benefit package which includes a health plan, dental plan, disability insurance, life insurance and worker compensation insurance coverage. Participation in this plan is paid by the Corporation in full. Any employee that elects to extend the coverage to members of their family must pay the additional premium. Operating leasesEffective for annual reporting periods beginning on or after January 1, 2019, IFRS 16 introduced a new approach to lessee accounting that requires a lessee to recognize assets and liabilities for the rights and obligations created by leases. IFRS 16 requires a lessee to recognize assets and liabilities for all leases with a term of more than 12 months. The IASB concluded that such an approach will result in a more faithful representation of a lessee’s assets and liabilities and, together with enhanced disclosures, greater transparency of a lessee’s financial leverage and capital employed. We adopted this standard on January 1, 2019, with an immaterial cumulative adjustment of $11,667 to accumulated deficit rather than retrospectively adjusting prior periods. Income taxesIncome tax expense comprises current and deferred taxes. Current tax and deferred tax are recognized in the statement of operations and comprehensive loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive loss.Current tax is the expected tax payable or receivable on the taxable income or loss of the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss and differences relating to investments in subsidiaries to the extent that it is probable that they will not reverse in the foreseeable future. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Earnings per shareBasic earnings per share are determined using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed in a manner consistent with basic earnings per share, except that the weighted average shares outstanding are increased to include additional shares from the assumed exercise of options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding options were exercised, and that the proceeds from such exercises as well as the assumed proceeds from future services were used to acquire shares of common stock at the average market price during the reporting period. ProvisionsA provision is recognized if, because of a past event, the Corporation has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as finance cost. Onerous contractsA provision for onerous contracts is recognized when the expected benefits to be derived by the Corporation from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Corporation recognizes any impairment loss on the assets associated with that contract. Reclassification Certain amounts in the consolidated financial statements for the prior years have been reclassified to conform to the current year presentation. These reclassifications had no impact on net earnings, financial position, or cash flows. The consolidated financial statements of the Corporation include the accounts of its subsidiaries. Subsidiaries are those entities over which the Group has control. Control is achieved when the Group is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Specifically, the Group controls an investee if, and only if, the Group has: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">-</td><td style="vertical-align:top;">power over the investee (i.e., existing rights that give it the current ability to direct the relevant activities of the investee);</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">-</td><td style="vertical-align:top;">exposure, or rights, to variable returns from its involvement with the investee; and</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td style="vertical-align:top;">-</td><td style="vertical-align:top;">The ability to use its power over the investee to affect its returns.</td></tr></tbody></table>Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their fair values at the acquisition date, irrespective of the extent of any non-controlling interest. The excess of the cost of acquisition is recorded as goodwill. If the cost of acquisition is less than fair value of the net assets of the subsidiary acquired, the difference is recognized directly in the consolidated statement of profit or loss. The assets, liabilities, income and expenses of subsidiary companies are consolidated on a line by line basis and the carrying value of investments held by the Holding Company is eliminated against the subsidiaries’ shareholders’ equity in the consolidated financial statements. All intra-group transactions, balances, income, expenses and unrealized gains and losses on transactions between Group companies are eliminated in full. Subsidiaries have same reporting period as that of the Holding Company. The accounting policies of subsidiaries have been same with the holding parent company. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. Intercompany balances and transactions have been eliminated on consolidation. The Corporation has classified its cash, trade accounts receivable and other receivables as “loans and receivables”, and its trade accounts payable, accrued liabilities, “other financial liabilities”. The Corporation must classify the fair value measurements of financial instruments according to a three-level hierarchy, based on the type of inputs used in making these measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Corporation initially recognizes receivables on the date that they are originated. Receivables are financial assets with fixed or determinable payments that are not quoted in an active market. Such assets are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, loans and receivables are measured at amortized cost using the effective interest method, less any impairment losses. The Corporation derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred. Financial assets and liabilities are offset, and the net amount presented in the consolidated statements of financial position when, and only when, the Corporation has a legal right to offset the amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. The Corporation initially recognizes other financial liabilities on the trade date at which the Corporation becomes a party to the contractual provisions of the instrument. Other financial liabilities are recognized initially at fair value plus any directly attributable transaction costs. Subsequent to initial recognition, these financial liabilities are measured at amortized cost using the effective interest method. The Corporation derecognizes a financial liability when its contractual obligations are discharged, cancelled or expired. Interest, losses and gains relating to a financial liability are recognized in the statement of operations and comprehensive loss. IFRS 9 – Financial Instruments (“IFRS 9”) ultimately replaces IAS 39 – Financial Instruments: Recognition and Measurement (“IAS 39”), with the objective of improving and simplifying the reporting for financial instruments. In July 2014, the IASB issued the final version of IFRS 9, Financial Instruments (IFRS 9). IFRS 9 supersedes IAS 39, IFRIC 9 and earlier versions of IFRS 9. This standard provides guidance on the classification and measurement of financial liabilities and the presentation of gains and losses on financial liabilities designated at fair value through profit and loss. When an entity elects to measure a financial liability at fair value, gains or losses due to changes in the credit risk of the instrument must be recognized in other comprehensive income. This standard was effective for annual periods beginning on or after January 1, 2018 with earlier adoption permitted. The Corporation has implemented this standard yet there is no impact of the adoption of this standard on its consolidated financial statements. Common shares are classified as equity. Incremental costs attributable to the issuance of common shares are recognized as an increase to deficit. Accounts receivable consists of trade receivables. Sales allowance for expected credit losses is recorded against trade receivables and is based on historical experience. The company has zero, zero and $4,000 trade receivables as of December 31, 2021, 2020 and 2019, respectively and no sales allowance was recorded during those three years.

4000

Inventory consists primarily of finished goods held for sale and materials and are carried at the lower of first-in, first-out cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less selling expenses. Property and equipment are measured at cost, less accumulated depreciation and accumulated impairment losses. Cost includes expenditure that is directly attributable to the acquisition of the asset. Purchased software that is integral to the functionality of the related equipment is capitalized as part of that equipment. When parts of an item of property and equipment have significantly different useful lives, they are accounted for as separate items (major components) of property and equipment. Gains and losses on disposal of an item of property and equipment are recognized as the difference in the proceeds from disposal and the carrying amount of property and equipment. The cost of replacing a part of an item of property and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Corporation, and its cost can be measured reliably. The carrying amount of the replaced part is derecognized. The costs of the day-to-day servicing of property and equipment are recognized in the statement of operations and comprehensive loss. Depreciation is calculated on the depreciable amount, which is the cost of an asset less its residual value. Depreciation is recognized on a straight-line basis over the estimated useful lives of each component of an item of property and equipment, since this most closely reflects the expected pattern of consumption of the future economic benefits embodied in the asset. The estimated useful lives for the current and comparative periods are represented by the following estimated useful lives: <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Asset Classification</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:10%;vertical-align:bottom;">Useful life</td></tr><tr style="height:15px"><td/><td/><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Laboratory equipment</td><td> </td><td style="vertical-align:bottom;">5 years</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Computer equipment</td><td> </td><td style="vertical-align:bottom;">3 years</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Office equipment and fixtures</td><td> </td><td style="vertical-align:bottom;">5 years</td></tr></tbody></table> Depreciation methods, useful lives and residual values are reviewed on an ongoing basis and adjusted if appropriate.

<table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Asset Classification</td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:10%;vertical-align:bottom;">Useful life</td></tr><tr style="height:15px"><td/><td/><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Laboratory equipment</td><td> </td><td style="vertical-align:bottom;">5 years</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:bottom;">Computer equipment</td><td> </td><td style="vertical-align:bottom;">3 years</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:bottom;">Office equipment and fixtures</td><td> </td><td style="vertical-align:bottom;">5 years</td></tr></tbody></table>

5 3 5 Expenditures on research activities, net of research tax credits, undertaken with the prospect of gaining new scientific or technical knowledge and understanding, as well as demonstrating product efficacy and regulatory compliance prior to launch, are expensed in the statement of comprehensive earnings (loss) as incurred. Development activities, net of research tax credits, involve a plan or design to produce new or substantially improved products and processes. Development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically, and commercially feasible, future economic benefits are probable, and the Corporation intends to and has sufficient resources to complete development and to use or sell the asset. Other development expenditures are recognized in research and development expenses as incurred. Amortization is calculated on the cost of the asset, less its residual value. Amortization methods, useful lives and residual values are reviewed on an ongoing basis and adjusted if appropriate. Indefinite lived intangibles are subject an assessment for impairment at each reporting date. Financial assets impairmentFinancial assets are assessed at each reporting date to determine whether there is objective evidence that they are impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. Objective evidence that financial assets are impaired can include default or delinquency by a debtor, restructuring of an amount due to the Corporation on terms that the Corporation would not consider otherwise, and indications that a debtor or issuer will enter bankruptcy. In assessing impairment, the Corporation uses historical trends of the probability of default, timing of recoveries and the amount of loss incurred, adjusted for management’s judgment as to whether current economic and credit conditions are such that the actual losses are likely to be greater or less than suggested by historical trends. An impairment loss in respect of a financial asset measured at amortized cost is calculated and recognized for the amount by which the asset’s carrying amount exceeds the present value of the estimated future cash flows discounted at the asset’s original effective interest rate. Losses are reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed. Non-financial assets impairmentThe carrying amounts of the Corporation’s non-financial assets, including property and equipment, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. The recoverable amount of an asset or cash-generating unit is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets that cannot be tested individually are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the “cash-generating unit, CGU or segment”). The Corporation’s corporate assets do not generate separate cash inflows. If there is an indication that a corporate asset may be impaired, then the recoverable amount is determined for the CGU to which the corporate asset belongs. An impairment loss is recognized if the carrying amount of an asset or its CGU exceeds its estimated recoverable amount. Impairment losses recognized in respect of CGUs are allocated to reduce the carrying amounts of the assets in the CGU on a pro rata basis. Impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Revenue from product sales is recognized when the product has been delivered and obligations as defined in the agreement are performed. Collaboration agreements that include multiple deliverables are considered to be multiple-element arrangements. Under this type of arrangement, the identification of separate units of accounting is required and revenue is allocated among the separate units based on their relative fair values. Payments received under a collaboration agreement may include upfront payments, milestone payments, sale of goods, royalties and license fees. Revenue for each unit of accounting is recorded as described below: Upfront paymentsUpfront payments are deferred and recognized as revenue on a systematic basis over the estimated service period. Changes in estimates are recognized prospectively when changes to the expected term are determined. Milestone paymentsRevenue subject to the achievement of milestones is recognized only when the specified events have occurred, and collectability is reasonably assured. Specifically, the criteria for recognizing milestone payments are that (i) the milestone is substantive in nature, (ii) the achievement was not reasonably assured at the inception of the agreement, and (iii) the Corporation has no further involvement or obligation to perform associated with the achievement of the milestone, as defined in the related collaboration arrangement. The company does not have any upfront payments, milestone payments or license revenue for the years ended December 31, 2021, 2020 and 2019. IFRS 15, Revenue from Contracts with CustomersIn May 2014, the IASB issued IFRS 15, Revenue from Contracts with Customers, which establishes principles for reporting the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. It provides a single model in order to depict the transfer of promised goods or services to customers. IFRS 15 supersedes the following standards: IAS 11, Construction Contracts, IAS 18, Revenue, IFRIC 13, Customer Loyalty Programs, IFRIC 15, Agreements for the Construction of Real Estate, IFRIC 18, Transfers of Assets from Customers, and SIC-31, Revenue – Barter Transactions Involving Advertising Service. The core principle of IFRS 15 is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. IFRS 15 also includes a cohesive set of disclosure requirements that would result in an entity providing comprehensive information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity’s contracts with customers. The Corporation has adopted this standard in these financial statements yet determined that there is no impact on reported results of operations from its implementation. Revenue from the sale of goods is recognized when the Corporation has transferred to the buyer the significant risks and rewards of ownership of the goods, there is no continuing management involvement with the goods, and the amount of revenue can be measured reliably. Monetary assets and liabilities of the Corporation’s Canadian and US subsidiaries denominated in currencies other than the US dollar are translated at the rates of exchange at the reporting date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Income and expenses denominated in foreign currencies are translated at the average rate prevailing during the year.Foreign exchange loss and gain are reported on a net basis, within finance costs or finance income. Until the corporation re-domiciled from Canada to the commonwealth of Bahamas in 2015, it is entitled to scientific research and experimental development tax credits (“research tax credits”) granted by the Canadian federal government and the government of the province of Québec. Federal research tax credits, which are non-refundable, are earned on qualified research and development expenditures and can only be used to offset federal income taxes otherwise payable. Provincial research tax credits, which are refundable, are earned on qualified research and development expenditures incurred in the province of Québec. These research tax credits are recognized as a reduction of research and development expenditures in the period in which they become receivable, provided that there is reasonable assurance that they will be received. The grant date fair value of stock-based compensation awards granted to employees, consultants and directors is recognized as an expense, with a corresponding increase in equity, over the period that the employees, consultants or directors unconditionally become entitled to the awards. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service vesting conditions are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service at the vesting date. The fair value of the stock options is measured using the binomial pricing model. Measurement inputs include share price on measurement date, exercise price of the instrument, expected volatility (based on weighted average historic volatility), weighted average expected life of the instruments (based on historical experience and general option holder behavior), expected dividends, and the risk-free interest rate (based on government bonds). Service conditions attached to the transactions are not taken into account in determining fair value.Share based payment arrangements in which the Corporation receives goods or services as consideration for its own equity instruments are accounted for as equity-settled share-based payment transactions. Short-term employee benefits obligations are measured on an undiscounted basis and are expensed as the related service is provided. In addition to their salaries, employees of the Corporation are covered by a benefit package which includes a health plan, dental plan, disability insurance, life insurance and worker compensation insurance coverage. Participation in this plan is paid by the Corporation in full. Any employee that elects to extend the coverage to members of their family must pay the additional premium. Effective for annual reporting periods beginning on or after January 1, 2019, IFRS 16 introduced a new approach to lessee accounting that requires a lessee to recognize assets and liabilities for the rights and obligations created by leases. IFRS 16 requires a lessee to recognize assets and liabilities for all leases with a term of more than 12 months. The IASB concluded that such an approach will result in a more faithful representation of a lessee’s assets and liabilities and, together with enhanced disclosures, greater transparency of a lessee’s financial leverage and capital employed. We adopted this standard on January 1, 2019, with an immaterial cumulative adjustment of $11,667 to accumulated deficit rather than retrospectively adjusting prior periods. 11667 Income tax expense comprises current and deferred taxes. Current tax and deferred tax are recognized in the statement of operations and comprehensive loss except to the extent that it relates to a business combination, or items recognized directly in equity or in other comprehensive loss.Current tax is the expected tax payable or receivable on the taxable income or loss of the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss and differences relating to investments in subsidiaries to the extent that it is probable that they will not reverse in the foreseeable future. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Basic earnings per share are determined using the weighted average number of common shares outstanding during the period. Diluted earnings per share are computed in a manner consistent with basic earnings per share, except that the weighted average shares outstanding are increased to include additional shares from the assumed exercise of options and warrants, if dilutive. The number of additional shares is calculated by assuming that outstanding options were exercised, and that the proceeds from such exercises as well as the assumed proceeds from future services were used to acquire shares of common stock at the average market price during the reporting period. A provision is recognized if, because of a past event, the Corporation has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The unwinding of the discount is recognized as finance cost. A provision for onerous contracts is recognized when the expected benefits to be derived by the Corporation from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Corporation recognizes any impairment loss on the assets associated with that contract. Certain amounts in the consolidated financial statements for the prior years have been reclassified to conform to the current year presentation. These reclassifications had no impact on net earnings, financial position, or cash flows. NOTE 5 – NEW ACCOUNTING STANDARDS AND INTERPRETATIONS Standards, amendments and improvements to the approved accounting standards that are not yet effective for CFY’ 2021. The following standards, amendments and improvements to the approved accounting standards would be effective from the dates mentioned below against the respective standard or interpretation: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:18%;vertical-align:bottom;">Standard or Interpretation </td><td style="width:1%;"> </td><td style="width:50%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;">IASB Effective Date(Annual periods beginning on or after)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IFRS 03</td><td> </td><td style="vertical-align:top;">Reference to Conceptual Framework (Amendments) </td><td> </td><td style="vertical-align:top;">01 January 2022</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">IFRS 09</td><td> </td><td style="vertical-align:top;">Financial Instruments – Fees in the ‘10 percent’ test for derecognition of financial liabilities</td><td> </td><td style="vertical-align:top;">01 January 2022</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IFRS 10/IAS 28</td><td> </td><td style="vertical-align:top;">Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendment)</td><td> </td><td style="vertical-align:top;">Not Yet Finalized</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">IAS 01</td><td> </td><td style="vertical-align:top;">Classification of Liabilities as Current or Non-current liabilities (Amendments)</td><td> </td><td style="vertical-align:top;">01 January 2022*</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IAS 16</td><td> </td><td style="vertical-align:top;">Proceeds before Intended Use (Amendments)</td><td> </td><td style="vertical-align:top;">01 January 2022</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">IAS 37</td><td> </td><td style="vertical-align:top;">Onerous Contracts – Costs of Fulfilling a Contract (Amendments)</td><td> </td><td style="vertical-align:top;">01 January 2022</td></tr></tbody></table> *The IASB has issued an exposure draft proposing to defer the effective date of the Amendments to IAS 01 to 01 January 2023. The above standards and amendments are not expected to have any material impact on the Company’s unconsolidated financial statements in the period of initial application. <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:18%;vertical-align:bottom;">Standard or Interpretation </td><td style="width:1%;"> </td><td style="width:50%;"> </td><td style="width:1%;"> </td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;">IASB Effective Date(Annual periods beginning on or after)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IFRS 03</td><td> </td><td style="vertical-align:top;">Reference to Conceptual Framework (Amendments) </td><td> </td><td style="vertical-align:top;">01 January 2022</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">IFRS 09</td><td> </td><td style="vertical-align:top;">Financial Instruments – Fees in the ‘10 percent’ test for derecognition of financial liabilities</td><td> </td><td style="vertical-align:top;">01 January 2022</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IFRS 10/IAS 28</td><td> </td><td style="vertical-align:top;">Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendment)</td><td> </td><td style="vertical-align:top;">Not Yet Finalized</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">IAS 01</td><td> </td><td style="vertical-align:top;">Classification of Liabilities as Current or Non-current liabilities (Amendments)</td><td> </td><td style="vertical-align:top;">01 January 2022*</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">IAS 16</td><td> </td><td style="vertical-align:top;">Proceeds before Intended Use (Amendments)</td><td> </td><td style="vertical-align:top;">01 January 2022</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">IAS 37</td><td> </td><td style="vertical-align:top;">Onerous Contracts – Costs of Fulfilling a Contract (Amendments)</td><td> </td><td style="vertical-align:top;">01 January 2022</td></tr></tbody></table> NOTE 6 – PROPERTY AND EQUIPMENT The carrying value of property and equipment included the following changes for the years ended December 31, 2021, 2020 and 2019: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="17" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">LaboratoryEquipment</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Computer Equipment</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Office Equipment</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Cost</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at January 1, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">113</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">574</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Additions</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">113</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">574</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Additions</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">113</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">587</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Additions</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">418</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">59</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">116</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">593</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accumulated depreciation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at January1, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">541</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Depreciation for the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">550</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation for the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">41</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Depreciation for the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">418</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">48</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">105</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">571</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Carrying amounts</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">At December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">At December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">At December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> The depreciation expense of property and equipment amounts to $12,357, $9,236 and $8,684 for the years ended December 31, 2021, 2020 and 2019, respectively. . <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="17" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">LaboratoryEquipment</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Computer Equipment</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Office Equipment</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Cost</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at January 1, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">113</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">574</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Additions</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">43</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">113</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">574</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Additions</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">56</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">113</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">587</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Additions</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">418</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">59</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">116</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">593</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accumulated depreciation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at January1, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">33</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">541</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Depreciation for the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">37</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">95</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">550</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Depreciation for the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance at December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">418</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">41</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">100</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">559</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Depreciation for the year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Disposals</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">–</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance at December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">418</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">48</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">105</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">571</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Carrying amounts</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">At December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">At December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">At December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

418000

43000

113000

574000

418000

43000

113000

574000

13000

418000

56000

113000

587000

3000

6000

418000

59000

116000

593000

418000

33000 90000 4000 5000 9000

418000

37000 95000 4000 9000 418000 41000 100000 559000 7000 5000 12000 418000 48000 105000 571000 6000 19000 25000 15000 13000 11000 11000 22000

12357

9236

8684

NOTE 7 – INTANGIBLE ASSETS Intangible assets include patents and acquired intellectual property rights. The patent and intellectual property rights, having a cost of $2,222,661 and an accumulated amortization of $2,222,661 at December 31, 2021, 2020 and 2019, are still property of the Corporation. The patent and intellectual rights were fully amortized by year 2009.

2222661

NOTE 8 – ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts payable and accrued liabilities as of December 31, 2021, 2020 and 2019, consisted of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,273</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,403</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,629</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Payroll related liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">262</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">245</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">225</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other accrued liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">74</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Deposit</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">50</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total accounts payable and accrued liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,558</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,772</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,894</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts payable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,273</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,403</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,629</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued liabilities:</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Payroll related liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">262</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">245</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">225</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other accrued liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">74</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Deposit</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">50</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total accounts payable and accrued liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,558</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,772</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,894</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

1273000

1403000

1629000

262000 245000 225000

23000

74000

40000

0 50000 0

1558000

1772000

1894000

NOTE 9 – OPERATING LEASES AND COMMITMENTS Effective for annual reporting periods beginning on or after January 1, 2019, IFRS 16 introduced a new approach to lessee accounting that requires a lessee to recognize assets and liabilities for the rights and obligations created by leases. IFRS 16 requires a lessee to recognize assets and liabilities for all leases with a term of more than 12 months. The IASB concluded that such an approach will result in a more faithful representation of a lessee’s assets and liabilities and, together with enhanced disclosures, greater transparency of a lessee’s financial leverage and capital employed. We adopted this standard on January 1, 2019, with an immaterial cumulative adjustment of $11,667 to accumulated deficit rather than retrospectively adjusting prior periods. This adoption approach resulted in a balance sheet presentation that is not comparable to the prior period. We used an incremental borrowing rate as a discount rate for our operating leases. The discount rate ranges from 4.75% to 5.00% and the average remaining years for our lease are 1.71 years as of December 31, 2021. In August 2021, the Corporation renewed its operating lease agreements for its US (California) premises, which is effective from August 1, 2021 and will expire on July 31, 2023. This new lease results in the recognition of operating lease assets and liabilities of approximately $184,000 as of August 1,2021. <table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">53</td></tr><tr style="height:15px"><td></td></tr><tr style="height:15px"><td><a href="#TOCNOTES">Table of Contents</a></td></tr></tbody></table> The following table provides the changes in the Corporation’s operating lease right-of-use assets for the year ended December 31, 2021, 2020 and 2019 respectively: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Operationleaseright-of-useasset</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of January 1, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">422</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Renewed office lease</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accumulated amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(222 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances as of December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">384</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Operationleaseright-of-useasset</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of January 1, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">136</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Renewed office lease</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">533</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accumulated amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(247 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances as of December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">422</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Operationleaseright-of-useasset</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of January 1, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">393</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accumulated amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(247 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(4 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances as of December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">136</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">54</td></tr><tr style="height:15px"><td></td></tr><tr style="height:15px"><td><a href="#TOCNOTES">Table of Contents</a></td></tr></tbody></table> The following table provides the changes in the Corporation’s operating lease liability for the year ended December 31, 2021, 2020 and 2019 respectively: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of January 1, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">426</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Renewed office lease</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Repayments of lease liability</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(238 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">19</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">391</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lease liability due within one year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">228</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Lease liability long term</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">163</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The total future commitment payment amount for above lease is $409,279 compared to an outstanding lease liability of $391,459 as of December 31, 2021. The difference is due to borrowing rate discount. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of January 1, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">147</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Renewed office lease</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">533</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Repayments of lease liability</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(265 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">11</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">426</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lease liability due within one year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">193</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Lease liability long term</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">233</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The total future commitment payment amount for above lease is $454,092 compared to an outstanding lease liability of $425,620 as of December 31, 2020. The difference is due to borrowing rate discount. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of January 1, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">405</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Repayments of lease liability</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(277 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">19</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances as of December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">147</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Lease liability due within one year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lease liability long term</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The total future commitment payment amount for above lease is $151,805 compared to an outstanding lease liability of $147,036 as of December 31, 2019. The difference is due to borrowing rate discount. 11667 P1Y8M15D

184000

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Operationleaseright-of-useasset</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of January 1, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">422</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Renewed office lease</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accumulated amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(222 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances as of December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">384</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Operationleaseright-of-useasset</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of January 1, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">393</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accumulated amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(247 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Other</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(4 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances as of December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">136</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 422000 184000 -222000 384000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Operationleaseright-of-useasset</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of January 1, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">136</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Renewed office lease</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">533</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accumulated amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(247 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances as of December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">422</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Total</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of January 1, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">426</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Renewed office lease</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">184</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Repayments of lease liability</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(238 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Other</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">19</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances as of December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">391</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Lease liability due within one year</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">228</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Lease liability long term</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">163</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 136000 533000 -247000 422000 393000 -247000 -4000 136000 426000 184000 -238000 19000 391000 228000 163000 409279

391459

425620

405000 -277000 19000 147000 144000 3000 151805

147036

NOTE 10 – SHARE CAPITAL Common shares authorized, issued and related contributed capital by controlling shareholders as of December 31, 2021, 2020 and 2019 were as follows <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars and shares</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Authorized:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">An unlimited number of common shares, at no par value</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issued, outstanding:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Number of common shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">85,546</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">77,961</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">71,218</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Dollars</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">165,061</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">151,722</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">136,554</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> The holders of common shares are entitled to receive dividends as declared, which is at the discretion of the Corporation, and are entitled to one vote per share at the annual general meeting of the Corporation. The Corporation has never paid any dividends.Common Stock In February 2016, the Corporation filed a prospectus supplement and accompanying prospectus related to the potential issuance and sale of up to $12,000,000 of our common stock, no par value per share, from time to time through our sales agent, Chardan Capital Markets, LLC, or Chardan. These sales have been made under an equity distribution agreement, dated February 5, 2016, between the Corporation and Chardan, which we refer to as the equity distribution agreement. Sales of our common stock under this prospectus supplement and the accompanying prospectus are made by any method permitted by law deemed to be an “at-the-market” offering as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on The NASDAQ Capital Market, on any other existing trading market for our common. If expressly authorized by us, Chardan may also sell our common stock in privately negotiated transactions. Chardan acts as sales agent on a commercially reasonable efforts basis, consistent with its normal trading and sales practices and applicable state and federal laws, rules and regulations and the rules of NASDAQ. There is no specific date on which the offering will end, there are no minimum sale requirements and there are no arrangements to place any of the proceeds of this offering in an escrow, trust or similar account. On April 28, 2021, the company announced it has entered into a definitive agreement with institutional investors in a private placement of 3,669,724 shares of common stock and warrants to purchase 1,834,862 shares of common stock at a combined purchase price of $2.18 per share for gross proceeds of approximately $8,000,000 before deducting fees and other estimated offering expenses. The warrants will have an exercise price of $2.50 per share, will be immediately exercisable and will expire five years from the date of issuance. A.G.P./Alliance Global Partners is acting as sole placement agent for the private placement. The private placement was completed on April 30, 2021, and the company raised $7,318,348.46 after deducting fees and other offering expense. In addition, the Company agreed to issue A.G.P. or its assigns warrants to purchase up to 183,486 shares of common stock at an exercise price of $2.50 per share. The Placement Agent Warrants will be immediately exercisable and will expire on the five-year anniversary of the date of offer and are subject to customary anti-dilution provisions. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars and shares</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Authorized:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">An unlimited number of common shares, at no par value</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issued, outstanding:</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Number of common shares</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">85,546</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">77,961</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">71,218</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Dollars</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">165,061</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">151,722</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">136,554</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 85546000 77961000 71218000 165061000 151722000 136554000 3669724 1834862 8000000 2.50 $7,318,348.46 183486 2.50 NOTE 11 – STOCK OPTIONS The Corporation has established a stock option plan (the “Plan”) for its key employees, officers and directors, and certain consultants. The Plan is administered by the Board of Directors of the Corporation. The Board may from time to time designate individuals to whom options to purchase common shares of the Corporation may be granted, the number of shares to be optioned to each, and the option price per share. The option price per share cannot involve a discount to the market price at the time the option is granted. The maximum number of shares which may be optioned under the stock option plan is 15,000,000. The maximum number of shares which may be optioned to any one individual is 15% of the total issued and outstanding common shares. Options under the Plan expire up to ten years after the grant date and vest either immediately or over periods up to six years and are equity-settled. As of December 31, 2021, 1,072,000 options could still be granted by the Corporation. The following table provides the activity of stock option awards for the years ended December 31, 2021, 2020 and 2019 and for options outstanding and exercisable as of December 31, 2021, the weighted average exercise price, and the weighted average remaining contractual life. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Options outstanding</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted averageexercise price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted averageremaining contractuallife (in years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding January 1, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,740,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.76</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.37</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(10,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.43</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">360,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.08</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9.26</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,090,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.78</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.61</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">410,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.34</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8.94</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.87</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(200,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Not vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">128,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.77</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9.48</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,428,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.86</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercisable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,348,833</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.80</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.80</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>The fair value of the options granted during the years ended December 31, 2021, 2020 and 2019, was determined using the Binomial Option pricing model using the following weighted average assumptions: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell"/><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2019</td><td style="white-space: nowrap;"> </td><td class="hdcell"/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Share price</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;">$ </td><td style="width:15%;">1.75~1.83 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:1%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;">$</td><td style="width:15%;"> 1.81~2.86</td><td style="width:2%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:1%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">2.08</td><td style="width:2%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercise price</td><td style="white-space: nowrap;"> </td><td>$</td><td> 1.75~1.83 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td>$</td><td> 1.81~2.86 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.08</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="white-space: nowrap;"> </td><td/><td>1.60%~1.64</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td/><td>1.12%~1.67</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.48</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="white-space: nowrap;"> </td><td/><td>107.05%~107.47</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td/><td>81.34%~106.56</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">105.36</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected option life in years</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">10.</td><td style="vertical-align:bottom;white-space: nowrap;">Yrs</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td/><td>4~10 </td><td style="vertical-align:bottom;white-space: nowrap;">Yrs</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">10</td><td style="vertical-align:bottom;white-space: nowrap;">Yrs</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected dividend yield</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td></tr></tbody></table> The weighted average grant-date fair value of options granted during the year ended December 31, 2021, and 2020 was $ 1.68 and 2.09 per option respectively. Expected volatility was estimated considering historic average share price volatility. Expected dividends were determined to be nil, since the Corporation has never had paid any dividends. The maximum number of shares which may be optioned under the stock option plan is 15,000,000. The maximum number of shares which may be optioned to any one individual is 15% of the total issued and outstanding common shares. Options under the Plan expire up to ten years after the grant date and vest either immediately or over periods up to six years and are equity-settled. 1072000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Options outstanding</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted averageexercise price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted averageremaining contractuallife (in years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding January 1, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,740,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.76</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6.37</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(10,000 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.43</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">360,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.08</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9.26</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,090,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.78</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.61</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">410,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2.34</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">8.94</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.87</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(200,000</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Not vested</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">128,000</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1.77</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9.48</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,428,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.81</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.86</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Options exercisable</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,348,833</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.80</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.80</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 5740000 1.76 P6Y4M13D -10000 3.43 360000 2.08 P9Y3M3D 6090000 1.78 P5Y7M9D 410000 2.34 P8Y11M8D 6500000 1.81 P4Y10M13D 200000 1.81 128000 1.77 P9Y5M23D 6428000 1.81 P3Y10M9D 6348833 1.80 P3Y9M18D <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell"/><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="4" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;">2019</td><td style="white-space: nowrap;"> </td><td class="hdcell"/></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Share price</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;">$ </td><td style="width:15%;">1.75~1.83 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:1%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;">$</td><td style="width:15%;"> 1.81~2.86</td><td style="width:2%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:1%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:15%;vertical-align:bottom;text-align:right;">2.08</td><td style="width:2%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercise price</td><td style="white-space: nowrap;"> </td><td>$</td><td> 1.75~1.83 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td>$</td><td> 1.81~2.86 </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.08</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="white-space: nowrap;"> </td><td/><td>1.60%~1.64</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td/><td>1.12%~1.67</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">2.48</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="white-space: nowrap;"> </td><td/><td>107.05%~107.47</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td/><td>81.34%~106.56</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">105.36</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expected option life in years</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">10.</td><td style="vertical-align:bottom;white-space: nowrap;">Yrs</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td/><td>4~10 </td><td style="vertical-align:bottom;white-space: nowrap;">Yrs</td><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">10</td><td style="vertical-align:bottom;white-space: nowrap;">Yrs</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected dividend yield</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" style="vertical-align:bottom;text-align:right;">-</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td></tr></tbody></table> 1.75 1.83 1.81 2.86 2.08 1.75 1.83 1.81 2.86 2.08

0.0160

0.0164

0.0112

0.0167

0.0248

1.0705

1.0747

0.8134

1.0656

1.0536

P10Y P4Y P10Y P10Y 1.68 2.09 NOTE 12 - SHARE BASED COMPENSATION On July 17, 2015, the Corporation approved the long-term employment agreement of Dr. Paul Averback as President and Chief Executive Officer. The employment agreement retains the services of Dr. Averback for an initial period of seven years. Dr Averback has agreed to forgo his salary until the Company receives a significant increase in its financing to expand its operations and execute its business plans.. Dr. Averback received 3,000,000 restricted shares in July, 2015 and shall receive 250,000 restricted stock each month for the duration of the contract, totaling up to 21,000,000 restricted shares, in lieu of cash salary. The Corporation determined that a grant date for all the restricted shares occurred on July 17, 2015 and established the fair value of each share at $1.36. The Corporation is recording the expense on a pro-rata basis and recorded an expense of $657,838 in 2021. The unrecognized compensation cost as at December 31, 2021, which will be recognized on a pro-rata basis over the duration of the employment contract as services are performed, assuming Dr. Averback continued to elect equity compensation, is $86,749. After the corporation raised gross proceeds of approximately $8,000,000 before deducting fees and other offering expenses in April,2021, Dr.Averback received total $750,000 compensation by December 31, 2021 as reward for his service. The stock and stock option-based compensation expense to the directors and employees are disaggregated in the statements of operations and comprehensive loss for the years ended December 31, 2021, 2020 and 2019, as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Functional Expense Category</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">General and administrative expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,124</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">702</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,839</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research and development expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">479</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,046</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,172</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,603</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,748</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,011</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 3000000 250000 21000000

1.36

657838 86749 8000000 750000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Functional Expense Category</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">General and administrative expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,124</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">702</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,839</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Research and development expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">479</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,046</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,172</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,603</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,748</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,011</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

2124000

702000

1839000

479000

1046000

1172000

2603000 1748000 3011000 NOTE 13 - WARRANTS In the first quarter of 2019, the Corporation issued 2,500,000 warrants in connection with one private placement. Each warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $8.00 with a five year term. The warrant was valued at $200,000. During the second quarter at the year ended December 31, 2021, the Corporation issued 1,834,862 warrants in connection with one private placement. Each warrant entitles the holder to acquire one common share of the Corporation at an exercise price of $2.50 with a five year term. The warrant was valued at $330,277. In addition, the Corporation issued the associated security broker warrants to purchase up to 183,486 shares of common stock at an exercise price of $2.50 per share for its service. The warrant was valued at $220,457. A detail of warrant activity for the years ended December 31, 2021, 2020 and 2019 is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted averageexercise price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted averageremaining contractuallife (in years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding 1-Jan-19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td/><td>2,500,000-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cancelled</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding 31-Dec-19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.04</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cancelled</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding 31-Dec-20</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.04</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,018,348</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.50</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cancelled</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding 31-Dec-21</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,518,348</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5.54</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.07</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 2500000

8.00

200000 1834862

2.50

330277 183486

2.50

220457 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted averageexercise price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted averageremaining contractuallife (in years)</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding 1-Jan-19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td/><td>2,500,000-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cancelled</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding 31-Dec-19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.04</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Cancelled</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding 31-Dec-20</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,500,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8.00</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.04</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Granted</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,018,348</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.50</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Cancelled</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding 31-Dec-21</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,518,348</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">5.54</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">3.07</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 2500000 2500000 8.00 2500000 8.00 2018348 4518348 5.54 NOTE 14 - INCOME TAXES The Corporation was re-domiciled to the Bahamas in 2015. The substantial portion of our operations are generated out of our executive offices in the Bahamas which has no corporate income taxes. We do have operations subject to income tax in the United States of America, primarily the sale of product out of our New Jersey facilities. The effect of the re-domiciliation from Canada to the Bahamas resulted in the expiration of several tax attributes relative to our prior operations in Canada including Canadian research tax credit carryforwards and Canadian loss carryforwards. Canadian research tax credit carryforwards and Canadian loss carryforwards expired upon determination of the re-domiciliation by the Canadian federal government amount to $1,686,270 and $55,850,632, respectively. Nymox recognized no provision (recovery) for federal income taxes for the years ended December 31, 2021, 2020 and 2019. <table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">58</td></tr><tr style="height:15px"><td></td></tr><tr style="height:15px"><td><a href="#TOCNOTES">Table of Contents</a></td></tr></tbody></table> The following table is a reconciliation of effective tax rate: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss for the year, before income taxes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,537 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,738 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,162 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss attributable to the Bahamas</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,781 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,012 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,841 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss attributable the United States</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(756 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(725 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(321 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Domestic tax rate applicable to the Corporation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income taxes at domestic tax statutory rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(159 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(152 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(67 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in valuation allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">159</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">152</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">67</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Deferred tax provision (recovery)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> As of December 31, 2021, 2020 and 2019, deferred tax assets not recognized were as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tax loss carry forward</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,404</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,386</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,402</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents capitalized and amortized for tax purposes</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unrecognized deferred tax assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,404</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.386</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,402</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Deferred tax assets have not been recognized in respect to these items because it is not probable that future taxable profit will be available against which the Corporation can utilize the benefits therefrom. The generation of future taxable profit is dependent on the successful commercialization of the Corporation’s products and technologies. The amount of net operating loss carryforwards for US Federal income tax purposes by year of origination and expiration is detailed below: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="15" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">YearOriginated</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Year ofExpiration</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">YearOriginated</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Year ofExpiration</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2002</td><td style="width:1%;white-space: nowrap;"> </td><td>2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">522</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2012</td><td style="width:1%;white-space: nowrap;"> </td><td>2032</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">177</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2003</td><td style="width:1%;white-space: nowrap;"> </td><td>2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">564</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2013</td><td style="width:1%;white-space: nowrap;"> </td><td>2033</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2004</td><td style="width:1%;white-space: nowrap;"> </td><td>2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">353</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2014</td><td style="width:1%;white-space: nowrap;"> </td><td>2034</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2005</td><td style="width:1%;white-space: nowrap;"> </td><td>2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2015</td><td style="width:1%;white-space: nowrap;"> </td><td>2035</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2006</td><td style="width:1%;white-space: nowrap;"> </td><td>2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">355</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2016</td><td style="width:1%;white-space: nowrap;"> </td><td>2036</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">147</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2007</td><td style="width:1%;white-space: nowrap;"> </td><td>2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">373</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2017</td><td style="width:1%;white-space: nowrap;"> </td><td>2037</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2008</td><td style="width:1%;white-space: nowrap;"> </td><td>2028 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">.351</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2018</td><td style="width:1%;white-space: nowrap;"> </td><td>2038</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">194</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2009</td><td style="width:1%;white-space: nowrap;"> </td><td>2029</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2019</td><td style="width:1%;white-space: nowrap;"> </td><td>2039</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">337</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2010</td><td style="width:1%;white-space: nowrap;"> </td><td>2030</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">541</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2020</td><td style="width:1%;white-space: nowrap;"> </td><td>2040</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">732</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2011</td><td style="width:1%;white-space: nowrap;"> </td><td>2031</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">480</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2021</td><td style="width:1%;white-space: nowrap;"> </td><td>2041</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">753</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">Total </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,687</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 1686270 55850632 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss for the year, before income taxes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,537 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,738 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(13,162 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net loss attributable to the Bahamas</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,781 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(11,012 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12,841 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Net loss attributable the United States</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(756 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(725 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(321 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Domestic tax rate applicable to the Corporation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Income taxes at domestic tax statutory rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(159 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(152 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(67 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in valuation allowance</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">159</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">152</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">67</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Deferred tax provision (recovery)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> -12537000 -11738000 -13162000 -11781000 -11012000 -12841000 -756000 -725000 -321000

0.21

-159000 -152000 -67000 159000 152000 67000 0 0 0 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tax loss carry forward</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,404</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,386</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,402</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Patents capitalized and amortized for tax purposes</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Unrecognized deferred tax assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,404</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.386</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,402</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 1404000 1386000 1402000 0 0 0 1404000 1386 1402000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="15" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">YearOriginated</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Year ofExpiration</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">YearOriginated</td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Year ofExpiration</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2002</td><td style="width:1%;white-space: nowrap;"> </td><td>2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">522</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2012</td><td style="width:1%;white-space: nowrap;"> </td><td>2032</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">177</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2003</td><td style="width:1%;white-space: nowrap;"> </td><td>2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">564</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2013</td><td style="width:1%;white-space: nowrap;"> </td><td>2033</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">121</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2004</td><td style="width:1%;white-space: nowrap;"> </td><td>2024</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">353</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2014</td><td style="width:1%;white-space: nowrap;"> </td><td>2034</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2005</td><td style="width:1%;white-space: nowrap;"> </td><td>2025</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">264</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2015</td><td style="width:1%;white-space: nowrap;"> </td><td>2035</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">127</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2006</td><td style="width:1%;white-space: nowrap;"> </td><td>2026</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">355</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2016</td><td style="width:1%;white-space: nowrap;"> </td><td>2036</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">147</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2007</td><td style="width:1%;white-space: nowrap;"> </td><td>2027</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">373</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2017</td><td style="width:1%;white-space: nowrap;"> </td><td>2037</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">140</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2008</td><td style="width:1%;white-space: nowrap;"> </td><td>2028 </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">.351</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2018</td><td style="width:1%;white-space: nowrap;"> </td><td>2038</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">194</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2009</td><td style="width:1%;white-space: nowrap;"> </td><td>2029</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">86</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2019</td><td style="width:1%;white-space: nowrap;"> </td><td>2039</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">337</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2010</td><td style="width:1%;white-space: nowrap;"> </td><td>2030</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">541</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2020</td><td style="width:1%;white-space: nowrap;"> </td><td>2040</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">732</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2011</td><td style="width:1%;white-space: nowrap;"> </td><td>2031</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">480</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td>2021</td><td style="width:1%;white-space: nowrap;"> </td><td>2041</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">753</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">Total </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">6,687</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 2002 2022 522000 2012 2032 177000 2003 2023 564000 2013 2033 121000 2004 2024 353000 2014 2034 70000 2005 2025 264000 2015 2035 127000 2006 2026 355000 2016 2036 147000 2007 2027 373000 2017 2037 140000 2008 2028 351000 2018 2038 194000 2009 2029 86000 2019 2039 337000 2010 2030 541000 2020 2040 732000 2011 2031 480000 2021 2041 753000 6687000 NOTE 15 - EARNINGS PER SHARE Weighted average number of common shares outstanding: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of Shares</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Issued common shares at January 1</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">77,961</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,218</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,676</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of shares issued</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,015</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,605</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,169</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average number of common shares outstanding at December 31</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">81,976</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,823</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">68,845</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Diluted loss per share was the same amount as basic loss per share, as the effect of options and warrants would have been anti-dilutive because the Corporation incurred losses in each of the years presented. All outstanding options could potentially be dilutive in the future. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of Shares</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Issued common shares at January 1</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">77,961</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,218</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,676</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Effect of shares issued</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,015</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,605</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,169</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Weighted average number of common shares outstanding at December 31</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">81,976</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,823</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">68,845</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 77961000 71218000 64676000

4015000

2605000

4169000

81976000 73823000 68845000 NOTE 16 - FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES The Corporation has determined that the carrying value of its short-term financial assets and liabilities approximates their fair value due to the immediate or short-term maturity of these financial instruments. NOTE 17 – FINANCE INCOME AND FINANCE COSTS Finance income and finance costs for the years ended December 31, 2021, 2020 and 2019, are detailed below: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest income</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net foreign exchange gain(loss)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finance income</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">24</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">201</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Interest and bank charges</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(20 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(18 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Financial costs</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(20 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(30 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(18 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Operating lease interest expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(20 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total finance income and costs</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(33 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(18 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">163</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Interest income</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">213</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Net foreign exchange gain(loss)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Finance income</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">24</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">201</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Interest and bank charges</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(20 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(30 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(18 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Financial costs</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(20 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(30 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(18 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Operating lease interest expense</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(19 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(12 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(20 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total finance income and costs</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(33 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(18 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">163</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

8000

27000

213000

-2000

-3000

-12000

6000

24000

201000

20000

30000

18000

20000

30000

18000

-19000 -12000 -20000

-33000

-18000

163000

NOTE 18 - SEGMENT DISCLOSURES The Corporation operates in one reportable segment, which is the Corporation’s strategic business unit -the research and development of products for the aging population.Information regarding the geographic reportable segment is as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Canada</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">UnitedStates</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Europe</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">91</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Property and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Revenues are attributed to geographic locations based on location of customers. Property and equipment is attributed to geographic locations based on its physical location. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Canada</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">UnitedStates</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Europe</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Revenues</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">91</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Property and equipment</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">12</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">9</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">19</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">December 31, 2019</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">–</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

3000

2000

1000

91000

24000

10000

12000

9000

19000

25000

NOTE 19 - CONCENTRATIONS Major customers Customers that accounted for greater than 10% of revenues from sales of goods in any of the last three years were as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Customer A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer B</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Customer C</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Customer A</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">23</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Customer B</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Customer C</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

23000

2000

36000

NOTE 20- RELATED PARTY TRANSACTIONS The transactions we have with related parties are compensation arrangements for both current compensation, share based compensation and compensation under options for our officers and directors. We also paid service fees to two corporations controlled by two of our officers. Executive officers and directors participate in the Corporation’s stock option plan. Executive officers are covered under the Corporation’s health plan. <table cellpadding="0" style="border-spacing:0;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td class="hpbhr"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">61</td></tr><tr style="height:15px"><td></td></tr><tr style="height:15px"><td><a href="#TOCNOTES">Table of Contents</a></td></tr></tbody></table> Key management personnel compensation is comprised of: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Salary and Compensation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">750</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Short-term employee benefits</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock-based compensation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,227</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,404</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,998</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,991</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,406</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> Total honorariums earned by the independent directors of the Corporation for participation in Board and Committee meetings were $0, $26,000 and $0 for the years ended December 31, 2021, 2020 and 2019, respectively. Our Chief Financial Officer receives no compensation as an individual and receives no deferred or incentive compensation. We do make payments in the form of contract for services rendered to a corporation controlled by him. Amounts paid under this arrangement were $580,000, $535,000 and $480,000 for the years ended December 31, 2021, 2020 and 2019, respectively. Our Corporate Legal Counsel received 900,000 restricted shares of common shares for his exemplary service for over 16 years during the period ended December 31, 2021.We also make payments in the form of contract for professional services rendered to a corporation controlled by him. Amounts paid under this arrangement were $435,289, $324,767 and $289,992 for the years ended December 31, 2021, 2020 and 2019, respectively. The above honorariums payment to directors and professional service fee paid to officers’ related party are part of the company’s G&A expense.

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Salary and Compensation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">750</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Short-term employee benefits</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">14</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Stock-based compensation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,227</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,404</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,998</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,991</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,406</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,000</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

750000

14000

2000

2227000

1404000

2998000

2991000

1406000

3000000

0 26000 0

580000

535000

480000

900000

435289

324767

289992

NOTE 21 – RESEARCH AND DEVELOPMENT EXPENSES Research and development expenses, excluding stock-based compensation, depreciation and lease amortization expenses, allocated to our major research and development programs are as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">For the Year Ended December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Research and Development Program</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Research and Development Program</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Alzheimer’s Disease: Therapeutics</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Anti-Infectives</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">BPH (Enlarged Prostate) and Prostate Cancer Therapeutics</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">5,944</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,162</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,932</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tobacco Exposure Tests: NicAlert™ and TobacAlert™</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">18</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,949</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,167</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,962</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="10" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">For the Year Ended December 31,</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Research and Development Program</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Research and Development Program</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Alzheimer’s Disease: Therapeutics</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Anti-Infectives</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">BPH (Enlarged Prostate) and Prostate Cancer Therapeutics</td><td style="width:1%;white-space: nowrap;"> </td><td colspan="2">5,944</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,162</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,932</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Tobacco Exposure Tests: NicAlert™ and TobacAlert™</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">18</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,949</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,167</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,962</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

4000

5944000

7162000

5932000

1000

18000

5949000

7167000

5962000

NOTE 22 - PERSONNEL EXPENSES A detailed analysis of employee personnel related expenses for the years ended December 31, 2021, 2020 and 2019 is provided below: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Salaries and compensation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,419</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">659</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">689</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Employer contributions</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Short-term employee benefits</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock-based compensation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,227</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,417</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,011</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,765</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,145</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,770</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>From above table, G&A related salary and compensation was $874,000, $98,000 and $90,000 for the years 2021, 2020 and 2019 respectively. G&A related stock compensation was $1,897,000, $702,000, and $ 1,839,000 for the years 2021, 2020 and 2019. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2021</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2020</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">2019</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Salaries and compensation</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,419</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">659</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">689</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Employer contributions</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">49</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">51</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">54</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Short-term employee benefits</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">70</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Stock-based compensation</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,227</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,417</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,011</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Total</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,765</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,145</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,770</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 1419000 659000 689000

49000

51000

54000

70000

18000

16000

2227000 1417000 3011000 3765000 2145000 3770000 874000 98000 90000 1897000 702000 1839000 NOTE 23 - CAPITAL DISCLOSURES AND FINANCIAL RISK During the second quarter of the year ended at December 31, 2021, the Corporation raised a total of $8,000,000 in share capital before various fee charges which totaled $681,652 and issued 3,669,724 common shares and 2,018,348 warrants to purchase up shares of common stock at an exercise price of $2.50 per share through one private placements. Approximately 97%, 97% and 98% of expenses that occurred during the years ended December 31, 2021, 2020 and 2019, respectively, were denominated in US dollars. Foreign exchange fluctuations had no meaningful impact on the Corporation’s results in 2021, 2020 or 2019. 8000000 681652 3669724 2018348 2.50 0.97 0.97 0.98 NOTE 24 - FOREIGN EXCHANGE RISK We have no significant items exposed to foreign exchange. Based on the Corporation’s foreign currency exposures, varying the above foreign exchange rates to reflect a 5% strengthening of the US dollar would have decreased the net loss for the year ended December 31, 2021 by approximately $17,653, assuming that all other variables remained constant. An assumed 5% weakening of the US dollar against the Canadian dollar would have had an equal but opposite effect on the amount shown above, on the basis that all other variables remained constant.

foreign currency exposures, varying the above foreign exchange rates to reflect a 5% strengthening of the US dollar would have decreased the net loss for the year ended December 31, 2021 by approximately $17,653, assuming that all other variables remained constant.

NOTE 25 - CREDIT RISK Credit risk results from the possibility that a loss may occur from the failure of another party to perform according to the terms of the contract. Financial instruments that potentially subject the Corporation to concentrations of credit risk consist primarily of cash and trade and other accounts receivable. Cash is maintained with high-credit quality financial institutions. For trade accounts receivable, the Corporation performs periodic credit evaluations and typically does not require collateral. Allowances are maintained for potential credit losses consistent with the credit risk, historical trends, general economic conditions and other information. The Corporation has a limited number of customers. Included in the consolidated statement of financial position as of December 31, 2021, 2020 and 2019 are trade accounts receivable of $0, $0 and $4,368, respectively, all of which were aged under 45 days. No bad debt expense was recorded on trade accounts receivable for the years ended December 31, 2021, 2020 or 2019. At December 31, 2021, the Corporation’s maximum credit exposure corresponded to the carrying amount of cash, and other receivables.

4368

NOTE 26 - INTEREST RATE RISK Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Cash bears interest at a variable rate. Trade accounts receivable, other receivables, trade accounts payable and accrued liabilities bear no interest. Based on the value of variable interest-bearing cash during the year ended December 31, 2021, an assumed 0.5% increase or 0.5% decrease in interest rates during such period would have had no significant effect on the net loss. Based on the value of variable interest-bearing cash during the year ended December 31, 2021, an assumed 0.5% increase or 0.5% decrease in interest rates during such period would have had no significant effect on the net loss. NOTE 27 - LIQUIDITY RISK Liquidity risk is the risk that the Corporation will not be able to meet its financial obligations as they fall due. The Corporation manages liquidity risk through the management of its capital structure, as outlined in Capital Disclosures above. The Corporation does not have an operating credit facility and has historically financed its activities primarily through an equity financing with various investment companies and the issuance of convertible notes. The following are the contractual maturities of financial liabilities: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Carrying Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Less than1 year</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">1 year to5 years</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Accounts payable and accrued liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,949</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,786</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">163</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,198</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,965</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">233</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td colspan="13" style="BORDER-BOTTOM: 1px solid;vertical-align:top;">In Thousands of US Dollars</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;">Description</td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Carrying Amount</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Less than1 year</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">1 year to5 years</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td style="vertical-align:top;">Accounts payable and accrued liabilities</td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">December 31, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,949</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,786</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">163</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">December 31, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,198</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,965</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">233</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

1949000

1786000

163000

2198000

1965000

233000

NOTE 28 - SUBSEQUENT EVENTS The Corporation has evaluated subsequent events through March 30, 2022, the date the financial statements were authorized for issuance by the Audit Committee of the Board of Directors. Although it has expressed no intention to do so the Audit Committee has the authorization to amend these financial statements. The corporation has determined there are no subsequent events except the following. On March 18, 2022 the Company entered into an agreement with a placement agent in connection with the Company’s issuance and sale of an aggregate of 3,878,789 shares of the Company’s common stock, no par value, at a purchase price of $1.65 per share to select institutional and accredited investors, and concurrent private placement of warrants. A.G.P./Alliance Global Partners is acting as sole placement agent for the private placement. On March 18, 2022, the Company and the Investors entered into securities purchase agreements (the “Purchase Agreements”) relating to the Offering and concurrent private placement of warrants up to an aggregate of 3,878,789 shares of common stock, at an initial exercise price equal to $2.00 per share and will expire five (5) years from the date of an effective registration statement covering the shares underlying the warrants, subject to customary anti-dilution provisions. James G. Robinson, a director of the company and one of the investors in the offering, purchased 1,151,515 shares and 1,151,515 shares of common stock underlying the warrants. On March 22, 2022, the company announced it closed the offering for gross proceeds of approximately $6.4 million before deducting placement agent fees and various expenses. In addition, the Company agreed to issue A.G.P. or its assigns warrants to purchase up to 193,939 shares of common stock at an exercise price of $2.06 per share. The Placement Agent Warrants will be immediately exercisable and will expire on the five-year anniversary of the date of offer and are subject to customary anti-dilution provisions.

3878789

1.65

3878789

2.00

five (5) years 1151515 1151515 6400000 193939 2.06 five-year EXCEL 103 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 104 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 105 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 106 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 211 314 1 false 64 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://nymox.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 2 false false R3.htm 000003 - Statement - Consolidated Statements of Financial Position Sheet http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition Consolidated Statements of Financial Position Statements 3 false false R4.htm 000004 - Statement - Consolidated Statements of Financial Position (Parenthetical) Sheet http://nymox.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical Consolidated Statements of Financial Position (Parenthetical) Statements 4 false false R5.htm 000005 - Statement - Consolidated Statements of Cash Flow Sheet http://nymox.com/role/ConsolidatedStatementsOfCashFlow Consolidated Statements of Cash Flow Statements 5 false false R6.htm 000006 - Statement - Consolidated Statements of Changes in Equity Sheet http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity Consolidated Statements of Changes in Equity Statements 6 false false R7.htm 000007 - Disclosure - BUSINESS ACTIVITIES AND BASIS OF PRESENTATION Sheet http://nymox.com/role/BusinessActivitiesAndBasisOfPresentation BUSINESS ACTIVITIES AND BASIS OF PRESENTATION Notes 7 false false R8.htm 000008 - Disclosure - GOING CONCERN CONSIDERATIONS Sheet http://nymox.com/role/GoingConcernConsiderations GOING CONCERN CONSIDERATIONS Notes 8 false false R9.htm 000009 - Disclosure - SIGNIFICANT ESTIMATES Sheet http://nymox.com/role/SignificantEstimates SIGNIFICANT ESTIMATES Notes 9 false false R10.htm 000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://nymox.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 000011 - Disclosure - NEW ACCOUNTING STANDARDS AND INTERPRETATIONS Sheet http://nymox.com/role/NewAccountingStandardsAndInterpretations NEW ACCOUNTING STANDARDS AND INTERPRETATIONS Notes 11 false false R12.htm 000012 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://nymox.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 12 false false R13.htm 000013 - Disclosure - INTANGIBLE ASSETS Sheet http://nymox.com/role/IntangibleAssets INTANGIBLE ASSETS Notes 13 false false R14.htm 000014 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://nymox.com/role/AccountsPayableAndAccruedLiabilities ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 14 false false R15.htm 000015 - Disclosure - OPERATING LEASES AND COMMITMENTS Sheet http://nymox.com/role/OperatingLeasesAndCommitments OPERATING LEASES AND COMMITMENTS Notes 15 false false R16.htm 000016 - Disclosure - SHARE CAPITAL Sheet http://nymox.com/role/ShareCapital SHARE CAPITAL Notes 16 false false R17.htm 000017 - Disclosure - STOCK OPTIONS Sheet http://nymox.com/role/StockOptions STOCK OPTIONS Notes 17 false false R18.htm 000018 - Disclosure - SHARE BASED COMPENSATION Sheet http://nymox.com/role/ShareBasedCompensation SHARE BASED COMPENSATION Notes 18 false false R19.htm 000019 - Disclosure - WARRANTS Sheet http://nymox.com/role/WARRANTS WARRANTS Notes 19 false false R20.htm 000020 - Disclosure - INCOME TAXES Sheet http://nymox.com/role/IncomeTaxes INCOME TAXES Notes 20 false false R21.htm 000021 - Disclosure - EARNINGS PER SHARE Sheet http://nymox.com/role/EarningsPerShare EARNINGS PER SHARE Notes 21 false false R22.htm 000022 - Disclosure - FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES Sheet http://nymox.com/role/FinancialInstrumentsFairValueDisclosures FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES Notes 22 false false R23.htm 000023 - Disclosure - FINANCE INCOME AND FINANCE COSTS Sheet http://nymox.com/role/FinanceIncomeAndFinanceCosts FINANCE INCOME AND FINANCE COSTS Notes 23 false false R24.htm 000024 - Disclosure - SEGMENT DISCLOSURES Sheet http://nymox.com/role/SegmentDisclosures SEGMENT DISCLOSURES Notes 24 false false R25.htm 000025 - Disclosure - CONCENTRATIONS Sheet http://nymox.com/role/CONCENTRATIONS CONCENTRATIONS Notes 25 false false R26.htm 000026 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://nymox.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 26 false false R27.htm 000027 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES Sheet http://nymox.com/role/ResearchAndDevelopmentExpenses RESEARCH AND DEVELOPMENT EXPENSES Notes 27 false false R28.htm 000028 - Disclosure - PERSONNEL EXPENSES Sheet http://nymox.com/role/PersonnelExpenses PERSONNEL EXPENSES Notes 28 false false R29.htm 000029 - Disclosure - CAPITAL DISCLOSURES AND FINANCIAL RISK Sheet http://nymox.com/role/CapitalDisclosuresAndFinancialRisk CAPITAL DISCLOSURES AND FINANCIAL RISK Notes 29 false false R30.htm 000030 - Disclosure - FOREIGN EXCHANGE RISK Sheet http://nymox.com/role/ForeignExchangeRisk FOREIGN EXCHANGE RISK Notes 30 false false R31.htm 000031 - Disclosure - CREDIT RISK Sheet http://nymox.com/role/CreditRisk CREDIT RISK Notes 31 false false R32.htm 000032 - Disclosure - INTEREST RATE RISK Sheet http://nymox.com/role/InterestRateRisk INTEREST RATE RISK Notes 32 false false R33.htm 000033 - Disclosure - LIQUIDITY RISK Sheet http://nymox.com/role/LiquidityRisk LIQUIDITY RISK Notes 33 false false R34.htm 000034 - Disclosure - SUBSEQUENT EVENTS Sheet http://nymox.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 34 false false R35.htm 000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://nymox.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 35 false false R36.htm 000036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://nymox.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://nymox.com/role/SignificantAccountingPolicies 36 false false R37.htm 000037 - Disclosure - NEW ACCOUNTING STANDARDS AND INTERPRETATIONS (Tables) Sheet http://nymox.com/role/NewAccountingStandardsAndInterpretationsTables NEW ACCOUNTING STANDARDS AND INTERPRETATIONS (Tables) Tables http://nymox.com/role/NewAccountingStandardsAndInterpretations 37 false false R38.htm 000038 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://nymox.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://nymox.com/role/PropertyAndEquipment 38 false false R39.htm 000039 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://nymox.com/role/AccountsPayableAndAccruedLiabilitiesTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://nymox.com/role/AccountsPayableAndAccruedLiabilities 39 false false R40.htm 000040 - Disclosure - OPERATING LEASES AND COMMITMENTS (Tables) Sheet http://nymox.com/role/OperatingLeasesAndCommitmentsTables OPERATING LEASES AND COMMITMENTS (Tables) Tables http://nymox.com/role/OperatingLeasesAndCommitments 40 false false R41.htm 000041 - Disclosure - SHARE CAPITAL (Tables) Sheet http://nymox.com/role/ShareCapitalTables SHARE CAPITAL (Tables) Tables http://nymox.com/role/ShareCapital 41 false false R42.htm 000042 - Disclosure - STOCK OPTIONS (Tables) Sheet http://nymox.com/role/StockOptionsTables STOCK OPTIONS (Tables) Tables http://nymox.com/role/StockOptions 42 false false R43.htm 000043 - Disclosure - SHARE BASED COMPENSATION (Tables) Sheet http://nymox.com/role/ShareBasedCompensationTables SHARE BASED COMPENSATION (Tables) Tables http://nymox.com/role/ShareBasedCompensation 43 false false R44.htm 000044 - Disclosure - WARRANTS (Tables) Sheet http://nymox.com/role/WarrantsTables WARRANTS (Tables) Tables http://nymox.com/role/WARRANTS 44 false false R45.htm 000045 - Disclosure - INCOME TAXES (Tables) Sheet http://nymox.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://nymox.com/role/IncomeTaxes 45 false false R46.htm 000046 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://nymox.com/role/EarningsPerShareTables EARNINGS PER SHARE (Tables) Tables http://nymox.com/role/EarningsPerShare 46 false false R47.htm 000047 - Disclosure - FINANCE INCOME AND FINANCE COSTS (Tables) Sheet http://nymox.com/role/FinanceIncomeAndFinanceCostsTables FINANCE INCOME AND FINANCE COSTS (Tables) Tables http://nymox.com/role/FinanceIncomeAndFinanceCosts 47 false false R48.htm 000048 - Disclosure - SEGMENT DISCLOSURES (Tables) Sheet http://nymox.com/role/SegmentDisclosuresTables SEGMENT DISCLOSURES (Tables) Tables http://nymox.com/role/SegmentDisclosures 48 false false R49.htm 000049 - Disclosure - CONCENTRATIONS (Tables) Sheet http://nymox.com/role/ConcentrationsTables CONCENTRATIONS (Tables) Tables http://nymox.com/role/CONCENTRATIONS 49 false false R50.htm 000050 - Disclosure - RELATED PARTY TRANSACTIONS (Tables) Sheet http://nymox.com/role/RelatedPartyTransactionsTables RELATED PARTY TRANSACTIONS (Tables) Tables http://nymox.com/role/RelatedPartyTransactions 50 false false R51.htm 000051 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables) Sheet http://nymox.com/role/ResearchAndDevelopmentExpensesTables RESEARCH AND DEVELOPMENT EXPENSES (Tables) Tables http://nymox.com/role/ResearchAndDevelopmentExpenses 51 false false R52.htm 000052 - Disclosure - PERSONNEL EXPENSES (Tables) Sheet http://nymox.com/role/PersonnelExpensesTables PERSONNEL EXPENSES (Tables) Tables http://nymox.com/role/PersonnelExpenses 52 false false R53.htm 000053 - Disclosure - LIQUIDITY RISK (Tables) Sheet http://nymox.com/role/LiquidityRiskTables LIQUIDITY RISK (Tables) Tables http://nymox.com/role/LiquidityRisk 53 false false R54.htm 000054 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://nymox.com/role/SignificantAccountingPoliciesDetails SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://nymox.com/role/SignificantAccountingPoliciesTables 54 false false R55.htm 000055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://nymox.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://nymox.com/role/SignificantAccountingPoliciesTables 55 false false R56.htm 000056 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://nymox.com/role/PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://nymox.com/role/PropertyAndEquipmentTables 56 false false R57.htm 000057 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://nymox.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://nymox.com/role/PropertyAndEquipmentTables 57 false false R58.htm 000058 - Disclosure - INTANGIBLE ASSETS (Details Narrative) Sheet http://nymox.com/role/IntangibleAssetsDetailsNarrative INTANGIBLE ASSETS (Details Narrative) Details http://nymox.com/role/IntangibleAssets 58 false false R59.htm 000059 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Sheet http://nymox.com/role/AccountsPayableAndAccruedLiabilitiesDetails ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Details http://nymox.com/role/AccountsPayableAndAccruedLiabilitiesTables 59 false false R60.htm 000060 - Disclosure - INTEREST RATE RISK (Details Narrative) Sheet http://nymox.com/role/InterestRateRiskDetailsNarrative INTEREST RATE RISK (Details Narrative) Details http://nymox.com/role/InterestRateRisk 60 false false R61.htm 000061 - Disclosure - CREDIT RISK (Details Narrative) Sheet http://nymox.com/role/CreditRiskDetailsNarrative CREDIT RISK (Details Narrative) Details http://nymox.com/role/CreditRisk 61 false false R62.htm 000062 - Disclosure - FOREIGN EXCHANGE RISK (Details Narrative) Sheet http://nymox.com/role/ForeignExchangeRiskDetailsNarrative FOREIGN EXCHANGE RISK (Details Narrative) Details http://nymox.com/role/ForeignExchangeRisk 62 false false R63.htm 000063 - Disclosure - CAPITAL DISCLOSURES AND FINANCIAL RISK (Details Narrative) Sheet http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative CAPITAL DISCLOSURES AND FINANCIAL RISK (Details Narrative) Details http://nymox.com/role/CapitalDisclosuresAndFinancialRisk 63 false false R64.htm 000064 - Disclosure - OPERATING LEASES AND COMMITMENT (Details) Sheet http://nymox.com/role/OperatingLeasesAndCommitmentDetails OPERATING LEASES AND COMMITMENT (Details) Details http://nymox.com/role/OperatingLeasesAndCommitmentsTables 64 false false R65.htm 000065 - Disclosure - OPERATING LEASES AND COMMITMENT (Details 1) Sheet http://nymox.com/role/OperatingLeasesAndCommitmentDetails1 OPERATING LEASES AND COMMITMENT (Details 1) Details http://nymox.com/role/OperatingLeasesAndCommitmentsTables 65 false false R66.htm 000066 - Disclosure - OPERATING LEASES AND COMMITMENT (Details Narrative) Sheet http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative OPERATING LEASES AND COMMITMENT (Details Narrative) Details http://nymox.com/role/OperatingLeasesAndCommitmentsTables 66 false false R67.htm 000067 - Disclosure - Operating leases and other commitment (Details Narrative) Sheet http://nymox.com/role/OperatingLeasesAndOtherCommitmentDetailsNarrative Operating leases and other commitment (Details Narrative) Details 67 false false R68.htm 000068 - Disclosure - SHARE CAPITAL (Details) Sheet http://nymox.com/role/ShareCapitalDetails SHARE CAPITAL (Details) Details http://nymox.com/role/ShareCapitalTables 68 false false R69.htm 000069 - Disclosure - Share capital (Details Narrative) Sheet http://nymox.com/role/ShareCapitalDetailsNarrative Share capital (Details Narrative) Details 69 false false R70.htm 000070 - Disclosure - STOCK OPTIONS (Details) Sheet http://nymox.com/role/StockOptionsDetails STOCK OPTIONS (Details) Details http://nymox.com/role/StockOptionsTables 70 false false R71.htm 000071 - Disclosure - STOCK OPTIONS (Details 1) Sheet http://nymox.com/role/StockOptionsDetails1 STOCK OPTIONS (Details 1) Details http://nymox.com/role/StockOptionsTables 71 false false R72.htm 000072 - Disclosure - STOCK OPTIONS (Details Narrative) Sheet http://nymox.com/role/StockOptionsDetailsNarrative STOCK OPTIONS (Details Narrative) Details http://nymox.com/role/StockOptionsTables 72 false false R73.htm 000073 - Disclosure - SHARE BASED COMPENSATION (Details) Sheet http://nymox.com/role/ShareBasedCompensationDetails SHARE BASED COMPENSATION (Details) Details http://nymox.com/role/ShareBasedCompensationTables 73 false false R74.htm 000074 - Disclosure - SHARE BASED COMPENSATION (Details Narrative) Sheet http://nymox.com/role/ShareBasedCompensationDetailsNarrative SHARE BASED COMPENSATION (Details Narrative) Details http://nymox.com/role/ShareBasedCompensationTables 74 false false R75.htm 000075 - Disclosure - WARRANTS (Details) Sheet http://nymox.com/role/WarrantsDetails WARRANTS (Details) Details http://nymox.com/role/WarrantsTables 75 false false R76.htm 000076 - Disclosure - WARRANTS (Details Narrative) Sheet http://nymox.com/role/WarrantsDetailsNarrative WARRANTS (Details Narrative) Details http://nymox.com/role/WarrantsTables 76 false false R77.htm 000077 - Disclosure - INCOME TAXES (Details) Sheet http://nymox.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://nymox.com/role/IncomeTaxesTables 77 false false R78.htm 000078 - Disclosure - INCOME TAXES (Details 1) Sheet http://nymox.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) Details http://nymox.com/role/IncomeTaxesTables 78 false false R79.htm 000079 - Disclosure - INCOME TAXES (Details 2) Sheet http://nymox.com/role/IncomeTaxesDetails2 INCOME TAXES (Details 2) Details http://nymox.com/role/IncomeTaxesTables 79 false false R80.htm 000080 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://nymox.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://nymox.com/role/IncomeTaxesTables 80 false false R81.htm 000081 - Disclosure - EARNINGS PER SHARE (Details) Sheet http://nymox.com/role/EarningsPerShareDetails EARNINGS PER SHARE (Details) Details http://nymox.com/role/EarningsPerShareTables 81 false false R82.htm 000082 - Disclosure - FINANCE INCOME AND FINANCE COSTS (Details) Sheet http://nymox.com/role/FinanceIncomeAndFinanceCostsDetails FINANCE INCOME AND FINANCE COSTS (Details) Details http://nymox.com/role/FinanceIncomeAndFinanceCostsTables 82 false false R83.htm 000083 - Disclosure - SEGMENT DISCLOSURES (Details) Sheet http://nymox.com/role/SegmentDisclosuresDetails SEGMENT DISCLOSURES (Details) Details http://nymox.com/role/SegmentDisclosuresTables 83 false false R84.htm 000084 - Disclosure - CONCENTRATIONS (Details) Sheet http://nymox.com/role/ConcentrationsDetails CONCENTRATIONS (Details) Details http://nymox.com/role/ConcentrationsTables 84 false false R85.htm 000085 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://nymox.com/role/RelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) Details http://nymox.com/role/RelatedPartyTransactionsTables 85 false false R86.htm 000086 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://nymox.com/role/RelatedPartyTransactionsTables 86 false false R87.htm 000087 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details) Sheet http://nymox.com/role/ResearchAndDevelopmentExpensesDetails RESEARCH AND DEVELOPMENT EXPENSES (Details) Details http://nymox.com/role/ResearchAndDevelopmentExpensesTables 87 false false R88.htm 000088 - Disclosure - PERSONNEL EXPENSES (Details) Sheet http://nymox.com/role/PersonnelExpensesDetails PERSONNEL EXPENSES (Details) Details http://nymox.com/role/PersonnelExpensesTables 88 false false R89.htm 000089 - Disclosure - PERSONNEL EXPENSES (Details Narrative) Sheet http://nymox.com/role/PersonnelExpensesDetailsNarrative PERSONNEL EXPENSES (Details Narrative) Details http://nymox.com/role/PersonnelExpensesTables 89 false false R90.htm 000090 - Disclosure - LIQUIDITY RISK (Details) Sheet http://nymox.com/role/LiquidityRiskDetails LIQUIDITY RISK (Details) Details http://nymox.com/role/LiquidityRiskTables 90 false false R91.htm 000091 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://nymox.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://nymox.com/role/SubsequentEvents 91 false false All Reports Book All Reports nymox_20f.htm nymox-20211231.xsd nymox-20211231_cal.xml nymox-20211231_def.xml nymox-20211231_lab.xml nymox-20211231_pre.xml nymox_ex12a.htm nymox_ex12b.htm nymox_ex13a.htm nymox_ex13b.htm http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full http://xbrl.sec.gov/dei/2021q4 true true JSON 109 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nymox_20f.htm": { "axisCustom": 0, "axisStandard": 18, "contextCount": 211, "dts": { "calculationLink": { "local": [ "nymox-20211231_cal.xml" ] }, "definitionLink": { "local": [ "nymox-20211231_def.xml" ] }, "inline": { "local": [ "nymox_20f.htm" ] }, "labelLink": { "local": [ "nymox-20211231_lab.xml" ] }, "presentationLink": { "local": [ "nymox-20211231_pre.xml" ] }, "schema": { "local": [ "nymox-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 495, "entityCount": 1, "hidden": { "http://nymox.com/20211231": 48, "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full": 12, "http://xbrl.sec.gov/dei/2021q4": 8, "total": 68 }, "keyCustom": 203, "keyStandard": 111, "memberCustom": 63, "memberStandard": 1, "nsprefix": "nymox", "nsuri": "http://nymox.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://nymox.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://nymox.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfNewAccountingStandardsAndInterpretationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - NEW ACCOUNTING STANDARDS AND INTERPRETATIONS", "role": "http://nymox.com/role/NewAccountingStandardsAndInterpretations", "shortName": "NEW ACCOUNTING STANDARDS AND INTERPRETATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfNewAccountingStandardsAndInterpretationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:PropertyAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://nymox.com/role/PropertyAndEquipment", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:PropertyAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:IntangibleAssetsTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - INTANGIBLE ASSETS", "role": "http://nymox.com/role/IntangibleAssets", "shortName": "INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:IntangibleAssetsTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:AccountsPayableAndAccuruedLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "role": "http://nymox.com/role/AccountsPayableAndAccruedLiabilities", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:AccountsPayableAndAccuruedLiabilitiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:OperatingLeasesAndCommitmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - OPERATING LEASES AND COMMITMENTS", "role": "http://nymox.com/role/OperatingLeasesAndCommitments", "shortName": "OPERATING LEASES AND COMMITMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:OperatingLeasesAndCommitmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note10ShareCapitalTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - SHARE CAPITAL", "role": "http://nymox.com/role/ShareCapital", "shortName": "SHARE CAPITAL", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note10ShareCapitalTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfStockOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - STOCK OPTIONS", "role": "http://nymox.com/role/StockOptions", "shortName": "STOCK OPTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfStockOptionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note12ShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - SHARE BASED COMPENSATION", "role": "http://nymox.com/role/ShareBasedCompensation", "shortName": "SHARE BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note12ShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note13WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - WARRANTS", "role": "http://nymox.com/role/WARRANTS", "shortName": "WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note13WarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromSaleOfGoods", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "lang": null, "name": "ifrs-full:CostOfSales", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:IncomeTaxesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - INCOME TAXES", "role": "http://nymox.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:IncomeTaxesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:EarningsPerShare", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - EARNINGS PER SHARE", "role": "http://nymox.com/role/EarningsPerShare", "shortName": "EARNINGS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:EarningsPerShare", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:FinancialInstrumentsFairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES", "role": "http://nymox.com/role/FinancialInstrumentsFairValueDisclosures", "shortName": "FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:FinancialInstrumentsFairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:FinanceIncomeAndFinanceCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - FINANCE INCOME AND FINANCE COSTS", "role": "http://nymox.com/role/FinanceIncomeAndFinanceCosts", "shortName": "FINANCE INCOME AND FINANCE COSTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:FinanceIncomeAndFinanceCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SegmentDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - SEGMENT DISCLOSURES", "role": "http://nymox.com/role/SegmentDisclosures", "shortName": "SEGMENT DISCLOSURES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SegmentDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfConcentrationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - CONCENTRATIONS", "role": "http://nymox.com/role/CONCENTRATIONS", "shortName": "CONCENTRATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfConcentrationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:RelatedPartyTransactionsTextBlck", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - RELATED PARTY TRANSACTIONS", "role": "http://nymox.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:RelatedPartyTransactionsTextBlck", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:ResearchAndDevelopmentExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES", "role": "http://nymox.com/role/ResearchAndDevelopmentExpenses", "shortName": "RESEARCH AND DEVELOPMENT EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:ResearchAndDevelopmentExpensesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfPersonnelExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - PERSONNEL EXPENSES", "role": "http://nymox.com/role/PersonnelExpenses", "shortName": "PERSONNEL EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfPersonnelExpensesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:CapitalDisclosuresAndFinancialsRiskTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - CAPITAL DISCLOSURES AND FINANCIAL RISK", "role": "http://nymox.com/role/CapitalDisclosuresAndFinancialRisk", "shortName": "CAPITAL DISCLOSURES AND FINANCIAL RISK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:CapitalDisclosuresAndFinancialsRiskTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - Consolidated Statements of Financial Position", "role": "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition", "shortName": "Consolidated Statements of Financial Position", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note24ForeignExchangeRiskTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - FOREIGN EXCHANGE RISK", "role": "http://nymox.com/role/ForeignExchangeRisk", "shortName": "FOREIGN EXCHANGE RISK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note24ForeignExchangeRiskTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note25CreditRiskAbstract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - CREDIT RISK", "role": "http://nymox.com/role/CreditRisk", "shortName": "CREDIT RISK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note25CreditRiskAbstract", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfInterestRateRiskExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - INTEREST RATE RISK", "role": "http://nymox.com/role/InterestRateRisk", "shortName": "INTEREST RATE RISK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfInterestRateRiskExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note27LiquidityRiskTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - LIQUIDITY RISK", "role": "http://nymox.com/role/LiquidityRisk", "shortName": "LIQUIDITY RISK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:Note27LiquidityRiskTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - SUBSEQUENT EVENTS", "role": "http://nymox.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "nymox:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://nymox.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "nymox:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "nymox:PropertyAndEquipmentPolicyTetblock", "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000036 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://nymox.com/role/SignificantAccountingPoliciesTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:PropertyAndEquipmentPolicyTetblock", "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "nymox:DisclosureOfNewAccountingStandardsAndInterpretationsExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:ScheduleOfAccountingStandardsTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000037 - Disclosure - NEW ACCOUNTING STANDARDS AND INTERPRETATIONS (Tables)", "role": "http://nymox.com/role/NewAccountingStandardsAndInterpretationsTables", "shortName": "NEW ACCOUNTING STANDARDS AND INTERPRETATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:DisclosureOfNewAccountingStandardsAndInterpretationsExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:ScheduleOfAccountingStandardsTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "nymox:PropertyAndEquipmentTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:ScheduleOfPropertyAndEquipmentTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000038 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://nymox.com/role/PropertyAndEquipmentTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:PropertyAndEquipmentTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:ScheduleOfPropertyAndEquipmentTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "nymox:AccountsPayableAndAccuruedLiabilitiesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:AccountsPayableAndAccruedLiabilitiesTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000039 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "role": "http://nymox.com/role/AccountsPayableAndAccruedLiabilitiesTables", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:AccountsPayableAndAccuruedLiabilitiesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:AccountsPayableAndAccruedLiabilitiesTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfCommonSharesAuthorizedIssuedAndRelatedContributedCapitalByControllingShareholders", "nymox:Note10ShareCapitalTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:ShareCapitalSharesOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - Consolidated Statements of Financial Position (Parenthetical)", "role": "http://nymox.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical", "shortName": "Consolidated Statements of Financial Position (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "nymox:OperatingLeasesAndCommitmentsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfOperatingLeaseRightOfUseAssetsTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000040 - Disclosure - OPERATING LEASES AND COMMITMENTS (Tables)", "role": "http://nymox.com/role/OperatingLeasesAndCommitmentsTables", "shortName": "OPERATING LEASES AND COMMITMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:OperatingLeasesAndCommitmentsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfOperatingLeaseRightOfUseAssetsTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "nymox:Note10ShareCapitalTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfCommonSharesAuthorizedIssuedAndRelatedContributedCapitalByControllingShareholders", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000041 - Disclosure - SHARE CAPITAL (Tables)", "role": "http://nymox.com/role/ShareCapitalTables", "shortName": "SHARE CAPITAL (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:Note10ShareCapitalTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfCommonSharesAuthorizedIssuedAndRelatedContributedCapitalByControllingShareholders", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "nymox:DisclosureOfStockOptionsExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfStockOptionAwardTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000042 - Disclosure - STOCK OPTIONS (Tables)", "role": "http://nymox.com/role/StockOptionsTables", "shortName": "STOCK OPTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:DisclosureOfStockOptionsExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfStockOptionAwardTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "nymox:Note12ShareBasedCompensationTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfStockOptionBasedCompensationExpenseTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000043 - Disclosure - SHARE BASED COMPENSATION (Tables)", "role": "http://nymox.com/role/ShareBasedCompensationTables", "shortName": "SHARE BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:Note12ShareBasedCompensationTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfStockOptionBasedCompensationExpenseTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "nymox:Note13WarrantsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfWarrantsOutstandingTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000044 - Disclosure - WARRANTS (Tables)", "role": "http://nymox.com/role/WarrantsTables", "shortName": "WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:Note13WarrantsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfWarrantsOutstandingTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "nymox:IncomeTaxesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfEffectiveTaxRateTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000045 - Disclosure - INCOME TAXES (Tables)", "role": "http://nymox.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:IncomeTaxesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfEffectiveTaxRateTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "nymox:EarningsPerShare", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:ScheduleOfWeightedAverageNumberOfShareTableTextBlockExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000046 - Disclosure - EARNINGS PER SHARE (Tables)", "role": "http://nymox.com/role/EarningsPerShareTables", "shortName": "EARNINGS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:EarningsPerShare", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:ScheduleOfWeightedAverageNumberOfShareTableTextBlockExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "nymox:FinanceIncomeAndFinanceCostsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfFinanceIncomeAndFinanceCotsTableTextbock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000047 - Disclosure - FINANCE INCOME AND FINANCE COSTS (Tables)", "role": "http://nymox.com/role/FinanceIncomeAndFinanceCostsTables", "shortName": "FINANCE INCOME AND FINANCE COSTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:FinanceIncomeAndFinanceCostsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfFinanceIncomeAndFinanceCotsTableTextbock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfGeographicReportableSegmentTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000048 - Disclosure - SEGMENT DISCLOSURES (Tables)", "role": "http://nymox.com/role/SegmentDisclosuresTables", "shortName": "SEGMENT DISCLOSURES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfGeographicReportableSegmentTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "nymox:DisclosureOfConcentrationsExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfRevenuesFromSalesTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000049 - Disclosure - CONCENTRATIONS (Tables)", "role": "http://nymox.com/role/ConcentrationsTables", "shortName": "CONCENTRATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:DisclosureOfConcentrationsExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfRevenuesFromSalesTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - Consolidated Statements of Cash Flow", "role": "http://nymox.com/role/ConsolidatedStatementsOfCashFlow", "shortName": "Consolidated Statements of Cash Flow", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "lang": null, "name": "nymox:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "nymox:RelatedPartyTransactionsTextBlck", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000050 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)", "role": "http://nymox.com/role/RelatedPartyTransactionsTables", "shortName": "RELATED PARTY TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:RelatedPartyTransactionsTextBlck", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "nymox:ResearchAndDevelopmentExpensesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfResearchAndDevelopmentExpensesTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000051 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Tables)", "role": "http://nymox.com/role/ResearchAndDevelopmentExpensesTables", "shortName": "RESEARCH AND DEVELOPMENT EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:ResearchAndDevelopmentExpensesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfResearchAndDevelopmentExpensesTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "nymox:DisclosureOfPersonnelExpensesExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfPersonnelRelatedExpensesTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000052 - Disclosure - PERSONNEL EXPENSES (Tables)", "role": "http://nymox.com/role/PersonnelExpensesTables", "shortName": "PERSONNEL EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:DisclosureOfPersonnelExpensesExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfPersonnelRelatedExpensesTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "nymox:Note27LiquidityRiskTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfContractualMaturitiesOfFinancialLiabilitiesTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000053 - Disclosure - LIQUIDITY RISK (Tables)", "role": "http://nymox.com/role/LiquidityRiskTables", "shortName": "LIQUIDITY RISK (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "nymox:Note27LiquidityRiskTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SummaryOfContractualMaturitiesOfFinancialLiabilitiesTableTextblock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "nymox:PropertyAndEquipmentPolicyTetblock", "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31_nymox_LaboratoryEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:PropertyAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000054 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)", "role": "http://nymox.com/role/SignificantAccountingPoliciesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "nymox:PropertyAndEquipmentPolicyTetblock", "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31_nymox_LaboratoryEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:PropertyAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "nymox:AccountReceivablePolicyTextblock", "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentReceivables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000055 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://nymox.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:AccountReceivablePolicyTextblock", "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentReceivables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:ScheduleOfPropertyAndEquipmentTableTextblock", "nymox:PropertyAndEquipmentTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2020-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000056 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "role": "http://nymox.com/role/PropertyAndEquipmentDetails", "shortName": "PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:ScheduleOfPropertyAndEquipmentTableTextblock", "nymox:PropertyAndEquipmentTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2018-12-31", "decimals": "-3", "lang": null, "name": "ifrs-full:PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "nymox:PropertyAndEquipmentTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:DepreciationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000057 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "role": "http://nymox.com/role/PropertyAndEquipmentDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:PropertyAndEquipmentTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:DepreciationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "nymox:IntangibleAssetsTextblock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31_nymox_IntellectualPropertyRightsMember", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000058 - Disclosure - INTANGIBLE ASSETS (Details Narrative)", "role": "http://nymox.com/role/IntangibleAssetsDetailsNarrative", "shortName": "INTANGIBLE ASSETS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:IntangibleAssetsTextblock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31_nymox_IntellectualPropertyRightsMember", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:IntangibleAssetsAndGoodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:AccountsPayableAndAccruedLiabilitiesTableTextblock", "nymox:AccountsPayableAndAccuruedLiabilitiesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherPayables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000059 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "role": "http://nymox.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:AccountsPayableAndAccruedLiabilitiesTableTextblock", "nymox:AccountsPayableAndAccuruedLiabilitiesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherPayables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2018-12-31_nymox_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - Consolidated Statements of Changes in Equity", "role": "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity", "shortName": "Consolidated Statements of Changes in Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2018-12-31_nymox_CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "nymox:DisclosureOfInterestRateRiskExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:IncreaseDecreaseInterestRatesPercentageDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000060 - Disclosure - INTEREST RATE RISK (Details Narrative)", "role": "http://nymox.com/role/InterestRateRiskDetailsNarrative", "shortName": "INTEREST RATE RISK (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:DisclosureOfInterestRateRiskExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:IncreaseDecreaseInterestRatesPercentageDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "nymox:Note25CreditRiskAbstract", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:TradeReceivables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000061 - Disclosure - CREDIT RISK (Details Narrative)", "role": "http://nymox.com/role/CreditRiskDetailsNarrative", "shortName": "CREDIT RISK (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:Note25CreditRiskAbstract", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:TradeReceivables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "nymox:Note24ForeignExchangeRiskTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2019-01-01to2019-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfFunctionalCurrency", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000062 - Disclosure - FOREIGN EXCHANGE RISK (Details Narrative)", "role": "http://nymox.com/role/ForeignExchangeRiskDetailsNarrative", "shortName": "FOREIGN EXCHANGE RISK (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:Note24ForeignExchangeRiskTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2019-01-01to2019-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfFunctionalCurrency", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "p", "nymox:CapitalDisclosuresAndFinancialsRiskTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "nymox:PercentagesOfExpenses", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000063 - Disclosure - CAPITAL DISCLOSURES AND FINANCIAL RISK (Details Narrative)", "role": "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative", "shortName": "CAPITAL DISCLOSURES AND FINANCIAL RISK (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:CapitalDisclosuresAndFinancialsRiskTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "nymox:PercentagesOfExpenses", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryofoperatingleaseliabilityTableTextblock", "nymox:OperatingLeasesAndCommitmentsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2019-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:BegininngBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000064 - Disclosure - OPERATING LEASES AND COMMITMENT (Details)", "role": "http://nymox.com/role/OperatingLeasesAndCommitmentDetails", "shortName": "OPERATING LEASES AND COMMITMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryofoperatingleaseliabilityTableTextblock", "nymox:OperatingLeasesAndCommitmentsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2019-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:BegininngBalance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "nymox:OperatingLeasesAndCommitmentsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:OperatingLeasesLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000065 - Disclosure - OPERATING LEASES AND COMMITMENT (Details 1)", "role": "http://nymox.com/role/OperatingLeasesAndCommitmentDetails1", "shortName": "OPERATING LEASES AND COMMITMENT (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "nymox:OperatingLeasesAndCommitmentsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:OperatingLeasesLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "nymox:OperatingLeasesAndCommitmentsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000066 - Disclosure - OPERATING LEASES AND COMMITMENT (Details Narrative)", "role": "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative", "shortName": "OPERATING LEASES AND COMMITMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:OperatingLeasesAndCommitmentsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "nymox:FuturePaymentAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "nymox:OperatingLeasesAndCommitmentsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:LeaseLiabilities", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000067 - Disclosure - Operating leases and other commitment (Details Narrative)", "role": "http://nymox.com/role/OperatingLeasesAndOtherCommitmentDetailsNarrative", "shortName": "Operating leases and other commitment (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfCommonSharesAuthorizedIssuedAndRelatedContributedCapitalByControllingShareholders", "nymox:Note10ShareCapitalTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:ShareCapitalSharesOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000068 - Disclosure - SHARE CAPITAL (Details)", "role": "http://nymox.com/role/ShareCapitalDetails", "shortName": "SHARE CAPITAL (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfCommonSharesAuthorizedIssuedAndRelatedContributedCapitalByControllingShareholders", "nymox:Note10ShareCapitalTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "lang": null, "name": "nymox:NumberOfCommonSharesValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "nymox:Note13WarrantsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "nymox:ProceesFromIssuanceOfWarrants", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000069 - Disclosure - Share capital (Details Narrative)", "role": "http://nymox.com/role/ShareCapitalDetailsNarrative", "shortName": "Share capital (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-04-01to2021-04-30_nymox_PrivatePlacementsMember", "decimals": "INF", "lang": null, "name": "nymox:ExercisePriceOrWarrants", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfBasisOfConsolidationExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - BUSINESS ACTIVITIES AND BASIS OF PRESENTATION", "role": "http://nymox.com/role/BusinessActivitiesAndBasisOfPresentation", "shortName": "BUSINESS ACTIVITIES AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:DisclosureOfBasisOfConsolidationExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfStockOptionAwardTableTextblock", "nymox:DisclosureOfStockOptionsExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2019-01-01to2019-12-31_nymox_StockOptionsMember", "decimals": "0", "first": true, "lang": null, "name": "nymox:NumberOfOutstandingBalanceBeginning", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000070 - Disclosure - STOCK OPTIONS (Details)", "role": "http://nymox.com/role/StockOptionsDetails", "shortName": "STOCK OPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfStockOptionAwardTableTextblock", "nymox:DisclosureOfStockOptionsExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2019-01-01to2019-12-31_nymox_StockOptionsMember", "decimals": "0", "first": true, "lang": null, "name": "nymox:NumberOfOutstandingBalanceBeginning", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfFairValueOfTheOptionsGrantedTableTextblock", "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2019-01-01to2019-12-31", "decimals": "INF", "first": true, "lang": null, "name": "nymox:OptionSharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000071 - Disclosure - STOCK OPTIONS (Details 1)", "role": "http://nymox.com/role/StockOptionsDetails1", "shortName": "STOCK OPTIONS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfFairValueOfTheOptionsGrantedTableTextblock", "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2019-01-01to2019-12-31", "decimals": "INF", "first": true, "lang": null, "name": "nymox:OptionSharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "p", "nymox:DisclosureOfStockOptionsExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:StockOptionPlanDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000072 - Disclosure - STOCK OPTIONS (Details Narrative)", "role": "http://nymox.com/role/StockOptionsDetailsNarrative", "shortName": "STOCK OPTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:DisclosureOfStockOptionsExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:StockOptionPlanDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000073 - Disclosure - SHARE BASED COMPENSATION (Details)", "role": "http://nymox.com/role/ShareBasedCompensationDetails", "shortName": "SHARE BASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfStockOptionBasedCompensationExpenseTableTextblock", "nymox:Note12ShareBasedCompensationTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31_nymox_StockOptionsMember", "decimals": "-3", "lang": null, "name": "ifrs-full:DistributionAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "nymox:Note12ShareBasedCompensationTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "nymox:SharesBasedCompensationRecognizedExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000074 - Disclosure - SHARE BASED COMPENSATION (Details Narrative)", "role": "http://nymox.com/role/ShareBasedCompensationDetailsNarrative", "shortName": "SHARE BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:Note12ShareBasedCompensationTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "nymox:SharesBasedCompensationRecognizedExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfWarrantsOutstandingTableTextblock", "nymox:Note13WarrantsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31_nymox_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "nymox:WarrantsNumberOfOutstandingBalanceBeginning", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000075 - Disclosure - WARRANTS (Details)", "role": "http://nymox.com/role/WarrantsDetails", "shortName": "WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfWarrantsOutstandingTableTextblock", "nymox:Note13WarrantsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31_nymox_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "nymox:WarrantsNumberOfOutstandingBalanceBeginning", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "p", "nymox:Note13WarrantsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "nymox:NumberOfWarrantsIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000076 - Disclosure - WARRANTS (Details Narrative)", "role": "http://nymox.com/role/WarrantsDetailsNarrative", "shortName": "WARRANTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:Note13WarrantsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2019-03-31_nymox_PrivatePlacementsMember", "decimals": "INF", "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfEffectiveTaxRateTableTextblock", "nymox:IncomeTaxesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:ProfitLossBeforeTaxes", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000077 - Disclosure - INCOME TAXES (Details)", "role": "http://nymox.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfEffectiveTaxRateTableTextblock", "nymox:IncomeTaxesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:ProfitLossBeforeTaxes", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfUnrecognizedDeferredTaxAssetsTableTextblock", "nymox:IncomeTaxesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:TaxLossCarryForward", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000078 - Disclosure - INCOME TAXES (Details 1)", "role": "http://nymox.com/role/IncomeTaxesDetails1", "shortName": "INCOME TAXES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfUnrecognizedDeferredTaxAssetsTableTextblock", "nymox:IncomeTaxesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:TaxLossCarryForward", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfNetOperatingLossCarryforwardsForOriginationAndExpirationTableTextblock", "nymox:IncomeTaxesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:NetOperatingLossCarryforwardsForUsFederalIncomeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000079 - Disclosure - INCOME TAXES (Details 2)", "role": "http://nymox.com/role/IncomeTaxesDetails2", "shortName": "INCOME TAXES (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfNetOperatingLossCarryforwardsForOriginationAndExpirationTableTextblock", "nymox:IncomeTaxesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:NetOperatingLossCarryforwardsForUsFederalIncomeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:GoingConcernConsiderationsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - GOING CONCERN CONSIDERATIONS", "role": "http://nymox.com/role/GoingConcernConsiderations", "shortName": "GOING CONCERN CONSIDERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:GoingConcernConsiderationsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "p", "nymox:IncomeTaxesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2015-12-31", "decimals": "0", "first": true, "lang": null, "name": "nymox:CanadianResearchTaxCreditCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000080 - Disclosure - INCOME TAXES (Details Narrative)", "role": "http://nymox.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:IncomeTaxesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2015-12-31", "decimals": "0", "first": true, "lang": null, "name": "nymox:CanadianResearchTaxCreditCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:ScheduleOfWeightedAverageNumberOfShareTableTextBlockExplanatory", "nymox:EarningsPerShare", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:IssuedCommonSharesAtJanuary", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000081 - Disclosure - EARNINGS PER SHARE (Details)", "role": "http://nymox.com/role/EarningsPerShareDetails", "shortName": "EARNINGS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:ScheduleOfWeightedAverageNumberOfShareTableTextBlockExplanatory", "nymox:EarningsPerShare", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:IssuedCommonSharesAtJanuary", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfFinanceIncomeAndFinanceCotsTableTextbock", "nymox:FinanceIncomeAndFinanceCostsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000082 - Disclosure - FINANCE INCOME AND FINANCE COSTS (Details)", "role": "http://nymox.com/role/FinanceIncomeAndFinanceCostsDetails", "shortName": "FINANCE INCOME AND FINANCE COSTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfFinanceIncomeAndFinanceCotsTableTextbock", "nymox:FinanceIncomeAndFinanceCostsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000083 - Disclosure - SEGMENT DISCLOSURES (Details)", "role": "http://nymox.com/role/SegmentDisclosuresDetails", "shortName": "SEGMENT DISCLOSURES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfGeographicReportableSegmentTableTextblock", "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31_nymox_GeographicalAreasUnitedStatesMember", "decimals": "-3", "lang": null, "name": "ifrs-full:Revenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:RevenueFromSaleOfGoods", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000084 - Disclosure - CONCENTRATIONS (Details)", "role": "http://nymox.com/role/ConcentrationsDetails", "shortName": "CONCENTRATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfRevenuesFromSalesTableTextblock", "nymox:DisclosureOfConcentrationsExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31_nymox_CustomerBMember", "decimals": "-3", "lang": null, "name": "ifrs-full:RevenueFromSaleOfGoods", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nymox:RelatedPartyTransactionsTextBlck", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31_nymox_OfficersAndDirectorsMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000085 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "role": "http://nymox.com/role/RelatedPartyTransactionsDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nymox:RelatedPartyTransactionsTextBlck", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31_nymox_OfficersAndDirectorsMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "p", "nymox:RelatedPartyTransactionsTextBlck", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31_nymox_ChiefFinancialOfficersMember", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000086 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "role": "http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:RelatedPartyTransactionsTextBlck", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31_nymox_ChiefFinancialOfficersMember", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfResearchAndDevelopmentExpensesTableTextblock", "nymox:ResearchAndDevelopmentExpensesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PaymentsForDevelopmentProjectExpenditure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000087 - Disclosure - RESEARCH AND DEVELOPMENT EXPENSES (Details)", "role": "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails", "shortName": "RESEARCH AND DEVELOPMENT EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfResearchAndDevelopmentExpensesTableTextblock", "nymox:ResearchAndDevelopmentExpensesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:PaymentsForDevelopmentProjectExpenditure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfPersonnelRelatedExpensesTableTextblock", "nymox:DisclosureOfPersonnelExpensesExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:Salaries", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000088 - Disclosure - PERSONNEL EXPENSES (Details)", "role": "http://nymox.com/role/PersonnelExpensesDetails", "shortName": "PERSONNEL EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfPersonnelRelatedExpensesTableTextblock", "nymox:DisclosureOfPersonnelExpensesExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "lang": null, "name": "ifrs-full:EmployerContributions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfPersonnelRelatedExpensesTableTextblock", "nymox:DisclosureOfPersonnelExpensesExplanatory", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "nymox:Salaries", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000089 - Disclosure - PERSONNEL EXPENSES (Details Narrative)", "role": "http://nymox.com/role/PersonnelExpensesDetailsNarrative", "shortName": "PERSONNEL EXPENSES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31_nymox_GeneralandAdminstrativeMember", "decimals": "0", "lang": null, "name": "nymox:Salaries", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SignificantEstimatesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - SIGNIFICANT ESTIMATES", "role": "http://nymox.com/role/SignificantEstimates", "shortName": "SIGNIFICANT ESTIMATES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "nymox:SignificantEstimatesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:AccountsPayableAndAccruedLiabilitiesTableTextblock", "nymox:AccountsPayableAndAccuruedLiabilitiesTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayables", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000090 - Disclosure - LIQUIDITY RISK (Details)", "role": "http://nymox.com/role/LiquidityRiskDetails", "shortName": "LIQUIDITY RISK (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "nymox:SummaryOfContractualMaturitiesOfFinancialLiabilitiesTableTextblock", "nymox:Note27LiquidityRiskTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31_nymox_LessThanOneYearMember", "decimals": "-3", "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "p", "nymox:Note13WarrantsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000091 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://nymox.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "nymox:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "nymox_20f.htm", "contextRef": "AsOf2022-03-22_nymox_SubsequentEventsMember", "decimals": "0", "lang": null, "name": "nymox:WarrantsToPurchaseSharesOfCommonStock", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } } }, "segmentCount": 64, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r170", "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r170", "r171", "r172" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r170", "r171", "r172" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelEmailAddress": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Email address of contact personnel.", "label": "Contact Personnel Email Address" } } }, "localname": "ContactPersonnelEmailAddress", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r170", "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityOtherIdentificationType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A unique identification type for the entity, other than Registrant Name, Central Index Key, Tax Identification Number, or Data Universal Numbering System Number.", "label": "Entity Other Identification Type" } } }, "localname": "EntityOtherIdentificationType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r170", "r171", "r172" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nymox.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "ifrs-full_AccountingEstimatesAxis": { "auth_ref": [ "r91" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Accounting estimates [axis]" } } }, "localname": "AccountingEstimatesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConcentrationsDetails", "http://nymox.com/role/StockOptionsDetails1" ], "xbrltype": "stringItemType" }, "ifrs-full_AccountingEstimatesMember": { "auth_ref": [ "r91" ], "lang": { "en": { "role": { "documentation": "This member stands for an asset, a liability or a periodic consumption of an asset, subject to adjustments that result from the assessment of the present status of, and expected future benefits and obligations associated with, assets and liabilities. It also represents the standard value for the 'Accounting estimates' axis if no other member is used." } } }, "localname": "AccountingEstimatesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConcentrationsDetails", "http://nymox.com/role/StockOptionsDetails1" ], "xbrltype": "domainItemType" }, "ifrs-full_AdditionalPaidinCapital": { "auth_ref": [ "r16" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 16.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders." } }, "en-us": { "role": { "label": "[Additional paid-in capital]", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidinCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Additions" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceCosts": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]" } }, "en-us": { "role": { "label": "[Adjustments for finance costs]", "negatedLabel": "Finance costs" } } }, "localname": "AdjustmentsForFinanceCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/FinanceIncomeAndFinanceCostsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceIncome": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]" } }, "en-us": { "role": { "label": "[Adjustments for finance income]", "verboseLabel": "Finance income" } } }, "localname": "AdjustmentsForFinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/FinanceIncomeAndFinanceCostsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]" } }, "en-us": { "role": { "label": "Total finance income and costs" } } }, "localname": "AdjustmentsForFinanceIncomeCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/FinanceIncomeAndFinanceCostsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r84" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Stock-based compensation" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r17", "r44", "r111", "r117", "r119", "r126", "r133", "r134", "r149", "r150", "r152", "r153" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/LiquidityRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AmortisationExpense": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives." } }, "en-us": { "role": { "label": "Accumulated amortization" } } }, "localname": "AmortisationExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "auth_ref": [ "r55", "r58" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Amounts paid contract for services" } } }, "localname": "AmountsPayableRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r16", "r105", "r106", "r107", "r138", "r141" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_BankAndSimilarCharges": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of bank and similar charges recognised by the entity as an expense." } }, "en-us": { "role": { "label": "Interest and bank charges" } } }, "localname": "BankAndSimilarCharges", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/FinanceIncomeAndFinanceCostsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r64", "r65" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic and diluted loss per share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r36", "r39", "r71", "r72", "r75", "r76", "r77", "r78", "r79", "r124", "r127", "r128", "r163", "r165" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairment And Gross Carrying Amount Axis" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/LiquidityRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r39", "r72", "r75", "r77", "r78", "r124", "r127", "r128", "r163", "r164" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "localname": "CarryingAmountMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/LiquidityRiskDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r88" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash" } } }, "localname": "Cash", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r14", "r88", "r101" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "[Cash and cash equivalents]", "periodEndLabel": "End of year", "periodStartLabel": "Beginning of year" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r80", "r89" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 16.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "[Cash flows from (used in) financing activities]", "totalLabel": "Net cash provided from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r80", "r89" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 17.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "[Cash flows from (used in) investing activities]", "totalLabel": "Net cash flows used in investing activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r80", "r89" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 18.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "[Cash flows from (used in) operating activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r57" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories Of Related Parties Axis" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetails", "http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative", "http://nymox.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsAxis": { "auth_ref": [ "r68", "r69", "r108", "r116" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Assets Axis" } } }, "localname": "ClassesOfAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/PersonnelExpensesDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfAssetsMember": { "auth_ref": [ "r68", "r108", "r116" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "localname": "ClassesOfAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/PersonnelExpensesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "auth_ref": [ "r131", "r132", "r148", "r156", "r157", "r158" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Financial Assets Axis" } } }, "localname": "ClassesOfFinancialAssetsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetails", "http://nymox.com/role/ShareCapitalDetails", "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": { "auth_ref": [ "r73" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Intangible Assets And Goodwill Axis" } } }, "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfLiabilitiesAxis": { "auth_ref": [ "r108" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes Of Liabilities Axis" } } }, "localname": "ClassesOfLiabilitiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfRegulatoryDeferralAccountBalancesAxis": { "auth_ref": [ "r109", "r110" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of regulatory deferral account balances [axis]" } } }, "localname": "ClassesOfRegulatoryDeferralAccountBalancesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfRegulatoryDeferralAccountBalancesMember": { "auth_ref": [ "r109", "r110" ], "lang": { "en": { "role": { "documentation": "This member stands for all classes (ie types of cost or income) of regulatory deferral account balances. It also represents the standard value for the 'Classes of regulatory deferral account balances' axis if no other member is used. [Refer: Regulatory deferral account balances [member]]" } } }, "localname": "ClassesOfRegulatoryDeferralAccountBalancesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r5" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components Of Equity [Axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConcentrationsDetails", "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_CostOfSales": { "auth_ref": [ "r2", "r30" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } }, "en-us": { "role": { "label": "Cost of goods sold" } } }, "localname": "CostOfSales", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": { "auth_ref": [ "r16" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]" } }, "en-us": { "role": { "label": "Other accrued liabilities" } } }, "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r18", "r97", "r98" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 10.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "[Current assets]", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r20", "r97", "r99" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 14.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "[Current liabilities]", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentPrepaidExpenses": { "auth_ref": [ "r6" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 7.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } }, "en-us": { "role": { "label": "Prepaid expenses and other current assets" } } }, "localname": "CurrentPrepaidExpenses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "auth_ref": [ "r38", "r40" ], "lang": { "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Depreciation expense of property and equipment" } } }, "localname": "DepreciationPropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "SHARE BASED COMPENSATION (Details)" } } }, "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForWarrantsExplanatory": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for warrants. Warrants are financial instruments that give the holder the right to purchase ordinary shares." } }, "en-us": { "role": { "label": "WARRANTS (Tables)" } } }, "localname": "DescriptionOfAccountingPolicyForWarrantsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r123" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/StockOptionsDetails1" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfFunctionalCurrency": { "auth_ref": [ "r48", "r49" ], "lang": { "en": { "role": { "documentation": "The description of the currency of the primary economic environment in which the entity operates." } }, "en-us": { "role": { "label": "Description of functional currency exposures" } } }, "localname": "DescriptionOfFunctionalCurrency", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ForeignExchangeRiskDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r123" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk-free interest rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/StockOptionsDetails1" ], "xbrltype": "percentItemType" }, "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": { "auth_ref": [ "r66" ], "lang": { "en": { "role": { "documentation": "The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options." } }, "en-us": { "role": { "label": "Effect of shares issued" } } }, "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of accrued expenses and other liabilities. [Refer: Accruals; Other liabilities]" } }, "en-us": { "role": { "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)" } } }, "localname": "DisclosureOfAccruedExpensesAndOtherLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory": { "auth_ref": [ "r90" ], "lang": { "en": { "role": { "documentation": "The disclosure of additional information that may be relevant to users of financial statements in understanding the financial position and liquidity of an entity." } }, "en-us": { "role": { "label": "NEW ACCOUNTING STANDARDS AND INTERPRETATIONS (Tables)" } } }, "localname": "DisclosureOfAdditionalInformationAboutUnderstandingFinancialPositionsAndLiquidityOfEntityExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } }, "en-us": { "role": { "label": "BUSINESS ACTIVITIES AND BASIS OF PRESENTATION" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHARE CAPITAL (Tables)" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "auth_ref": [ "r25" ], "lang": { "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } }, "en-us": { "role": { "label": "SHARE CAPITAL (Details)" } } }, "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": { "auth_ref": [ "r70" ], "lang": { "en": { "role": { "documentation": "The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "CONCENTRATIONS (Tables)" } } }, "localname": "DisclosureOfContingentLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCreditRiskExposureExplanatory": { "auth_ref": [ "r129" ], "lang": { "en": { "role": { "documentation": "The disclosure of the credit risk exposure. Credit risk exposure is the credit risk inherent in an entity\u2019s financial assets and commitments to extend credit." } }, "en-us": { "role": { "label": "CREDIT RISK (Details Narrative)" } } }, "localname": "DisclosureOfCreditRiskExposureExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDeferredIncomeExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of deferred income. [Refer: Deferred income including contract liabilities]" } }, "en-us": { "role": { "label": "INCOME TAXES (Details)" } } }, "localname": "DisclosureOfDeferredIncomeExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r67" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "EARNINGS PER SHARE (Details)" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "auth_ref": [ "r50" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } }, "en-us": { "role": { "label": "FOREIGN EXCHANGE RISK (Details Narrative)" } } }, "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfExpensesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of expenses." } }, "en-us": { "role": { "label": "PERSONNEL EXPENSES (Tables)" } } }, "localname": "DisclosureOfExpensesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } }, "en-us": { "role": { "label": "FINANCE INCOME AND FINANCE COSTS (Details)" } } }, "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r135" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for financial instruments." } }, "en-us": { "role": { "label": "CAPITAL DISCLOSURES AND FINANCIAL RISK (Details Narrative)" } } }, "localname": "DisclosureOfFinancialInstrumentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "INCOME TAXES (Tables)" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInsuranceRiskExplanatory": { "auth_ref": [ "r161" ], "lang": { "en": { "role": { "documentation": "The disclosure of risk, other than financial risk, transferred from the holder of an insurance contract to the issuer." } }, "en-us": { "role": { "label": "INTEREST RATE RISK (Details Narrative)" } } }, "localname": "DisclosureOfInsuranceRiskExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS (Details Narrative)" } } }, "localname": "DisclosureOfIntangibleAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIssuedCapitalExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of issued capital. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Share capital (Details Narrative)" } } }, "localname": "DisclosureOfIssuedCapitalExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfJointVenturesExplanatory": { "auth_ref": [ "r61", "r62", "r103" ], "lang": { "en": { "role": { "documentation": "The disclosure of joint ventures. [Refer: Joint ventures [member]]" } }, "en-us": { "role": { "label": "SEGMENT DISCLOSURES (Tables)" } } }, "localname": "DisclosureOfJointVenturesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfLiquidityRiskExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of liquidity risk. [Refer: Liquidity risk [member]]" } }, "en-us": { "role": { "label": "LIQUIDITY RISK (Tables)" } } }, "localname": "DisclosureOfLiquidityRiskExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "auth_ref": [ "r119" ], "lang": { "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } }, "en-us": { "role": { "label": "OPERATING LEASES AND COMMITMENTS (Tables)" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]" } }, "en-us": { "role": { "label": "CONCENTRATIONS (Details)" } } }, "localname": "DisclosureOfOtherOperatingExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]" } }, "en-us": { "role": { "label": "OPERATING LEASES AND COMMITMENT (Details)" } } }, "localname": "DisclosureOfOtherOperatingIncomeExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r42" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } }, "en-us": { "role": { "label": "Summary of Property and equipment estimated useful lives" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS (Tables)" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "RESEARCH AND DEVELOPMENT EXPENSES (Tables)" } } }, "localname": "DisclosureOfResearchAndDevelopmentExpenseExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "SHARE BASED COMPENSATION (Tables)" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSubordinatedLiabilitiesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of subordinated liabilities. [Refer: Subordinated liabilities]" } }, "en-us": { "role": { "label": "SEGMENT DISCLOSURES (Details)" } } }, "localname": "DisclosureOfSubordinatedLiabilitiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES (Tables)" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "auth_ref": [ "r34" ], "lang": { "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } }, "en-us": { "role": { "label": "WARRANTS (Details Narrative)" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "verboseLabel": "NOTE 20 - RELATED PARTY TRANSACTIONS" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DistributionAndAdministrativeExpense": { "auth_ref": [ "r29" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to distribution costs and administrative expenses. [Refer: Administrative expenses; Distribution costs]" } }, "en-us": { "role": { "label": "General and administrative expense" } } }, "localname": "DistributionAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_EmployerContributions": { "auth_ref": [ "r60" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of employer contributions to retirement benefit plans." } }, "en-us": { "role": { "label": "Employer contributions" } } }, "localname": "EmployerContributions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/PersonnelExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EntitysTotalForAssociatesMember": { "auth_ref": [ "r61", "r62", "r104", "r160", "r162" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "localname": "EntitysTotalForAssociatesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r57" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetails", "http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative", "http://nymox.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r16", "r22", "r92", "r94", "r105", "r106", "r107" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 20.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "[Equity]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total Stockholders' equity (deficit)" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity", "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity" } } }, "localname": "EquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r16" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "[Equity and liabilities]", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r5" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConcentrationsDetails", "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_ExpenseByNature": { "auth_ref": [ "r30" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 6.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity." } }, "en-us": { "role": { "label": "[Expenses, by nature]", "totalLabel": "Total operating expenses" } } }, "localname": "ExpenseByNature", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r29" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 8.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income" } } }, "localname": "FinanceIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsMember": { "auth_ref": [ "r131", "r132", "r148", "r156", "r157", "r158" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "localname": "FinancialAssetsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetails", "http://nymox.com/role/ShareCapitalDetails", "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r43", "r113", "r146", "r155" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical Areas Axis" } } }, "localname": "GeographicalAreasAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails", "http://nymox.com/role/SegmentDisclosuresDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r43", "r113", "r146", "r155" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "localname": "GeographicalAreasMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails", "http://nymox.com/role/SegmentDisclosuresDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Comprehensive Loss" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxesPaidRefund": { "auth_ref": [ "r87" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded." } }, "en-us": { "role": { "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidRefund", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "auth_ref": [ "r88" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "[Increase (decrease) in cash and cash equivalents after effect of exchange rate changes]", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwill": { "auth_ref": [ "r16" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets" } } }, "localname": "IntangibleAssetsAndGoodwill", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwillMember": { "auth_ref": [ "r73" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "localname": "IntangibleAssetsAndGoodwillMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_Inventories": { "auth_ref": [ "r12", "r19", "r46" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Inventory" } } }, "localname": "Inventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r22" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 18.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Share capital - unlimited authorized shares at no par value.85,546, 77,961 and 71,218 shares outstanding at December 31, 2021, 2020 and 2019, respectively" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r54" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "[Key management personnel compensation]", "verboseLabel": "Total" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r52" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "[Key management personnel compensation, post-employment benefits]", "verboseLabel": "Short-term employee benefits" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/PersonnelExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "[Key management personnel compensation, share-based payment]", "verboseLabel": "Stock-based compensation" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r51" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Short-term employee benefits" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r115" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Operating lease liability", "verboseLabel": "Operating lease liability" } } }, "localname": "LeaseLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative", "http://nymox.com/role/OperatingLeasesAndOtherCommitmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r16", "r105", "r106", "r107", "r138", "r142" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 19.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LiabilitiesMember": { "auth_ref": [ "r108" ], "lang": { "en": { "role": { "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]" } } }, "localname": "LiabilitiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/WarrantsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r17", "r44", "r111", "r117", "r119", "r126", "r130", "r133", "r149", "r150", "r152", "r153" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity Axis" } } }, "localname": "MaturityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/LiquidityRiskDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NetAssetsLiabilities": { "auth_ref": [ "r6", "r96" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } }, "en-us": { "role": { "label": "Operating lease assets and liability" } } }, "localname": "NetAssetsLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetForeignExchangeGain": { "auth_ref": [ "r9", "r47" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange gain(loss)" } } }, "localname": "NetForeignExchangeGain", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/FinanceIncomeAndFinanceCostsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r32" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r32" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "localname": "NonadjustingEventsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "[Number of shares issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "NumberOfSharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "ifrs-full_OtherReceivables": { "auth_ref": [ "r21" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r23" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Fair value per share", "terseLabel": "Issuance and sale of common stock per share", "verboseLabel": "Warrant exercise price per share" } } }, "localname": "ParValuePerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetailsNarrative", "http://nymox.com/role/SubsequentEventsDetailsNarrative", "http://nymox.com/role/WarrantsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ifrs-full_PaymentsForDevelopmentProjectExpenditure": { "auth_ref": [ "r81" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for expenditure related to development projects." } }, "en-us": { "role": { "label": "Research and development expenses" } } }, "localname": "PaymentsForDevelopmentProjectExpenditure", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r82" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 15.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds from the issuance of share capital" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProductsAndServicesAxis": { "auth_ref": [ "r112", "r144" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Products And Services Axis" } } }, "localname": "ProductsAndServicesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ProductsAndServicesMember": { "auth_ref": [ "r112", "r144" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "localname": "ProductsAndServicesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r3", "r26", "r83", "r93", "r95", "r97", "r138", "r140", "r151", "r159" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow", "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "auth_ref": [ "r27" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Net Loss attributable to Nymox share holders" } } }, "localname": "ProfitLossAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r1", "r2", "r125", "r138", "r140" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "[Profit (loss) before tax]", "totalLabel": "Loss before income taxes" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r29", "r63" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "[Profit (loss) from operating activities]", "totalLabel": "Loss from operations" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r11", "r39" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 8.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property and equipment", "verboseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition", "http://nymox.com/role/SegmentDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT (Details)" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis": { "auth_ref": [ "r118" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Property, plant and equipment by operating lease status [axis]" } } }, "localname": "PropertyPlantAndEquipmentByOperatingLeaseStatusAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails", "http://nymox.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember": { "auth_ref": [ "r118" ], "lang": { "en": { "role": { "documentation": "This member stands for all property, plant and equipment when disaggregated by the operating lease status by a lessor. It also represents the standard value for the 'Property, plant and equipment by operating lease status' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "localname": "PropertyPlantAndEquipmentByOperatingLeaseStatusMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails", "http://nymox.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets": { "auth_ref": [ "r41" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of property, plant and equipment that would have been recognised had the revalued assets been carried under the cost model. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "[Property, plant and equipment, revalued assets, at cost]", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "PropertyPlantAndEquipmentCarryingAmountAtCostOfRevaluedAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReclassifiedItemsAxis": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Reclassified items [axis]" } } }, "localname": "ReclassifiedItemsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2", "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative", "http://nymox.com/role/OperatingLeasesAndOtherCommitmentDetailsNarrative", "http://nymox.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_ReclassifiedItemsMember": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "This member stands for items that have been reclassified when the entity changes their presentation or classification in its financial statements. It also represents the standard value for the 'Reclassified items' axis if no other member is used." } } }, "localname": "ReclassifiedItemsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2", "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative", "http://nymox.com/role/OperatingLeasesAndOtherCommitmentDetailsNarrative", "http://nymox.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r74" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 4.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development", "verboseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://nymox.com/role/ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r22", "r31" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 15.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Accumulated deficit" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r1", "r2", "r28", "r97", "r100", "r125", "r136", "r139", "r144", "r145", "r147" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 7.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "[Revenue]", "totalLabel": "Total revenue", "verboseLabel": "Revenue" } } }, "localname": "Revenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://nymox.com/role/SegmentDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromInterest": { "auth_ref": [ "r6", "r102", "r137", "r143" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from interest." } }, "en-us": { "role": { "label": "Interest income" } } }, "localname": "RevenueFromInterest", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/FinanceIncomeAndFinanceCostsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromSaleOfGoods": { "auth_ref": [ "r6" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_Revenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Sales of goods", "verboseLabel": "Revenue From Sale Of Goods" } } }, "localname": "RevenueFromSaleOfGoods", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConcentrationsDetails", "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r29" ], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 5.0, "parentTag": "ifrs-full_ExpenseByNature", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to selling, general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": { "auth_ref": [ "r24" ], "lang": { "en": { "role": { "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares." } }, "en-us": { "role": { "label": "Issuance and sale of common stock" } } }, "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "auth_ref": [ "r61", "r62", "r104", "r160", "r162" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Significant Investments In Associates Axis" } } }, "localname": "SignificantInvestmentsInAssociatesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flow" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Changes in Equity" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidated Statements of Financial Position" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK OPTIONS (Tables)" } } }, "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxRateEffectOfForeignTaxRates": { "auth_ref": [ "r33" ], "lang": { "en": { "role": { "documentation": "The tax rate effect on the reconciliation between the average effective tax rate and the applicable tax rate resulting from the application of foreign tax rates. [Refer: Average effective tax rate; Applicable tax rate]" } }, "en-us": { "role": { "label": "Domestic tax rate applicable to the Corporation" } } }, "localname": "TaxRateEffectOfForeignTaxRates", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_TradeAndOtherCurrentPayables": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } }, "en-us": { "role": { "label": "Total accounts payable and accrued liabilities", "verboseLabel": "Trade accounts payable and accrued liabilities" } } }, "localname": "TradeAndOtherCurrentPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "http://nymox.com/role/LiquidityRiskDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentReceivables": { "auth_ref": [ "r13", "r21" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } }, "en-us": { "role": { "label": "[Trade and other current receivables]", "verboseLabel": "Accounts receivable" } } }, "localname": "TradeAndOtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherPayables": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]" } }, "en-us": { "role": { "label": "Accounts payable" } } }, "localname": "TradeAndOtherPayables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeReceivables": { "auth_ref": [ "r21" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount due from customers for goods and services sold." } }, "en-us": { "role": { "label": "Trade accounts receivable" } } }, "localname": "TradeReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/CreditRiskDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TypesOfContractsAxis": { "auth_ref": [ "r114", "r154" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types Of Contracts Axis" } } }, "localname": "TypesOfContractsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative", "http://nymox.com/role/ShareCapitalDetailsNarrative", "http://nymox.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfContractsMember": { "auth_ref": [ "r114", "r154" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } } }, "localname": "TypesOfContractsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative", "http://nymox.com/role/ShareCapitalDetailsNarrative", "http://nymox.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Salaries" } } }, "localname": "WagesAndSalaries", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": { "auth_ref": [ "r121", "r122" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "[Weighted average exercise price of share options outstanding in share-based payment arrangement]", "verboseLabel": "Exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r66" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of common shares outstanding" } } }, "localname": "WeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "nymox_AccountReceivablePolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Account Receivable" } } }, "localname": "AccountReceivablePolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_AccountsPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 12.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilities", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "nymox_AccountsPayableAndAccruedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesAbstract", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_AccountsPayableAndAccruedLiabilitiesTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/AccountsPayableAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "nymox_AccountsPayableAndAccuruedLiabilitiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 8 - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccuruedLiabilitiesTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/AccountsPayableAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "nymox_AccountsPayablesAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 12.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Accounts payable and accrued liabilities]", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayablesAndAccruedLiabilities", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_AccountsReceivable": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accounts receivable" } } }, "localname": "AccountsReceivable", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "nymox_AccountsReceivableAndOtherReceivables": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accounts receivable and other receivables" } } }, "localname": "AccountsReceivableAndOtherReceivables", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_AccumulatedAmortization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Accumulated amortization]", "verboseLabel": "Accumulated amortization" } } }, "localname": "AccumulatedAmortization", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetails" ], "xbrltype": "monetaryItemType" }, "nymox_AccumulatedDepreciationAndAmortizationAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Accumulated depreciation, beginning balance]", "periodEndLabel": "Accumulated depreciation, ending balance", "periodStartLabel": "Accumulated depreciation, beginning balance" } } }, "localname": "AccumulatedDepreciationAndAmortizationAssets", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "nymox_AccumulatedDepreciationDepreciationForTheYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accumulated depreciation, depreciation for the year" } } }, "localname": "AccumulatedDepreciationDepreciationForTheYear", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "nymox_AccumulatedDepreciationDisposalsForTheYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Accumulated depreciation, Disposals for the year]", "verboseLabel": "Accumulated depreciation, Disposals for the year" } } }, "localname": "AccumulatedDepreciationDisposalsForTheYear", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "nymox_AccumulatedDepreciationdisposalsForTheYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Accumulated depreciation, Disposals for the year" } } }, "localname": "AccumulatedDepreciationdisposalsForTheYear", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "nymox_AdditionalPaidinCapitalOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Additional paid-in capital 1]", "verboseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidinCapitalOneMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "nymox_AdjustmentsForSharebasedPayments1": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Total]", "verboseLabel": "Total" } } }, "localname": "AdjustmentsForSharebasedPayments1", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "nymox_AlzheimersDiseaseTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Alzheimer's Disease Therapeutics [Member]" } } }, "localname": "AlzheimersDiseaseTherapeuticsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails" ], "xbrltype": "domainItemType" }, "nymox_AmortizationAndOthers": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Amortization and others" } } }, "localname": "AmortizationAndOthers", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_AmortizationPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amortization" } } }, "localname": "AmortizationPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_AmountOfIssuanceOfShareCapitalFromWarrantExcise": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Excise" } } }, "localname": "AmountOfIssuanceOfShareCapitalFromWarrantExcise", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative" ], "xbrltype": "perShareItemType" }, "nymox_AntiInfectivesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Anti-Infectives [Member]" } } }, "localname": "AntiInfectivesMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails" ], "xbrltype": "domainItemType" }, "nymox_AugustTwoZeroTwoOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "August, 2021 [Member]" } } }, "localname": "AugustTwoZeroTwoOneMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative", "http://nymox.com/role/OperatingLeasesAndOtherCommitmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "nymox_AverageRemainingYears": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Average remaining years", "verboseLabel": "Average remaining years" } } }, "localname": "AverageRemainingYears", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative", "http://nymox.com/role/OperatingLeasesAndOtherCommitmentDetailsNarrative" ], "xbrltype": "durationItemType" }, "nymox_BPHEnlargedProstateAndProstateCancerTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BPH (Enlarged Prostate) and Prostate Cancer Therapeutics [Member]" } } }, "localname": "BPHEnlargedProstateAndProstateCancerTherapeuticsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails" ], "xbrltype": "domainItemType" }, "nymox_BahamasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bahamas [Member]" } } }, "localname": "BahamasMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "nymox_BegininngBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Begininng balance]", "periodStartLabel": "Begininng balance" } } }, "localname": "BegininngBalance", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetails" ], "xbrltype": "monetaryItemType" }, "nymox_CONCENTRATIONS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONCENTRATIONS" } } }, "localname": "CONCENTRATIONS", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_CanadianLossCarryforwards": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Canadian loss carryforwards" } } }, "localname": "CanadianLossCarryforwards", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_CanadianResearchTaxCreditCarryforwards": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Canadian research tax credit carryforwards" } } }, "localname": "CanadianResearchTaxCreditCarryforwards", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_CapitalDisclosuresAndFinancialRisk": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CAPITAL DISCLOSURES AND FINANCIAL RISK" } } }, "localname": "CapitalDisclosuresAndFinancialRisk", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_CapitalDisclosuresAndFinancialsRiskTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 23 - CAPITAL DISCLOSURES AND FINANCIAL RISK" } } }, "localname": "CapitalDisclosuresAndFinancialsRiskTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRisk" ], "xbrltype": "textBlockItemType" }, "nymox_CarryingAmountsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } } }, "localname": "CarryingAmountsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/LiquidityRiskDetails" ], "xbrltype": "domainItemType" }, "nymox_CarryingValueOfPropertyAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Carrying value of property and equipment]", "periodEndLabel": "Carrying value of property and equipment" } } }, "localname": "CarryingValueOfPropertyAndEquipment", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "nymox_CashAtBankAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH AT BANK" } } }, "localname": "CashAtBankAbstract", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "nymox_ChangeInValuationAllowance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Change in valuation allowance" } } }, "localname": "ChangeInValuationAllowance", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "nymox_ChangesInNonCashOperatingBalancesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in non-cash operating balances:" } } }, "localname": "ChangesInNonCashOperatingBalancesAbstract", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "nymox_ChiefFinancialOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Financial Officers [Member]" } } }, "localname": "ChiefFinancialOfficersMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nymox_CommonSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common shares issued" } } }, "localname": "CommonSharesIssued", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_CommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Shares" } } }, "localname": "CommonStockMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "nymox_ComputerEquipmentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Computer Equipment [member]" } } }, "localname": "ComputerEquipmentOneMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nymox_ComputerEquipmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Computer equipment [member]" } } }, "localname": "ComputerEquipmentsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "nymox_ConsolidationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_CorporateLegalCounselMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Corporate Legal Counsel [Member]" } } }, "localname": "CorporateLegalCounselMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nymox_CostOfGoodsSoldAndOperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of goods sold and operating Expenses" } } }, "localname": "CostOfGoodsSoldAndOperatingExpensesAbstract", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "nymox_CreditRisk": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CREDIT RISK" } } }, "localname": "CreditRisk", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_CurrentliabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "CurrentliabilitiesAbstract", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "nymox_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer A" } } }, "localname": "CustomerAMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "nymox_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer B [Member]" } } }, "localname": "CustomerBMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "nymox_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Customer C [Member]" } } }, "localname": "CustomerCMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "nymox_DeferredTaxProvisionRecovery": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred tax provision (recovery)" } } }, "localname": "DeferredTaxProvisionRecovery", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "nymox_Deposit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deposit" } } }, "localname": "Deposit", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nymox_Depreciation": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_DisclosureOfBasisOfConsolidationExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 1 - BUSINESS ACTIVITIES AND BASIS OF PRESENTATION" } } }, "localname": "DisclosureOfBasisOfConsolidationExplanatoryTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/BusinessActivitiesAndBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "nymox_DisclosureOfConcentrationsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 19 - CONCENTRATIONS" } } }, "localname": "DisclosureOfConcentrationsExplanatory", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CONCENTRATIONS" ], "xbrltype": "textBlockItemType" }, "nymox_DisclosureOfInterestRateRiskExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 26 - INTEREST RATE RISK" } } }, "localname": "DisclosureOfInterestRateRiskExplanatory", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/InterestRateRisk" ], "xbrltype": "textBlockItemType" }, "nymox_DisclosureOfNewAccountingStandardsAndInterpretationsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 5 - NEW ACCOUNTING STANDARDS AND INTERPRETATIONS" } } }, "localname": "DisclosureOfNewAccountingStandardsAndInterpretationsExplanatory", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/NewAccountingStandardsAndInterpretations" ], "xbrltype": "textBlockItemType" }, "nymox_DisclosureOfPersonnelExpensesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 22 - PERSONNEL EXPENSES" } } }, "localname": "DisclosureOfPersonnelExpensesExplanatory", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PersonnelExpenses" ], "xbrltype": "textBlockItemType" }, "nymox_DisclosureOfStockOptionsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 11 - STOCK OPTIONS" } } }, "localname": "DisclosureOfStockOptionsExplanatory", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptions" ], "xbrltype": "textBlockItemType" }, "nymox_DiscountRateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discount rate description" } } }, "localname": "DiscountRateDescription", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "nymox_DisposalsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Disposals" } } }, "localname": "DisposalsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "nymox_DrAverbackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dr. Averback [Member]" } } }, "localname": "DrAverbackMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "nymox_EarningsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 15 - EARNINGS PER SHARE" } } }, "localname": "EarningsPerShare", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "nymox_EarningsPerShareTablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EARNINGS PER SHARE (Tables)" } } }, "localname": "EarningsPerShareTablesAbstract", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_EarningsPerSharesPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from t", "label": "Earnings per share" } } }, "localname": "EarningsPerSharesPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_EmployeeBenefitsPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee benefits" } } }, "localname": "EmployeeBenefitsPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_EmployeeDepositOfOverpayment": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 11.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Employee deposit of overpayment" } } }, "localname": "EmployeeDepositOfOverpayment", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_EndingBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Ending balance]", "periodEndLabel": "Ending balance" } } }, "localname": "EndingBalance", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetails" ], "xbrltype": "monetaryItemType" }, "nymox_EndingBalanceOperatingLeaseLiabilty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Ending balance 1]", "verboseLabel": "Ending balance" } } }, "localname": "EndingBalanceOperatingLeaseLiabilty", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetails1" ], "xbrltype": "monetaryItemType" }, "nymox_EquityCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "equity compensation reward" } } }, "localname": "EquityCompensation", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_ExercisePriceOrWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price or warrants" } } }, "localname": "ExercisePriceOrWarrants", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalDetailsNarrative" ], "xbrltype": "perShareItemType" }, "nymox_ExpectedDividendYieldShareOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected dividend yield" } } }, "localname": "ExpectedDividendYieldShareOptionsGranted", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails1" ], "xbrltype": "percentItemType" }, "nymox_ExpectedOptionLifeInYears": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected option life in years" } } }, "localname": "ExpectedOptionLifeInYears", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails1" ], "xbrltype": "durationItemType" }, "nymox_FinanceCostsExpense": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 10.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Finance costs" } } }, "localname": "FinanceCostsExpense", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "nymox_FinanceIncomeAndFinanceCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCE INCOME AND FINANCE COSTS" } } }, "localname": "FinanceIncomeAndFinanceCosts", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_FinanceIncomeAndFinanceCostsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 17 - FINANCE INCOME AND FINANCE COSTS" } } }, "localname": "FinanceIncomeAndFinanceCostsTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/FinanceIncomeAndFinanceCosts" ], "xbrltype": "textBlockItemType" }, "nymox_FinancialInstrumentsFairValueDisclosures": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES" } } }, "localname": "FinancialInstrumentsFairValueDisclosures", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_FinancialInstrumentsFairValueDisclosuresTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 16 - FINANCIAL INSTRUMENTS FAIR VALUE DISCLOSURES" } } }, "localname": "FinancialInstrumentsFairValueDisclosuresTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/FinancialInstrumentsFairValueDisclosures" ], "xbrltype": "textBlockItemType" }, "nymox_FinancialLiabilitiesPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial liabilities" } } }, "localname": "FinancialLiabilitiesPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_FinancialassetspolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial assets" } } }, "localname": "FinancialassetspolicyTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_FinancialinstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial instruments" } } }, "localname": "FinancialinstrumentsPolicyTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_ForeignCurrencyPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Foreign currency" } } }, "localname": "ForeignCurrencyPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_ForeignExchangeRisk": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FOREIGN EXCHANGE RISK" } } }, "localname": "ForeignExchangeRisk", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_FuturePaymentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Future payment amount" } } }, "localname": "FuturePaymentAmount", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_GeneralandAdminstrativeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "General and Adminstrative [Member]" } } }, "localname": "GeneralandAdminstrativeMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PersonnelExpensesDetailsNarrative" ], "xbrltype": "domainItemType" }, "nymox_GeographicalAreasCanadaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Canada [Member]" } } }, "localname": "GeographicalAreasCanadaMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SegmentDisclosuresDetails" ], "xbrltype": "domainItemType" }, "nymox_GeographicalAreasEuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "localname": "GeographicalAreasEuropeMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SegmentDisclosuresDetails" ], "xbrltype": "domainItemType" }, "nymox_GeographicalAreasUnitedStatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[United States [Member]]", "verboseLabel": "United States [Member]" } } }, "localname": "GeographicalAreasUnitedStatesMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SegmentDisclosuresDetails" ], "xbrltype": "domainItemType" }, "nymox_GoingConcernConsiderations": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GOING CONCERN CONSIDERATIONS" } } }, "localname": "GoingConcernConsiderations", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_GoingConcernConsiderationsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 2 - GOING CONCERN CONSIDERATIONS" } } }, "localname": "GoingConcernConsiderationsTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/GoingConcernConsiderations" ], "xbrltype": "textBlockItemType" }, "nymox_GrossProceedsBeforeDeductingPlacementAgentFeesAndVariousExpense": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gross proceeds before deducting placement agent fees and various expenses" } } }, "localname": "GrossProceedsBeforeDeductingPlacementAgentFeesAndVariousExpense", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_ImmaterialCumulativeAdjustment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Immaterial cumulative adjustment", "periodEndLabel": "Immaterial cumulative adjustment", "verboseLabel": "Immaterial cumulative adjustment" } } }, "localname": "ImmaterialCumulativeAdjustment", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative", "http://nymox.com/role/OperatingLeasesAndOtherCommitmentDetailsNarrative", "http://nymox.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_ImpairmentPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment" } } }, "localname": "ImpairmentPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_IncomeTaxes": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxes", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_IncomeTaxesAtDomesticTaxStatutoryRate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Income taxes at domestic tax statutory rate" } } }, "localname": "IncomeTaxesAtDomesticTaxStatutoryRate", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "nymox_IncomeTaxesPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income taxes" } } }, "localname": "IncomeTaxesPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_IncomeTaxesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 14 - INCOME TAXES" } } }, "localname": "IncomeTaxesTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "nymox_IncomeTaxprovisionRecoveryContinuingOperations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Income tax provision (recovery)" } } }, "localname": "IncomeTaxprovisionRecoveryContinuingOperations", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "nymox_IncreaseDecreaseInterestRatesPercentageDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase decrease interest rates percentage description" } } }, "localname": "IncreaseDecreaseInterestRatesPercentageDescription", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/InterestRateRiskDetailsNarrative" ], "xbrltype": "stringItemType" }, "nymox_IndependentDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Independent Directors [Member]" } } }, "localname": "IndependentDirectorsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nymox_IntangibleAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssets", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_IntangibleAssetsTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 7 - INTANGIBLE ASSETS" } } }, "localname": "IntangibleAssetsTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "nymox_IntellectualPropertyRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intellectual Property Rights [Member]" } } }, "localname": "IntellectualPropertyRightsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IntangibleAssetsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nymox_InterestPaidRefund": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Interest paid" } } }, "localname": "InterestPaidRefund", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_InterestRateRisk": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INTEREST RATE RISK" } } }, "localname": "InterestRateRisk", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_InventoriesPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventories" } } }, "localname": "InventoriesPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_Inventory": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Inventory]", "verboseLabel": "Inventory" } } }, "localname": "Inventory", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_IssuanceOfShareCapitalFromWarrantExcise": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase up shares of common stock" } } }, "localname": "IssuanceOfShareCapitalFromWarrantExcise", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_IssuedCommonSharesAtJanuary": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued common shares at January 1" } } }, "localname": "IssuedCommonSharesAtJanuary", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "nymox_IssuedStockForServiceFee": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issued stock for service fee" } } }, "localname": "IssuedStockForServiceFee", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_JamesGRobinsonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "James G. Robinson [Member]" } } }, "localname": "JamesGRobinsonMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nymox_JanuaryOneTwoZeroOneNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "January 1, 2019 [Member]" } } }, "localname": "JanuaryOneTwoZeroOneNineMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative", "http://nymox.com/role/OperatingLeasesAndOtherCommitmentDetailsNarrative", "http://nymox.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "nymox_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Laboratory Equipment [Member]" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails", "http://nymox.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nymox_LeaseAdoptionPriorYearCumulativeEffect": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Lease adoption prior year cumulative effect" } } }, "localname": "LeaseAdoptionPriorYearCumulativeEffect", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "nymox_LeaseExpirydate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease expiry date" } } }, "localname": "LeaseExpirydate", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative" ], "xbrltype": "dateItemType" }, "nymox_LeaseLiabilityDueWithinOneYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Lease liability due within one year" } } }, "localname": "LeaseLiabilityDueWithinOneYear", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetails1" ], "xbrltype": "monetaryItemType" }, "nymox_LeaseLiabilityLongTerm": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Lease liability long term" } } }, "localname": "LeaseLiabilityLongTerm", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetails1" ], "xbrltype": "monetaryItemType" }, "nymox_LessThanOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Less than 1 year [Member]" } } }, "localname": "LessThanOneYearMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/LiquidityRiskDetails" ], "xbrltype": "domainItemType" }, "nymox_LiquidityRisk": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIQUIDITY RISK" } } }, "localname": "LiquidityRisk", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_LongTermOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 13.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Long term operating lease liability" } } }, "localname": "LongTermOperatingLeaseLiability", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "nymox_MaximumsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails1" ], "xbrltype": "domainItemType" }, "nymox_MinimumsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails1" ], "xbrltype": "domainItemType" }, "nymox_NetLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Net loss]", "verboseLabel": "Net loss" } } }, "localname": "NetLoss", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "nymox_NetOperatingLossCarryforwardsForUsFederalIncomeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards" } } }, "localname": "NetOperatingLossCarryforwardsForUsFederalIncomeTax", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "nymox_NewAccountingStandardsAndInterpretations": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NEW ACCOUNTING STANDARDS AND INTERPRETATIONS" } } }, "localname": "NewAccountingStandardsAndInterpretations", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_NoncashInvestingAndFinancingActivitiesactivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CASH INVESTING AND FINANCING ACTIVITIES" } } }, "localname": "NoncashInvestingAndFinancingActivitiesactivitiesAbstract", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "nymox_Note10ShareCapitalTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]", "label": "NOTE 10 - SHARE CAPITAL" } } }, "localname": "Note10ShareCapitalTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapital" ], "xbrltype": "textBlockItemType" }, "nymox_Note12ShareBasedCompensationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangements.", "label": "NOTE 12 - SHARE BASED COMPENSATION" } } }, "localname": "Note12ShareBasedCompensationTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "nymox_Note13WarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 13 - WARRANTS" } } }, "localname": "Note13WarrantsTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/WARRANTS" ], "xbrltype": "textBlockItemType" }, "nymox_Note24ForeignExchangeRiskTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 24 - FOREIGN EXCHANGE RISK" } } }, "localname": "Note24ForeignExchangeRiskTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ForeignExchangeRisk" ], "xbrltype": "textBlockItemType" }, "nymox_Note25CreditRiskAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 25 - CREDIT RISK" } } }, "localname": "Note25CreditRiskAbstract", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CreditRisk" ], "xbrltype": "textBlockItemType" }, "nymox_Note27LiquidityRiskTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 27 - LIQUIDITY RISK" } } }, "localname": "Note27LiquidityRiskTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/LiquidityRisk" ], "xbrltype": "textBlockItemType" }, "nymox_NumberOfCommonSharesValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Number of common shares, value" } } }, "localname": "NumberOfCommonSharesValue", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "nymox_NumberOfOutstandingBalanceBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of outstanding balance, Beginning" } } }, "localname": "NumberOfOutstandingBalanceBeginning", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "nymox_NumberOfOutstandingBalanceEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of outstanding balance, Ending" } } }, "localname": "NumberOfOutstandingBalanceEnding", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "nymox_NumberOfShareOptionsExpiredUnderlyingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expired / Cancelled", "verboseLabel": "Expired" } } }, "localname": "NumberOfShareOptionsExpiredUnderlyingShares", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalDetails", "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "nymox_NumberOfShareOptionsGrantedUnderlyingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Granted" } } }, "localname": "NumberOfShareOptionsGrantedUnderlyingShares", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "nymox_NumberOfShareOptionsOutstandingExercisableUnderlyingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options exercisable" } } }, "localname": "NumberOfShareOptionsOutstandingExercisableUnderlyingShares", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "sharesItemType" }, "nymox_NumberOfSharesIssuedfr": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock shares issued" } } }, "localname": "NumberOfSharesIssuedfr", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_NumberOfWarrantsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants issued", "verboseLabel": "Warrants issued" } } }, "localname": "NumberOfWarrantsIssued", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalDetailsNarrative", "http://nymox.com/role/WarrantsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_OfferingAndConcurrentPrivatePlacementOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offering and concurrent private placement of warrants" } } }, "localname": "OfferingAndConcurrentPrivatePlacementOfWarrants", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_OfferingAndConcurrentPrivatePlacementOfWarrantsExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offering and concurrent private placement of warrants expired" } } }, "localname": "OfferingAndConcurrentPrivatePlacementOfWarrantsExpired", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "nymox_OfficeEquipmentAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Office Equipment And Fixtures [Member]" } } }, "localname": "OfficeEquipmentAndFixturesMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails", "http://nymox.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "nymox_OfficeEquipmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Office equipment [member]" } } }, "localname": "OfficeEquipmentsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "nymox_OfficersAndDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Officers And Directors [Member]" } } }, "localname": "OfficersAndDirectorsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "nymox_OnerousContractsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Onerous contracts" } } }, "localname": "OnerousContractsPolicyTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_OneyearToFiveYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "1 year to 5 years [Member]" } } }, "localname": "OneyearToFiveYearsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/LiquidityRiskDetails" ], "xbrltype": "domainItemType" }, "nymox_OperatingLeaseInterestExpense": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 9.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Operating lease interest expense" } } }, "localname": "OperatingLeaseInterestExpense", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "nymox_OperatingLeaseLiabilityDueWithinOneYear": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 11.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Operating lease liability due within one year" } } }, "localname": "OperatingLeaseLiabilityDueWithinOneYear", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "nymox_OperatingLeasePOlicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating lease" } } }, "localname": "OperatingLeasePOlicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_OperatingLeaseRightOfUseAssetNet": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 9.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAssetNet", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "nymox_OperatingLeasesAndCommitments": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING LEASES AND COMMITMENTS" } } }, "localname": "OperatingLeasesAndCommitments", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_OperatingLeasesAndCommitmentsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 9 - OPERATING LEASES AND COMMITMENTS" } } }, "localname": "OperatingLeasesAndCommitmentsTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitments" ], "xbrltype": "textBlockItemType" }, "nymox_OperatingLeasesLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Beginning balance]", "verboseLabel": "Beginning balance" } } }, "localname": "OperatingLeasesLiability", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetails1" ], "xbrltype": "monetaryItemType" }, "nymox_OperatingLossCarryforwardExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Year of Expiration" } } }, "localname": "OperatingLossCarryforwardExpirationDate", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "stringItemType" }, "nymox_OperatingLossCarryforwardsOriginatedDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Year Originated" } } }, "localname": "OperatingLossCarryforwardsOriginatedDate", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "stringItemType" }, "nymox_OperationLeaseInterestExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operation lease interest expense" } } }, "localname": "OperationLeaseInterestExpense", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/FinanceIncomeAndFinanceCostsDetails" ], "xbrltype": "monetaryItemType" }, "nymox_OptionExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price" } } }, "localname": "OptionExercisePrice", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails1" ], "xbrltype": "perShareItemType" }, "nymox_OptionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share price" } } }, "localname": "OptionSharePrice", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails1" ], "xbrltype": "perShareItemType" }, "nymox_OtherLeaseLiabiltity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Other" } } }, "localname": "OtherLeaseLiabiltity", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetails1" ], "xbrltype": "monetaryItemType" }, "nymox_PatentsCapitalizedAndAmortizedForTaxPurposes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Patents capitalized and amortized for tax purposes" } } }, "localname": "PatentsCapitalizedAndAmortizedForTaxPurposes", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "nymox_PayrollRelatedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payroll related liabilities" } } }, "localname": "PayrollRelatedLiabilities", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "nymox_PercentagesOfExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominated percentages of expenses" } } }, "localname": "PercentagesOfExpenses", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative" ], "xbrltype": "percentItemType" }, "nymox_PersonnelExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PERSONNEL EXPENSES" } } }, "localname": "PersonnelExpenses", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_PersonnelRelatedExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Total 1]", "verboseLabel": "Total" } } }, "localname": "PersonnelRelatedExpenses", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PersonnelExpensesDetails" ], "xbrltype": "monetaryItemType" }, "nymox_PrepaidExpense": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid expense" } } }, "localname": "PrepaidExpense", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_PrivatePlacementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Placements [Member]" } } }, "localname": "PrivatePlacementsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative", "http://nymox.com/role/ShareCapitalDetailsNarrative", "http://nymox.com/role/WarrantsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nymox_ProceedFromPrivatePlacement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Proceed from private placement" } } }, "localname": "ProceedFromPrivatePlacement", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalDetailsNarrative" ], "xbrltype": "stringItemType" }, "nymox_ProceedsFromIssuanceOfShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from issuance of shares" } } }, "localname": "ProceedsFromIssuanceOfShares", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_ProceedsfromshareCapitalBeforeVariousFeeCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Share Capital Before Various Fee Charges" } } }, "localname": "ProceedsfromshareCapitalBeforeVariousFeeCharges", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_ProceedsfromshareCapitalRaisedTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Corporation Raised a Total Share Capital" } } }, "localname": "ProceedsfromshareCapitalRaisedTotal", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_ProceesFromIssuanceOfWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Warrant value", "verboseLabel": "Warrant value" } } }, "localname": "ProceesFromIssuanceOfWarrants", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalDetailsNarrative", "http://nymox.com/role/WarrantsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_ProfitLossBeforeTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net loss for the year, before income taxes" } } }, "localname": "ProfitLossBeforeTaxes", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "nymox_PropertyAndEquipment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyAndEquipment", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_PropertyAndEquipmentEstimatedUsefulLives": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property and equipment estimated useful lives" } } }, "localname": "PropertyAndEquipmentEstimatedUsefulLives", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "nymox_PropertyAndEquipmentPolicyTetblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Property and equipment]", "verboseLabel": "Property and equipment" } } }, "localname": "PropertyAndEquipmentPolicyTetblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_PropertyAndEquipmentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 6 - PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyAndEquipmentTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "nymox_ProvisionsPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Provisions" } } }, "localname": "ProvisionsPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_PurchaseOfPropertyPlantAndEquipmentInvestingActivities": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 13.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Purchase of property and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentInvestingActivities", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_PurchasedOfferingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchased offering shares" } } }, "localname": "PurchasedOfferingShares", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_ReceviedForRestrictedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted shares granted" } } }, "localname": "ReceviedForRestrictedShare", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_ReceviedForRestrictedShareMonthly": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted shares granted monthly" } } }, "localname": "ReceviedForRestrictedShareMonthly", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_ReclassificationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reclassifications" } } }, "localname": "ReclassificationsPolicyTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_RelatedPartyTransactions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactions", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_RelatedPartyTransactionsTextBlck": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 20 - RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsTextBlck", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "nymox_RenewedOfficeLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Renewed office lease]", "terseLabel": "Renewed office lease", "verboseLabel": "Renewed office lease" } } }, "localname": "RenewedOfficeLease", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetails", "http://nymox.com/role/OperatingLeasesAndCommitmentDetails1" ], "xbrltype": "monetaryItemType" }, "nymox_Renewedofficelease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Renewed office lease", "verboseLabel": "Renewed office lease" } } }, "localname": "Renewedofficelease", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetails", "http://nymox.com/role/OperatingLeasesAndCommitmentDetails1" ], "xbrltype": "monetaryItemType" }, "nymox_RepaymentOfOperatingLeaseAndFinancingObligation": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 14.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Repayment of operating lease and financing obligation]", "negatedLabel": "Repayment of operating lease and financing obligation" } } }, "localname": "RepaymentOfOperatingLeaseAndFinancingObligation", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_RepaymentsOfLeaseLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Repayments of lease liability" } } }, "localname": "RepaymentsOfLeaseLiability", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentDetails1" ], "xbrltype": "monetaryItemType" }, "nymox_RerestrictedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total rerestricted shares granted" } } }, "localname": "RerestrictedShares", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_ResearchAndDevelopmentExpendituresPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and development expenditures" } } }, "localname": "ResearchAndDevelopmentExpendituresPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_ResearchAndDevelopmentExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RESEARCH AND DEVELOPMENT EXPENSES" } } }, "localname": "ResearchAndDevelopmentExpenses", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_ResearchAndDevelopmentExpensesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 21 - RESEARCH AND DEVELOPMENT EXPENSES" } } }, "localname": "ResearchAndDevelopmentExpensesTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpenses" ], "xbrltype": "textBlockItemType" }, "nymox_ResearchAndDevelopmentProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research and Development Program [Member]" } } }, "localname": "ResearchAndDevelopmentProgramMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails" ], "xbrltype": "domainItemType" }, "nymox_ResearchTaxCreditsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Research tax credits" } } }, "localname": "ResearchTaxCreditsTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_RestrictedSharesOfCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted shares of common shares" } } }, "localname": "RestrictedSharesOfCommonShares", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_RetainedEarningsAccumulatedDeficitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficitMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "nymox_RevenueRecognitionsPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue recognitions" } } }, "localname": "RevenueRecognitionsPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_Salaries": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Salaries]", "terseLabel": "Salaries", "verboseLabel": "Salaries" } } }, "localname": "Salaries", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PersonnelExpensesDetails", "http://nymox.com/role/PersonnelExpensesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_SaleOfGoodsPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sale of goods" } } }, "localname": "SaleOfGoodsPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_ScheduleOfAccountingStandardsTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of accounting standards" } } }, "localname": "ScheduleOfAccountingStandardsTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/NewAccountingStandardsAndInterpretationsTables" ], "xbrltype": "textBlockItemType" }, "nymox_ScheduleOfPropertyAndEquipmentTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of property and equipment" } } }, "localname": "ScheduleOfPropertyAndEquipmentTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "nymox_ScheduleOfWeightedAverageNumberOfShareTableTextBlockExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of weighted average number of share" } } }, "localname": "ScheduleOfWeightedAverageNumberOfShareTableTextBlockExplanatory", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "nymox_SecurityDeposit": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 6.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "nymox_SecurityDeposits": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfCashFlow": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Security deposit]", "verboseLabel": "Security deposit" } } }, "localname": "SecurityDeposits", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_SegmentDisclosures": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEGMENT DISCLOSURES" } } }, "localname": "SegmentDisclosures", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_SegmentDisclosuresTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 18 - SEGMENT DISCLOSURES" } } }, "localname": "SegmentDisclosuresTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SegmentDisclosures" ], "xbrltype": "textBlockItemType" }, "nymox_ShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SHARE BASED COMPENSATION" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_ShareCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]", "label": "SHARE CAPITAL" } } }, "localname": "ShareCapital", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_ShareCapitalSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]", "label": "Share capital, shares outstanding", "verboseLabel": "Share capital, shares outstanding" } } }, "localname": "ShareCapitalSharesOutstanding", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPositionParenthetical", "http://nymox.com/role/ShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "nymox_ShareCapitalSubscriptionReceivable": { "auth_ref": [], "calculation": { "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition": { "order": 17.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Share capital subscription receivable" } } }, "localname": "ShareCapitalSubscriptionReceivable", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "nymox_ShareSubscriptionsPremiumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Subscriptions]", "verboseLabel": "Subscriptions" } } }, "localname": "ShareSubscriptionsPremiumMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConcentrationsDetails" ], "xbrltype": "domainItemType" }, "nymox_ShareSubscriptionsPremiumsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subscriptions" } } }, "localname": "ShareSubscriptionsPremiumsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "nymox_SharecapitalPolicytextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share capital" } } }, "localname": "SharecapitalPolicytextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_SharesAndWarrantsIssuedOnConnectionWithConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares and warrants issued on connection with convertible notes" } } }, "localname": "SharesAndWarrantsIssuedOnConnectionWithConvertibleNotes", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "nymox_SharesBasedCompensationRecognizedExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Shares based compensation recognized expense" } } }, "localname": "SharesBasedCompensationRecognizedExpense", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_SharesBasedCompensationUnrecognizedCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares based compensation unrecognized compensation" } } }, "localname": "SharesBasedCompensationUnrecognizedCompensation", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_SharesIssuanceForCashAndSubscriptionsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issuance for cash and subscriptions, amount" } } }, "localname": "SharesIssuanceForCashAndSubscriptionsAmount", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "nymox_SharesIssuanceForCashAndSubscriptionsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issuance for cash and subscriptions, shares" } } }, "localname": "SharesIssuanceForCashAndSubscriptionsShares", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "nymox_SignificantAccountingPolicies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPolicies", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_SignificantAccountingPoliciesPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES (Policies)" } } }, "localname": "SignificantAccountingPoliciesPoliciesAbstract", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_SignificantAccountingPoliciesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 4 - SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_SignificantEstimates": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ESTIMATES" } } }, "localname": "SignificantEstimates", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_SignificantEstimatesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 3 - SIGNIFICANT ESTIMATES" } } }, "localname": "SignificantEstimatesTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantEstimates" ], "xbrltype": "textBlockItemType" }, "nymox_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative", "http://nymox.com/role/ConcentrationsDetails", "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity", "http://nymox.com/role/IncomeTaxesDetails", "http://nymox.com/role/IncomeTaxesDetails2", "http://nymox.com/role/IntangibleAssetsDetailsNarrative", "http://nymox.com/role/LiquidityRiskDetails", "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative", "http://nymox.com/role/OperatingLeasesAndOtherCommitmentDetailsNarrative", "http://nymox.com/role/PersonnelExpensesDetailsNarrative", "http://nymox.com/role/PropertyAndEquipmentDetails", "http://nymox.com/role/RelatedPartyTransactionsDetails", "http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative", "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails", "http://nymox.com/role/SegmentDisclosuresDetails", "http://nymox.com/role/ShareBasedCompensationDetails", "http://nymox.com/role/ShareBasedCompensationDetailsNarrative", "http://nymox.com/role/ShareCapitalDetails", "http://nymox.com/role/ShareCapitalDetailsNarrative", "http://nymox.com/role/SignificantAccountingPoliciesDetails", "http://nymox.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://nymox.com/role/StockOptionsDetails", "http://nymox.com/role/StockOptionsDetails1", "http://nymox.com/role/SubsequentEventsDetailsNarrative", "http://nymox.com/role/WarrantsDetails", "http://nymox.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "nymox_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/CapitalDisclosuresAndFinancialRiskDetailsNarrative", "http://nymox.com/role/ConcentrationsDetails", "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity", "http://nymox.com/role/IncomeTaxesDetails", "http://nymox.com/role/IncomeTaxesDetails2", "http://nymox.com/role/IntangibleAssetsDetailsNarrative", "http://nymox.com/role/LiquidityRiskDetails", "http://nymox.com/role/OperatingLeasesAndCommitmentDetailsNarrative", "http://nymox.com/role/OperatingLeasesAndOtherCommitmentDetailsNarrative", "http://nymox.com/role/PersonnelExpensesDetailsNarrative", "http://nymox.com/role/PropertyAndEquipmentDetails", "http://nymox.com/role/RelatedPartyTransactionsDetails", "http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative", "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails", "http://nymox.com/role/SegmentDisclosuresDetails", "http://nymox.com/role/ShareBasedCompensationDetails", "http://nymox.com/role/ShareBasedCompensationDetailsNarrative", "http://nymox.com/role/ShareCapitalDetails", "http://nymox.com/role/ShareCapitalDetailsNarrative", "http://nymox.com/role/SignificantAccountingPoliciesDetails", "http://nymox.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://nymox.com/role/StockOptionsDetails", "http://nymox.com/role/StockOptionsDetails1", "http://nymox.com/role/SubsequentEventsDetailsNarrative", "http://nymox.com/role/WarrantsDetails", "http://nymox.com/role/WarrantsDetailsNarrative" ], "xbrltype": "stringItemType" }, "nymox_StockBasedCompensationAndServiceFeeAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock-based compensation and service fee, amount" } } }, "localname": "StockBasedCompensationAndServiceFeeAmount", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "nymox_StockBasedCompensationPolicyTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Stock-based compensation]", "verboseLabel": "Stock-based compensation" } } }, "localname": "StockBasedCompensationPolicyTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "nymox_StockOptionAviableToBeGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock option granted" } } }, "localname": "StockOptionAviableToBeGranted", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_StockOptionPlanDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock option plan, description" } } }, "localname": "StockOptionPlanDescription", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "nymox_StockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK OPTIONS" } } }, "localname": "StockOptions", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option [Member]" } } }, "localname": "StockOptionsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensationDetails", "http://nymox.com/role/ShareCapitalDetails", "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "domainItemType" }, "nymox_StockbasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Stock-based compensation 1]", "terseLabel": "Stock-based compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "StockbasedCompensation", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PersonnelExpensesDetails", "http://nymox.com/role/PersonnelExpensesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_StockbasedCompensationAndServiceFeeShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-based compensation and service fee, shares" } } }, "localname": "StockbasedCompensationAndServiceFeeShares", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "nymox_SubsequentEvents": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEvents", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS (Details Narrative)" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_SubsequentEventsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "nymox_SubsequentEventsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NOTE 28 - SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfCommonSharesAuthorizedIssuedAndRelatedContributedCapitalByControllingShareholders": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Common shares authorized, issued and related contributed capital by controlling shareholders" } } }, "localname": "SummaryOfCommonSharesAuthorizedIssuedAndRelatedContributedCapitalByControllingShareholders", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfContractualMaturitiesOfFinancialLiabilitiesTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Contractual maturities of financial liabilities" } } }, "localname": "SummaryOfContractualMaturitiesOfFinancialLiabilitiesTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/LiquidityRiskTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfEffectiveTaxRateTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Effective tax rate" } } }, "localname": "SummaryOfEffectiveTaxRateTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfFairValueOfTheOptionsGrantedTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Fair value of the options granted" } } }, "localname": "SummaryOfFairValueOfTheOptionsGrantedTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfFinanceIncomeAndFinanceCotsTableTextbock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Finance income and finance cots" } } }, "localname": "SummaryOfFinanceIncomeAndFinanceCotsTableTextbock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/FinanceIncomeAndFinanceCostsTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfGeographicReportableSegmentTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Geographic reportable segment" } } }, "localname": "SummaryOfGeographicReportableSegmentTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SegmentDisclosuresTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfNetOperatingLossCarryforwardsForOriginationAndExpirationTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Net operating loss carryforwards for origination and expiration" } } }, "localname": "SummaryOfNetOperatingLossCarryforwardsForOriginationAndExpirationTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfOperatingLeaseRightOfUseAssetsTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Operating lease right-of-use assets" } } }, "localname": "SummaryOfOperatingLeaseRightOfUseAssetsTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfPersonnelRelatedExpensesTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of personnel related expenses" } } }, "localname": "SummaryOfPersonnelRelatedExpensesTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/PersonnelExpensesTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfResearchAndDevelopmentExpensesTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Research and development expenses" } } }, "localname": "SummaryOfResearchAndDevelopmentExpensesTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpensesTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfRevenuesFromSalesTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of revenues from sales" } } }, "localname": "SummaryOfRevenuesFromSalesTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfStockOptionAwardTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Stock option award" } } }, "localname": "SummaryOfStockOptionAwardTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfStockOptionBasedCompensationExpenseTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of stock option-based compensation expense" } } }, "localname": "SummaryOfStockOptionBasedCompensationExpenseTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfUnrecognizedDeferredTaxAssetsTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Unrecognized deferred tax assets" } } }, "localname": "SummaryOfUnrecognizedDeferredTaxAssetsTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryOfWarrantsOutstandingTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Warrants outstanding" } } }, "localname": "SummaryOfWarrantsOutstandingTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/WarrantsTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryofleaseLiabilitytabletextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of lease liability" } } }, "localname": "SummaryofleaseLiabilitytabletextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "nymox_SummaryofoperatingleaseliabilityTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of operating lease liability" } } }, "localname": "SummaryofoperatingleaseliabilityTableTextblock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/OperatingLeasesAndCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "nymox_SupplementalDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE" } } }, "localname": "SupplementalDisclosureAbstract", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "nymox_TaxLossCarryForward": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Tax loss carry forward" } } }, "localname": "TaxLossCarryForward", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "nymox_TobaccoExposureTestsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tobacco Exposure Tests [Member]" } } }, "localname": "TobaccoExposureTestsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ResearchAndDevelopmentExpensesDetails" ], "xbrltype": "domainItemType" }, "nymox_TotalHonorariums": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total honorariums" } } }, "localname": "TotalHonorariums", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "nymox_TweentyHundredEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2018 [Member]" } } }, "localname": "TweentyHundredEighteenMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredElevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2011 [Member]" } } }, "localname": "TweentyHundredElevenMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredFifteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2015 [Member]" } } }, "localname": "TweentyHundredFifteenMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredFourteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2014 [Member]" } } }, "localname": "TweentyHundredFourteenMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredSeventeenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2017 [Member]" } } }, "localname": "TweentyHundredSeventeenMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredSixteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2016 [Member]" } } }, "localname": "TweentyHundredSixteenMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredTenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2010 [Member]" } } }, "localname": "TweentyHundredTenMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredThirteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2013 [Member]" } } }, "localname": "TweentyHundredThirteenMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredTwelveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2012 [Member]" } } }, "localname": "TweentyHundredTwelveMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredZeroEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2008 [Member]" } } }, "localname": "TweentyHundredZeroEightMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredZeroFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2005 [Member]" } } }, "localname": "TweentyHundredZeroFiveMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredZeroFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2004 [Member]" } } }, "localname": "TweentyHundredZeroFourMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredZeroOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2001 [Member]" } } }, "localname": "TweentyHundredZeroOneMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredZeroSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2007 [Member]" } } }, "localname": "TweentyHundredZeroSevenMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredZeroSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2006 [Member]" } } }, "localname": "TweentyHundredZeroSixMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredZeroThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2003 [Member]" } } }, "localname": "TweentyHundredZeroThreeMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TweentyHundredZeroTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2002 [Member]" } } }, "localname": "TweentyHundredZeroTwoMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TwoHundredNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2019 [Member]" } } }, "localname": "TwoHundredNineteenMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TwoThousandNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2009 [Member]" } } }, "localname": "TwoThousandNineMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2020 [Member]" } } }, "localname": "TwoThousandTwentyMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_TwoThousandTwentyoneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "2021 [Member]" } } }, "localname": "TwoThousandTwentyoneMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails2" ], "xbrltype": "domainItemType" }, "nymox_UnitedStatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States [Member]" } } }, "localname": "UnitedStatesMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "nymox_UnrecognizedDeferredTaxAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Unrecognized deferred tax assets" } } }, "localname": "UnrecognizedDeferredTaxAssets", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "nymox_WARRANTS": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS" } } }, "localname": "WARRANTS", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_WarrantGrantedOutstandingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Granted]", "verboseLabel": "Granted" } } }, "localname": "WarrantGrantedOutstandingShares", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "nymox_WarrantIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Warrant issued" } } }, "localname": "WarrantIssued", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "nymox_WarrantsDetailsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WARRANTS (Details)" } } }, "localname": "WarrantsDetailsAbstract", "nsuri": "http://nymox.com/20211231", "xbrltype": "stringItemType" }, "nymox_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/WarrantsDetails" ], "xbrltype": "domainItemType" }, "nymox_WarrantsNumberOfOutstandingBalanceBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Number of outstanding balance, Beginning]", "verboseLabel": "Number of outstanding balance, Beginning" } } }, "localname": "WarrantsNumberOfOutstandingBalanceBeginning", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "nymox_WarrantsNumberOfOutstandingBalanceEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Number of outstanding balance, Ending]", "verboseLabel": "Number of outstanding balance, Ending" } } }, "localname": "WarrantsNumberOfOutstandingBalanceEnding", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/WarrantsDetails" ], "xbrltype": "sharesItemType" }, "nymox_WarrantsToPurchaseSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase shares of common stock" } } }, "localname": "WarrantsToPurchaseSharesOfCommonStock", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "nymox_WarrantsToPurchaseSharesOfCommonStockExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase shares of common stock exercise price" } } }, "localname": "WarrantsToPurchaseSharesOfCommonStockExercisePrice", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "nymox_WarrantsWeightedAverageExercisePriceBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average exercise price, Beginning]", "verboseLabel": "Weighted average exercise price, Beginning" } } }, "localname": "WarrantsWeightedAverageExercisePriceBeginning", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "nymox_WarrantsWeightedAverageExercisePriceEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average exercise price, Ending]", "verboseLabel": "Weighted average exercise price, Ending" } } }, "localname": "WarrantsWeightedAverageExercisePriceEnding", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/WarrantsDetails" ], "xbrltype": "perShareItemType" }, "nymox_WeightedAverageExercisePriceBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Beginning", "verboseLabel": "Weighted average exercise price, Beginning" } } }, "localname": "WeightedAverageExercisePriceBeginning", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalDetails", "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "nymox_WeightedAverageExercisePriceEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Ending" } } }, "localname": "WeightedAverageExercisePriceEnding", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "nymox_WeightedAverageExercisePriceExpired": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Expired" } } }, "localname": "WeightedAverageExercisePriceExpired", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "nymox_WeightedAverageExercisePriceGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Granted" } } }, "localname": "WeightedAverageExercisePriceGranted", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "nymox_WeightedAverageExercisePriceOptionsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, Options exercisable" } } }, "localname": "WeightedAverageExercisePriceOptionsExercisable", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "perShareItemType" }, "nymox_WeightedAverageGrantdateFairValueOfPerOptionsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average grant-date fair value" } } }, "localname": "WeightedAverageGrantdateFairValueOfPerOptionsGranted", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "nymox_WeightedAverageNumberOfCommonSharesOutstandingAtDecember31": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of common shares outstanding at December 31" } } }, "localname": "WeightedAverageNumberOfCommonSharesOutstandingAtDecember31", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "nymox_WeightedAverageRemainingContractualLifeEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life (in years), Ending" } } }, "localname": "WeightedAverageRemainingContractualLifeEnding", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalDetails" ], "xbrltype": "durationItemType" }, "nymox_WeightedAverageRemainingContractualLifeInExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life options exercisable (in years)", "verboseLabel": "Weighted average remaining contractual life options exercisable (in years)" } } }, "localname": "WeightedAverageRemainingContractualLifeInExercisable", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalDetails", "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "durationItemType" }, "nymox_WeightedAverageRemainingContractualLifeInYear": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Weighted average remaining contractual life (in years)]", "verboseLabel": "Weighted average remaining contractual life (in years)" } } }, "localname": "WeightedAverageRemainingContractualLifeInYear", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/WarrantsDetails" ], "xbrltype": "stringItemType" }, "nymox_WeightedAverageRemainingContractualLifeInYearsBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life (in years)" } } }, "localname": "WeightedAverageRemainingContractualLifeInYearsBeginning", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "durationItemType" }, "nymox_WeightedAverageRemainingContractualLifeInYearsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life (in years), Granted", "verboseLabel": "Weighted average remaining contractual life (in years), Granted" } } }, "localname": "WeightedAverageRemainingContractualLifeInYearsGranted", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/ShareCapitalDetails", "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "durationItemType" }, "nymox_WeightedAverageRemainingContractualLifeOptionsOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life options outstanding" } } }, "localname": "WeightedAverageRemainingContractualLifeOptionsOutstanding", "nsuri": "http://nymox.com/20211231", "presentation": [ "http://nymox.com/role/StockOptionsDetails" ], "xbrltype": "durationItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "41", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_41&doctype=Standard", "URIDate": "2021-03-24" }, "r100": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r101": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r102": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r103": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r104": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r105": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r106": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r107": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r108": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93&doctype=Standard", "URIDate": "2021-03-24" }, "r109": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "30", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_30_c&doctype=Standard", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2021-03-24" }, "r110": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r111": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r112": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r113": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r114": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r115": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2021-03-24" }, "r116": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r117": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard", "URIDate": "2021-03-24" }, "r118": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "95", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_95&doctype=Standard", "URIDate": "2021-03-24" }, "r119": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard", "URIDate": "2021-03-24" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2021-03-24" }, "r120": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_44&doctype=Standard", "URIDate": "2021-03-24" }, "r121": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r122": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2021-03-24" }, "r123": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2021-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r124": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r125": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r126": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r127": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2021-03-24" }, "r128": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2021-03-24" }, "r129": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2021-03-24" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2021-03-24" }, "r130": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2021-03-24" }, "r131": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42I", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2021-03-24" }, "r132": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_6&doctype=Standard", "URIDate": "2021-03-24" }, "r133": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r134": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r135": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Scope", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2021-03-24" }, "r136": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2021-03-24" }, "r137": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2021-03-24" }, "r138": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r139": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2021-03-24" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r140": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r141": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r142": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2021-03-24" }, "r143": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2021-03-24" }, "r144": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r145": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2021-03-24" }, "r146": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r147": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r148": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "9", "Paragraph": "7.2.34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2021-03-24" }, "r149": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard", "URIDate": "2021-03-24" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2021-03-24" }, "r150": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2021-03-24" }, "r151": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24" }, "r152": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24" }, "r153": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2021-03-24" }, "r154": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2021-03-24" }, "r155": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2021-03-24" }, "r156": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "C32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2021-03-24" }, "r157": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "9", "Paragraph": "7.2.42", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2021-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2021-03-24" }, "r158": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2021-03-24" }, "r159": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r160": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39M", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39M&doctype=Standard", "URIDate": "2021-03-24" }, "r161": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "4", "Paragraph": "39", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39_c&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r162": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "4", "Paragraph": "39J", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39J&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r163": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r164": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r165": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2021-03-24" }, "r166": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r167": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r168": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r169": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard", "URIDate": "2021-03-24" }, "r170": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r171": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r172": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r173": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r174": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r175": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "68", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_68&doctype=Standard", "URIDate": "2021-03-24" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24" }, "r21": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24" }, "r22": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r23": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r24": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r27": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2021-03-24" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r3": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard", "URIDate": "2021-03-24" }, "r31": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r32": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard", "URIDate": "2021-03-24" }, "r33": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r34": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2021-03-24" }, "r35": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2021-03-24" }, "r36": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2021-03-24" }, "r37": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "Clause": "vii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2021-03-24" }, "r39": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Paragraph": "77", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&anchor=para_77_e&doctype=Standard", "URIDate": "2021-03-24" }, "r42": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "16", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=16&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2021-03-24" }, "r43": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_9&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2021-03-24" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2021-03-24" }, "r48": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "57", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_57_c&doctype=Standard", "URIDate": "2021-03-24" }, "r5": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2021-03-24" }, "r51": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r53": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r54": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r55": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r56": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard", "URIDate": "2021-03-24" }, "r57": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24" }, "r58": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r59": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2021-03-24" }, "r6": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r61": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r64": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2021-03-24" }, "r67": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2021-03-24" }, "r68": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r7": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Paragraph": "86", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_86&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2021-03-24" }, "r72": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_118&doctype=Standard", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_76&doctype=Standard", "URIDate": "2021-03-24" }, "r76": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2021-03-24" }, "r77": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=40&code=ifrs-tx-2021-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2021-03-24" }, "r78": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard", "URIDate": "2021-03-24" }, "r79": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=41&code=ifrs-tx-2021-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2021-03-24" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r81": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_16&doctype=Standard", "URIDate": "2021-03-24" }, "r82": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r83": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r84": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2021-03-24" }, "r85": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_c&doctype=Standard", "URIDate": "2021-03-24" }, "r86": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r87": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r88": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r89": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r90": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50&doctype=Standard", "URIDate": "2021-03-24" }, "r91": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "8", "Paragraph": "39", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=8&code=ifrs-tx-2021-en-r&anchor=para_39&doctype=Standard", "URIDate": "2021-03-24" }, "r92": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r93": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r94": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r95": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r96": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "IG63", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r97": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r98": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r99": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" } }, "version": "2.1" } ZIP 110 0001640334-22-000622-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001640334-22-000622-xbrl.zip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˟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�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end